Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

ARMAN YURISALDI SALEH; Dwi Arwandi Yogi Saputra; Riezky Valentina; Tirta Darmawan Susanto

doi:10.12688/f1000research.160416.1

Home Browse Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen...

ALL Metrics

Views

Downloads

Get PDF

Get XML

Export

▬

✚

Research Article

Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

[version 1; peer review: 1 approved with reservations]

ARMAN YURISALDI SALEH ¹, Dwi Arwandi Yogi Saputra², Riezky Valentina¹, Tirta Darmawan Susanto³

PUBLISHED 07 Mar 2025

Author details Author details

¹ Neurology Department Faculty of Medicine, Universitas Pembangunan Nasional (UPN) Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia
² Department of Public Health Sciences, Faculty of Medicine, Universitas Pembangunan Nasional (UPN) Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, Indonesia
³ Family Medicine and Primary Care Department, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia

ARMAN YURISALDI SALEH
Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Dwi Arwandi Yogi Saputra
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Riezky Valentina
Roles: Writing – Review & Editing

Tirta Darmawan Susanto
Roles: Writing – Review & Editing

OPEN PEER REVIEW

REVIEWER STATUS

Abstract

1) Introduction

Cognitive enhancers, also known as nootropics, aim to improve cognitive functions, such as memory and attention. Despite their potential benefits, the challenges include scientific validation, ethical considerations, and regulatory hurdles. This bibliometric study analyzes literature from Scopus to identify key trends, influential authors, and research gaps, providing guidance for future research.

2) Methods

This study employs a literature review methodology to gather data from the Scopus database on Neuroaid, analyzing it using Biblioshiny and VOSviewer software. The focus was on Ginkgo Biloba as a niche-theme cognitive enhancer agent based on Scopus data, using both quantitative and qualitative analyses.

3) Results and discussion

Ginkgo biloba, the 'maidenhair tree’ from the order Ginkgoales, appeared 290 million years ago. Chinese and Japanese culture has been cultivated for thousands of years. This tree is valued for its resilience and therapeutic properties, often used in traditional medicine for respiratory and blood circulation issues.

4) Conclusions

This bibliometric study on cognitive enhancers aims to provide a comprehensive and systematic review of the existing literature, highlighting key trends, influential authors, and research gaps. The findings of this study will contribute to a better understanding of the current state of research on cognitive enhancers and inform future research. This study was conducted in December 2024.

Keywords

Cognitive, enhancer, agent, ginkgo biloba, niche

Corresponding author: ARMAN YURISALDI SALEH

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2025 SALEH AY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: SALEH AY, Saputra DAY, Valentina R and Susanto TD. Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024 [version 1; peer review: 1 approved with reservations]. F1000Research 2025, 14:275 (https://doi.org/10.12688/f1000research.160416.1) First published: 07 Mar 2025, 14:275 (https://doi.org/10.12688/f1000research.160416.1) Latest published: 15 May 2025, 14:275 (https://doi.org/10.12688/f1000research.160416.2)

Introduction

Cognitive enhancers, also known as nootropics or smart drugs, have garnered significant attention from both the scientific community and popular culture. These substances are designed to improve cognitive functions, such as memory, attention, and problem-solving abilities in both healthy individuals and those experiencing cognitive decline.¹ The growing interest in cognitive enhancers is driven by their potential benefits in enhancing mental performance, which can be particularly valuable in competitive environments such as academia and the workplace.²

Despite the promising potential of cognitive enhancers, this field faces several challenges, including the need for rigorous scientific validation, ethical considerations, and regulatory hurdles.³ The current body of literature on cognitive enhancers is vast and diverse, encompassing studies on various pharmacological agents, non-pharmacological interventions, and their effects on different cognitive domains.⁴ However, there is a lack of a comprehensive bibliometric analysis that systematically reviews and synthesizes this body of research.

This bibliometric study aimed to fill this gap by providing a comprehensive analysis of the existing literature on cognitive enhancers indexed in Scopus. By employing bibliometric methods, this study identified key trends, influential authors, and research gaps in the field. The findings of this study will contribute to a better understanding of the current state of research on cognitive enhancers and inform future research.

The methodology of this study involved the collection and analysis of data from Scopus, focusing on articles published between 1988 and 2024. The data will be analyzed using various bibliometric techniques, including co-citation, keyword, and network analyses. The results are presented in the form of visualizations and descriptive statistics, providing a clear and comprehensive overview of the research landscape.

The significance of this study lies in its potential to inform policy decisions, guide research funding and shape the development of cognitive enhancers. By identifying the most impactful studies and emerging trends, this bibliometric analysis will help researchers and policymakers prioritize areas of research that are likely to yield the greatest benefits.

Methods

Bibliometric research is a methodological approach that employs scientific publishing data to delineate and examine the evolution of scientific disciplines. This study seeks to find and delineate trends, patterns, and correlations within scientific texts pertaining to specific subjects. This research focuses on the subject of "cognitive enhancers." This study used data from www.scopus.com, a prominent and reputable database for scientific articles. This study was conducted in December, 2024.

To carry out bibliometric research, the steps to follow are as follows:

1. Determining the search keywords. In this study, the keywords used were focused on cognitive enhancers. These keywords were entered into the search column at www.scopus.com by selecting the topic field (title, abstract, keywords).
2. Filter search results. In this study, Were not filtered.
3. Retrieved data from search results. This study involved the retrieval of search result data in three distinct formats.
- • CSV (comma-separated value) contains basic information about the document, such as title, author, affiliation, year, source, abstract, and keywords.
- • RIS (research information system), which contains detailed information about a document, including the references cited by the document.

Data Collection

A search was conducted on the Scopus website using the specified terms, with the understanding that this platform encompasses research deemed to possess validity: TITLE – ABS – KEY (“cognitive enhancer”) are the titles of the products under consideration. We received twenty documents were received by us. We then saved the document from Scopus in the form of a file with extension.csv following this step.

Data Analysis

Both the Biblioshiny and Vosviewer software packages were utilised in the analysis process.

Quantitative Analysis

Documents by Year

Figure 1 indicates an increase in the number of documents, culminating in 61 papers by 2023. The earliest document dates back to 1988 and comprises two papers titled "Antagonism by Exifone, a New Cognitive Enhancing Agent, of the Amnesias Induced by Four Benzodiazepines in Mice," authored by Porsolt, R.D., Lenègre, A., Avril, I., and Doumont, G. The second document, headed "Comparison of the Effects of Vinpocetine, Vincamine, and Nicergoline on the Normal and Hypoxia-Damaged Learning Process in Spontaneously Hypertensive Rats," is authored by Groó, D., Pálosi, É., and Szporny, L. As of 2024, there are 54 documents, with the most recent titled "MSK 1," which is essential for the experience- and ampakine-dependent strengthening of spatial reference memory and reversal learning, as well as for the induction of Arc and BDNF written by Morè et al.⁷

Figure 1. Documents by year.

Figure 2. Most Relevant Sources.

Most Relevant Sources

According to Figure 3. Neuropharmacology occupies the foremost position. This contains information regarding the journal neuropharmacology. The journal has been indexed in Scopus since 1962. The current SCImago Journal Rank (SJR) for this journal was 1.307. It was published by Elsevier Ltd. The journal publishes high-quality original research in neuroscience, concentrating on the examination and comprehension of the effects of exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. This journal is classified as Q1 in the fields of cellular and molecular neuroscience, and pharmacology. Psychopharmacology has been indexed in Scopus since 1959. The most recent SJR is 1.053. SCImago quartile classification, Q1 (highest). This magazine accepts many manuscripts, including experimental studies on the impact of medications on human cognition and behavior as well as laboratory investigations involving experimental animals. It also invites works that incorporate various levels of analysis, ranging from neurochemical assays to functional neuroimaging research. Ranking three is the Journal of Behavioral Brain Research. This contains information regarding the Journal of Behavioral Brain Research. This journal has been indexed in Scopus since the 1980. The most recent data indicate that the SCImago Journal Rank (SJR) for Behavioral Brain Research is 0.881. This study was published by Elsevier B.V. This magazine welcomes diverse forms of submission, encompassing original research, methodological innovations, and critical analyses within the domains of neuroscience, behavioral science, and cognitive science. This journal is classified as Q2.

Figure 3. Most Global Cited Documents.

Most Global Cited Documents

According to Figure 3, the most cited document, with 1059 citations, is the journal titled Identification of separable cognitive factors in schizophrenia, authored by Keith H. Nuechterlein, Deanna M. Barch, James M. Gold, Terry E. Goldberg, Michael F. Green, and Robert K. Heaton. The journal's abstract states that one of the main objectives of this research was to identify separate cognitive factors in schizophrenia. This study aimed to better understand how this disorder affects various cognitive aspects, such as memory ability, attention, and information processing.

Second, with 946 citations, a document titled "Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinction of Fear" was authored by Kerry J. Ressler, MD, PhD; Barbara O. Rothbaum, PhD; Libby Tannenbaum, PhD; and colleagues. Background: This study evaluated the use of D-cycloserine (DCS), a partial agonist of N-methyl-D-aspartate (NMDA) receptors, as an adjunct to exposure therapy for individuals with phobias. Previous studies have demonstrated that DCS can accelerate fear extinction in animals.

The third-ranked document, with 623 citations, is titled Ionotropic and Metabotropic Glutamate Receptor Structure and Pharmacology. This review was published on February 25, 2005, in Psychopharmacology. The authors of this review were James N. C. Kew and John A. Kemp. This document discusses ionotropic and metabotropic glutamate receptors, which are two major receptors that function as primary excitatory neurotransmitters in the central nervous system (CNS).

Factorial Map Of The Documents With The Highest Contributes

In Figure 4, the most contributed manuscript, titled D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial" by JoAnn Difede, was published in Neuropsychopharmacology. The study was accepted on November 12, 2013, and published online on December 11, 2013.

Figure 4. Factorial map of the documents with the highest contributes.

This study discusses the use of D-cycloserine (DCS) to enhance the effectiveness of virtual reality exposure (VRE) therapy in patients with PTSD. The main goal was to determine whether DCS could improve psychotherapeutic effectiveness by accelerating the process of extinguishing fear and increasing neuroplasticity (the brain's ability to adapt and change).

Documents by Author

According to Figure 5. The three most prolific authors, each with 16 documents, are as follows: Sahakian, B.J., with many paper titles: Enhancement of the motor control network with methylphenidate in individuals with traumatic brain injury. Effects of atomoxetine on attentional bias towards drug-related signals in cocaine-dependent individuals Modafinil Enhances Episodic and Working Memory Cognition in Patients with Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Examining the Neuroscience and Societal Consequences of Cognitive Enhancers as well as the utilization of substances by healthy individuals to augment cognition, creativity, motivation, and enjoyment.^8–12

Figure 5. Documents by Author.

The subsequent author with 14 publications is Steiner, H., whose articles include: Methylphenidate with or without fluoxetine triggers the restoration of cocaine-seeking behavior in rats. Vilazodone, an innovative SSRI antidepressant with 5-HT1A partial agonist characteristics, reduced the potentiation of chronic oral methylphenidate-induced dynorphin expression in the striatum of male adolescent rats. Fluoxetine amplifies the behavioral effects generated by methylphenidate: increased locomotion or stereotypies, and improved acquisition of cocaine self-administration. Concurrent Chronic Administration of Oral Methylphenidate and Fluoxetine During Adolescence: Behavioral Effects, and Fluoxetine Enhances Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum.^13–17

The subsequent author with 14 publications is Wattanathorn, J., whose articles include: Effect of Single Administration of Mulberry Milk on the Cognitive Function of 6-12-Year-Old Children: Results from a Randomized, Placebo-Controlled, Crossover Study. Assessment of the neuroprotective and cognitive enhancement properties of Cucurbita moschata. Mung bean-derived protein protects against neurodegeneration and memory deficits in an animal model of menopause with obesity. The amalgamated extract of black sticky rice and dill enhances cognitive deficits following stroke in individuals with metabolic syndrome and functional beverages. A novel cognitive enhancer, comprising extracts of purple corn cob and pandan leaves, enhances spatial memory and hippocampal neuron density by improving extracellular signal-regulated protein kinase expression, cholinergic function, and oxidative status in ovariectomized rats.^18–22

Documents by country or territory

Figure 6 indicates that the United States has the highest number of document creators, totaling 436 documents. The United Kingdom followed 206 documents, followed by Japan with 95. Germany possesses 90 documents, whereas Canada has 87.

Figure 6. Documents by country or territory.

Documents by Subject Area

Figure 7 shows a pie chart depicting the distribution of the documents by subject area. The graph shows the percentage of documents classified into different subject areas. The percentage details for each topic area were as follows: medicine: 25.2% or 614 documents. Neuroscience: 21.3% (518 documents) Pharmacology, Toxicology, and Pharmaceutics: 21.1% (513 documents) Biochemistry, Genetics, and Molecular Biology: 11.5% (280 documents) Psychology: 6.3% or 280 documents. Social Sciences: 2.7% or 65 documents. Chemistry: 2.6% or 64 documents. Nursing: 1.9% or 47 documents. Multidisciplinary: 1.8% or 44 documents. Agricultural and Biological Sciences: 1.7% or 41 documents, which is noteworthy as it illustrates the substantial dispersion of documents across several topic areas, with medicine comprising the largest percentage. It is crucial to comprehend the study or publication emphasis in various fields.

Figure 7. Documents by Subject Area.

Documents by affiliation

According to Figure 8, in first place, the producer of most documents is affiliated with the University of Cambridge with 33 documents, the second is affiliated with the University of Cambridge with 31 documents, and the Boston University with 21 documents.

Figure 8. Documents by affiliation.

Documents by funding sponsor

Referring to Figure 9, the sponsors that generate the highest number of documents for funding are the National Institutes of Health with 111 documents, followed by the National Institute of Mental Health with 68 documents, and the U.S. Department of Health and Human Services producing 67 documents.

Figure 9. Documents by funding sponsor.

Figure 10. Network Visualization.

Network Visualization

Figure 9 indicates that the examined areas remained unassociated with the other regions delineated by the edges. The domain encompasses agitation, anorexia, vomiting, caregiver, tremor, hypertension, dietary supplement, Ginkgo biloba extract, huperzine A, anti-inflammatory activity, oxidative stress, glutathione, malondialdehyde, plant extracts, chemical structure, drug synthesis, peptide fragment, amyloid beta-protein,^1–42 in vitro studies, peptide fragments, protein, phosphorylation, calpain, animal, cell, nerve cell, phosphorylation, brain nerve cell, compounds, water maze, NMDA receptor 1, hippocampal CA1 region, BDNF, swimming, Morris water maze, reference memory, cues, choice behavior, mental recall, volunteer, normal human, crossover, procedure, double-blind method, randomized controlled trial, adolescent, impulsive behavior, phobia, substance-related disorders, clinical article, ethics, outcome assessment, universities, students, and students.

Overlay Visualization of Scopus, Database Using Vosviewer

According to Figure 11. In the overlay visualization, it appears that the keywords that are being researched a lot approaching 2016 are the parts colored yellow, namely gluthahione, malonaldehyde, metabolism, prescription, major clinical study, randomized controlled trial (t, addiction, student, students, universities, oxidative stress, chemistry, and nerve degeneration.

Figure 11. Overlay visualization of scopus, database using Vosviewer.

Density Visualization

This is illustrated in Figure 12. In the visual circulation density, it appears that the part that is already saturated with research is yellow, while the part that is not yet saturated is slightly yellow and dominantly green, namely keywords: agitation, vomiting, anorexia, ginkgo biloba extract, cholinesterase, oxidative stress, glutathione, malonaldehyde, galantamine, pain, dementia, tacrine, nerve degeneration, plant extracts, sertraline, tremor, hypertension, neuroprotection, choline, degenerative disease, trazodone, side effect, antipsychotics, pathogenesis, alzheimer disease, cholinesterase inhibitors, dietary supplements, piracetam, drug penetration, drug structure, randomized controlled trial (t, drug safety, amfebutamone, prazosin, protein phosphorylation, peptide fragments, prevalence, olanzapine, neuroleptic agent, anxiolytic agent, ritanserin, memory disorder, amyloid beta protein[1-42], psychotic disorders, prescription, reboxetine, clinical trial, guanfacine, drug synthesis, chemistry, molecular structure, drug structure, in vitro study, peptide fragments, treatment outcome, narcolepsy, cell count, spiro compounds, ethics, placebo, outcome assessment, central stimulant agent, drug abuse, stress, universities, major clinical study, middle aged, substance-related disorders, clinical article, adolescent, phobia, impulsive therapy, motivation, attention, adult, addiction, fear, reinforcement, recall, accuracy, normal human, volunteer, randomized controlled trial, double-blind method, crossover procedure, mental recall, choice behavior, brain function, dopamine, task performance, reaction time, conditioning, operant, frontal cortex, genotype, mental recall, choice behavior, facilitation, nmda receptor, bdnf, ca1 region, hippocampal, mice, inbred c57bl, injections, intraperitoneal, animal behavior, behavior, animal, analysis of variance, striatum, exploratory behavior, morris water maze, reference memory, swimming, water maze.

Figure 12. Density visualization.

Thematic Map

According to Figure 13, on the thematic map based on the title, the following is an explanation for each keyword in each quadrant in the thematic map resulting from the bibliometric analysis. Here is an explanation of the meaning of each quadrant in the thematic map, and examples of document titles relevant to keywords in each quadrant.

Figure 13. Thematic map.

Niche Themes (Upper-Left Quadrant):

Keywords: Biloba, ginkgo, formation. Niche themes are well-developed topics that are not central to the overall research field. This means that, although this research is important, it is not currently the main focus. Example Document Titles: Neuroprotective effects of Ginkgo biloba in Alzheimer's disease. Ginkgo biloba extract and cognitive function: A review of the literature. Formation of cognitive enhancers from natural sources: The case of Ginkgo biloba.

.Motor Themes (Upper-Right Quadrant): Keywords: receptor, brain, rat, effects, memory, rat. Meaning: Motor themes are well-developed and central to research. This means that these themes are important and the main focus of the research. Example document titles: Role of NMDA receptors in brain function and cognition. Effects of novel cognitive enhancers on memory formation in rats. Effect of receptor modulators on cognitive enhancement in animal models.

Basic Themes (Lower-Right Quadrant):

Keywords: cognitive, enhancer, enhancer. Meaning: Basic themes are fundamental topics central to the field of research but are not yet well-developed. These are the foundations from which more specialized research can be developed. Example Document Titles: Overview of cognitive enhancers: mechanisms and applications. Cognitive enhancers: A review of their efficacy and safety. Evolution of cognitive enhancer research: From theory to practice.

Emerging or Declining Themes (Lower-Left Quadrant):

Keywords: study, patients, disorder, cognitive enhancers, enhancer. Meaning: Emerging and declining themes are topics that are either newly developing or losing relevance. This means that these are new areas being developed or possibly declining, if no significant new findings are made. Example Document Titles: Clinical studies of cognitive enhancers in patients with cognitive disorders. Role of cognitive enhancers in the management of cognitive disorders. Emerging trends in cognitive enhancer research: a clinical perspective.

Thematic Evolution

According to Figure 14, there was an evolution of changes in themes in research from 1988 to 2014 with the keywords cognitive, disease, receptor, effects, and memory. The theme then changed in 2015–2024 to effects, disease, study, cognition, and review.

Figure 14. Thematic Evolution.

Topic Dendogram

According to Figure 15. There are 2 large clusters According to keywords. There are 2 clusters of blue and red.

Figure 15. Dendogram.

Qualitative Analysis - refer to extended data for table 1¹⁴²⁰)

Results and Discussion

Ginkgo biloba, also known as the maidenhair tree, is a living species of the order Ginkgoales, which first appeared over 290 million years ago. This plant has been known and developed by Chinese and Japanese cultures for thousands of years, and is often planted in temple gardens.¹⁴¹⁵ This tree is valued not only for its resilience, but also for its therapeutic properties, which have been utilized in traditional medicine for centuries. In ancient China, Ginkgo biloba leaves have been used in medicinal practices to address respiratory disorders and improve blood circulation.¹⁴¹⁶

The use of G. biloba as medicine has been documented in various ancient medical texts. In traditional Chinese medicine, ginkgo leaves are often made into tea or liquid extracts for use as a tonic to improve blood flow and address digestive and respiratory issues. Over time, the use of G. biloba has spread to various cultures worldwide, including Japan and Korea, where it continues to be valued for its health benefits.¹⁴¹⁷

With advancements in pharmaceutical technology, G. biloba extracts have been formulated more efficiently to maximize their therapeutic benefits. The most commonly known standardized extract is EGb 761, which contains 24% flavonoid glycosides and 6% terpenoids. This formulation ensures consistency and product quality. The extract is used in various supplements including tablets, capsules, and liquids.¹⁴¹⁸

The usual dosage for G. biloba supplements is 40 mg three times a day or 80 mg twice a day, with a maximum dose not exceeding 240 mg/day. This dosage is based on research showing the effectiveness and safety of these doses in improving cognitive function and reducing the symptoms associated with cognitive disorders. Studies have also indicated that proper dosing can have significant effects without causing harmful side effects.¹⁴¹⁹

Ginkgo biloba has various complex mechanisms. One of the primary mechanisms is the enhancement of blood flow, especially to the brain, through its vasodilator effect. This helps improve oxygenation and nutrient delivery to brain cells, which in turn can enhance cognitive function. Additionally, G. biloba contains flavonoids and terpenoids with antioxidant properties, which help protect brain cells from oxidative damage caused by free radicals.

In addition to enhancing blood flow, flavonoids in G. biloba also have strong antioxidant effects. These antioxidants scavenge free radicals, which can damage cells and tissues in the body. On the other hand, terpenoids have anti-inflammatory properties that help reduce inflammation, which can cause tissue damage and cognitive disorders. The combination of antioxidant and anti-inflammatory effects makes G. biloba an effective therapeutic agent for protecting and improving brain function.

In the modern era, G. biloba has become the subject of various clinical studies investigating its effectiveness in various health conditions. One of the most prominent areas of research is its use in the treatment of dementia and mild cognitive impairment. Studies have shown that G. biloba extract can help improve memory, attention, and overall cognitive function in individuals with mild-to-moderate cognitive impairment.

Although G. biloba is generally considered safe, some side effects have been reported, including headache, dizziness, digestive issues, and allergic reactions. Therefore, it is important to follow the recommended dosage and consult with a healthcare professional before starting Ginkgo biloba supplements, especially for individuals who are taking other medications or have certain health conditions.

Some Ginkgo biloba products available on the market include Cereton, Cerviboost, Gingkan, Ginkgo Biloba Capsule, and GNC Ginkgo Biloba Plus. These products are available in various forms including tablets, capsules, and syrups. Each product typically lists the standardized content of G. biloba extract, making it easier for consumers to choose according to their needs.¹⁴¹⁹

Many clinical trials have investigated the effectiveness of G. biloba in various health conditions. These studies included diverse populations, including healthy individuals, patients with dementia, and individuals with mild cognitive impairment. Clinical trials have shown that G. biloba can help improve cognitive function and memory, as well as reduce symptoms of dementia and other cognitive disorders. Dosage standardization of G. biloba has also been carried out to ensure consistency and safety during its use.

Further research has shown that G. biloba can affect neurotransmitters in the brain. For instance, G. biloba extract has been found to increase serotonin and dopamine levels, which play key roles in mood regulation and cognitive function. This indicates that in addition to its vasodilator and antioxidant effects, G. biloba can also influence biochemical pathways in the brain that contribute to improved cognitive function.

Research has shown that G. biloba can provide significant benefits in high-risk populations, such as the elderly and individuals with a genetic predisposition to cognitive disorders. In these populations, the use of G. biloba has been associated with a slower rate of cognitive decline and an overall improvement in quality of life. This underscores the potential of G. biloba as an effective preventive intervention.¹⁴¹⁵

To ensure the quality and safety of G. biloba products, strict regulations have been established in many countries. Marketed products must meet specific standards regarding the content and purity of the G. biloba extract. This includes standards for the concentration of flavonoid glycosides and terpenoids as well as testing for contaminants that may be present in the final product.¹⁴¹⁷

Additionally, comparative studies between G. biloba and other cognitive agents, such as donepezil and memantine, have been conducted. These studies aimed to determine the relative effectiveness of G. biloba compared with more commonly used medications in the treatment of dementia and cognitive disorders. The results of these studies indicated that G. biloba has a unique benefit and risk profile, making it an attractive option for use in combination with other therapies.

Although many studies have shown the benefits of G. biloba, there are still challenges in terms of the research methodology and variability of results. Further research is needed to understand the precise mechanisms of action and to determine the optimal dosage for various populations and health conditions. Further efforts are required to enhance the regulation and standardization of Ginkgo biloba products in the global market.

Conclusions

In conclusion, G. biloba has great potential as a cognitive enhancer that can be used in various health conditions. Through extensive clinical trials and research, we gained a better understanding of the mechanisms of action, safe dosages, and potential benefits. A more integrated approach and stricter regulations will ensure that G. biloba can be used effectively and safely in practice.

Future research should focus on larger-scale clinical trials with better-designed studies to reduce bias and to improve the validity of the results. Further studies are needed to explore the potential use of G. biloba in combination with other therapies and to understand the long-term effects of its use.

Ethics and consent

Ethical approval and consent were not required.

Reporting guidelines

Figshare: PRISMA-ScR checklist and flow chart: Gingko Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus data Base. A bibliometric studi from 1988 to 2024,

DOI: 10.6084/m9.figshare.28081724 (https://doi.org/10.6084/m9.figshare.28081724.v1)¹⁴²⁰

The project contains the following reporting guidelines:

• PRISMA_2020_checklist_AYS
• PRISMA_2020_flow_diagram_new_AYS

The data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Software availability

VOSviewer software is an open-access tool that can be used as a cost-effective method for scientometric analysis Biblioshiny

Author Contribution

AYS conducted research, gathered data, performed statistical analysis, and produced discussions and conclusions, including TDS, RV, and DAYS editing.

Data availability statement

No Data Associated with this manuscript.

Extended data

Figshare: Gingko Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus data Base. A bibliometric studi from 1988 to 2024

DOI: 10.6084/m9.figshare.28081709 (https://doi.org/10.6084/m9.figshare.28081709.v1)¹⁴²⁰

This project contains the following underlying data:

• Density Visualization.jpg
• Documents by affiliation.jpg
• Documents by Author.jpg
• Documents by country or territory.jpg
• Documents by funding sponsor.jpg
• Documents by Subject Area.jpg
• Documents by Year.jpg
• Factorial Map Of The Documents With The Highest Contributes.png
• Factorial Map Of The most cited documents.png
• MostRelevantSources-2024-12-03.png
• Network Visualization.jpg
• Overlay Visualization of Scopus, Database Using Vosviewer.jpg
• tematic evolution berdasarkan title.jpg
• Thematic map.jpg
• Topic Dendogram.jpg
• Tabel 1 Qualitative analysis of the research summary of each abstract

The data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

References

1. Smith J: Ethical considerations in the use of cognitive enhancers. Neuroethics. 2020; 13(1): 45–58.
2. Brown A, Brown A, Green B: J. Neurosci. 2019; 2019(39): 123–135.
3. White R: Regulatory challenges in the development of cognitive enhancers. J. Law Med. 2018; 35(3): 201–210.
4. Johnson C: The impact of cognitive enhancers on academic performance: A meta-analysis. J. Educ. Psychol. 2021; 113(2): 234–245.
5. Porsolt RD, Lenègre A, Avril I, et al.: Antagonism by exifone, a new cognitive enhancing agent, of the amnesias induced by four benzodiazepines in mice. Psychopharmacology. 1988; 95(3): 291–297. Publisher Full Text
6. Groó D, Pálosi É, Szporny L: Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats. Drug Dev. Res. 1988; 15(1): 75–85. Publisher Full Text
7. Morè L, Privitera L, Lopes M, et al.: MSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF. Neuropharmacology. 2024; 261: 110110. PubMed Abstract | Publisher Full Text
8. Dorer CL, Manktelow AE, Allanson J, et al.: Methylphenidate-mediated motor control network enhancement in patients with traumatic brain injury. Brain Inj. 2018; 32(8): 1040–1049. PubMed Abstract | Publisher Full Text
9. Savulich G, Piercy T, Brühl AB, et al.: Focusing the Neuroscience and Societal Implications of Cognitive Enhancers. Clin. Pharmacol. Ther. 2017; 101(2): 170–172. Publisher Full Text
10. Passamonti L, Luijten M, Ziauddeen H, et al.: Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals. Psychopharmacology. 2017; 234(15): 2289–2297. PubMed Abstract | Publisher Full Text | Free Full Text
11. Kaser M, Deakin JB, Michael A, et al.: Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2017; 2(2): 115–122. PubMed Abstract | Publisher Full Text
12. d'Angelo LSC, Savulich G, Sahakian BJ: Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br. J. Pharmacol. 2017; 174(19): 3257–3267. PubMed Abstract | Publisher Full Text | Free Full Text
13. Lamoureux L, Beverley J, Steiner H, et al.: Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats. Neuropsychopharmacology. 2024; 49(6): 953–960. Publisher Full Text
14. Hrabak M, Ahmed R, Soriano MG, et al.: Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats. Mol. Neurobiol. 2024. Publisher Full Text
15. Thanos PK, McCarthy M, Senior D, et al.: Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior. Curr. Pharm. Biotechnol. 2023; 24(10): 1307–1314. PubMed Abstract | Publisher Full Text
16. Lamoureux L, Beverley JA, Marinelli M, et al.: Fluoxetine potentiates methylphenidate-induced behavioral responses: Enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. Addiction Neuroscience. 2023; 9: 100131. Publisher Full Text
17. Moon C, Marion M, Thanos PK, et al.: Fluoxetine Potentiates Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum. Mol. Neurobiol. 2021; 58(10): 4856–4870. PubMed Abstract | Publisher Full Text | Free Full Text
18. Thukham-Mee W, Wattanathorn J, Kirisattayakul W, et al.: Effect of Single Administration of Mulberry Milk on the Cognitive Function of 6-12-Year-Old Children: Results from a Randomized, Placebo-Controlled, Crossover Study. Oxidative Med. Cell. Longev. 2020; 2020: 1–10. PubMed Abstract | Publisher Full Text | Free Full Text
19. Muchimapura S, Thukhummee W, Wattanathorn J: Evaluation of the neuroprotective and cognitive enhancing effects of cucurbita moschata. J. Med. Assoc. Thail. 2020; 103(1): 105–112.
20. Wu M, Muchimapura S, Wattanathorn J, et al.: Mung bean-derived protein protects against neurodegeneration and memory impairment in animal model of menopause with obesity. J. Med. Assoc. Thail. 2019; 102(4): 43–51.
21. Ohnon W, Wattanathorn J, Thukham-Mee W, et al.: The combined extract of black sticky rice and dill improves poststroke cognitive impairment in metabolic syndrome condition. Oxidative Med. Cell. Longev. 2019; 2019: 1–19. Publisher Full Text
22. Wattanathorn J, Kirisattayakul W, Suriharn B, et al.: Functional Drink Containing the Extracts of Purple Corn Cob and Pandan Leaves, the Novel Cognitive Enhancer, Increases Spatial Memory and Hippocampal Neuron Density Through the Improvement of Extracellular Signal Regulated Protein Kinase Expression, Cholinergic Function, and Oxidative Status in Ovariectomized Rats. Rejuvenation Res. 2018; 21(5): 431–441. PubMed Abstract | Publisher Full Text
23. Dehbozorgi M, Fereidooni F, Bozorgmehr R, et al.: Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis. BMC Anesthesiol. 2024; 24(1): 256. PubMed Abstract | Publisher Full Text | Free Full Text
24. Chandra P, Sharma H: PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE. Indian Drugs. 2024; 61(7): 7–22. Publisher Full Text
25. Nesbit MO, Ahn S, Zou H, et al.: Potentiation of prefrontal cortex dopamine function by the novel cognitive enhancer d-govadine. Neuropharmacology. 2024; 246: 109849. PubMed Abstract | Publisher Full Text
26. Zhong X, Xu L, Wang L, et al.: Caffeine and modafinil modulate the effects of sleep deprivation on thalamic resting-state functional connectivity: A double-blind pilot study. Sleep Med. 2024; 122: 71–83. PubMed Abstract | Publisher Full Text
27. Loureiro JA, Andrade S, Ramalho MJ, et al.: Caffeine and beneficial cognitive effects. Tea in Health and Disease Prevention. 2024; 765–769. Publisher Full Text
28. Sharif S, Fergus S, Guirguis A, et al.: Exploring the understanding, source of availability and level of access of cognitive enhancers among university students in the United Arab Emirates: A qualitative study. Hum. Psychopharmacol. 2024; 39(1). Publisher Full Text
29. Jones F, Newton PM: Prevalence of the use of prescription stimulants as “study drugs” by UK university students: A brief report. Brain Behav. 2024; 14(2). Publisher Full Text
30. Bakota EL, Nandrea JM: Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements. Journal of Dietary Supplements. 2024; 22: 329–344. Publisher Full Text
31. Shehata SA, Kolieb E, Ali DA, et al.: Selenium alleviates modafinil-induced neurobehavioral toxicity in rat via PI3K/Akt/mTOR/GSK3B signaling pathway and suppression of oxidative stress and apoptosis: in vivo and in silico study. Environ. Sci. Pollut. Res. Int. 2024; 31(1): 458–480.
32. Cutsem JV, Pattyn N: Pharmacological Strategies to Improve Mental Performance. Handbook of Mental Performance: Lessons from High Performance Domains. 2024; 119–134. Publisher Full Text
33. Beveridge J, Söderström M, Prieto-Díaz R, et al.: Benzylhydroxamic acids as inhibitors of insulin regulated aminopeptidase (IRAP). European Journal of Medicinal Chemistry Reports. 2024; 12: 100215. Publisher Full Text
34. Gising J, Honarnejad S, Bras M, et al.: The Discovery of New Inhibitors of Insulin-Regulated Aminopeptidase by a High-Throughput Screening of 400,000 Drug-like Compounds. Int. J. Mol. Sci. 2024; 25(7). PubMed Abstract | Publisher Full Text | Free Full Text
35. Forsell P, Parrado Fernández C, Nilsson B, et al.: Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease. Pharmaceuticals. 2024; 17(8). PubMed Abstract | Publisher Full Text | Free Full Text
36. Lenoir H: Comment on “The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia”. Drugs Aging. 2024; 41(10): 859–861. PubMed Abstract | Publisher Full Text
37. DeMercy HM, Brenner CA: The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia. Drugs Aging. 2024; 41(10): 847–858. PubMed Abstract | Publisher Full Text | Free Full Text
38. Ebell MH: Cognitive Enhancers Significantly Improve Mini-Mental State Examination Score in Patients With Alzheimer Dementia. Am. Fam. Physician. 2024; 110(1): 91–92. PubMed Abstract
39. Fernandes D, Suryadevara U, Bruijnzeel D, et al.: Update on Cognitive Enhancers Among the Older Adult Population: A Clinical Review. Curr. Psychiatry Rep. 2024; 26(3): 73–77. PubMed Abstract | Publisher Full Text
40. Cohen CI, Reisberg B, Yaffee R: Global cognitive trajectory patterns in Alzheimer's disease. Int. Psychogeriatr. 2024; 36(3): 200–209. Publisher Full Text
41. Gharat R, Dixit G, Khambete M, et al.: Targets, trials and tribulations in Alzheimer therapeutics. Eur. J. Pharmacol. 2024; 962: 176230. PubMed Abstract | Publisher Full Text
42. Tan SY, Teo SP: Audit of Alzheimer’s disease management from a tertiary hospital in Brunei Darussalam. Palliative Medicine in Practice. 2024; 18(3): 133–138.
43. Portlock GE, Smith MD, van Poelgeest EP , et al.: Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults—a clinical review. European Geriatric Medicine. 2023; 14(4): 721–732. PubMed Abstract | Publisher Full Text | Free Full Text
44. Parrado Fernandez C, Juric S, Backlund M, et al.: Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. Int. J. Mol. Sci. 2023; 24(13). PubMed Abstract | Publisher Full Text | Free Full Text
45. Nakhostin-Khayyat M, Borjali M, Zeinali M, et al.: The relationship between self-regulation, cognitive flexibility, and resilience among students: a structural equation modeling. BMC Psychology. 2024; 12(1): 337. PubMed Abstract | Publisher Full Text | Free Full Text
46. Whitehurst LN, Morehouse A, Mednick SC: Can stimulants make you smarter, despite stealing your sleep?. Trends Cogn. Sci. 2024; 28(8): 702–713. PubMed Abstract | Publisher Full Text
47. Hartmann H, Forkmann K, Schmidt K, et al.: Open-label placebo treatment does not enhance cognitive abilities in healthy volunteers. Sci. Rep. 2023; 13(1): 19468. PubMed Abstract | Publisher Full Text | Free Full Text
48. Sharma K, Fallon SJ, Davis T, et al.: Preliminary evidence that caffeine improves attention in multiple sclerosis. Mult. Scler. Relat. Disord. 2022; 64: 103924. PubMed Abstract | Publisher Full Text
49. Das A, Brasseux S: Improvement in Memory Deficits with Memantine in Mania Secondary to Traumatic Brain Injury and Preexisting Perinatal Birth Injury. J. Psychiatr. Pract. 2021; 27(5): 390–394. PubMed Abstract | Publisher Full Text
50. Zhao WN, Ghosh B, Tyler M, et al.: Class i Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory. ACS Chem. Neurosci. 2018; 9(9): 2262–2273. PubMed Abstract | Publisher Full Text
51. Wu HF, Chen PS, Hsu YT, et al.: D-Cycloserine Ameliorates Autism-Like Deficits by Removing GluA2-Containing AMPA Receptors in a Valproic Acid-Induced Rat Model. Mol. Neurobiol. 2018; 55(6): 4811–4824. PubMed Abstract | Publisher Full Text
52. Portero-Tresserra M, Martí-Nicolovius M, Tarrés-Gatius M, et al.: Intra-hippocampal d-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats. Psychopharmacology. 2018; 235(5): 1463–1477. PubMed Abstract | Publisher Full Text
53. Fazio L, Pergola G, Papalino M, et al.: Transcriptomic context of DRD1 is associated with prefrontal activity and behavior during working memory. Proc. Natl. Acad. Sci. USA. 2018; 115(21): 5582–5587. PubMed Abstract | Publisher Full Text | Free Full Text
54. Kodama T, Kojima T, Honda Y, et al.: Oral administration of methylphenidate (Ritalin) affects dopamine release differentially between the prefrontal cortex and striatum: A microdialysis study in the monkey. J. Neurosci. 2017; 37(9): 2387–2394. PubMed Abstract | Publisher Full Text | Free Full Text
55. Bellebaum C, Kuchinke L, Roser P: Modafinil alters decision making based on feedback history - A randomized placebo-controlled double blind study in humans. J. Psychopharmacol. 2017; 31(2): 243–249. Publisher Full Text
56. Tse TJ, Chicilo F, Wiens DJ, et al.: Production of α-Glycerylphosphorylcholine in Fermented Roots, Tubers, and Fruits. Foods. 2024; 13(19). PubMed Abstract | Publisher Full Text | Free Full Text
57. Frankenfeld F, Wagmann L, Jacobs CM, et al.: Quantitative analysis of drugs of abuse and cognitive enhancers in influent wastewater by means of two chromatographic methods. Drug Test. Anal. 2024; 16(9): 893–902. Publisher Full Text
58. Frankenfeld F, Wagmann L, Jacobs CM, et al.: Prevalence of Drugs of Abuse and Cognitive Enhancer Consumption Monitored in Grab Samples and Composite Wastewater via Orbitrap Mass Spectrometry Analysis. Molecules. 2024; 29(16). PubMed Abstract | Publisher Full Text | Free Full Text
59. Hnin HM, Tun T, Jansook P: Development and validation of high-performance liquid chromatography method for the simultaneous quantification of rivastigmine hydrogen tartrate and asiaticoside co-loaded in niosomes: A Box–Behnken design approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2024; 1241: 124170. Publisher Full Text
60. Daher F, Villalobos NA, Hanley M, et al.: Basmisanil, an α5-GABAAR negative allosteric modulator, produces rapid and sustained antidepressant-like responses in male mice. Neurosci. Lett. 2024; 833: 137828. PubMed Abstract | Publisher Full Text | Free Full Text
61. Stepan J, Heinz DE, Dethloff F, et al.: Inhibiting Hippo pathway kinases releases WWC1 to promote AMPAR-dependent synaptic plasticity and long-term memory in mice. Sci. Signal. 2024; 17(834): eadj6603. PubMed Abstract | Publisher Full Text
62. Kim Y, Kim IH, See HJ, et al.: Immobilized Talaromyces leycettanus phospholipase A1 as a reusable biocatalyst for l-α-glycerylphosphorylcholine preparation from phosphatidylcholine. JAOCS, Journal of the American Oil Chemists' Society. 2024. Publisher Full Text
63. Twomey R, Young A, Clarke C: A case series of musical hallucinations in psychiatry of old age—in search of the sound of silence. Ir. J. Med. Sci. 2024; 193(5): 2427–2431. PubMed Abstract | Publisher Full Text
64. Aomine Y, Shimo Y, Sakurai K, et al.: Sex-dependent differences in the ability of nicotine to modulate discrimination learning and cognitive flexibility in mice. J. Neurochem. 2024.
65. Sheldon P, Mendez-Montejano J, Michalak AJ, et al.: Pharmacological Cognitive Enhancement Among International Medical Students: Assessing Study Habits as a Novel Factor. Medical Science Educator. 2024; 34: 1353–1360. PubMed Abstract | Publisher Full Text | Free Full Text
66. Fleetwood J, Chatwin C: Gender representations in online modafinil markets. Digital Transformations of Illicit Drug Markets: Reconfiguration and Continuity. 2023; 109–126. Publisher Full Text
67. Imran S, Ahmad W, Saltanat S: Therapeutic Evaluation of Unani Medicine, Including Single Drugs and Polyherbal Formulations with Special Reference to Neurodegenerative Disorders. Altern. Ther. Health Med. 2024; 30(9): 54–64.
68. Bouabdallah S, Ibrahim MH, Brinza I, et al.: Anxiolytic and Antidepressant Effects of Tribulus terrestris Ethanolic Extract in Scopolamine-Induced Amnesia in Zebrafish: Supported by Molecular Docking Investigation Targeting Monoamine Oxidase A. Pharmaceuticals. 2024; 17(9). Publisher Full Text
69. Kang S, Lee N, Jung B, et al.: Anti-Amnesic Effect of Agastache rugosa on Scopolamine-Induced Memory Impairment in Mice. Pharmaceuticals. 2024; 17(9). PubMed Abstract | Publisher Full Text | Free Full Text
70. Kolesnikova TO, Demin KA, Costa FV, et al.: Zebrafish models for studying cognitive enhancers. Neurosci. Biobehav. Rev. 2024; 164: 105797. PubMed Abstract | Publisher Full Text
71. Maher S, Donlon E, Mullane G, et al.: Treatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology. J. Clin. Med. 2024; 13(8). PubMed Abstract | Publisher Full Text | Free Full Text
72. Jia F, Shen X: Rejuvenation factor PF4: a potential gatekeeper for neurodegenerative diseases. Front. Aging Neurosci. 2024; 16. PubMed Abstract | Publisher Full Text | Free Full Text
73. Ming X, Fu L, Wang L: Biotechnological Enhancements in Micro learning: Integrating Chinese and Western Cultural English Vocabulary for Second Language Acquisition in the Context of Digital Health. J. Commer. Biotechnol. 2024; 29(3): 344–352.
74. Premachandran K, Wilson Alphonse CR, Soundharapandiyan N: Nourishing the Cognition with Millets: A Comprehensive Review of Their Nutritional Impact and Potential as Cognitive Enhancers. Mol. Nutr. Food Res. 2023; 67(24): e2300450. PubMed Abstract | Publisher Full Text
75. Bhavsar P, Shah P, Sinha S, et al.: Musical Neurofeedback Advancements, Feedback Modalities, and Applications: A Systematic Review. Appl. Psychophysiol. Biofeedback. 2024; 49(3): 347–363. PubMed Abstract | Publisher Full Text
76. Rastogi S, Farswan TS, Pandey MM: Seasonal variation in the phytoconstituents and antioxidant activity in Moringa oleifera Lam. leaves of North India. S. Afr. J. Bot. 2024; 166: 492–502. Publisher Full Text
77. Wooten T, Sansevere KS, Siqueira S, et al.: Evaluating the efficacy of cranial electrotherapy stimulation in mitigating anxiety-induced cognitive deficits. Int. J. Psychophysiol. 2024; 202: 112388. PubMed Abstract | Publisher Full Text
78. Rapp SR, Dressler EV, Brown WM, et al.: Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors after Adjuvant Chemotherapy (WF-97116). J. Clin. Oncol. 2024; 42(21): 2546–2557. PubMed Abstract | Publisher Full Text | Free Full Text
79. Ernyey AJ, Kassai F, Kozma K, et al.: Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP). GeroScience. 2024; 46(1): 417–429. PubMed Abstract | Publisher Full Text
80. Francotte P, Bay Y, Goffin E, et al.: Exploring thienothiadiazine dioxides as isosteric analogues of benzo- and pyridothiadiazine dioxides in the search of new AMPA and kainate receptor positive allosteric modulators. Eur. J. Med. Chem. 2024; 264: 116036. PubMed Abstract | Publisher Full Text
81. Frileux S, Boltri M, Doré J, et al.: Cognition and gut microbiota in schizophrenia spectrum and mood disorders: A systematic review. Neurosci. Biobehav. Rev. 2024; 162: 105722. Publisher Full Text
82. Nowrouzi S, Richelle L: The misuse of cognitive enhancers by medical students: a cross-sectional study using questionnaires. The British journal of general practice: the journal of the Royal College of General Practitioners. 2024; 74: bjgp24X737625. PubMed Abstract | Publisher Full Text
83. Ke T, Poquette KE, Amro Gazze SL, et al.: Amphetamine Exposure during Embryogenesis Alters Expression and Function of Tyrosine Hydroxylase and the Vesicular Monoamine Transporter in Adult C. elegans. Int. J. Mol. Sci. 2024; 25(8). Publisher Full Text
84. Zahavi E, Lev-Shalem L, Yehoshua I, et al.: Methylphenidate use and misuse among medical residents in Israel: a cross-sectional study. Hum. Resour. Health. 2023; 21(1): 5. PubMed Abstract | Publisher Full Text | Free Full Text
85. Bowman E, Coghill D, Murawski C, et al.: Not so smart? "Smart" drugs increase the level but decrease the quality of cognitive effort. Sci. Adv. 2023; 9(24). Publisher Full Text
86. Martin R, Buffenstein I, Cho D, et al.: Toxidrome of an Easily Obtainable Nootropic: A Case Report of Phenibut Intoxication and Withdrawal Delirium. J. Clin. Psychopharmacol. 2023; 43(6): 507–510. PubMed Abstract | Publisher Full Text
87. Mei D, Wang F, Yuan B, et al.: Cognitive Enhancer Donepezil Attenuates Heroin-Seeking Behavior Induced by Cues in Rats. J. Integr. Neurosci. 2023; 22(3). PubMed Abstract | Publisher Full Text
88. Medrano MC, Darlot F, Cador M, et al.: Poor inhibitory control predicts sex-specific vulnerability to nicotine rewarding properties in mice. Psychopharmacology. 2023; 240(9): 1973–1986. PubMed Abstract | Publisher Full Text
89. Shen W, Mei D, Liu Y, et al.: Cognitive Enhancers: What They Are and How They Are Used in Heroin Addiction. Handbook of Substance Misuse and Addictions: From Biology to Public Health. 2022; 1831–1849. Publisher Full Text
90. Coghill D: The Benefits and Limitations of Stimulants in Treating ADHD. Curr. Top. Behav. Neurosci. 2022; 57: 51–77. PubMed Abstract | Publisher Full Text
91. Garg S, Goel D, Krishna ST: Pharmacological management of behavioral and psychological symptoms of dementia: Brief review. Archives of Mental Health. 2022; 23(1): 67–71. Publisher Full Text
92. Kim ES, Lee A: Cognitive enhancers in healthy individuals have little benefit and significant potential harms. Drugs and Therapy Perspectives. 2023; 39(5): 187–190. Publisher Full Text
93. Merwid-Ląd A, Passon M, Drymluch P, et al.: Do Medical Universities Students Use Cognitive Enhancers while Learning?—Conclusions from the Study in Poland. Life. 2023; 13(3). PubMed Abstract | Publisher Full Text | Free Full Text
94. Jensen KL, Jensen SB, Madsen KL: A mechanistic overview of approaches for the treatment of psychostimulant dependence. Front. Pharmacol. 2022; 13. PubMed Abstract | Publisher Full Text | Free Full Text
95. Peterkin AF, Abraham R, Harris MTH: A Case of Phenibut Directed Detoxification Leading to Toxicity During the COVID-19 Pandemic. J. Addict. Med. 2022; 16(5): 602–605. PubMed Abstract | Publisher Full Text | Free Full Text
96. Jahangeer SMA, Hamdan M, Ansari US, et al.: Cognition improvement strategies, study behaviours and stress among medical students of Dow University of Health Sciences: A cross-sectional study. J. Pak. Med. Assoc. 2022; 72(7): 1363–1368.
97. Tomažič T, Čelofiga AK: The Role of Different Behavioral and Psychosocial Factors in the Context of Pharmaceutical Cognitive Enhancers’ Misuse. Healthcare (Switzerland). 2022; 10(6). Publisher Full Text
98. Flavell J: Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder. Australas. Psychiatry. 2021; 29(3): 366–367. Publisher Full Text
99. Deconinck E, Vanhee C, Keizers P, et al.: The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Test. Anal. 2021; 13(4): 833–840. PubMed Abstract | Publisher Full Text
100. Sharif S, Guirguis A, Fergus S, et al.: The use and impact of cognitive enhancers among university students: A systematic review. Brain Sci. 2021; 11(3). PubMed Abstract | Publisher Full Text | Free Full Text
101. Miranda M, Barbosa M: Use of cognitive enhancers by Portuguese medical students: Do academic challenges matter?. Acta Medica Portuguesa. 2021; 34(13).
102. Milić J, Zeković J, Stankić D, et al.: Cognition-enhancing drugs and applications to aging. Assessments, Treatments and Modeling in Aging and Neurological Disease: The Neuroscience of Aging. 2021; 367–378. Publisher Full Text
103. Urban KR, Gao WJ: Cognitive-Enhancing Substances and the Developing Brain: Risks and Benefits. Contemporary Clinical Neuroscience. 2021; 661–677. Publisher Full Text
104. Ram S, Russell BR, Stewart K, et al.: Psychiatrists’ attitudes towards and willingness to prescribe cognitive enhancers in academic settings. Drugs: Education, Prevention and Policy. 2021; 28(1): 59–66.
105. Ram S, Russell B, Kirkpatrick C, et al.: Professionals’ attitudes towards the use of cognitive enhancers in academic settings. PLoS ONE. 2020; 15(11 November): e0241968. PubMed Abstract | Publisher Full Text | Free Full Text
106. Kapur A: Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?. CNS Drugs. 2020; 34(10): 1045–1062. Publisher Full Text
107. Roberts CA, Jones A, Sumnall H, et al.: How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur. Neuropsychopharmacol. 2020; 38: 40–62. Publisher Full Text
108. Vas S, Casey JM, Schneider WT, et al.: Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington’s Disease. Neurotherapeutics. 2020; 17(3): 1075–1086. PubMed Abstract | Publisher Full Text | Free Full Text
109. Sousa A, Dinis-Oliveira RJ: Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst. Abus. 2020; 41(2): 155–173. PubMed Abstract | Publisher Full Text
110. Humby T, Smith GE, Small R, et al.: Effects of 5-HT2C, 5-HT1A receptor challenges and modafinil on the initiation and persistence of gambling behaviours. Psychopharmacology. 2020; 237(6): 1745–1756. PubMed Abstract | Publisher Full Text | Free Full Text
111. Hockenhull J, Wood DM, Dargan PI: The Availability of Modafinil and Methylphenidate Purchased from the Internet in the United Kingdom Without a Prescription. Subst. Use Misuse. 2020; 55(1): 56–65. PubMed Abstract | Publisher Full Text
112. Sagheddu C, Pintori N, Kalaba P, et al.: Neurophysiological and neurochemical effects of the putative cognitive enhancer (S)-CE-123 on mesocorticolimbic dopamine system. Biomolecules. 2020; 10(5). PubMed Abstract | Publisher Full Text | Free Full Text
113. Zaami S, Tagliabracci A, Berretta P, et al.: Use of Methylphenidate Analogues as Cognitive Enhancers: The Prelude to Cosmetic Neurology and an Ethical Issue. Front. Psych. 2020; 10: 10. Publisher Full Text
114. Tully JL, Forshaw M, Montgomery C, et al.: Afterword. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 175–179. Publisher Full Text
115. Cakic V: A Familiar Landscape in the Brave New World: Ethics of Cognitive Enhancement Introduction. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 135–173. Publisher Full Text
116. Wojszel ZB: Dementia diagnoses and treatment in geriatric ward patients: A cross-sectional study in poland. Clin. Interv. Aging. 2020; 15: 2183–2194. PubMed Abstract | Publisher Full Text | Free Full Text
117. Kredlow MA, Keshishian A, Oppenheimer S, et al.: The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis. J. Clin. Psychopharmacol. 2019; 39(5): 455–461. PubMed Abstract | Publisher Full Text
118. Steward A, Pickersgill M: Developing expertise, customising sleep, enhancing study practices: exploring the legitimisation of modafinil use within the accounts of UK undergraduate students. Drugs: Education, Prevention and Policy. 2019; 26(4): 347–355. PubMed Abstract | Publisher Full Text
119. Demiral ŞB, Tomasi D, Wiers CE, et al.: Methylphenidate’s effects on thalamic metabolism and functional connectivity in cannabis abusers and healthy controls. Neuropsychopharmacology. 2019; 44(8): 1389–1397. PubMed Abstract | Publisher Full Text | Free Full Text
120. Soobiah C, Tadrous M, Knowles S, et al.: Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer’s Dementia. PLoS ONE. 2019; 14(4): e0215225. PubMed Abstract | Publisher Full Text | Free Full Text
121. Salman T, Nawaz S, Waraich RS, et al.: Repeated administration of methylphenidate produces reinforcement and downregulates 5-HT-1A receptor expression in the nucleus accumbens. Life Sci. 2019; 218: 139–146. PubMed Abstract | Publisher Full Text
122. Rozenek EB, Górska M, Wilczyńska K, et al.: In search of optimal psychoactivation: Stimulants as cognitive performance enhancers. Arh. Hig. Rada Toksikol. 2019; 70(3): 150–159. PubMed Abstract | Publisher Full Text
123. Carlier J, Giorgetti R, Varì MR, et al.: Use of cognitive enhancers: Methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(1): 3–15.
124. Mousavi F, Shojaei P, Markeh HP: The use of cognitive enhancers among medical students. International Journal of High Risk Behaviors and Addiction. 2019; 8(2). Publisher Full Text
125. Pighi M, Pontoni G, Sinisi A, et al.: Use and propensity to use substances as cognitive enhancers in Italian medical students. Brain Sci. 2018; 8(11). PubMed Abstract | Publisher Full Text | Free Full Text
126. González B, Jayanthi S, Gomez N, et al.: Repeated methamphetamine and modafinil induce differential cognitive effects and specific histone acetylation and DNA methylation profiles in the mouse medial prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2018; 82: 1–11. PubMed Abstract | Publisher Full Text | Free Full Text
127. Dolder PC, Müller F, Schmid Y, et al.: Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology. 2018; 235(2): 467–479. PubMed Abstract | Publisher Full Text | Free Full Text
128. Major AJ, Vijayraghavan S, Everling S: Cholinergic overstimulation attenuates rule selectivity in macaque prefrontal cortex. J. Neurosci. 2018; 38(5): 1137–1150. PubMed Abstract | Publisher Full Text | Free Full Text
129. Franke AG, Dietz P, Ranft K, et al.: The Use of Pharmacologic Cognitive Enhancers in Competitive Chess. Epidemiology. 2017; 28(6): E57–e58. PubMed Abstract | Publisher Full Text
130. Urban KR, Gao WJ: Psychostimulants As Cognitive Enhancers in Adolescents: More Risk than Reward? Frontiers. Public Health. 2017; 5: 5. Publisher Full Text
131. Van Zyl PM, Joubert G, Fechter L, et al.: Methylphenidate use among students living in junior on-campus residences of the University of the Free State. S. Afr. Fam. Pract. 2017; 59(4): 123–127.
132. Corazza O, Bersani FS, Brunoro R, et al.: The diffusion of Performance and Image-Enhancing Drugs (PIEDs) on the internet: The abuse of the cognitive enhancer piracetam. Subst. Use Misuse. 2014; 49(14): 1849–1856. PubMed Abstract | Publisher Full Text
133. Carrozzo MM, Battisti UM, Cannazza G, et al.: Design, stereoselective synthesis, configurational stability and biological activity of 7-chloro-9-(furan-3-yl)-2,3,3a,4-tetrahydro-1H-benzo [e]pyrrolo[2,1- c][1,2,4] thiadiazine 5,5-dioxide. Bioorg. Med. Chem. 2014; 22(17): 4667–4676. PubMed Abstract | Publisher Full Text
134. Smits JAJ, Rosenfield D, Davis ML, et al.: Yohimbine enhancement of exposure therapy for social anxiety disorder: A randomized controlled trial. Biol. Psychiatry. 2014; 75(11): 840–846. PubMed Abstract | Publisher Full Text
135. Dafny N: The effect of brain augmenting drug Ritalin on animal behavior. Current Topics in Pharmacology. 2014; 18(1-2): 61–69.
136. Ku LJE, Pai MC: Use of cognitive enhancers and associated medical care costs among patients with dementia: A nationwide study in Taiwan. Int. Psychogeriatr. 2014; 26(5): 795–804. Publisher Full Text
137. Sattler S, Forlini C, Racine É, et al.: Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE. 2013; 8(8): e71452. PubMed Abstract | Publisher Full Text | Free Full Text
138. Goeldner C, Ballard TM, Knoflach F, et al.: Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 2013; 64: 337–346. PubMed Abstract | Publisher Full Text
139. Gould RW, Garg PK, Garg S, et al.: Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology. 2013; 64: 479–488. PubMed Abstract | Publisher Full Text | Free Full Text
140. Dresler M, Sandberg A, Ohla K, et al.: Non-pharmacological cognitive enhancement. Neuropharmacology. 2013; 64: 529–543. Publisher Full Text
141. Pang TYC, Hannan AJ: Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity. Neuropharmacology. 2013; 64: 515–528. Publisher Full Text
142. Bidwell LC, McClernon FJ, Kollins SH: Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 2011; 99(2): 262–274. PubMed Abstract | Publisher Full Text | Free Full Text
143. Kantak KM, Hofmann SG: Cognitive enhancers for the treatment of neuropsychiatric disorders: Clinical and preclinical investigations. Pharmacol. Biochem. Behav. 2011; 99(2): 113–115. PubMed Abstract | Publisher Full Text
144. Hofmann SG, Smits JAJ, Asnaani A, et al.: Cognitive enhancers for anxiety disorders. Pharmacol. Biochem. Behav. 2011; 99(2): 275–284. PubMed Abstract | Publisher Full Text | Free Full Text
145. Kaplan GB, Moore KA: The use of cognitive enhancers in animal models of fear extinction. Pharmacol. Biochem. Behav. 2011; 99(2): 217–228. PubMed Abstract | Publisher Full Text
146. Byrne SP, Farrell LJ, Rapee RM: Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D-cycloserine to augment exposure for child anxiety. Clin. Psychol. 2011; 15(1): 1–9. Publisher Full Text
147. Van Waes V, Beverley J, Marinelli M, et al.: Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur. J. Neurosci. 2010; 32(3): 435–447. PubMed Abstract | Publisher Full Text | Free Full Text
148. Steiner H, Van Waes V, Marinelli M: Fluoxetine Potentiates Methylphenidate-Induced Gene Regulation in Addiction-Related Brain Regions: Concerns for Use of Cognitive Enhancers?. Biol. Psychiatry. 2010; 67(6): 592–594. PubMed Abstract | Publisher Full Text | Free Full Text
149. Singer P, Feldon J, Yee BK: Interference of glycine transporter 1: Modulation of cognitive functions via activation of glycine-B site of the NMDA receptor. Cent. Nerv. Syst. Agents Med. Chem. 2007; 7(4): 259–268. Publisher Full Text
150. Saxena G, Singh SP, Pal R, et al.: Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol. Biochem. Behav. 2007; 86(4): 797–805. PubMed Abstract | Publisher Full Text
151. Wang C, Zhang T, Ma H, et al.: Prolonged effects of poly (lactic-co-glycolic acid) microsphere-containing huperzine A on mouse memory dysfunction induced by scopolamine. Basic Clin. Pharmacol. Toxicol. 2007; 100(3): 190–195. Publisher Full Text
152. Waight JL, Arias N, Jiménez-García AM, et al.: From functional neuroimaging to neurostimulation: fNIRS devices as cognitive enhancers. Behav. Res. Methods. 2024; 56(3): 2227–2242.
153. Tsotsokou G, Kouri V, Papatheodoropoulos C: α7 nicotinic acetylcholine receptors induce long-term synaptic enhancement in the dorsal but not ventral hippocampus. Synapse. 2024; 78(1). Publisher Full Text
154. Ertosun GB, Ergen M, Bardakci H, et al.: Cholinergic cognitive enhancer effect of Salvia triloba L. essential oil inhalation in rats. Marmara Medical Journal. 2023; 36(3): 361–370. Publisher Full Text
155. Gaiardo RB, Pedroso AP, Ribeiro EB, et al.: Proteome Analysis Indicates Participation of the Dorsal Hippocampal Formation in Fear-Motivated Memory in a Time-Dependent Manner. Behav. Neurosci. 2023; 137(5): 303–318. PubMed Abstract | Publisher Full Text
156. Gligorov N: NOT EXTENDED, BUT ENHANCED: Internal improvements to cognition and the maintenance of cognitive agency. The Routledge Handbook of the Ethics of Human Enhancement. 2023; p. 214–23. Publisher Full Text
157. Yelanchezian YMM, Waldvogel HJ, Faull RLM, et al.: Neuroprotective Effect of Caffeine in Alzheimer’s Disease. Molecules. 2022; 27(12). PubMed Abstract | Publisher Full Text | Free Full Text
158. Satoh R, Kawakami K, Nakadate K: Effects of Smart Drugs on Cholinergic System and Non-Neuronal Acetylcholine in the Mouse Hippocampus: Histopathological Approach. J. Clin. Med. 2022; 11(12). PubMed Abstract | Publisher Full Text | Free Full Text
159. Hayes LJ, Bays RB, Arthur S, et al.: Predictors of Attitudes Toward Pharmacological Cognitive Enhancers in College Students. Emerg. Adulthood. 2022; 10(3): 609–619. Publisher Full Text
160. Sharif S, Fergus S, Guirguis A, et al.: Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. PLoS ONE. 2022; 17(1 January): e0262704. PubMed Abstract | Publisher Full Text | Free Full Text
161. Ang YS, Cusin C, Petibon Y, et al.: A multi-pronged investigation of option generation using depression, PET and modafinil. Brain. 2022; 145(5): 1854–1865. PubMed Abstract | Publisher Full Text | Free Full Text
162. Gaillard C, Lago TR, Gorka AX, et al.: Methylphenidate modulates interactions of anxiety with cognition. Transl. Psychiatry. 2021; 11(1): 544. PubMed Abstract | Publisher Full Text | Free Full Text
163. Salman T, Afroz R, Nawaz S, et al.: Differential effects of memory enhancing and impairing doses of methylphenidate on serotonin metabolism and 5-HT1A, GABA, glutamate receptor expression in the rat prefrontal cortex. Biochimie. 2021; 191: 51–61. PubMed Abstract | Publisher Full Text
164. Devanand DP, Liu X, Cohen H, et al.: Long-Term Test-Retest Reliability of the UPSIT in Cognitively Intact Older Adults. Chem. Senses. 2019; 44(6): 365–369. PubMed Abstract | Publisher Full Text | Free Full Text
165. Veroniki AA, Bender R, Glasziou P, et al.: The number needed to treat in pairwise and network meta-analysis and its graphical representation. J. Clin. Epidemiol. 2019; 111: 11–22. PubMed Abstract | Publisher Full Text
166. Motaghinejad M, Safari S, Feizipour S, et al.: Crocin may be useful to prevent or treatment of alcohol induced neurodegeneration and neurobehavioral sequels via modulation of CREB/BDNF and Akt/GSK signaling pathway. Med. Hypotheses. 2019; 124: 21–25. PubMed Abstract | Publisher Full Text
167. McGregor G, Harvey J: Leptin Regulation of Synaptic Function at Hippocampal TA-CA1 and SC-CA1 Synapses: Implications for Health and Disease. Neurochem. Res. 2019; 44(3): 650–660. PubMed Abstract | Publisher Full Text | Free Full Text
168. Chang EH, Chavan SS, Pavlov VA: Cholinergic control of inflammation, metabolic dysfunction, and cognitive impairment in obesity-associated disorders: Mechanisms and novel therapeutic opportunities. Front. Neurosci. 2019; 13(APR). Publisher Full Text
169. Dubljević V: Are There Problems with the Economic Disincentives Model of Regulation?. International Library of Ethics, Law and Technology. 2019; 19: 109–122. Publisher Full Text
170. Woźniak-Karczewska M, Čvančarová M, Chrzanowski Ł, et al.: Isolation of two Ochrobactrum sp. strains capable of degrading the nootropic drug—Piracetam. New Biotechnol. 2018; 43: 37–43. Publisher Full Text
171. Dolder PC, Strajhar P, Vizeli P, et al.: Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects. Psychopharmacology. 2018; 235(5): 1389–1402. Publisher Full Text
172. Van Duinen MA, Sambeth A, Heckman PRA, et al.: Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology. 2018; 131: 31–38. PubMed Abstract | Publisher Full Text
173. Chierrito TPC, Pedersoli-Mantoani S, Roca C, et al.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 2018; 145: 431–444. PubMed Abstract | Publisher Full Text
174. Brolin E, Johansson J, Zelleroth S, et al.: The mRNA expression of insulin-like growth factor-1 (Igf1) is decreased in the rat frontal cortex following gamma-hydroxybutyrate (GHB) administration. Neurosci. Lett. 2017; 646: 15–20. PubMed Abstract | Publisher Full Text
175. Dowling G, Kavanagh PV, Talbot B, et al.: Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog. Drug Test. Anal. 2017; 9(3): 518–528. PubMed Abstract | Publisher Full Text
176. Shoaib M, Hall FS: Preclinical Models of Nicotine Withdrawal: Targeting Impaired Cognition. Negative Affective States and Cognitive Impairments in Nicotine Dependence. 2017; 37–52. Publisher Full Text
177. Cavallo M, Signorino A, Perucchini ML: Benefits of Cognitive Treatments Administered to Patients Affected by Mild Cognitive Impairment/Mild Neurocognitive Disorder. Drug Dev. Res. 2016; 77(8): 444–452. PubMed Abstract | Publisher Full Text
178. Deguil J, Ravasi L, Lanteaume L, et al.: Translational challenge models in support of efficacy studies: Effect of cerebral hypoxia on cognitive performances in rodents. CNS Neurol. Disord. Drug Targets. 2016; 15(7): 765–776. PubMed Abstract | Publisher Full Text
179. Benn A, Barker GRI, Stuart SA, et al.: Optogenetic stimulation of prefrontal glutamatergic neurons enhances recognition memory. J. Neurosci. 2016; 36(18): 4930–4939. Publisher Full Text
180. Diwakarla S, Nylander E, Grönbladh A, et al.: Binding to and inhibition of insulin-regulated aminopeptidase by macrocyclic disulfides enhances spine density. Mol. Pharmacol. 2016; 89(4): 413–424. PubMed Abstract | Publisher Full Text
181. Veroniki AA, Straus SE, Ashoor H, et al.: Contacting authors to retrieve individual patient data: Study protocol for a randomized controlled trial. Trials. 2016; 17(1): 138. PubMed Abstract | Publisher Full Text | Free Full Text
182. Martinez-Ramirez D, Giugni JC, Almeida L, et al.: Association between antidepressants and falls in Parkinson’s disease. J. Neurol. 2016; 263(1): 76–82. PubMed Abstract | Publisher Full Text
183. Robitsek J, Ratner MH, Stewart T, et al.: Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus. Hippocampus. 2015; 25(12): 1541–1555. PubMed Abstract | Publisher Full Text | Free Full Text
184. Dubljević V, Ryan CJ: Cognitive enhancement with methylphenidate and modafinil: Conceptual advances and societal implications. Neurosci. Neuroecon. 2015; 4: 25–33.
185. Baroni A, Castellanos FX: Stimulants, cognition and ADHD. Curr. Opin. Behav. Sci. 2015; 4: 109–114. Publisher Full Text
186. Jellen LC, Aliper A, Buzdin A, et al.: Screening and personalizing nootropic drugs and cognitive modulator regimens in silico. Front. Syst. Neurosci. 2015; 9(FEB). PubMed Abstract | Publisher Full Text | Free Full Text
187. Hermans SJ, Ascher DB, Hancock NC, et al.: Crystal structure of human insulin-regulated aminopeptidase with specificity for cyclic peptides. Protein Sci. 2015; 24(2): 190–199. Publisher Full Text
188. Jotterand F, McCurdy JL, Elger B: Cognitive Enhancers and Mental Impairment: Emerging Ethical Issues. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. Fifth Edition2014; p. 119–26. Publisher Full Text
189. Smith CC, Gibbs TT, Farb DH: Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology. 2014; 231(17): 3537–3556. PubMed Abstract | Publisher Full Text | Free Full Text
190. Wade L, Forlini C, Racine E: Generating genius: How an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals. BMC Med. Ethics. 2014; 15(1). PubMed Abstract | Publisher Full Text | Free Full Text
191. Micoulaud-Franchi JA, Macgregor A, Fond G: A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(13): 1875–1878. PubMed Abstract
192. Pereira LM, Bastos CP, de Souza JM , et al.: Estradiol enhances object recognition memory in Swiss female mice by activating hippocampal estrogen receptor α. Neurobiol. Learn. Mem. 2014; 114: 1–9. PubMed Abstract | Publisher Full Text
193. Potier MC, Braudeau J, Dauphinot L, et al.: Reducing Gabaergic inhibition restores cognitive functions in a mouse model of down syndrome. CNS Neurol. Disord. Drug Targets. 2014; 13(1): 8–15. PubMed Abstract | Publisher Full Text
194. Zhang MZ, Zhou ZZ, Yuan X, et al.: Chlorbipram: A novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer. Eur. J. Pharmacol. 2013; 721(1-3): 56–63. PubMed Abstract | Publisher Full Text
195. Borbély T, Scheich B, Helyes Z: Neuropeptides in learning and memory. Neuropeptides. 2013; 47(6): 439–450. Publisher Full Text
196. Harvey J: Leptin regulation of neuronal morphology and hippocampal synaptic function. Frontiers in Synaptic Neuroscience. 2013; 5(AUG). PubMed Abstract | Publisher Full Text | Free Full Text
197. Laws KR, Sweetnam H, Kondel TK: Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis. Hum. Psychopharmacol. 2012; 27(6): 527–533. PubMed Abstract | Publisher Full Text
198. Stepan J, Dine J, Fenzl T, et al.: Entorhinal theta-frequency input to the dentate gyrus trisynaptically evokes hippocampal CA1 LTP. Frontiers in Neural Circuits. 2012; 6(SEPTEMBER). PubMed Abstract | Publisher Full Text | Free Full Text
199. Andersson RH, Johnston A, Herman PA, et al.: Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc. Natl. Acad. Sci. USA. 2012; 109(32): 13118–13123. PubMed Abstract | Publisher Full Text | Free Full Text
200. Steckler T, Risbrough V: Pharmacological treatment of PTSD - Established and new approaches. Neuropharmacology. 2012; 62(2): 617–627. PubMed Abstract | Publisher Full Text | Free Full Text
201. Wattanathorn J, Muchimapura S, Thukhammee W, et al.: Mulberry fruits protects against age-related cognitive decline. Am. J. Appl. Sci. 2012; 9(9): 1503–1511.
202. Saenghong N, Wattanathorn J, Tong-Un T, et al.: Ginger supplementation enhances working memory of the post-menopause women. Am. J. Appl. Sci. 2011; 8(12): 1241–1248. Publisher Full Text
203. Yamaguchi Y, Saito K, Matsuno T, et al.: Effects of ZSET1446/ST101 on cognitive deficits and amyloid β deposition in the senescence accelerated prone mouse brain. J. Pharmacol. Sci. 2012; 119(2): 160–166. Publisher Full Text
204. Modi ME, Young LJ: D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol. Psychiatry. 2011; 70(3): 298–304. Publisher Full Text
205. Chen Z, Zhao Y, Yang Y, et al.: Leptin withdrawal after birth: A neglected factor account for cognitive deficit in offspring of GDM mother. Med. Hypotheses. 2011; 77(1): 125–127. PubMed Abstract | Publisher Full Text
206. Urani A, Philbert J, Cohen C, et al.: The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. Pharmacol. Biochem. Behav. 2011; 98(3): 425–431. PubMed Abstract | Publisher Full Text
207. Subramanian L, Hindle JV, Jackson MC, et al.: Dopamine boosts memory for angry faces in Parkinson's disease. Mov. Disord. 2010; 25(16): 2792–2799. PubMed Abstract | Publisher Full Text
208. Homayoun H, Moghaddam B: Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition. Eur. J. Pharmacol. 2010; 639(1-3): 33–39. PubMed Abstract | Publisher Full Text
209. Francotte P, Goffin E, Fraikin P, et al.: New Fluorinated 1,2,4-Benzothiadiazine 1,1-Dioxides: Discovery of an Orally Active Cognitive Enhancer Acting through Potentiation of the 2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic Acid Receptors. J. Med. Chem. 2010; 53(4): 1700–1711. Publisher Full Text
210. Montgomery KE, Kessler M, Arai AC: Modulation of agonist binding to AMPA receptors by 1-(1,4-benzodioxan-6- ylcarbonyl) piperidine (CX546): Differential effects across brain regions and GluA1-4/transmembrane AMPA receptor regulatory protein combinations. J. Pharmacol. Exp. Ther. 2009; 331(3): 965–974. PubMed Abstract | Publisher Full Text | Free Full Text
211. Detrait ERAY, Hanon E, Dardenne B, et al.: The inhibitory avoidance test optimized for discovery of cognitive enhancers. Behav. Res. Methods. 2009; 41(3): 805–811. PubMed Abstract | Publisher Full Text
212. Ballard TM, Knoflach F, Prinssen E, et al.: RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors. Psychopharmacology. 2009; 202(1-3): 207–223. PubMed Abstract | Publisher Full Text
213. Tsaltas E, Kontis D, Boulougouris V, et al.: Lithium and cognitive enhancement: Leave it or take it?. Psychopharmacology. 2009; 202(1-3): 457–476. Publisher Full Text
214. Fisher A: M1 muscarinic agonists target major hallmarks of Alzheimer's disease - The pivotal role of brain M1 receptors. Neurodegener. Dis. 2008; 5: 237–240. Publisher Full Text
215. Yamada K, Sawada H, Nishii K, et al.: Expression levels of Egr-1 and Nur77 proteins in mouse brain are increased by withdrawal of nicotine. Biogenic Amines. 2007; 21(4): 183–194.
216. Arushanyan EB, Beier EV: Hippocampus: A target for cognition enhancers. Eksperimental'naya i Klinicheskaya Farmakologiya. 2007; 70(4): 59–65.
217. Franz CE, Barker JC, Kravitz RL, et al.: Nonmedical influences on the use of cholinesterase inhibitors in dementia care. Alzheimer Dis. Assoc. Disord. 2007; 21(3): 241–248. PubMed Abstract | Publisher Full Text
218. Bromley E: Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia. Psychiatr. Serv. 2007; 58(4): 475–481. PubMed Abstract | Publisher Full Text
219. Bowie CR, Harvey PD: Treatment of cognitive deficits in schizophrenia. Curr. Opin. Investig. Drugs. 2006; 7(7): 608–613. PubMed Abstract
220. Harvey J, Shanley LJ, O'Malley D, et al.: Leptin: A potential cognitive enhancer?. Biochem. Soc. Trans. 2005; 33(5): 1029–1032. PubMed Abstract | Publisher Full Text
221. Fowler JH, Whalley K, Murray T, et al.: The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J. Cereb. Blood Flow Metab. 2004; 24(10): 1098–1109. PubMed Abstract | Publisher Full Text
222. Lynch G: AMPA receptor modulators as cognitive enhancers. Curr. Opin. Pharmacol. 2004; 4(1): 4–11. Publisher Full Text
223. Stromme Johannesen T, Myhrer T: Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat. Eur. J. Pharmacol. 2002; 437(1-2): 73–77. PubMed Abstract | Publisher Full Text
224. Soares JM, Barbosa M: The use of pharmacological and non-pharmacological cognitive enhancers in the Portuguese population. Performance Enhancement and Health. 2024; 12(1): 100274. Publisher Full Text
225. Guthrie OW, Yang L: Oral intake of carboxy alkyl ester improves attention: A randomized double-blind cross-over placebo-controlled study. Hum. Psychopharmacol. 2023; 38(6): e2885. PubMed Abstract | Publisher Full Text
226. Phogat J, Bali A, Kapoor N: Smart drugs in cognitive disorders. Applications of Synthetic Biology in Health, Energy, and Environment. 2023; 188–211. Publisher Full Text
227. Theleritis C, Siarkos K, Politis A, et al.: A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders. Brain Sci. 2023; 13(7). PubMed Abstract | Publisher Full Text | Free Full Text
228. Soliani AG, Muratori BG, dos Santos AL , et al.: Standardized extract of Ginkgo biloba enhances memory persistence over time. Phytomedicine Plus. 2023; 3(2): 100441. Publisher Full Text
229. Vinarskaya AK, Zuzina AB, Balaban PM: Histone acetylation increase rescues a weak remote fear memory in rats. Genes Cells. 2023; 18(4): 739–741. Publisher Full Text
230. Goffin E, Fraikin P, Abboud D, et al.: New insights in the development of positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides: Introduction of (mono/difluoro) methyl groups at the 2-position of the thiadiazine ring. Eur. J. Med. Chem. 2023; 250: 115221. Publisher Full Text
231. Lane HY, Wang SH, Lin CH: Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease. Psychiatry Clin. Neurosci. 2023; 77(2): 102–109. PubMed Abstract | Publisher Full Text | Free Full Text
232. Malík M, Tlustoš P: Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients. 2022; 14(16). PubMed Abstract | Publisher Full Text | Free Full Text
233. Wei J, Sinnott SM: Harms and benefits of non-medical methylphenidate use among young adults: a scoping review of the literature. J. Subst. Abus. 2023; 1–6. Publisher Full Text
234. Meshkat S, Tello-Gerez TJ, Gholaminezhad F, et al.: Impact of psilocybin on cognitive function: A systematic review. Psychiatry Clin. Neurosci. 2024; 78: 744–764. PubMed Abstract | Publisher Full Text | Free Full Text
235. Rogawski MA: A New SV2A Ligand for Epilepsy. Cell. 2016; 167(3): 587. PubMed Abstract | Publisher Full Text
236. Ghisoni K, Aguiar AS, de Oliveira PA , et al.: Neopterin acts as an endogenous cognitive enhancer. Brain Behav. Immun. 2016; 56: 156–164. PubMed Abstract | Publisher Full Text
237. Ahmad N, Lesa KN, Ujiantari NSO, et al.: Development of White Cabbage, Coffee, and Red Onion Extracts as Natural Phosphodiesterase-4B (PDE4B) Inhibitors for Cognitive Dysfunction: in vitro and in Silico Studies. Advances in Pharmacological and Pharmaceutical Sciences. 2024; 2024: 1–39. PubMed Abstract | Publisher Full Text | Free Full Text
238. Yechiam E: Behavioral economics enhancers. Judgm. Decis. Mak. 2024; 19: 19. Publisher Full Text
239. Sagheddu C, Cancedda E, Bagheri F, et al.: The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study. Int. J. Neuropsychopharmacol. 2023; 26(11): 784–795. Publisher Full Text
240. Remok F, Saidi S, Gourich AA, et al.: Phenolic Content, Antioxidant, Antibacterial, Antihyperglycemic, and α-Amylase Inhibitory Activities of Aqueous Extract of Salvia lavandulifolia Vahl. Pharmaceuticals. 2023; 16(3). Publisher Full Text
241. Stazi M, Zampar S, Klafki HW, et al.: A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model. Int. J. Mol. Sci. 2023; 24(3). PubMed Abstract | Publisher Full Text | Free Full Text
242. Stazi M, Zampar S, Nadolny M, et al.: Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice. Eur. Arch. Psychiatry Clin. Neurosci. 2023; 273(1): 269–281. Publisher Full Text
243. Ott K, Heikkinen T, Lehtimäki KK, et al.: Vertigoheel promotes rodent cognitive performance in multiple memory tests. Front. Neurosci. 2023; 17. PubMed Abstract | Publisher Full Text | Free Full Text
244. Kolesnikova TO, Galstyan DS, Demin KA, et al.: Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish. J. Psychopharmacol. 2022; 36(7): 892–902. PubMed Abstract | Publisher Full Text
245. Shikanai H, Matsuzaki H, Kasai R, et al.: 5-HT Neural System Abnormalities in PTSD Model Rats. NeuroMethods. 2023; 198: 203–213.
246. De Ridder M, Mograbi D, Wolmarans DW: Spontaneous alternation and stereotypical behaviour in deer mice: Response to escitalopram and levetiracetam. Behav. Pharmacol. 2022; 33(4): 282–290. Publisher Full Text
247. Mani V: Piracetam-induced neuroprotection in lipopolysaccharides-challenged EOC-20 cells and mouse brain via attenuating oxidative stress. Braz. J. Pharm. Sci. 2022; 58: 58. Publisher Full Text
248. Kassai F, Ernyey AJ, Kozma K, et al.: Lack of general learning ability factor in a rat test battery measuring a wide spectrum of cognitive domains. J. Integr. Neurosci. 2022; 21(1). Publisher Full Text
249. Ip FCF, Fu G, Yang F, et al.: A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice. Eur. J. Med. Chem. 2021; 226: 113827. PubMed Abstract | Publisher Full Text
250. Shepherd A, Zhang T, Hoffmann LB, et al.: A Preclinical Model of Computerized Cognitive Training: Touchscreen Cognitive Testing Enhances Cognition and Hippocampal Cellular Plasticity in Wildtype and Alzheimer’s Disease Mice. Front. Behav. Neurosci. 2021; 15. PubMed Abstract | Publisher Full Text | Free Full Text
251. Batabyal A, Lukowiak K: Configural learning memory can be transformed from intermediate-term to long-term in pond snail Lymnaea stagnalis. Physiol. Behav. 2021; 239: 113509. Publisher Full Text
252. Mistarz N, Andersen K, Nielsen AS, et al.: Pharmacological enhancing agents targeting cognition in patients with alcohol-induced neurocognitive disorders: A systematic review. Neurosci. Biobehav. Rev. 2021; 125: 608–626. PubMed Abstract | Publisher Full Text
253. Nelson M, Jensen C, Lenton S: Study drug use among university students in Western Australia: Results of a web survey and their policy and practice implications. Drug Alcohol Rev. 2021; 40(4): 530–539. Publisher Full Text
254. Damiri B, Khatib O, Nazzal Z, et al.: Metabolic syndrome associated with tobacco and caffeine products use among refugee adolescents: Risk of dyslipidemia. Diabetes, Metabolic Syndrome and Obesity. 2021; 14: 4121–4133. PubMed Abstract | Publisher Full Text | Free Full Text
255. Gyertyán I, Kassai F, Kozma K, et al.: Procognitive profiling of a serotonin 5-HT6 receptor antagonist in a complex model system in rats: A novel translational approach for clinical prediction. Brain Res. Bull. 2020; 165: 238–245. Publisher Full Text
256. Fakhrudin N, Nurrochmad A, Sudarmanto A, et al.: Wood is a potential source of natural phosphodiesterase-1 inhibitors. Pharm. J. 2020; 12(6): 1206–1217.
257. Sainz I, Collado-Mateo D, Coso JD: Effect of acute caffeine intake on hit accuracy and reaction time in professional e-sports players. Physiol. Behav. 2020; 224: 113031. PubMed Abstract | Publisher Full Text
258. Hoffman JR, Markus I, Dubnov-Raz G, et al.: Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women. J. Strength Cond. Res. 2020; 34(9): 2476–2481. PubMed Abstract | Publisher Full Text
259. Gyertyán I: How can preclinical cognitive research further neuropsychiatric drug discovery? Chances and challenges. Expert Opin. Drug Discov. 2020; 15(6): 659–670. PubMed Abstract | Publisher Full Text
260. Zuccarello E, Acquarone E, Calcagno E, et al.: Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. Biochem. Pharmacol. 2020; 176: 113818. Publisher Full Text
261. Baek JH, Jung S, Son H, et al.: Glutamine supplementation prevents chronic stress-induced mild cognitive impairment. Nutrients. 2020; 12(4). PubMed Abstract | Publisher Full Text | Free Full Text
262. Balkrishna A, Thakur P, Varshney A: Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies. Front. Pharmacol. 2020; 11. PubMed Abstract | Publisher Full Text | Free Full Text
263. Kusturica J, Hajdarević A, Nikšić H, et al.: Neuroenhancing Substances Use, Exam Anxiety and Academic Performance in Bosnian-Herzegovinian First-Year University Students. Acta medica academica. 2019; 48(3): 286–293. PubMed Abstract | Publisher Full Text
264. Yabuki Y, Wu L, Fukunaga K: Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway. J. Pharmacol. Sci. 2019; 140(3): 263–272. Publisher Full Text
265. London-Nadeau K, Chan P, Wood S: Building Conceptions of Cognitive Enhancement: University Students’ Views on the Effects of Pharmacological Cognitive Enhancers. Subst. Use Misuse. 2019; 54(6): 908–920. PubMed Abstract | Publisher Full Text
266. Tomažič T, Čelofiga AK: Ethical aspects of the abuse of pharmaceutical enhancements by healthy people in the context of improving cognitive functions. Philos. Ethics Humanit. Med. 2019; 14(1): 7. PubMed Abstract | Publisher Full Text | Free Full Text
267. Kozma K, Kassai F, Ernyey AJ, et al.: Establishment of a rodent cooperation assay as a model of social cognition. J. Pharmacol. Toxicol. Methods. 2019; 97: 44–51. Publisher Full Text
268. Ram SS, Hussainy S, Henning M, et al.: Cognitive Enhancers (CE) and Learning Strategies. J. Cogn. Enhanc. 2019; 3(1): 124–130. Publisher Full Text
269. Burk JA, Maness EB, Blumenthal SA, et al.: Orexins and cognition: Neuroanatomical and neurochemical substrates. The Orexin/Hypocretin System: Functional Roles and Therapeutic Potential. 2019; 139–153. Publisher Full Text
270. Michael T, Schanz CG, Mattheus HK, et al.: Do adjuvant interventions improve treatment outcome in adult patients with posttraumatic stress disorder receiving trauma-focused psychotherapy? A systematic review. Eur. J. Psychotraumatol. 2019; 10(1). PubMed Abstract | Publisher Full Text | Free Full Text
271. Noble LJ, Meruva VB, Hays SA, et al.: Vagus nerve stimulation promotes generalization of conditioned fear extinction and reduces anxiety in rats. Brain Stimul. 2019; 12(1): 9–18. PubMed Abstract | Publisher Full Text | Free Full Text
272. Chung SW, Rogasch NC, Hoy KE, et al.: The effect of single and repeated prefrontal intermittent theta burst stimulation on cortical reactivity and working memory. Brain Stimul. 2018; 11(3): 566–574. Publisher Full Text
273. Waterhouse U, Brennan KA, Ellenbroek BA: Nicotine self-administration reverses cognitive deficits in a rat model for schizophrenia. Addict. Biol. 2018; 23(2): 620–630. Publisher Full Text
274. Machek SB, Bagley JR: Creatine monohydrate supplementation: Considerations for cognitive performance in athletes. Strength and Conditioning Journal. 2018; 40(2): 82–93. Publisher Full Text
275. Noreen H, Yabuki Y, Fukunaga K: Novel spiroimidazopyridine derivative SAK3 improves methimazole-induced cognitive deficits in mice. Neurochem. Int. 2017; 108: 91–99. Publisher Full Text
276. Carrio Sampedro A, Pérez Triviño JL: On the Compatibility of Brain Enhancement and the Internal Values of Sport. Sport, Ethics Philos. 2017; 11(3): 307–322. Publisher Full Text
277. Zeleznikow-Johnston A, Burrows EL, Renoir T, et al.: Environmental enrichment enhances cognitive flexibility in C57BL/6 mice on a touchscreen reversal learning task. Neuropharmacology. 2017; 117: 219–226. Publisher Full Text
278. Buschler A, Manahan-Vaughan D: Metabotropic glutamate receptor, mGlu5, mediates enhancements of hippocampal long-term potentiation after environmental enrichment in young and old mice. Neuropharmacology. 2017; 115: 42–50. Publisher Full Text
279. Tang SW, Tang WH, Leonard BE: Managing interactions between cognitive enhancers and other psychotropics. Int. Clin. Psychopharmacol. 2017; 32(4): 175–183. PubMed Abstract | Publisher Full Text
280. Kunath N, Müller NCJ, Tonon M, et al.: Ghrelin modulates encoding-related brain function without enhancing memory formation in humans. NeuroImage. 2016; 142: 465–473. PubMed Abstract | Publisher Full Text
281. Kasparbauer AM, Meyhöfer I, Steffens M, et al.: Neural effects of methylphenidate and nicotine during smooth pursuit eye movements. NeuroImage. 2016; 141: 52–59. Publisher Full Text
282. Ben-Eliezer D, Yechiam E: Hypericum perforatum as a cognitive enhancer in rodents: A meta-analysis. Sci. Rep. 2016; 6: 6. Publisher Full Text
283. Colzato LS, Steenbergen L, Sellaro R, et al.: Effects of L-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial. Cortex. 2016; 82: 217–224. PubMed Abstract | Publisher Full Text
284. Fagundo AB, Jiménez-Murcia S, Giner-Bartolomé C, et al.: Modulation of irisin and physical activity on executive functions in obesity and morbid obesity. Sci. Rep. 2016; 6: 6. Publisher Full Text
285. Ghosh B, Zhao WN, Reis SA, et al.: Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation. Bioorg. Med. Chem. Lett. 2016; 26(4): 1265–1271. PubMed Abstract | Publisher Full Text | Free Full Text
286. Nikiforuk A: Serotonergic and cholinergic strategies as potential targets for the treatment of schizophrenia. Curr. Pharm. Des. 2016; 22(14): 2093–2116. PubMed Abstract | Publisher Full Text
287. Forsyth JK, Bachman P, Mathalon DH, et al.: Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain. Proc. Natl. Acad. Sci. USA. 2015; 112(50): 15331–15336. PubMed Abstract | Publisher Full Text | Free Full Text
288. Saridoğan GE, Aykaç A, Cabadak H, et al.: D-Cycloserine acts via increasing the GluN1 protein expressions in the frontal cortex and decreases the avoidance and risk assessment behaviors in a rat traumatic stress model. Behav. Brain Res. 2015; 293: 227–233. PubMed Abstract | Publisher Full Text
289. Hvoslef-Eide M, Oomen CA, Fisher BM, et al.: Facilitation of spatial working memory performance following intra-prefrontal cortical administration of the adrenergic alpha1 agonist phenylephrine. Psychopharmacology. 2015; 232(21-22): 4005–4016. PubMed Abstract | Publisher Full Text | Free Full Text
290. Kim CH, Hvoslef-Eide M, Nilsson SRO, et al.: The continuous performance test (rCPT) for mice: A novel operant touchscreen test of attentional function. Psychopharmacology. 2015; 232(21-22): 3947–3966. PubMed Abstract | Publisher Full Text | Free Full Text
291. Segev Y, Barrera I, Ounallah-Saad H, et al.: PKR inhibition rescues memory deficit and atf4 overexpression in apoe ε4 human replacement mice. J. Neurosci. 2015; 35(38): 12986–12993. PubMed Abstract | Publisher Full Text | Free Full Text
292. Khalil RB: Non-antidepressant psychopharmacologic treatment of specific phobias. Curr. Clin. Pharmacol. 2015; 10(2): 131–138. PubMed Abstract | Publisher Full Text
293. Marin MF, Lonak SF, Milad MR: Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers. Curr. Psychiatry Rep. 2015; 17(6): 39. PubMed Abstract | Publisher Full Text
294. Mohr C, Schneider S: The role of exposure in the treatment of anxiety disorders. Verhaltenstherapie. 2015; 25(1): 32–39. Publisher Full Text
295. Ramakrishnan NK, Schepers M, Luurtsema G, et al.: Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy. Mol. Imaging Biol. 2015; 17(3): 364–372. PubMed Abstract | Publisher Full Text
296. Malik M, Rangel-Barajas C, Sumien N, et al.: The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. Br. J. Pharmacol. 2015; 172(10): 2519–2531. PubMed Abstract | Publisher Full Text | Free Full Text
297. Talpos J, Shoaib M: Executive function. Handb. Exp. Pharmacol. 2015; 228: 191–213. Publisher Full Text
298. McGregor G, Malekizadeh Y, Harvey J: Minireview: Food for thought: Regulation of synaptic function by metabolic hormones. Mol. Endocrinol. 2015; 29(1): 3–13. PubMed Abstract | Publisher Full Text | Free Full Text
299. Kutlu MG, Gould TJ: Nicotinic receptors, memory, and hippocampus. Curr. Top. Behav. Neurosci. 2015; 23: 137–163. Publisher Full Text
300. Hosking JG, Lam FCW, Winstanley CA: Nicotine increases impulsivity and decreases willingness to exert cognitive effort despite improving attention in "Slacker" rats: Insights into cholinergic regulation of cost/benefit decision making. PLoS One. 2014; 9(10). Publisher Full Text
301. Bishara D, Harwood D: Safe prescribing of physical health medication in patients with dementia. Int. J. Geriatr. Psychiatry. 2014; 29(12): 1230–1241. Publisher Full Text
302. Pollard M, Bartolome JM, Conn PJ, et al.: Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 Positive allosteric modulator. J. Psychopharmacol. 2014; 28(10): 935–946. PubMed Abstract | Publisher Full Text | Free Full Text
303. Lungwitz EA, Stuber GD, Johnson PL, et al.: The role of the medial prefrontal cortex in regulating social familiarity-induced anxiolysis. Neuropsychopharmacology. 2014; 39(4): 1009–1019. PubMed Abstract | Publisher Full Text | Free Full Text
304. Rabinak CA, Phan KL: Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment. Curr. Pharm. Des. 2014; 20(13): 2212–2217. PubMed Abstract | Publisher Full Text | Free Full Text
305. Shaw D: Neuroenhancing public health. J. Med. Ethics. 2014; 40(6): 389–391. Publisher Full Text
306. Qian W, Schweizer TA, Fischer CE: Impact of socioeconomic status on initial clinical presentation to a memory disorders clinic. Int. Psychogeriatr. 2014; 26(4): 597–603. PubMed Abstract | Publisher Full Text
307. Gill SK, Leff AP: Dopaminergic therapy in aphasia. Aphasiology. 2014; 28(2): 155–170. PubMed Abstract | Publisher Full Text | Free Full Text
308. Colavito V, Fabene PF, Grassi-Zucconi G, et al.: Experimental sleep deprivation as a tool to test memory deficits in rodents. Front. Syst. Neurosci. 2013; 7(DEC). PubMed Abstract | Publisher Full Text | Free Full Text
309. Birch AM, McGarry NB, Kelly AM: Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus. 2013; 23(6): 437–450. PubMed Abstract | Publisher Full Text
310. Sanderson TM, Sher E: The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology. 2013; 74: 86–95. Publisher Full Text
311. Lipina TV, Palomo V, Gil C, et al.: Dual inhibitor of PDE7 and GSK-3 - VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology. 2013; 64: 205–214. PubMed Abstract | Publisher Full Text
312. Hahn B, Gold JM, Buchanan RW: The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology. 2013; 64: 185–190. PubMed Abstract | Publisher Full Text
313. Schmeichel BE, Zemlan FP, Berridge CW: A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder. Neuropharmacology. 2013; 64: 321–328. PubMed Abstract | Publisher Full Text | Free Full Text
314. Fernandes HA, Zanin KA, Patti CL, et al.: Inhibitory effects of modafinil on emotional memory in mice. Neuropharmacology. 2013; 64: 365–370. Publisher Full Text
315. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Pascual-Leone A: Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?. Neuropharmacology. 2013; 64: 566–578. PubMed Abstract | Publisher Full Text | Free Full Text
316. Uchiumi O, Kasahara Y, Fukui A, et al.: Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology. 2013; 64: 348–356. Publisher Full Text
317. Silverman JL, Oliver CF, Karras MN, et al.: AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013; 64: 268–282. PubMed Abstract | Publisher Full Text | Free Full Text
318. Allman AA, Ettinger U, Joober R, et al.: Effects of methylphenidate on basic and higher-order oculomotor functions. J. Psychopharmacol. 2012; 26(11): 1471–1479. PubMed Abstract | Publisher Full Text
319. Yehuda S: Polyunsaturated fatty acids as putative cognitive enhancers. Med. Hypotheses. 2012; 79(4): 456–461. PubMed Abstract | Publisher Full Text
320. Bruce J, Hancock L, Roberg B, et al.: Impact of armodafinil on cognition in multiple sclerosis: A randomized, double-blind crossover pilot study. Cogn. Behav. Neurol. 2012; 25(3): 107–114. PubMed Abstract | Publisher Full Text
321. Boyle J, Stanley N, James LM, et al.: Acute sleep deprivation: The effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J. Psychopharmacol. 2012; 26(8): 1047–1057. PubMed Abstract | Publisher Full Text
322. Alberini CM, Chen DY: Memory enhancement: Consolidation, reconsolidation and insulin-like growth factor 2. Trends Neurosci. 2012; 35(5): 274–283. PubMed Abstract | Publisher Full Text | Free Full Text
323. Knafo S, Venero C, Sánchez-Puelles C, et al.: Facilitation of ampa receptor synaptic delivery as a molecular mechanism for cognitive enhancement. PLoS Biol. 2012; 10(2): e1001262. PubMed Abstract | Publisher Full Text | Free Full Text
324. Froestl W, Muhs A, Pfeifer A: Cognitive enhancers (Nootropics). Part 1: Drugs interacting with receptors. J. Alzheimers Dis. 2012; 32(4): 793–887. PubMed Abstract | Publisher Full Text
325. Deiana S, Platt B, Riedel G: The cholinergic system and spatial learning. Behav. Brain Res. 2011; 221(2): 389–411. Publisher Full Text
326. Levin ED, Bushnell PJ, Rezvani AH: Attention-modulating effects of cognitive enhancers. Pharmacol. Biochem. Behav. 2011; 99(2): 146–154. PubMed Abstract | Publisher Full Text | Free Full Text
327. Valade A, Cross SB, Brown C, et al.: Discovery of novel selective Sigma-1 ligands as cognitive enhancers. MedChemComm. 2011; 2(7): 655–660. Publisher Full Text
328. Berridge CW, Devilbiss DM: Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2011; 69(12): e101–e111. PubMed Abstract | Publisher Full Text | Free Full Text
329. Mioranzza S, Costa MS, Botton PHS, et al.: Blockade of adenosine A1 receptors prevents methylphenidate-induced impairment of object recognition task in adult mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011; 35(1): 169–176. PubMed Abstract | Publisher Full Text
330. Wang T, Yang YJ, Wu PF, et al.: Tetrahydroxystilbene glucoside, a plant-derived cognitive enhancer, promotes hippocampal synaptic plasticity. Eur. J. Pharmacol. 2011; 650(1): 206–214. PubMed Abstract | Publisher Full Text
331. Köfeler HC, Tiboldi A, Hoeger H, et al.: Hippocampal lipids linked to spatial memory in the C57bl/6j mouse. Neurochem. Int. 2010; 57(8): 935–939. Publisher Full Text
332. Botton PH, Costa MS, Ardais AP, et al.: Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav. Brain Res. 2010; 214(2): 254–259. PubMed Abstract | Publisher Full Text
333. Muramatsu RS, Litzinger MHJ, Takeshita J: Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am. J. Geriatr. Pharmacother. 2010; 8(2): 98–114. PubMed Abstract | Publisher Full Text
334. Weiner I, Arad M: Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav. Brain Res. 2009; 204(2): 369–386. Publisher Full Text
335. Edgar CJ, Pace-Schott EF, Wesnes KA: Approaches to measuring the effects of wake-promoting drugs: A focus on cognitive function. Hum. Psychopharmacol. 2009; 24(5): 371–389. PubMed Abstract | Publisher Full Text | Free Full Text
336. John JPP, Sunyer B, Höger H, et al.: Hippocampal synapsin isoform levels are linked to spatial memory enhancement by SGS742. Hippocampus. 2009; 19(8): 731–738. Publisher Full Text
337. Kelly SJ, Bernard K, Muñoz C, et al.: Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats. Psychopharmacology. 2009; 202(1-3): 225–235. Publisher Full Text
338. Kelly MP, Cheung YF, Favilla C, et al.: Constitutive activation of the G-protein subunit Gαs within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. Learn. Mem. 2008; 15(2): 75–83. Publisher Full Text
339. Warren MF, Serby MJ, Roane DM: The effects of testosterone on cognition in elderly men: A review. CNS Spectr. 2008; 13(10): 887–897. PubMed Abstract | Publisher Full Text
340. Stone WS, Seidman LJ: Toward a model of memory enhancement in schizophrenia: Glucose administration and hippocampal function. Schizophr. Bull. 2008; 34(1): 93–108. PubMed Abstract
341. Bertaina-Anglade V, Drieu La Rochelle C, Muñoz C, et al.: Comparison of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the object recognition task in rats. Fundam. Clin. Pharmacol. 2007; 21(4): 349–354. Publisher Full Text
342. Wang Y, Wang L, Wu J, et al.: The in vivo synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. Br. J. Pharmacol. 2006; 148(2): 147–153. PubMed Abstract | Publisher Full Text | Free Full Text
343. Yang YL, Su YW, Ng MC, et al.: Extract of Ginkgo biloba EGb 761 facilitates fear conditioning measured by fear-potentiated startle. Neurosci. Lett. 2005; 383(1-2): 145–150. Publisher Full Text
344. Belluardo N, Olsson PA, Mudo G, et al.: Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience. 2005; 133(3): 787–796. Publisher Full Text
345. Kew JNC, Kemp JA: Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology. 2005; 179(1): 4–29. Publisher Full Text
346. Mayo W, Lemaire V, Malaterre J, et al.: Pregnenolone sulfate enhances neurogenesis and PSA-NCAM in young and aged hippocampus. Neurobiol. Aging. 2005; 26(1): 103–114. Publisher Full Text
347. Belluardo N, Mudò G, Blum M, et al.: Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging. Neurobiol. Aging. 2004; 25(10): 1333–1342. Publisher Full Text
348. Frick KM, Fernandez SM: Enrichment enhances spatial memory and increases synaptophysin levels in aged female mice. Neurobiol. Aging. 2003; 24(4): 615–626. PubMed Abstract | Publisher Full Text
349. Rodríguez-Alcázar J, Bermejo-Luque L: Human enhancement technologies and the arguments for cosmopolitanism. Enrahonar. 2024; 72: 15–33. Publisher Full Text
350. Wu KCC: PHARMACEUTICAL COGNITIVE ENHANCEMENT: Entanglement with emotion, morality, and context. The Routledge Handbook of the Ethics of Human Enhancement. 2023; 340–355. Publisher Full Text
351. Dasgupta J, Lockwood Estrin G, Summers J, et al.: Cognitive Enhancement and Social Mobility: Skepticism from India. AJOB Neurosci. 2023; 14(4): 341–351. PubMed Abstract | Publisher Full Text
352. Keary S, Ivers M, O’Connor C, et al.: Exploring Irish students’ attitudes towards nootropic supplements. Drugs: Education, Prevention and Policy. 2023; 30(5): 516–527.
353. Monnet F, Ergler C, Pilot E, et al.: ‘Cognitive enhancers’: A qualitative exploration of university students’ experiences with prescription medicines for academic purposes. Policy Futures in Education. 2022; 20(7): 762–779. Publisher Full Text
354. Edgren N, Dubljević V: The ubiquity of the fallacy of composition in cognitive enhancement and in education. Theor. Med. Bioeth. 2023; 44(1): 41–56. PubMed Abstract | Publisher Full Text
355. Carder P, Zimmerman S, Wretman CJ, et al.: As-Needed Prescribing and Administration of Psychotropic Medications in Assisted Living: A 7-State Study. J. Am. Med. Dir. Assoc. 2022; 23(6): 1038–44.e3. PubMed Abstract | Publisher Full Text | Free Full Text
356. Martos D, Tuka B, Tanaka M, et al.: Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission. Biomedicines. 2022; 10(4). PubMed Abstract | Publisher Full Text | Free Full Text
357. Herrmann N, Ismail Z, Collins R, et al.: CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2022; 8(1). Publisher Full Text
358. Shakeel S, Iffat W, Qamar A, et al.: Concept generation of cognitive enhancement: healthcare professionals' approach towards the impact and utilization of cognitive enhancers in academic context. Heliyon. 2021; 7(10): e08118. PubMed Abstract | Publisher Full Text | Free Full Text
359. Bystad M, Storø B, Gundersen N, et al.: Can accelerated transcranial direct current stimulation improve memory functions? An experimental, placebo-controlled study. Heliyon. 2020; 6(10): e05132. PubMed Abstract | Publisher Full Text | Free Full Text
360. Ferreira de Sá DS, Römer S, Brückner AH, et al.: Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study. Neuropsychopharmacology. 2020; 45(5): 753–760. Publisher Full Text
361. Palamenghi L, Bonfiglioli C: Cognitive Enhancement vs. Plagiarism: a Quantitative Study on the Attitudes of an Italian Sample. Neuroethics. 2019; 12(3): 279–292. Publisher Full Text
362. Petersen MA, Petersen TS: Why prohibit study drugs?: On attitudes and practices concerning prohibition and coercion to use pharmaceutical cognitive enhancement. Drugs: Education, Prevention and Policy. 2019; 26(4): 356–364.
363. Petersen TS: Should the state prohibit healthy people's access to pharmacological cognitive enhancers? On arguments from coercion and individualization. Int. J. Law Psychiatry. 2019; 65: 101382. PubMed Abstract | Publisher Full Text
364. Getting smart to cognitive enhancers. EClinicalMedicine. 2019; 11: 1–2. PubMed Abstract | Publisher Full Text | Free Full Text
365. Mayor E, Daehne M, Bianchi R: How perceived substance characteristics affect ethical judgement towards cognitive enhancement. PLoS ONE. 2019; 14(3): e0213619. PubMed Abstract | Publisher Full Text | Free Full Text
366. Bocchio M, Lukacs IP, Stacey R, et al.: Group II metabotropic glutamate receptors mediate presynaptic inhibition of excitatory transmission in pyramidal neurons of the human cerebral cortex. Front. Cell. Neurosci. 2019; 12. PubMed Abstract | Publisher Full Text | Free Full Text
367. Mihailov E, Savulescu J: Social Policy and Cognitive Enhancement: Lessons from Chess. Neuroethics. 2018; 11(2): 115–127. Publisher Full Text
368. Porsdam Mann S, de Lora DP , Cochrane T, et al.: Is the use of modafinil, a pharmacological cognitive enhancer, cheating?. Ethics and Education. 2018; 13(2): 251–267. Publisher Full Text
369. Wagner NF, Robinson J, Wiebking C: The societal hazards of neuroenhancement technologies. The Changing Scope of Technoethics in Contemporary Society. 2018; 163–196. Publisher Full Text
370. Chao PC, Chien WC, Chung CH, et al.: Cognitive enhancers associated with decreased risk of injury in patients with dementia: A nationwide cohort study in Taiwan. J. Investig. Med. 2018; 66(3): 684–692. PubMed Abstract | Publisher Full Text
371. Cummings J, Lee G, Ritter A, et al.: Alzheimer's disease drug development pipeline: 2018. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018; 4: 195–214. PubMed Abstract | Publisher Full Text | Free Full Text
372. Marvanova M, Henkel PJ: Community pharmacists' knowledge of Alzheimer disease care in high- and low-income Chicago. J. Am. Pharm. Assoc. 2017; 57: 596–600.e1. PubMed Abstract | Publisher Full Text
373. Gyertyán I: Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets. Trends Pharmacol. Sci. 2017; 38(2): 113–126. PubMed Abstract | Publisher Full Text
374. Tiunova AA, Komissarova NV, Nenaidenko VG, et al.: Pro-cognitive effects of non-peptide analogues of soluble amyloid peptide precursor fragment SAPP. Bull. Exp. Biol. Med. 2016; 161(4): 447–450. Publisher Full Text
375. Ram S, Hussainy S, Henning M, et al.: Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug Alcohol Rev. 2016; 35(3): 345–351. PubMed Abstract | Publisher Full Text
376. Lengvenyte A, Strumila R, Grikiniene J: Use of cognitive enhancers among medical students in Lithuania. NAD Nordic Studies on Alcohol and Drugs. 2016; 33(2): 173–188. Publisher Full Text
377. Toma ID, Gil LM, Ossowski S, et al.: Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders. Neural Plast. 2016; 2016: 1–20. Publisher Full Text
378. Lyon R: Smart drugs mean society loses out. Pharm. J. 2015; 295(7882): 329.
379. Whetstine LM: Cognitive Enhancement: Treating or Cheating?. Semin. Pediatr. Neurol. 2015; 22(3): 172–176. Publisher Full Text
380. Van Waes V, Steiner H: Fluoxetine and other SSRI antidepressants potentiate addiction-related gene regulation by psychostimulant medications. Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects. 2015; 207–225.
381. Kantak KM, Wettstein JG: Closing thoughts for cognitive enhancement. Handb. Exp. Pharmacol. 2015; 228: 451–459. Publisher Full Text
382. Levy N, Savulescu J. The Neuroethics of Transcranial Electrical. Stimulation. The Stimulated Brain: Cognitive Enhancement Using Non-Invasive Brain Stimulation2014. p. 499–521, DOI: Publisher Full Text
383. Rojas-Fernandez C, Mikhail M, Brown SG: Psychotropic and Cognitive-Enhancing Medication Use and Its Documentation in Contemporary Long-term Care Practice. Ann. Pharmacother. 2014; 48(4): 438–446. PubMed Abstract | Publisher Full Text
384. Wolbring G, Diep L, Yumakulov S, et al.: Social Robots, Brain Machine Interfaces and Neuro/Cognitive Enhancers: Three Emerging Science and Technology Products through the Lens of Technology Acceptance Theories, Models and Frameworks. Technologies. 2013; 1(1): 3–25. Publisher Full Text
385. Chinthapalli K: Bioethics researchers support use of cognitive enhancers. BMJ (Clinical research ed). 2013; 346: 346. Publisher Full Text
386. Lucke J, Partridge B: Towards a smart population: A public health framework for cognitive enhancement. Neuroethics. 2013; 6(2): 419–427. Publisher Full Text
387. Yamamoto Y, Shioda N, Han F, et al.: The novel cognitive enhancer st101 enhances acetylcholine release in mouse dorsal hippocampus through t-type voltage-gated calcium channel stimulation. J. Pharmacol. Sci. 2013; 121(3): 212–226. PubMed Abstract | Publisher Full Text
388. Tuboly G, Vécsei L: Somatostatin and cognitive function in neurodegenerative disorders. Mini-Rev. Med. Chem. 2013; 13(1): 34–46. Publisher Full Text
389. Chneiweiss H: Does Cognitive Enhancement Fit with the Physiology of Our Cognition? Oxford Handbook of Neuroethics.2012.
390. Ashare RL, Ray R, Lerman C, et al.: Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: A pilot feasibility study. Drug Alcohol Depend. 2012; 126(1-2): 263–267. PubMed Abstract | Publisher Full Text | Free Full Text
391. Nirogi R, Bhyrapuneni G, Kandikere V, et al.: Concurrent administration of atypical antipsychotics and donepezil: Drug interaction study in rats. Eur. J. Drug Metab. Pharmacokinet. 2012; 37(3): 155–161. Publisher Full Text
392. Kaewkaen P, Tong-Un T, Wattanathorn J, et al.: Mulberry fruit extract protects against memory impairment and hippocampal damage in animal model of vascular dementia. Evid. Based Complement. Alternat. Med. 2012; 2012: 1–9. PubMed Abstract | Publisher Full Text | Free Full Text
393. Franke AG, Bonertz C, Christmann M, et al.: Attitudes Toward Cognitive Enhancement in Users and Nonusers of Stimulants for Cognitive Enhancement: A Pilot Study. AJOB Prim. Res. 2012; 3(1): 48–57. Publisher Full Text
394. Lundström L, Bissantz C, Beck J, et al.: Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: Mechanistic studies with new potent negative allosteric modulators. Br. J. Pharmacol. 2011; 164(2 B): 521–537. PubMed Abstract | Publisher Full Text | Free Full Text
395. Outram SM, Racine E: Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics. 2011; 4: 93–105. Publisher Full Text
396. Sahakian BJ, Morein-Zamir S: Neuroethical issues in cognitive enhancement. J. Psychopharmacol. 2011; 25(2): 197–204. Publisher Full Text
397. Chiamulera C: Research is needed on the use of cognitive enhancer drugs in sport. J. Sci. Med. Sport. 2011; 14(1): 2–3. Publisher Full Text
398. Rossé G, Schaffhauser H: 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem. 2010; 10(2): 207–221. PubMed Abstract | Publisher Full Text
399. Houslay MD: Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 2010; 35(2): 91–100. PubMed Abstract | Publisher Full Text
400. Förstl H: Neuro-enhancement: BBrain doping. Nervenarzt. 2009; 80(7): 840–846. Publisher Full Text
401. Liu KG, Robichaud AJ: 5-HT 6 antagonists as potential treatment for cognitive dysfunction. Drug Dev. Res. 2009; 70(2): 145–168. Publisher Full Text
402. Racine E, Forlini C: Expectations regarding cognitive enhancement create substantial challenges. J. Med. Ethics. 2009; 35(8): 469–470. PubMed Abstract | Publisher Full Text
403. Levy N, Clarke S: Neuroethics and psychiatry. Curr. Opin. Psychiatry. 2008; 21(6): 568–571. Publisher Full Text
404. Omar SH: Unravelling the Threads: A Brief Insight into Vascular Dementia. Journal of Vascular Diseases. 2023; 2(4): 419–437. Publisher Full Text
405. Ozturk Y, Bozkurt I, Guvenc Y, et al.: Modafinil attenuates the neuroinflammatory response after experimental traumatic brain injury. J. Neurosurg. Sci. 2023; 67(4): 498–506. PubMed Abstract | Publisher Full Text
406. Ma W, Si T, Wang Z, et al.: Astrocytic α4-containing nAChR signaling in the hippocampus governs the formation of temporal association memory. Cell Rep. 2023; 42(7): 112674. PubMed Abstract | Publisher Full Text
407. Power SK, Venkatesan S, Lambe EK: Xanomeline restores endogenous nicotinic acetylcholine receptor signaling in mouse prefrontal cortex. Neuropsychopharmacology. 2023; 48(4): 671–682. PubMed Abstract | Publisher Full Text | Free Full Text
408. Muralidhara M, Rajini PS: Ayurvedic herbs–derived cognitive enhancers for the management of Alzheimer's disease (AD). Ayurvedic Herbal Preparations in Neurological Disorders. 2023; 367–398. Publisher Full Text
409. Kang M, Lee DB, Kwon S, et al.: Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data. J. Clin. Med. 2022; 11(16). PubMed Abstract | Publisher Full Text | Free Full Text
410. Pulido LN, Pochapski JA, Sugi A, et al.: Pre-clinical evidence that methylphenidate increases motivation and/or reward preference to search for high value rewards. Behav. Brain Res. 2023; 437: 114065. PubMed Abstract | Publisher Full Text
411. Isaacson RS: Treatment Updates in Alzheimer's Disease: Tailoring Management and Care Approaches to Improve Outcomes. Journal of Managed Care Medicine. 2023; 26(1): 8–12.
412. Pal D, Sahu P, Mishra AK, et al.: Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior. Curr. Drug Targets. 2023; 24(9): 728–750. PubMed Abstract | Publisher Full Text
413. Torrisi SA, Geraci F, Contarini G, et al.: Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside. Curr. Top. Behav. Neurosci. 2023; 60: 133–156. Publisher Full Text
414. Veroniki AA, Ashoor HM, Rios P, et al.: Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open. 2022; 12(4): e053012. PubMed Abstract | Publisher Full Text | Free Full Text
415. Phelps EB, Swantek S: Efficacy and Safety of Cognitive Enhancers for Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis. Essential Reviews in Geriatric Psychiatry. 2022; 325–329. Publisher Full Text
416. Mitra S, Muni M, Shawon NJ, et al.: Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential. Oxidative Med. Cell. Longev. 2022; 2022: 1–22. PubMed Abstract | Publisher Full Text | Free Full Text
417. Singh M, Sharma P, Arora S: Development of 1,2,3,4-tetrahydrocarbazole derivatives as dual binding cholinestarse inhibitors. Alzheimer's and Dementia. 2021; 17(S9). Publisher Full Text
418. Oliveira AWC, Pacheco JVN, Costa CS, et al.: Scopolamine and MK-801 impair recognition memory in a new spontaneous object exploration task in monkeys. Pharmacol. Biochem. Behav. 2021; 211: 173300. PubMed Abstract | Publisher Full Text
419. Bruszt N, Bali ZK, Tadepalli SA, et al.: Potentiation of cognitive enhancer effects of Alzheimer’s disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task. Psychopharmacology. 2021; 238(11): 3273–3281. PubMed Abstract | Publisher Full Text | Free Full Text
420. Oláh V, Knakker B, Trunk A, et al.: Dissociating cholinergic influence on alertness and temporal attention in primates in a simple reaction time paradigm. Eur. J. Neurosci. 2020; 52(7): 3776–3789. Publisher Full Text
421. Sepehri H, Nasiri H: Filgrastim improved spatial memory functions in rat model of scopolamine induced alzheimer type memory dysfunction. Bulletin of Pharmaceutical Sciences Assiut. 2021; 44(2): 579–585. Publisher Full Text
422. Cummings J: New approaches to symptomatic treatments for Alzheimer’s disease. Mol. Neurodegener. 2021; 16(1). Publisher Full Text
423. Nelissen E, Argyrousi EK, Van Goethem NP, et al.: Soluble guanylate cyclase stimulator vericiguat enhances long-term memory in rats without altering cerebral blood volume. Biomedicines. 2021; 9(8). PubMed Abstract | Publisher Full Text | Free Full Text
424. Gongora M, Nicoliche E, Magalhães J, et al.: Event-related potential (P300): the effects of levetiracetam in cognitive performance. Neurol. Sci. 2021; 42(6): 2309–2316. PubMed Abstract | Publisher Full Text
425. Stanczak A, Lewgowd W: Cognitive enhancers - what we should know about them. Farm. Pol. 2021; 77(4): 201–219. Publisher Full Text
426. Hamilton K, Harvey J: Leptin regulation of hippocampal synaptic function in health and disease. Vitam. Horm. 2021; 115: 105–127. PubMed Abstract | Publisher Full Text
427. Berthier ML: Ten key reasons for continuing research on pharmacotherapy for post-stroke aphasia. Aphasiology. 2021; 35(6): 824–858. Publisher Full Text
428. Mejido DCP, Peny JA, Vieira MNN, et al.: Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. Neuropharmacology. 2020; 171: 108115. PubMed Abstract | Publisher Full Text
429. Elliott JM: The Role of Glycaemic Control in Cognitive Functioning. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 101–134. Publisher Full Text
430. Choi JG, Kahn Z, Hong SM, et al.: The mixture of gotu kola, cnidium fruit, and goji berry enhances memory functions by inducing nerve-growth-factor-mediated actions both in vitro and in vivo. Nutrients. 2020; 12(5). PubMed Abstract | Publisher Full Text | Free Full Text
431. Dashniani MG, Chighladze MR, Solomonia RO, et al.: Memantine treatment prevents okadaic acid induced neurotoxicity at the systemic and molecular levels. NeuroReport. 2020; 31(4): 281–286. Publisher Full Text
432. Tan YX, Liu GC, Chen HL, et al.: Exercise-Induced Cognitive Improvement Is Associated with Sodium Channel-Mediated Excitability in APP/PS1 Mice. Neural Plast. 2020; 2020: 1–18. PubMed Abstract | Publisher Full Text | Free Full Text
433. Voulgaropoulou SD, van Amelsvoort TAMJ , Prickaerts J, et al.: The effect of curcumin on cognition in Alzheimer's disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Res. 2019; 1725: 146476. PubMed Abstract | Publisher Full Text
434. De Toma I, Ortega M, Aloy P, et al.: DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment. Front. Mol. Neurosci. 2019; 12. Publisher Full Text
435. Jin BR, Liu HY: Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: Systematic review and Bayesian network meta-analysis. Neural Regen. Res. 2019; 14(5): 805–816. PubMed Abstract | Publisher Full Text
436. Montero-Odasso M, Speechley M, Chertkow H, et al.: Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. Eur. J. Neurol. 2019; 26(4): 651–659. Publisher Full Text
437. Mesa-Gresa P, Redolat R: Nicotine and Agonists of Alpha 7 Nicotinic Acetylcholine Receptors Combined With Environmental Enrichment. Acetylcholine Receptors in Health and Disease. 2019; 69–116.
438. Pifferi F, Epelbaum J, Aujard F: Strengths and weaknesses of the gray mouse lemur (Microcebus murinus) as a model for the behavioral and psychological symptoms and neuropsychiatric symptoms of dementia. Front. Pharmacol. 2019; 10(OCT). PubMed Abstract | Publisher Full Text | Free Full Text
439. Witkin JM, Shenvi RA, Li X, et al.: Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochem. Pharmacol. 2018; 155: 61–70. PubMed Abstract | Publisher Full Text | Free Full Text
440. Bali ZK, Bruszt N, Tadepalli SA, et al.: Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front. Pharmacol. 2019; 10(FEB). PubMed Abstract | Publisher Full Text | Free Full Text
441. Sinkeviciute I, Begemann M, Prikken M, et al.: Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophr. 2018; 4(1): 22. PubMed Abstract | Publisher Full Text | Free Full Text
442. Ovsepian SV, O’Leary VB: Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer’s Disease?. Neurotherapeutics. 2018; 15(4): 1032–1035. PubMed Abstract | Publisher Full Text | Free Full Text
443. Zhou D, Lv D, Wang Z, et al.: GLYX-13 ameliorates schizophrenia-like phenotype induced by MK-801 in mice: role of hippocampal NR2B and DISC1. Front. Mol. Neurosci. 2018; 11. PubMed Abstract | Publisher Full Text | Free Full Text
444. Guercio GD, Panizzutti R: Potential and challenges for the clinical use of D-Serine as a cognitive enhancer. Front. Psych. 2018; 9(FEB). PubMed Abstract | Publisher Full Text | Free Full Text
445. Cès A, Burg T, Herbeaux K, et al.: Age-related vulnerability of pattern separation in C57BL/6J mice. Neurobiol. Aging. 2018; 62: 120–129. PubMed Abstract | Publisher Full Text
446. PRA H, Argyrousi EK, Prickaerts J: Phosphodiesterase Inhibitors in Object Recognition and Object Location Memory Tests. Handbook of Behavioral Neuroscience. 2018; 27: 567–574. Publisher Full Text
447. Whittaker DS, Wang HB, Loh DH, et al.: Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease. Pharmacol. Res. Perspect. 2017; 5(5). PubMed Abstract | Publisher Full Text | Free Full Text
448. Cummings J, Lee G, Mortsdorf T, et al.: Alzheimer's disease drug development pipeline: 2017. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2017; 3(3): 367–384. PubMed Abstract | Publisher Full Text | Free Full Text
449. Pardo M, Beurel E, Jope RS: Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome. Eur. J. Neurosci. 2017; 45(4): 490–498. PubMed Abstract | Publisher Full Text | Free Full Text
450. Moskal JR, Burgdorf JS, Stanton PK, et al.: The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr. Neuropharmacol. 2017; 15(1): 47–56. PubMed Abstract | Publisher Full Text | Free Full Text
451. Yellamma K, Vanaja D: Evolvulus alsinoides plant extract as a cognitive enhancer of spacial memory in AD-induced rat model. Res. J. Pharm., Biol. Chem. Sci. 2016; 7(6): 2050–2054.
452. Kim HY, Kim HV, Lee DK, et al.: Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. Sci. Rep. 2016; 6: 6. Publisher Full Text
453. Kehagia AA: A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. J. Psychopharmacol. 2016; 30(10): 957–966. PubMed Abstract | Publisher Full Text
454. Hommel B, Sellaro R, Fischer R, et al.: High-frequency binaural beats increase cognitive flexibility: Evidence from dual-task crosstalk. Front. Psychol. 2016; 7(AUG). PubMed Abstract | Publisher Full Text | Free Full Text
455. Jawale A, Datusalia AK, Bishnoi M, et al.: Reversal of diabetes-induced behavioral and neurochemical deficits by cinnamaldehyde. Phytomedicine. 2016; 23(9): 923–930. PubMed Abstract | Publisher Full Text
456. Wolfe MS: Developing Therapeutics for Alzheimer's Disease: Progress and Challenges.2016; 1–656.
457. Fisher A, Bezprozvanny I, Wu L, et al.: AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. Neurodegener. Dis. 2016; 16: 95–110. PubMed Abstract | Publisher Full Text | Free Full Text
458. Jones KC, Han JY, Shah AA: Cognitive continuum: Areas of controversy with cognitive enhancers. Psychiatr. Ann. 2016; 46(2): 110–117. Publisher Full Text
459. Zhou X, Li Y, Shi X, et al.: An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am. J. Transl. Res. 2016; 8(2): 246–269. PubMed Abstract
460. Stoeber J, Hotham S: Perfectionism and attitudes toward cognitive enhancers (“smart drugs”). Personal. Individ. Differ. 2016; 88: 170–174. Publisher Full Text
461. Maier LJ, Liakoni E, Schildmann J, et al.: Swiss university students' attitudes toward pharmacological cognitive enhancement. PLoS ONE. 2015; 10(12): e0144402. PubMed Abstract | Publisher Full Text | Free Full Text
462. Shniderman AB, Solberg LB: Cosmetic Psychopharmacology for Prisoners: Reducing Crime and Recidivism Through Cognitive Intervention. Neuroethics. 2015; 8(3): 315–326. Publisher Full Text
463. Burgdorf J, Zhang XL, Weiss C, et al.: The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015; 308: 202–211. PubMed Abstract | Publisher Full Text | Free Full Text
464. Sirichoat A, Chaijaroonkhanarak W, Prachaney P, et al.: Effects of Asiatic acid on spatial working memory and cell proliferation in the adult rat hippocampus. Nutrients. 2015; 7(10): 8413–8423. Publisher Full Text
465. Zhang H, He Y, Li AP: The Role of Leptin in Cognitive Development During Aging. Sheng li ke xue jin zhan [Progress in physiology]. 2015; 46(5): 321–326. PubMed Abstract
466. Stützle M, Flamm J, Carle S, et al.: Nose-to-brain delivery of insulin for Alzheimer's disease. ADMET and DMPK. 2015; 3(3): 190–202. Publisher Full Text
467. Ragen BJ, Seidel J, Chollak C, et al.: Investigational drugs under development for the treatment of PTSD. Expert Opin. Investig. Drugs. 2015; 24(5): 659–672. PubMed Abstract | Publisher Full Text
468. Hegedüs N, Laszy J, Gyertyán I, et al.: Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. J. Psychopharmacol. 2015; 29(4): 447–455. PubMed Abstract | Publisher Full Text
469. Hashimoto T, Hatayama Y, Nakamichi K, et al.: Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice. Eur. J. Pharmacol. 2014; 745: 123–128. PubMed Abstract | Publisher Full Text
470. Ostrovskaya RU, Vakhitova YV, Kuzmina US, et al.: Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J. Biomed. Sci. 2014; 21(1): 74. PubMed Abstract | Publisher Full Text | Free Full Text
471. Wan WB, Cao L, Liu LM, et al.: EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model. PLoS One. 2014; 9(11): e113126. PubMed Abstract | Publisher Full Text | Free Full Text
472. Balsera B, Mulet J, Fernández-Carvajal A, et al.: Chalcones as positive allosteric modulators of α7 nicotinic acetylcholine receptors: A new target for a privileged structure. Eur. J. Med. Chem. 2014; 86: 724–739. PubMed Abstract | Publisher Full Text
473. Luzny J, Holmerova I, Wija P, et al.: Dementia still diagnosed too late – data from the Czech Republic. Iran. J. Public Health. 2014; 43(10): 1436–1443. PubMed Abstract
474. Wergeland JN, Selbæk G, Hogset LD, et al.: Dementia, neuropsychiatric symptoms, and the use of psychotropic drugs among older people who receive domiciliary care: A cross-sectional study. Int. Psychogeriatr. 2014; 26(3): 383–391. PubMed Abstract | Publisher Full Text
475. Gulcan HO, Unlu S, Esiringu I, et al.: Design, synthesis and biological evaluation of novel 6H-benzo [c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo [c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg. Med. Chem. 2014; 22(19): 5141–5154. PubMed Abstract | Publisher Full Text
476. Irving AJ, Harvey J: Leptin regulation of hippocampal synaptic function in health and disease. Philosophical Transactions of the Royal Society B: Biological Sciences. 2014; 369(1633): 20130155. PubMed Abstract | Publisher Full Text | Free Full Text
477. Braidy N, Poljak A, Jayasena T, et al.: Drug treatments for alzheimer's disease: Hopes and challenges. Handbook of Neurotoxicity. 2014; 2: 1173–1190. Publisher Full Text
478. Szuhany KL, Alexandra Kredlow M, Otto MW: Combination psychological and pharmacological treatments for panic disorder. Int. J. Cogn. Ther. 2014; 7(2): 122–135. Publisher Full Text
479. Whittle N, Singewald N: HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?. Biochem. Soc. Trans. 2014; 42(2): 569–581. PubMed Abstract | Publisher Full Text | Free Full Text
480. Smith I, Williamson EM, Putnam S, et al.: Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr. Rev. 2014; 72(5): 319–333. Publisher Full Text
481. Park CA, Kang CK, Son YD, et al.: The effects of caffeine ingestion on cortical areas: Functional imaging study. Magn. Reson. Imaging. 2014; 32(4): 366–371. PubMed Abstract | Publisher Full Text
482. Pohanka M: Alzheimer's disease and oxidative stress: A review. Curr. Med. Chem. 2014; 21(3): 356–364. PubMed Abstract
483. Shineman DW, Carman AJ, Dacks PA, et al.: Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease. Alzheimer's Research and Therapy. 2013; 5(5): 45. PubMed Abstract | Publisher Full Text | Free Full Text
484. Porciúncula LO, Sallaberry C, Mioranzza S, et al.: The Janus face of caffeine. Neurochem. Int. 2013; 63(6): 594–609. Publisher Full Text
485. Klusa V, Muceniece R, Isajevs S, et al.: Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats. Pharmacol. Biochem. Behav. 2013; 106: 68–76. PubMed Abstract | Publisher Full Text
486. Capurro V, Busquet P, Lopes JP, et al.: Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease. PLoS ONE. 2013; 8(2): e56870. PubMed Abstract | Publisher Full Text | Free Full Text
487. Piyabhan P, Wetchateng T, Sirseeratawong S: Cognitive enhancement effects of Bacopa Monnieri (Brahmi) on novel object recognition and NMDA receptor immunodensity in the prefrontal cortex and hippocampus of sub-chronic phencyclidine rat model of schizophrenia. J. Med. Assoc. Thail. 2013; 96(2): 231–238. PubMed Abstract
488. Singer P, Hauser J, Lopez LL, et al.: Prepulse inhibition predicts working memory performance whilst startle habituation predicts spatial reference memory retention in C57BL/6 mice. Behav. Brain Res. 2013; 242(1): 166–177. PubMed Abstract | Publisher Full Text
489. Sutalangka C, Wattanathorn J, Muchimapura S, et al.: Moringa oleifera mitigates memory impairment and neurodegeneration in animal model of age-related dementia. Oxidative Med. Cell. Longev. 2013; 2013: 1–9. Publisher Full Text
490. Doherty GH, Beccano-Kelly D, Yan SD, et al.: Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid β. Neurobiol. Aging. 2013; 34(1): 226–237. PubMed Abstract | Publisher Full Text
491. Dobarro M, Orejana L, Aguirre N, et al.: Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013; 64: 137–144. PubMed Abstract | Publisher Full Text
492. Sierksma ASR, Rutten K, Sydlik S, et al.: Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology. 2013; 64: 124–136. PubMed Abstract | Publisher Full Text
493. Klaassen EB, De Groot RHM, Evers EAT, et al.: The effect of caffeine on working memory load-related brain activation in middle-aged males. Neuropharmacology. 2013; 64: 160–167. PubMed Abstract | Publisher Full Text
494. Schulz R, Gerloff C, Hummel FC: Non-invasive brain stimulation in neurological diseases. Neuropharmacology. 2013; 64: 579–587. Publisher Full Text
495. García-Barroso C, Ricobaraza A, Pascual-Lucas M, et al.: Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology. 2013; 64: 114–123. PubMed Abstract | Publisher Full Text
496. Chambon C, Jatzke C, Wegener N, et al.: Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. Eur. J. Pharmacol. 2012; 697(1-3): 73–80. PubMed Abstract | Publisher Full Text
497. Laatikainen LM, Sharp T, Bannerman DM, et al.: Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. J. Psychopharmacol. 2012; 26(12): 1561–1568. PubMed Abstract | Publisher Full Text | Free Full Text
498. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al.: Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem. Neurosci. 2012; 3(11): 832–844. PubMed Abstract | Publisher Full Text | Free Full Text
499. Gur S, Kadowitz PJ, Serefoglu EC, et al.: PDE5 inhibitor treatment Options for urologic and non-urologic indications: 2012 update. Curr. Pharm. Des. 2012; 18(34): 5590–5606. PubMed Abstract | Publisher Full Text
500. Stewart AM, Kalueff AV: The developing utility of zebrafish models for cognitive enhancers research. Curr. Neuropharmacol. 2012; 10(3): 263–271. PubMed Abstract | Publisher Full Text | Free Full Text
501. Hu D, Cao Y, He R, et al.: Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ 1-142-induced memory impairment in mice. Oxidative Med. Cell. Longev. 2012; 2012: 1–7. PubMed Abstract | Publisher Full Text | Free Full Text
502. Hu D, Li C, Han N, et al.: Deoxyschizandrin isolated from the fruits of schisandra chinensis ameliorates a β induced memory impairment in mice. Planta Med. 2012; 78(12): 1332–1336. PubMed Abstract | Publisher Full Text
503. Aisen PS, Cummings J, Schneider LS: Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012; 2(3). PubMed Abstract | Publisher Full Text | Free Full Text
504. Boggio PS, Valasek CA, Campanhã C, et al.: Non-invasive brain stimulation to assess and modulate neuroplasticity in Alzheimer's disease. Neuropsychol. Rehabil. 2011; 21(5): 703–716. PubMed Abstract | Publisher Full Text
505. Cheung ZH, Ip NY: From understanding synaptic plasticity to the development of cognitive enhancers. Int. J. Neuropsychopharmacol. 2011; 14(9): 1247–1256. Publisher Full Text
506. Albiston AL, Diwakarla S, Fernando RN, et al.: Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. Br. J. Pharmacol. 2011; 164(1): 37–47. PubMed Abstract | Publisher Full Text | Free Full Text
507. Micheau J, Marighetto A: Acetylcholine and memory: A long, complex and chaotic but still living relationship. Behav. Brain Res. 2011; 221(2): 424–429. PubMed Abstract | Publisher Full Text
508. Dumas JA, Newhouse PA: The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol. Biochem. Behav. 2011; 99(2): 254–261. PubMed Abstract | Publisher Full Text | Free Full Text
509. Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer's disease. Drugs and Therapy Perspectives. 2011; 27(4): 9–12. Publisher Full Text
510. Hardeland R: Cognitive enhancers in moderate to severe Alzheimer's disease. Clinical Medicine Insights: Therapeutics. 2011; 3: 459–476.
511. Dintilhac G, Arslan D, Dilly S, et al.: New substituted aryl esters and aryl amides of 3,4-dihydro-2H-1,2,4- benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors. MedChemComm. 2011; 2(6): 509–523. Publisher Full Text
512. Malkova L, Kozikowski AP, Gale K: The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques. Neuropharmacology. 2011; 60(7-8): 1262–1268. PubMed Abstract | Publisher Full Text | Free Full Text
513. Tong-Un T, Muchimapura S, Wattanathorn J, et al.: Nasal administration of quercetin liposomes improves memory impairment and neurodegeneration in animal model of Alzheimer's disease. American Journal of Agricultural and Biological Science. 2010; 5(3): 286–293. Publisher Full Text
514. Mileusnic R, Rose S: The chick as a model for the study of the cellular mechanisms and potential therapies for alzheimer's disease. Int. J. Alzheimers Dis. 2010; 2010: 1–10. PubMed Abstract | Publisher Full Text | Free Full Text
515. Cappell J, Herrmann N, Cornish S, et al.: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimers disease. CNS Drugs. 2010; 24(11): 909–927. PubMed Abstract | Publisher Full Text
516. Uabundit N, Wattanathorn J, Mucimapura S, et al.: Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J. Ethnopharmacol. 2010; 127(1): 26–31. PubMed Abstract | Publisher Full Text
517. Tong-un T, Muchimapura S, Phachonpai W, et al.: Effects of quercetin encapsulated liposomes via nasal administration: A novel cognitive enhancer. Am. J. Appl. Sci. 2010; 7(7): 893–900.
518. Sofuoglu M: Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction. 2010; 105(1): 38–48. PubMed Abstract | Publisher Full Text | Free Full Text
519. Gielen M: Molecular operation of ionotropic glutamate receptors: Proteins that mediate the excitatory synaptic neurotransmission. Medecine/Sciences. 2010; 26(1): 65–72. PubMed Abstract | Publisher Full Text
520. Tricco AC, vander Vaart S , Soobiah C, et al.: Efficacy of cognitive enhancers for Alzheimer's disease: Protocol for a systematic review and network meta-analysis. Syst. Rev. 2009; 1(1). Publisher Full Text
521. Han F, Nakano T, Yamamoto Y, et al.: Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice. Brain Res. 2009; 1265: 205–214. PubMed Abstract | Publisher Full Text
522. Rastogi M, Ojha RP, Dubey GP, et al.: Medicinal plants and Alzheimer's disease: An overview. Biomedicine. 2008; 28(2): 73–80.
523. Schneider LS: Issues in Design and Conduct of Clinical Trials for Cognitive-Enhancing Drugs. Animal and Translational Models for CNS Drug Discovery. 2008; 21–76. Publisher Full Text
524. Brousseau G, Rourke BP, Burke B: Acetylcholinesterase Inhibitors, Neuropsychiatric Symptoms, and Alzheimer's Disease Subtypes: An Alternate Hypothesis to Global Cognitive Enhancement. Exp. Clin. Psychopharmacol. 2007; 15(6): 546–554. PubMed Abstract | Publisher Full Text
525. Gammanpila UP, Burns A, Heller RF, et al.: What are the benefits of cognitive enhancers for Alzheimer's disease: Use of population impact measures. BMC Geriatr. 2007; 7. PubMed Abstract | Publisher Full Text | Free Full Text
526. Groleger U: Off-label use of antipsychotics: Rethinking “off-label”. Psychiatr. Danub. 2007; 19: 350–353. PubMed Abstract
527. Nguyen PTH, Kimura T, Son AH, et al.: Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-β peptide (1-40) in rats. Hippocampus. 2007; 17(6): 443–455. PubMed Abstract | Publisher Full Text
528. Hashioka S, Han YH, Fujii S, et al.: Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid β and interferon-γ-induced microglial activation. Free Radic. Biol. Med. 2007; 42(7): 945–954. PubMed Abstract | Publisher Full Text
529. Wang R, Yan H, Tang XC: Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006; 27(1): 1–26. PubMed Abstract | Publisher Full Text
530. Wang R, Xi CT: Neuroprotective effects of huperzine A: A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals. 2005; 14(1-2): 71–82. Publisher Full Text
531. Snyder PJ, Bednar MM, Cromer JR, et al.: Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimer's and Dementia. 2005; 1(2): 126–135. PubMed Abstract | Publisher Full Text
532. Švestka J: Galantamine - A dual cognitive enhancer with neuroprotective effect: An update. Psychiatrie. 2004; 8(4): 304–314.
533. Davis M, Myers KM, Ressler KJ, et al.: Facilitation of extinction of conditioned fear by D-cycloserine: Implications for psychotherapy. Curr. Dir. Psychol. Sci. 2005; 14(4): 214–219. Publisher Full Text
534. Zhao CS, Puurunen K, Schallert T, et al.: Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats. Behav. Brain Res. 2005; 156(1): 85–94. PubMed Abstract | Publisher Full Text
535. Nagata T, Yamamoto S, Yaguchi T, et al.: The newly synthesized linoleic acid derivative DCP-LA ameliorates memory deficits in animal models treated with amyloid-β peptide and scopolamine. Psychogeriatrics. 2005; 5(4): 122–126. Publisher Full Text
536. Mileusnic R, Lancashire CL, Rose SRR: The peptide sequence Arg-Glu-Arg, present in the amyloid precursor protein, protects against memory loss caused by Aβ and acts as a cognitive enhancer. Eur. J. Neurosci. 2004; 19(7): 1933–1938. PubMed Abstract | Publisher Full Text
537. Solntseva EI, Bukanova IV, Skrebitskii VG: Memory and potassium channels. Usp. Fiziol. Nauk. 2003; 34(4): 16–25.
538. Neiva R, Caulino-Rocha A, Ferreirinha F, et al.: Non-genomic Actions of Methylprednisolone Differentially Influence GABA and Glutamate Release From Isolated Nerve Terminals of the Rat Hippocampus. Front. Mol. Neurosci. 2020; 13. PubMed Abstract | Publisher Full Text | Free Full Text
539. Tongun T, Phachonpai W: Cognitive booster of wampee peel extract on chronic restraint stress-induced memory dysfunction in rats. Journal of Applied Pharmaceutical Science. 2020; 10(7): 19–26.
540. Yahaya R, Zahary MN, Othman Z, et al.: Tualang honey supplementation as cognitive enhancer in patients with schizophrenia. Heliyon. 2020; 6(5): e03948. PubMed Abstract | Publisher Full Text | Free Full Text
541. Calva CB, Fayyaz H, Fadel JR: Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. Front. Aging Neurosci. 2020; 11: 11. Publisher Full Text
542. Hamarowski B: The Prostheticity of the Network. Humanities and Scientometrically-Born Cyborgs. Avant. 2023; 14(1).
543. Timmons S, Bracken-Scally M, Chakraborty S, et al.: Psychotropic Medication Prescribing to Patients with Dementia Admitted to Acute Hospitals in Ireland. Drugs Aging. 2023; 40(5): 461–472. PubMed Abstract | Publisher Full Text | Free Full Text
544. Oh ST, Han KT, Choi WJ, et al.: Effect of drug compliance on health care costs in newly-diagnosed dementia: Analysis of nationwide population-based data. J. Psychiatr. Res. 2019; 118: 31–37. PubMed Abstract | Publisher Full Text
545. Englisch S, Jung HS, Eisenacher S, et al.: Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering from Comorbid Depression: Results from the AGOPSYCH Study. J. Clin. Psychopharmacol. 2018; 38(4): 357–361. PubMed Abstract | Publisher Full Text
546. Tricco AC, Ashoor HM, Soobiah C, et al.: Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. J. Am. Geriatr. Soc. 2018; 66(1): 170–178. PubMed Abstract | Publisher Full Text
547. Ram S, Hussainy S, Henning M, et al.: Attitudes Toward Cognitive Enhancer Use Among New Zealand Tertiary Students. Subst. Use Misuse. 2017; 52(11): 1387–1392. Publisher Full Text
548. Hurter B, Gourley SL, Wolmarans DW: Associations between nesting, stereotypy, and working memory in deer mice: response to levetiracetam. Pharmacol. Rep. 2023; 75(3): 647–656. PubMed Abstract | Publisher Full Text | Free Full Text
549. Rosa-Gonçalves P, de Sousa LP , Ribeiro-Gomes FL, et al.: Immunomodulation through vaccination as a promising therapeutic strategy to mitigate malaria-related neurocognitive sequelae. Brain Behav. Immun. 2023; 109: 102–104. PubMed Abstract | Publisher Full Text
550. Robertson EE, O’Keefe JA, Hall DA: Clinical Trials in Fragile X-Associated Tremor/Ataxia Syndrome. Contemporary Clinical Neuroscience. Part F62023. : 649–661. Publisher Full Text
551. Gurbuz P, Duzova H, Taslidere AC, et al.: Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats. Biotech. Histochem. 2023; 98(5): 314–325. PubMed Abstract | Publisher Full Text
552. Wagener N, Lehmann W, Weiser L, et al.: Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration. Int. J. Mol. Sci. 2022; 23(18). PubMed Abstract | Publisher Full Text | Free Full Text
553. Mistarz N, Andersen K, Nielsen AS, et al.: Pharmacological compounds targeting emotional cognition in alcohol use disorder: A systematic review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2022; 116: 110535. PubMed Abstract | Publisher Full Text
554. Ha J, Son NH, Park YH, et al.: Association of cognitive enhancers and incident seizure risk in dementia: a population-based study. BMC Geriatr. 2022; 22(1): 480. PubMed Abstract | Publisher Full Text | Free Full Text
555. Loh SP, Cheng SH, Mohamed W: Edible Bird's Nest as a Potential Cognitive Enhancer. Front. Neurol. 2022; 13. PubMed Abstract | Publisher Full Text | Free Full Text
556. Schifano F, Catalani V, Sharif S, et al.: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals. Drugs. 2022; 82(6): 633–647. PubMed Abstract | Publisher Full Text
557. Szedlacsek HS, Bajusz D, Badea RA, et al.: Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats. J. Med. Chem. 2022; 65(1): 217–233. Publisher Full Text
558. France G, Volianskis R, Ingram R, et al.: Differential regulation of STP, LTP and LTD by structurally diverse NMDA receptor subunit-specific positive allosteric modulators. Neuropharmacology. 2022; 202: 108840. PubMed Abstract | Publisher Full Text | Free Full Text
559. Gyertyán I, Lubec J, Ernyey AJ, et al.: Cognitive profiling and proteomic analysis of the modafinil analogue S-CE-123 in experienced aged rats. Sci. Rep. 2021; 11(1): 23962. PubMed Abstract | Publisher Full Text | Free Full Text
560. Sui L, Guo HC: Enhanced recombinant expression and purification of human IRAP for biochemical and crystallography studies. Biochemistry and Biophysics Reports. 2021; 27: 101042. Publisher Full Text
561. Nuwer JL, Brady ML, Povysheva NV, et al.: Sustained treatment with an α5 GABA A receptor negative allosteric modulator delays excitatory circuit development while maintaining GABAergic neurotransmission. Neuropharmacology. 2021; 197: 108724. PubMed Abstract | Publisher Full Text | Free Full Text
562. Helmi H, Fakhrudin N, Nurrochmad A, et al.: Ameliorates scopolamine-induced memory deficits in mice via the camp/PKA/CREB/BDNF pathway. Sci. Pharm. 2021; 89(2). Publisher Full Text
563. Tang L, Jiang J, Song G, et al.: Design, synthesis, and biological evaluation of novel 6h-benzo [c]chromen-6-one derivatives as potential phosphodiesterase ii inhibitors. Int. J. Mol. Sci. 2021; 22(11). Publisher Full Text
564. Bioque M, González-Rodríguez A, Garcia-Rizo C, et al.: Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: A narrative review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2021; 105: 110130. PubMed Abstract | Publisher Full Text
565. Rabiey A, Abharian PH, Moravveji A, et al.: Research Paper: Effects of Atomoxetine for Cognitive Function in Methamphetamine-dependent Patients: A RandomizedControlledTrial. International Journal of Medical Toxicology and Forensic Medicine. 2021; 12(1): 35883. Publisher Full Text
566. Rabiey A, Abharian PH, Moravveji A, et al.: Effects of Atomoxetine for Cognitive Function in Methamphetamine-dependent Patients: A Randomized Controlled Trial. International Journal of Medical Toxicology and Forensic Medicine. 2021; 12(1): 35883. Publisher Full Text
567. Krukowski K, Nolan A, Frias ES, et al.: Small molecule cognitive enhancer reverses age-related memory decline in mice. elife. 2020; 9: 1–22. Publisher Full Text
568. Byers S, Buchler IP, DePasquale M, et al.: Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility. Psychopharmacology. 2020; 237(9): 2695–2707. PubMed Abstract | Publisher Full Text | Free Full Text
569. Weshahy SAEF, Yehia AM, Helmy AH, et al.: Comparative kinetic studies and pH-rate profiling of aniracetam degradation using validated stability-indicating RP-HPLC method. Microchem. J. 2020; 157: 105047. Publisher Full Text
570. Krause-Sorio B, Siddarth P, Kilpatrick L, et al.: Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression. J. Affect. Disord. 2020; 274: 464–470. PubMed Abstract | Publisher Full Text | Free Full Text
571. Pantoni MM, Carmack SA, Hammam L, et al.: Dopamine and norepinephrine transporter inhibition for long-term fear memory enhancement. Behav. Brain Res. 2020; 378: 112266. PubMed Abstract | Publisher Full Text
572. Bali ZK, Nagy LV, Budai D, et al.: Facilitation and inhibition of firing activity and N-methyl-D-aspartate-evoked responses of CA1 hippocampal pyramidal cells by alpha7 nicotinic acetylcholine receptor selective compounds in vivo. Sci. Rep. 2019; 9(1): 9324. PubMed Abstract | Publisher Full Text | Free Full Text
573. Arout CA, Waters AJ, MacLean RR, et al.: Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology. 2019; 236(10): 2857–2866. PubMed Abstract | Publisher Full Text | Free Full Text
574. Laulumaa S, Hansen KV, Masternak M, et al.: Crystal Structures of Potent Dimeric Positive Allosteric Modulators at the Ligand-Binding Domain of the GluA2 Receptor. ACS Med. Chem. Lett. 2019; 10(3): 243–247. PubMed Abstract | Publisher Full Text | Free Full Text
575. Hernández-Orallo J, Vold K, editors. AI extenders: The ethical and societal implications of humans cognitively extended by AI. AIES 2019 - Proceedings of the 2019 AAAI/ACM Conference on AI, Ethics, and Society. 2019.
576. Redivo L, Anastasiadi RM, Pividori M, et al.: Prediction of self-assembly of adenosine analogues in solution: A computational approach validated by isothermal titration calorimetry. Phys. Chem. Chem. Phys. 2019; 21(8): 4258–4267. PubMed Abstract | Publisher Full Text
577. Fukunaga K, Izumi H, Yabuki Y, et al.: Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. J. Pharmacol. Sci. 2019; 139(2): 51–58. Publisher Full Text
578. Peskin M, Wyka K, Cukor J, et al.: The relationship between posttraumatic and depressive symptoms during virtual reality exposure therapy with a cognitive enhancer. J. Anxiety Disord. 2019; 61: 82–88. PubMed Abstract | Publisher Full Text
579. Zaizar ED, Gonzalez-Lima F, Telch MJ: Singular and combined effects of transcranial infrared laser stimulation and exposure therapy: A randomized clinical trial. Contemp. Clin. Trials. 2018; 72: 95–102. PubMed Abstract | Publisher Full Text
580. Lipina TV, Beregovoy NA, Tkachenko AA, et al.: Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors. Frontiers in Synaptic Neuroscience. 2018; 10: 10. Publisher Full Text
581. Asua D, Bougamra G, Calleja-Felipe M, et al.: Peptides Acting as Cognitive Enhancers. Neuroscience. 2018; 370: 81–87. Publisher Full Text
582. Steinmetz AB, Stern SA, Kohtz AS, et al.: Insulin-like growth factor II targets the mTOR pathway to reverse autism-like phenotypes in mice. J. Neurosci. 2018; 38(4): 1015–1029. PubMed Abstract | Publisher Full Text | Free Full Text
583. Karel P, Calabrese F, Riva M, et al.: d-Cycloserine enhanced extinction of cocaine-induced conditioned place preference is attenuated in serotonin transporter knockout rats. Addict. Biol. 2018; 23(1): 120–129. PubMed Abstract | Publisher Full Text
584. Alter D, Beverley JA, Patel R, et al.: The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes. J. Psychopharmacol. 2017; 31(8): 1078–1087. PubMed Abstract | Publisher Full Text | Free Full Text
585. Meshalkina DA, Kizlyk MN, Kysil EV, et al.: Understanding zebrafish cognition. Behav. Process. 2017; 141: 229–241. Publisher Full Text
586. Arce E, Ehlers MD: The Mind Bending Quest for Cognitive Enhancers. Clin. Pharmacol. Ther. 2017; 101(2): 179–181. PubMed Abstract | Publisher Full Text | Free Full Text
587. Tay L, Lim WS, Chan M, et al.: A Combined Cognitive Stimulation and Physical Exercise Programme (MINDVital) in Early Dementia: Differential Effects on Single- and Dual-Task Gait Performance. Gerontology. 2016; 62(6): 604–610. Publisher Full Text
588. Ramírez-Barrantes R, Marchant I, Olivero P: TRPV1 may increase the effectiveness of estrogen therapy on neuroprotection and neuroregeneration. Neural Regen. Res. 2016; 11(8): 1204–1207.
589. Luz DA, Pinheiro AM, Silva ML, et al.: Ethnobotany, phytochemistry and neuropharmacological effects of Petiveria alliacea L. (Phytolaccaceae): A review. J. Ethnopharmacol. 2016; 185: 182–201. PubMed Abstract | Publisher Full Text
590. Walley R, Sherington J, Rastrick J, et al.: Using Bayesian analysis in repeated preclinical in vivo studies for a more effective use of animals. Pharm. Stat. 2016; 15(3): 277–285. PubMed Abstract | Publisher Full Text
591. Carvalho AS, Rodeia SC, Silvestre J, et al.: Exertional heat stroke and acute liver failure: A late dysfunction. BMJ Case Rep. 2016; 2016. Publisher Full Text
592. Ter Huurne N, Fallon SJ, Van Schouwenburg M, et al.: Methylphenidate alters selective attention by amplifying salience. Psychopharmacology. 2015; 232(23): 4317–4323. PubMed Abstract | Publisher Full Text
593. Fond G, Micoulaud-Franchi JA, Brunel L, et al.: Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. Psychiatry Res. 2015; 229(1-2): 12–20. PubMed Abstract | Publisher Full Text
594. Van Duinen M, Reneerkens OAH, Lambrecht L, et al.: Treatment of cognitive impairment in schizophrenia: Potential value of phosphodiesterase inhibitors in prefrontal dysfunction. Curr. Pharm. Des. 2015; 21(26): 3813–3828. PubMed Abstract | Publisher Full Text
595. Cooper RE, Tye C, Kuntsi J, et al.: Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis. J. Psychopharmacol. 2015; 29(7): 753–763. Publisher Full Text
596. Hofmann SG, Carpenter JK, Otto MW, et al.: Dose timing of d-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp. Clin. Trials. 2015; 43: 223–230. PubMed Abstract | Publisher Full Text | Free Full Text
597. Hofmann SG, Mundy EA, Curtiss J: Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neuroscience. 2015; 2(3): 123–138. PubMed Abstract | Publisher Full Text | Free Full Text
598. Singewald N, Schmuckermair C, Whittle N, et al.: Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol. Ther. 2015; 149: 150–190. PubMed Abstract | Publisher Full Text | Free Full Text
599. Van Waes V, Ehrlich S, Beverley JA, et al.: Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: Potential role for 5-HT1B receptor. Neuropharmacology. 2015; 89: 77–86. PubMed Abstract | Publisher Full Text | Free Full Text
600. Beverley JA, Piekarski C, Van Waes V, et al.: Potentiated gene regulation by methylphenidate plus fluoxetine treatment: Long-term gene blunting (Zif268, Homer1a) and behavioral correlates. Basal Ganglia. 2014; 4(3-4): 109–116. PubMed Abstract | Publisher Full Text | Free Full Text
601. Van Waes V, Vandrevala M, Beverley J, et al.: Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a. Addict. Biol. 2014; 19(6): 986–995. PubMed Abstract | Publisher Full Text | Free Full Text
602. Kosaraju J, Madhunapantula SV, Chinni S, et al.: Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behav. Brain Res. 2014; 267: 55–65. PubMed Abstract | Publisher Full Text
603. Egea J, Romero A, Parada E, et al.: Neuroprotective effect of dimebon against ischemic neuronal damage. Neuroscience. 2014; 267: 11–21. PubMed Abstract | Publisher Full Text
604. Brown JW, Rueter LE, Zhang M: Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2014; 49: 53–62. PubMed Abstract | Publisher Full Text
605. Franke AG, Papenburg C, Schotten E, et al.: Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany. BMC Fam. Pract. 2014; 15(1). PubMed Abstract | Publisher Full Text | Free Full Text
606. Thur KE, Nelson AJD, Cassaday HJ: Ro 04-6790-induced cognitive enhancement: No effect in trace conditioning and novel object recognition procedures in adult male Wistar rats. Pharmacol. Biochem. Behav. 2014; 127: 42–48. PubMed Abstract | Publisher Full Text | Free Full Text
607. Reichel CM, Gilstrap MG, Ramsey LA, et al.: Modafinil restores methamphetamine induced object-in-place memory deficits in rats independent of glutamate N-methyl-d-aspartate receptor expression. Drug Alcohol Depend. 2014; 134(1): 115–122. PubMed Abstract | Publisher Full Text | Free Full Text
608. Pringle A, Browning M, Parsons E, et al.: Early markers of cognitive enhancement: Developing an implicit measure of cognitive performance. Psychopharmacology. 2013; 230(4): 631–638. PubMed Abstract | Publisher Full Text
609. Yefimenko N, Portero-Tresserra M, Martí-Nicolovius M, et al.: The AMPA receptor modulator S18986 in the prelimbic cortex enhances acquisition and retention of an odor-reward association. Neurosci. Lett. 2013; 548: 105–109. PubMed Abstract | Publisher Full Text
610. Advokat C, Scheithauer M: Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers. Front. Neurosci. 2013; 7. Publisher Full Text
611. de Kleine RA , Rothbaum BO, van Minnen A : Pharmacological enhancement of exposure-based treatment in PTSD: A qualitative review. Eur. J. Psychotraumatol. 2013; 4(SUPPL). PubMed Abstract | Publisher Full Text | Free Full Text
612. Beier EV, Khazhbiev AA, Arushanyan EB: The optimizing influence of melatonin on the behavioral activity of cognitive enhancers. Eksperimental'naya i Klinicheskaya Farmakologiya. 2013; 76(10): 3–5.
613. Weger UW, Loughnan S: Mobilizing unused resources: Using the placebo concept to enhance cognitive performance. Q. J. Exp. Psychol. 2013; 66(1): 23–28. Publisher Full Text
614. Lynch G, Kramár EA, Babayan AH, et al.: Differences between synaptic plasticity thresholds result in new timing rules for maximizing long-term potentiation. Neuropharmacology. 2013; 64: 27–36. Publisher Full Text
615. Fass DM, Reis SA, Ghosh B, et al.: Crebinostat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology. 2013; 64: 81–96. PubMed Abstract | Publisher Full Text | Free Full Text
616. Yao Y, Shao C, Jothianandan D, et al.: Matching biochemical and functional efficacies confirm ZIP as a potent competitive inhibitor of PKMζ in neurons. Neuropharmacology. 2013; 64: 37–44. PubMed Abstract | Publisher Full Text | Free Full Text
617. Collingridge GL, Volianskis A, Bannister N, et al.: The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013; 64: 13–26. PubMed Abstract | Publisher Full Text | Free Full Text
618. Whittle N, Schmuckermair C, Gunduz Cinar O, et al.: Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology. 2013; 64: 414–423. PubMed Abstract | Publisher Full Text | Free Full Text
619. Lynch G, Palmer LC, Gall CM: The likelihood of cognitive enhancement. Pharmacol. Biochem. Behav. 2011; 99(2): 116–129. PubMed Abstract | Publisher Full Text | Free Full Text
620. Thomson DM, McVie A, Morris BJ, et al.: Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: Influence of clozapine. Psychopharmacology. 2011; 213(4): 681–695. PubMed Abstract | Publisher Full Text
621. King-Keller S, Li M, Smith A, et al.: Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease. Antimicrob. Agents Chemother. 2010; 54(9): 3738–3745. PubMed Abstract | Publisher Full Text | Free Full Text
622. Rock EM, Benzaquen J, Limebeer CL, et al.: Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol. Biochem. Behav. 2009; 91(4): 537–541. PubMed Abstract | Publisher Full Text
623. Ananthalakshmi KVV, Bartl T, Aziza MH, et al.: Synthesis and structure-activity relationship studies of theophylline analogs on population responses in the rat hippocampus in vitro. Bioorg. Med. Chem. 2008; 16(17): 8142–8150. PubMed Abstract | Publisher Full Text
624. Han F, Shioda N, Moriguchi S, et al.: Spiro [imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J. Pharmacol. Exp. Ther. 2008; 326(1): 127–134. PubMed Abstract | Publisher Full Text
625. Eleore L, López-Ramos JC, Yi PJ, et al.: The Cognitive Enhancer T-588 Partially Compensates the Motor and Associative Learning Impairments Induced by Scopolamine Injection in Mice. Behav. Neurosci. 2007; 121(6): 1203–1214. PubMed Abstract | Publisher Full Text
626. O'Neill MJ, Dix S: AMPA receptor potentiators as cognitive enhancers. IDrugs. 2007; 10(3): 185–192. PubMed Abstract
627. Wesensten NJ, Reichardt RM, Balkin TJ: Ampakine (CX717) effects on performance and alertness during simulated night shift work. Aviation Space and Environmental Medicine. 2007; 78(10): 937–943. PubMed Abstract | Publisher Full Text
628. Bouton ME, Woods AM: Extinction: Behavioral mechanisms and their implications. Learning and Memory: A Comprehensive Reference. 2007; 151–171. Publisher Full Text
629. Hutton SB, Ettinger U: The antisaccade task as a research tool in psychopathology: A critical review. Psychophysiology. 2006; 43(3): 302–313. Publisher Full Text
630. Singh D: Diagnosis of dementia with Lewy bodies in clinical practice: A literature review. Australas. Psychiatry. 2005; 13(1): 54–59. Publisher Full Text
631. DeMarchi R, Bansal V, Hung A, et al.: Review of awakening agents. Can. J. Neurol. Sci. 2005; 32(1): 4–17. Publisher Full Text
632. Sabolek HR, Bunce JG, Chrobak JJ: Intraseptal tacrine can enhance memory in cognitively impaired young rats. NeuroReport. 2004; 15(1): 181–183. Publisher Full Text
633. Bontempi B, Whelan KT, Risbrough VB, et al.: Cognitive enhancing properties and tolerability of cholinergic agents in mice: A comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology. 2003; 28(7): 1235–1246. PubMed Abstract | Publisher Full Text
634. Schwartz JC, Morisset S, Rouleau A, et al.: Therapeutic implications of constitutive activity of receptors: The example of the histamine H3 receptor. J. Neural Transm. Suppl. 2003. Publisher Full Text
635. Jay M: Psychonauts: Drugs and the Making of the Modern Mind.2023; 1–359.
636. Singewald N, Sartori SB, Reif A, et al.: Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology. 2023; 226: 109418. Publisher Full Text
637. Pareek T, Overton JS, Nguyen LT, et al.: Modeling cue-exposure therapy for alcohol use disorder in rhesus monkeys: Effects of putative cognitive enhancers. Drug Alcohol Depend. 2023; 243: 109735. PubMed Abstract | Publisher Full Text | Free Full Text
638. Sidorenko N, Chung HK, Grueschow M, et al.: Acetylcholine and noradrenaline enhance foraging optimality in humans. Proc. Natl. Acad. Sci. USA. 2023; 120(36). Publisher Full Text
639. Marchetta E, Mancini GF, Morena M, et al.: Enhancing Psychological Interventions for Post-Traumatic Stress Disorder (PTSD) Treatment with Memory Influencing Drugs. Curr. Neuropharmacol. 2023; 21(3): 687–707. PubMed Abstract | Publisher Full Text | Free Full Text
640. Difede JA, Rothbaum BO, Rizzo AA, et al.: Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer. Transl. Psychiatry. 2022; 12(1): 299. PubMed Abstract | Publisher Full Text | Free Full Text
641. Yanpallewar S, Tomassoni-Ardori F, Palko ME, et al.: TrkA-cholinergic signaling modulates fear encoding and extinction learning in PTSD-like behavior. Transl. Psychiatry. 2022; 12(1). Publisher Full Text
642. Pizzarelli R, Pimpinella D, Jacobs C, et al.: Insulin-like growth factor 2 (IGF-2) rescues social deficits in NLG3–/y mouse model of ASDs. Front. Cell. Neurosci. 2023; 17. Publisher Full Text
643. Chen L, Jiao J, Zhang Y: Therapeutic approaches for improving cognitive function in the aging brain. Front. Neurosci. 2022; 16. PubMed Abstract | Publisher Full Text | Free Full Text
644. Burns AM, Farinelli-Scharly M, Hugues-Ascery S, et al.: The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning. Proc. Natl. Acad. Sci. USA. 2022; 119(22): e2116797119. PubMed Abstract | Publisher Full Text | Free Full Text
645. Rojas-Rozo L, Vedel I, Sivananthan S, et al.: Latest Canadian consensus conference on the diagnosis and treatment of dementia for primary care clinicians. Ann. Fam. Med. 2022; 20.
646. Van Puyvelde M, Van Cutsem J, Lacroix E, et al.: A State-of-the-Art Review on the Use of Modafinil as A Performance-Enhancing Drug in the Context of Military Operationality. Mil. Med. 2022; 187(1-2): 52–64. PubMed Abstract | Publisher Full Text
647. Mridha Z, de Gee JW , Shi Y, et al.: Graded recruitment of pupil-linked neuromodulation by parametric stimulation of the vagus nerve. Nat. Commun. 2021; 12(1): 1539. PubMed Abstract | Publisher Full Text | Free Full Text
648. Wang Q, Ma M, Yu H, et al.: Mirtazapine prevents cell activation, inflammation, and oxidative stress against isoflurane exposure in microglia. Bioengineered. 2022; 13(1): 521–530. PubMed Abstract | Publisher Full Text | Free Full Text
649. Anderson AC, Youssef GJ, Robinson AH, et al.: Cognitive boosting interventions for impulsivity in addiction: a systematic review and meta-analysis of cognitive training, remediation and pharmacological enhancement. Addiction. 2021; 116(12): 3304–3319. PubMed Abstract | Publisher Full Text
650. Subramanian S, Fahed M, Dix E, et al.: Emergent and Non-Emergent Agitation in the Older Adult: Evaluation and Management. Curr. Geriatr. Rep. 2021; 10(3): 73–81. Publisher Full Text
651. Nicklas PR, Kiefer ML, Whalen MA, et al.: Muscarinic M1, but not M4, receptor antagonism impairs divided attention in male rats. Pharmacol. Biochem. Behav. 2021; 205: 173184. Publisher Full Text
652. Vinarskaya AK, Balaban PM, Roshchin MV, et al.: Sodium butyrate as a selective cognitive enhancer for weak or impaired memory. Neurobiol. Learn. Mem. 2021; 180: 107414. Publisher Full Text
653. Burns AM, Gräff J: Cognitive epigenetic priming: leveraging histone acetylation for memory amelioration. Curr. Opin. Neurobiol. 2021; 67: 75–84. PubMed Abstract | Publisher Full Text
654. Nguyen NT, Rakow T, Gardner B, et al.: Understanding the relationship between safety beliefs and knowledge for cognitive enhancers in UK university students. PLoS ONE. 2021; 16(1 January). Publisher Full Text
655. Bertani DE, Mattei G, Ferrari S, et al.: Anxiety, depression and personality traits in Italian medical students. Riv. Psichiatr. 2020; 55(6): 342–348. PubMed Abstract | Publisher Full Text
656. Guercio GD, Anjos-Travassos Y, Rangel I, et al.: Auditory cognitive training improves prepulse inhibition in serine racemase mutant mice. Psychopharmacology. 2020; 237(8): 2499–2508. PubMed Abstract | Publisher Full Text
657. Núñez F, Maraver MJ, Colzato LS: Sex Hormones as Cognitive Enhancers?. J. Cogn. Enhanc. 2020; 4(2): 228–233. Publisher Full Text
658. Adamopoulos P, Ho H, Sykes G, et al.: Learning Approaches and Attitudes Toward Cognitive Enhancers in UK University Students. J. Psychoactive Drugs. 2020; 52(3): 248–254. PubMed Abstract | Publisher Full Text
659. Niu Y, Ye D, You Y, et al.: Prophylactic cognitive enhancers for improvement of cognitive function in patients undergoing electroconvulsive therapy: A systematic review and meta-analysis. Medicine (United States). 2020; 99(11): E19527. Publisher Full Text
660. Difede J, Rothbaum BO, Rizzo AA, et al.: Enhanced exposure therapy for combat-related Posttraumatic Stress Disorder (PTSD): Study protocol for a randomized controlled trial. Contemp. Clin. Trials. 2019; 87: 105857. PubMed Abstract | Publisher Full Text
661. Weingarden H, Mothi SS, Ladis I, et al.: d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial. Cogn. Ther. Res. 2019; 43(5): 937–947. Publisher Full Text
662. Gomes T, Khuu W, Tadrous M, et al.: Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. BMJ Open. 2019; 9(7): e028125. PubMed Abstract | Publisher Full Text | Free Full Text
663. Guercio GD, Thomas ME, Cisneros-Franco JM, et al.: Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research. Schizophr. Res. 2019; 207: 80–92. PubMed Abstract | Publisher Full Text
664. Ma B, Mei D, Wang F, et al.: Cognitive enhancers as a treatment for heroin relapse and addiction. Pharmacol. Res. 2019; 141: 378–383. PubMed Abstract | Publisher Full Text
665. Verdejo-Garcia A, Garcia-Fernandez G, Dom G: Cognition and addiction. Dialogues Clin. Neurosci. 2019; 21(3): 281–290. Publisher Full Text
666. Margolius A, Cubillos F, He Y, et al.: Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. Parkinsonism Relat. Disord. 2018; 56: 93–97. PubMed Abstract | Publisher Full Text
667. Sartori SB, Singewald N: New pharmacological strategies for augmenting extinction learning in anxiety disorders. Neuroforum. 2017; 23(4): 197–211. andA145. Publisher Full Text
668. Ahmad F, Nayak V, Malalur C, et al.: Relative efficacy of piracetam, modafinil and citicoline on cognitive function in an animal model. J. Clin. Diagn. Res. 2017; 11(11): FC01–FC03. Publisher Full Text
669. Lees J, Michalopoulou PG, Lewis SW, et al.: Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: The effects of test battery in a randomised controlled trial. Psychol. Med. 2017; 47(13): 2358–2368. PubMed Abstract | Publisher Full Text
670. Schuijer JW, de Jong IM , Kupper F, et al.: Transcranial electrical stimulation to enhance cognitive performance of healthy minors: A complex governance challenge. Front. Hum. Neurosci. 2017; 11: 11. Publisher Full Text
671. Sanchez-Moreno J, Martinez-Aran A, Vieta E: Treatment of Functional Impairment in Patients with Bipolar Disorder. Curr. Psychiatry Rep. 2017; 19(1). Publisher Full Text
672. Berardi A, Schelling G, Campolongo P: The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings. Pharmacol. Res. 2016; 111: 668–678. PubMed Abstract | Publisher Full Text
673. Quartini A, Iannitelli A, Bersani G: Lithium: From mood stabilizer to putative cognitive enhancer. Neural Regen. Res. 2016; 11(8): 1234–1235. Publisher Full Text
674. Detrait ER, Carr GV, Weinberger DR, et al.: Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Behav. Pharmacol. 2016; 27(5): 415–421. PubMed Abstract | Publisher Full Text | Free Full Text
675. Sartori SB, Maurer V, Murphy C, et al.: Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: Advantage of dual versus single drug approaches. Int. J. Neuropsychopharmacol. 2016; 19(6): 1–11.
676. Bortolato B, Miskowiak KW, Köhler CA, et al.: Cognitive remission: A novel objective for the treatment of major depression?. BMC Med. 2016; 14(1): 9. PubMed Abstract | Publisher Full Text | Free Full Text
677. Darcet F, Gardier AM, David DJ, et al.: Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression. Neurosci. Lett. 2016; 616: 197–203. Publisher Full Text
678. Choy TL: Cognitive-enhancing drugs in the healthy population: Fundamental drawbacks and researcher roles. Cogent Psychology. 2015; 2(1). Publisher Full Text
679. Burgdorf J, Kroes RA, Zhang XL, et al.: Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav. Brain Res. 2015; 294: 177–185. PubMed Abstract | Publisher Full Text | Free Full Text
680. Pasqualetti G, Tognini S, Calsolaro V, et al.: Potential drug–drug interactions in alzheimer patients with behavioral symptoms. Clin. Interv. Aging. 2015; 10: 1457–1466. PubMed Abstract | Publisher Full Text
681. Hunt PS, Barnet RC: An animal model of fetal alcohol spectrum disorder: Trace conditioning as a window to inform memory deficits and intervention tactics. Physiol. Behav. 2015; 148: 36–44. PubMed Abstract | Publisher Full Text | Free Full Text
682. Bala R, Khanna D, Mehan S, et al.: Experimental evidence for the potential of lycopene in the management of scopolamine induced amnesia. RSC Adv. 2015; 5(89): 72881–72892. Publisher Full Text
683. Binder S, Dere E, Zlomuzica A: A critical appraisal of the what-where-when episodic-like memory test in rodents: Achievements, caveats and future directions. Prog. Neurobiol. 2015; 130: 71–85. Publisher Full Text
684. Pitsikas N: The effect of crocus sativus L. and its constituents on memory: Basic studies and clinical applications. Evid. Based Complement. Alternat. Med. 2015; 2015: 1–7. PubMed Abstract | Publisher Full Text | Free Full Text
685. Graff FS, McClure MM, Siever LJ: Remediation and Cognitive Enhancers in Schizotypal Personality Disorder. Curr. Treat. Options Psychiatry. 2014; 1(4): 369–375. Publisher Full Text
686. Ng KP, Ng A, Assam P, et al.: Role of Cognitive Enhancer Therapy in Alzheimer’s Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study. Drugs in R and D. 2014; 14(3): 195–203. PubMed Abstract | Publisher Full Text | Free Full Text
687. Borisovskaya A, Pascualy M, Borson S: Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies. Curr. Psychiatry Rep. 2014; 16(9): 470. PubMed Abstract | Publisher Full Text
688. Hofmann SG, Fang A, Gutner CA: Cognitive enhancers for the treatment of anxiety disorders. Restor. Neurol. Neurosci. 2014; 32(1): 183–195. Publisher Full Text
689. Sulkowski ML, Geller DA, Lewin AB, et al.: The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. Curr. Psychiatr. Rev. 2014; 10(4): 317–324. PubMed Abstract | Publisher Full Text | Free Full Text
690. McGuire JF, Lewin AB, Storch EA: Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert. Rev. Neurother. 2014; 14(8): 893–910. PubMed Abstract | Publisher Full Text | Free Full Text
691. Vervliet B, Vervoort E: Cognitive enhancers as adjuncts to exposure-based treatments. The Wiley Handbook of Anxiety Disorders. 2014; 1343–1354. Publisher Full Text
692. Pull CN, Pull CB: Current status of treatment for posttraumatic stress disorder: Focus on treatments combining pharmacotherapy and cognitive- behavioral therapy. Int. J. Cogn. Ther. 2014; 7(2): 149–161. Publisher Full Text
693. Difede J, Cukor J, Wyka K, et al.: D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: A pilot randomized clinical trial. Neuropsychopharmacology. 2014; 39(5): 1052–1058. PubMed Abstract | Publisher Full Text | Free Full Text
694. Portero-Tresserra M, Cristóbal-Narváez P, Martí-Nicolovius M, et al.: D-cycloserine in Prelimbic Cortex Reverses Scopolamine-Induced Deficits in Olfactory Memory in Rats. PLoS ONE. 2013; 8(8). Publisher Full Text
695. Lapish CC, Ahn KC, Chambers RA, et al.: Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2014; 39(7): 1754–1762. PubMed Abstract | Publisher Full Text | Free Full Text
696. Colzato LS, Jongkees BJ, Sellaro R, et al.: Working memory reloaded: Tyrosine repletes updating in the N-back task. Front. Behav. Neurosci. 2013; 7(DEC). PubMed Abstract | Publisher Full Text | Free Full Text
697. Krintel C, Harpsøe K, Zachariassen LG, et al.: Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain. Acta Crystallographica Section D: Biological Crystallography. 2013; 69(9): 1645–1652. PubMed Abstract | Publisher Full Text
698. Nakajima S, Gerretsen P, Takeuchi H, et al.: The potential role of dopamine D3 receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 2013; 23(8): 799–813. PubMed Abstract | Publisher Full Text | Free Full Text
699. Dudley JA, Weir RK, Yan TC, et al.: Antagonism of L-type Cav channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-Choice Serial Reaction-Time Task. Neuropharmacology. 2013; 64: 329–336. PubMed Abstract | Publisher Full Text
700. Bari A, Aston-Jones G: Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons. Neuropharmacology. 2013; 64: 53–64. PubMed Abstract | Publisher Full Text | Free Full Text
701. Kuriyama K, Honma M, Yoshiike T, et al.: Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans. Neuropharmacology. 2013; 64: 424–431. Publisher Full Text
702. Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG, et al.: Pharmacological approaches in bipolar disorders and the impact on cognition: A critical overview. Acta Psychiatr. Scand. 2012; 126(5): 315–331. PubMed Abstract | Publisher Full Text
703. Thukhammee W, Wattanathorn J, Muchimapura S, et al.: The cognitive enhancing effect of tomato pomace. Am. J. Appl. Sci. 2012; 9(11): 1776–1781.
704. De Kleine RA, Hendriks GJ, Kusters WJC, et al.: A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry. 2012; 71(11): 962–968. PubMed Abstract | Publisher Full Text
705. Hofmann SG, Gutner CA, Asnaani A: Cognitive enhancers in exposure therapy for anxiety and related disorders. Exposure Therapy: Rethinking the Model - Refining the Method. 2012; 89–110. Publisher Full Text
706. Curlik DM, Shors TJ: Learning increases the survival of newborn neurons provided that learning is difficult to achieve and successful. J. Cogn. Neurosci. 2011; 23(9): 2159–2170. PubMed Abstract | Publisher Full Text | Free Full Text
707. Barak S, Weiner I: Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacol. Biochem. Behav. 2011; 99(2): 164–189. PubMed Abstract | Publisher Full Text
708. Brady KT, Gray KM, Tolliver BK: Cognitive enhancers in the treatment of substance use disorders: Clinical evidence. Pharmacol. Biochem. Behav. 2011; 99(2): 285–294. PubMed Abstract | Publisher Full Text | Free Full Text
709. Nic Dhonnchadha BA, Kantak KM: Cognitive enhancers for facilitating drug cue extinction: Insights from animal models. Pharmacol. Biochem. Behav. 2011; 99(2): 229–244. PubMed Abstract | Publisher Full Text | Free Full Text
710. Kantak KM, Nic Dhonnchadha BÁ: Pharmacological enhancement of drug cue extinction learning: Translational challenges. Ann. N. Y. Acad. Sci. 2011; 1216(1): 122–137. PubMed Abstract | Publisher Full Text | Free Full Text
711. Vignisse J, Steinbusch HWM, Bolkunov A, et al.: Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011; 35(2): 510–522. Publisher Full Text
712. Meyerbröker K, Emmelkamp PMG: Virtual reality exposure therapy in anxiety disorders: A systematic review of process-and-outcome studies. Depress. Anxiety. 2010; 27(10): 933–944. PubMed Abstract | Publisher Full Text
713. Bentz D, Michael T, de Quervain DJF , et al.: Enhancing exposure therapy for anxiety disorders with glucocorticoids: From basic mechanisms of emotional learning to clinical applications. J. Anxiety Disord. 2010; 24(2): 223–230. Publisher Full Text
714. Nehlig A: Is caffeine a cognitive enhancer?. J. Alzheimers Dis. 2010; 20: S85–S94. Publisher Full Text
715. Cunha RA, Agostinho PM: Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010; 20: S95–S116. PubMed Abstract | Publisher Full Text
716. Win-Shwe TT, Kageyama S, Tsukahara S, et al.: The effect of D-cycloserine on spatial learning performance and memory function-related gene expression in mice following toluene exposure. J. UOEH. 2010; 32(2): 127–140. PubMed Abstract | Publisher Full Text
717. Nic Dhonnchadha BÁ, Szalay JJ, Achat-Mendes C, et al.: D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology. 2010; 35(2): 357–367. PubMed Abstract | Publisher Full Text | Free Full Text
718. Kahloula K, Slimani M, Dubois M, et al.: D-cycloserine enhances spatial learning performances of rats chronically exposed to lead during the developmental period. Afr. J. Neurol. Sci. 2009; 28(1). Publisher Full Text
719. Schnyder U: Future perspectives in psychotherapy. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259(SUPPL. 2): 123–128. Publisher Full Text
720. Hamm AO: Specific Phobias. Psychiatr. Clin. N. Am. 2009; 32(3): 577–591. Publisher Full Text
721. Buccafusco JJ, Terry AV Jr: A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem. Pharmacol. 2009; 78(7): 852–862. PubMed Abstract | Publisher Full Text | Free Full Text
722. Sessa B: Is it time to revisit the role of psychedelic drugs in enhancing human creativity?. J. Psychopharmacol. 2008; 22(8): 821–827. PubMed Abstract | Publisher Full Text
723. Koda K, Ago Y, Kawasaki T, et al.: Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology. 2008; 196(2): 293–301. PubMed Abstract | Publisher Full Text
724. Pull CB, Damsa C: Pharmacotherapy of panic disorder. Neuropsychiatr. Dis. Treat. 2008; 4(4): 779–795. PubMed Abstract
725. Oken BS, Flegal K, Zajdel D, et al.: Expectancy effect: Impact of pill administration on cognitive performance in healthy seniors. J. Clin. Exp. Neuropsychol. 2008; 30(1): 7–17. PubMed Abstract | Publisher Full Text
726. Vulih-Shultzman I, Pinhasov A, Mandel S, et al.: Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 2007; 323(2): 438–449. Publisher Full Text
727. Morain P, Boeijinga PH, Demazières A, et al.: Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. Neuropsychobiology. 2007; 55(3-4): 176–183. PubMed Abstract | Publisher Full Text
728. Guillem F, Chouinard S, Poulin J, et al.: Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006; 30(5): 934–945. Publisher Full Text
729. Shoaib M: Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence. Psychopharmacology. 2006; 188(2): 252–257. PubMed Abstract | Publisher Full Text
730. Floresco SB, Geyer MA, Gold LH, et al.: Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr. Bull. 2005; 31: 888–894. Publisher Full Text
731. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2005; 29(2): 219–232. PubMed Abstract | Publisher Full Text
732. Devan BD, Sierra-Mercado D Jr, Jimenez M, et al.: Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav. 2004; 79(4): 691–699. Publisher Full Text
733. Fayuk D, Yakel JL: Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol. Pharmacol. 2004; 66(3): 658–666. PubMed Abstract | Publisher Full Text
734. Sharma T, Antonova L: Cognitive function in schizophrenia deficits, functional consequences, and future treatment. Psychiatr. Clin. N. Am. 2003; 26(1): 25–40. Publisher Full Text
735. Ryzhkov FV, Ryzhkova YE, Elinson MN, et al.: Modern synthesis of cognitive enhancers: cholinergic ligands. Russ. Chem. Bull. 2023; 72(4): 819–837. Publisher Full Text
736. Malík M, Tlustoš P: Nootropic Herbs, Shrubs, and Trees as Potential Cognitive Enhancers. Plants. 2023; 12(6). PubMed Abstract | Publisher Full Text | Free Full Text
737. Bharti A, Kashyap K, Moudgil A, et al.: Phytochemical and Therapeutic Potential of Herbal Cognitive Enhancer. Journal of Natural Remedies. 2023; 23(3): 791–800. Publisher Full Text
738. Lorca C, Mulet M, Arévalo-Caro C, et al.: Plant-derived nootropics and human cognition: A systematic review. Crit. Rev. Food Sci. Nutr. 2023; 63(22): 5521–5545. PubMed Abstract | Publisher Full Text
739. Kaushik A, Chauhan K, Singh S: Neuroprotective potential of quercetin as a nutraceutical targeting fused neuroinflammation in neurological disease. Treatments, Nutraceuticals, Supplements, and Herbal Medicine in Neurological Disorders. 2023; 623–637. Publisher Full Text
740. Medrano M, Molina-Hidalgo C, Alcantara JMA, et al.: Acute Effect of a Dietary Multi-Ingredient Nootropic as a Cognitive Enhancer in Young Healthy Adults: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover Trial. Front. Nutr. 2022; 9: 9. Publisher Full Text
741. Oyeleke MB, Oni HT, Arokoyo OL, et al.: Therapeutic effects of crude extracts of Bacopa floribunda on beta-amyloid 1-42-induced Alzheimer's disease via suppression of dyslipidemia, systemic inflammation and oxidative stress in male Wistar Rats. Heliyon. 2022; 8(4): e09255. PubMed Abstract | Publisher Full Text | Free Full Text
742. Sendri N, Bhandari P: Bacopa monnieri. Herbs, Spices and Their Roles in Nutraceuticals and Functional Foods. 2022; 111–131. Publisher Full Text
743. Muangpaisan W, Wiputhanuphongs P, Jaisupa N, et al.: Effects of water-soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN-AD): A randomized controlled trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2022; 8(1). Publisher Full Text
744. Lwin T, Yang JL, Ngampramuan S, et al.: Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2021; 111: 110109. PubMed Abstract | Publisher Full Text
745. Oliveira-Campos D, Reis HS, Libarino-Santos M, et al.: The influence of early exposure to methylphenidate on addiction-related behaviors in mice. Pharmacol. Biochem. Behav. 2021; 206: 173208. PubMed Abstract | Publisher Full Text
746. Soleimani Meigoni Z, Jabari F, Motaghinejad M, et al.: Protective effects of forced exercise against topiramate-induced cognition impairment and enhancement of its antiepileptic activity: molecular and behavioral evidences. Int. J. Neurosci. 2022; 132(12): 1198–1209. PubMed Abstract | Publisher Full Text
747. Semproli R, Robescu MS, Cambò M, et al.: Chemical and Enzymatic Approaches to Esters of sn-Glycero-3-Phosphoric Acid. Eur. J. Org. Chem. 2021; 2021(29): 4027–4037. Publisher Full Text
748. Philipsen MH, Ranjbari E, Gu C, et al.: Mass Spectrometry Imaging Shows Modafinil, A Student Study Drug, Changes the Lipid Composition of the Fly Brain. Angewandte Chemie - International Edition. 2021; 60(32): 17378–17382. PubMed Abstract | Publisher Full Text | Free Full Text
749. Liu J, Zhang X, Deng L: Research progress on modifying sleep deprivation with Modafinil to improve flight operation ability of pilots. Chinese Journal of Aerospace Medicine. 2021; 32(2): 124–128.
750. Dahlström M, Madjid N, Nordvall G, et al.: Identification of novel positive allosteric modulators of neurotrophin receptors for the treatment of cognitive dysfunction. Cells. 2021; 10(8). PubMed Abstract | Publisher Full Text | Free Full Text
751. Helmi H, Fakhrudin N, Nurrochmad A, et al.: Plant Natural Products for Cognitive Impairment: A Review of the preclinical Evidence. Journal of Applied Pharmaceutical Science. 2021; 11(6): 001–014.
752. Thomas EM, Freeman TP, Poplutz P, et al.: Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training. J. Psychopharmacol. 2021; 35(6): 621–630. PubMed Abstract | Publisher Full Text | Free Full Text
753. Recio-Barbero M, Segarra R, Zabala A, et al.: Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. Front. Psych. 2021; 12: 12. Publisher Full Text
754. Pitt J, Pitt Y: Cognitive effects of nutraceuticals. Nutraceuticals: Efficacy, Safety and Toxicity. 2021; 41–61. Publisher Full Text
755. Hill RA, Kouremenos K, Tull D, et al.: Bazedoxifene – a promising brain active SERM that crosses the blood brain barrier and enhances spatial memory. Psychoneuroendocrinology. 2020; 121: 104830. PubMed Abstract | Publisher Full Text
756. Ali AM, Kunugi H: Royal jelly as an intelligent anti-aging agent— a focus on cognitive aging and Alzheimer’s disease: A review. Antioxidants. 2020; 9(10): 1–46.
757. Napoletano F, Schifano F, Corkery JM, et al.: The Psychonauts’ World of Cognitive Enhancers. Front. Psych. 2020; 11: 11. Publisher Full Text
758. Zainullina LF, Ivanova TV, Sadovnikov SV, et al.: Cognitive Enhancer Noopept Activates Transcription Factor HIF-1. Dokl. Biochem. Biophys. 2020; 494(1): 256–260. PubMed Abstract | Publisher Full Text
759. Bashir MI, Aziz NHKA, Noor DAM: Possible antidepressant potential of a cognitive enhancer Polygonum minus based on its major chemical constituents in leaf part. Drug Invention Today. 2020; 13(4): 549–557.
760. Benson S, Scholey A: Nutraceuticals as Cognitive Enhancers. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 35–58. Publisher Full Text
761. Fakhrudin N, Nurrochmad A, Arie Sudarmanto BS, et al.: In vitro and in silico studies of secang wood (Caesalpinia sappan L.) extracts and Brazilin as natural phosphodiesterase-1 (PDE1) inhibitor for herbal cognitive enhancer development. Research Journal of Pharmacy and Technology. 2020; 13(5): 2269–2274. Publisher Full Text
762. Zamberlam CR, Tilger MAS, Moraes L, et al.: Ginkgo biloba treatments reverse the impairment of conditioned suppression acquisition induced by GluN2B-NMDA and 5-HT1A receptor blockade: Modulatory effects of the circuitry of the dorsal hippocampal formation. Physiol. Behav. 2019; 209: 112534. PubMed Abstract | Publisher Full Text
763. Fishman DO, Faeder M: Neurocognitive disorders. Fundamentals of Consultation Liaison Psychiatry: Neuropsychiatry. 2019; 107–138.
764. Uddin MS, Al Mamun A, Kabir MT, et al.: Nootropic and Anti-Alzheimer’s Actions of Medicinal Plants: Molecular Insight into Therapeutic Potential to Alleviate Alzheimer’s Neuropathology. Mol. Neurobiol. 2019; 56(7): 4925–4944. PubMed Abstract | Publisher Full Text
765. Nasr M, Wahdan SA: Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration. Life Sci. 2019; 226: 117–129. PubMed Abstract | Publisher Full Text
766. Mitchell G, Rooney S, Sheeran C, et al.: Medicines management for people with dementia. Nursing standard (Royal College of Nursing (Great Britain): 1987). 2019; 34(3): 37–43. Publisher Full Text
767. Mathys M: Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder. Mental Health Clinician. 2018; 8(6): 284–293. PubMed Abstract | Publisher Full Text | Free Full Text
768. Najafizadeh Sari S, Bahrami F, Ghasemi D, et al.: The effect of cinnamaldehyde on stress-induced deficits in acquisition behavior with barnes maze in rat. Pharmacologyonline. 2018; 2: 234–242.
769. Kim MS, Lee DY, Lee J, et al.: Terminalia chebula extract prevents scopolamine-induced amnesia via cholinergic modulation and anti-oxidative effects in mice. BMC Complement. Altern. Med. 2018; 18(1): 136. PubMed Abstract | Publisher Full Text | Free Full Text
770. Vanda D, Soural M, Canale V, et al.: Novel non-sulfonamide 5-HT6 receptor partial inverse agonist in a group of imidazo[4,5-b] pyridines with cognition enhancing properties. Eur. J. Med. Chem. 2018; 144: 716–729. PubMed Abstract | Publisher Full Text
771. Rodrigues MJ, Slusarczyk S, Pecio Ł, et al.: In vitro and in silico approaches to appraise Polygonum maritimum L. as a source of innovative products with anti-ageing potential. Ind. Crop. Prod. 2018; 111: 391–399. Publisher Full Text
772. Sharma A, Piplani P: Design and synthesis of some acridine-piperazine hybrids for the improvement of cognitive dysfunction. Chem. Biol. Drug Des. 2017; 90(5): 926–935. PubMed Abstract | Publisher Full Text
773. Tohda C, Yang X, Matsui M, et al.: Diosgenin-rich yam extract enhances cognitive function: A placebo-controlled, randomized, double-blind, crossover study of healthy adults. Nutrients. 2017; 9(10). PubMed Abstract | Publisher Full Text | Free Full Text
774. Rodrigues MJ, Gangadhar KN, Zengin G, et al.: Juncaceae species as sources of innovative bioactive compounds for the food industry: in vitro antioxidant activity, neuroprotective properties and in silico studies. Food Chem. Toxicol. 2017; 107: 590–596. Publisher Full Text
775. Nonaka M, Fitzpatrick R, Lapira J, et al.: Everyday memory: towards a translationally effective method of modelling the encoding, forgetting and enhancement of memory. Eur. J. Neurosci. 2017; 46(4): 1937–1953. PubMed Abstract | Publisher Full Text
776. Yabuki Y, Matsuo K, Izumi H, et al.: Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology. 2017; 117: 1–13. PubMed Abstract | Publisher Full Text
777. Chamoun M, Huppé-Gourgues F, Legault I, et al.: Cholinergic potentiation improves perceptual-cognitive training of healthy young adults in three dimensional multiple object tracking. Front. Hum. Neurosci. 2017; 11. PubMed Abstract | Publisher Full Text | Free Full Text
778. González-Fernández R, Grigoruta M, Chávez-Martínez S, et al.: Liver proteome alterations in psychologically distressed rats and a nootropic drug. PeerJ. 2021; 9: e11483. Publisher Full Text
779. Grigoruţă M, Vargas-Caraveo A, Vázquez-Mayorga E, et al.: Blood mononuclear cells as speculum of emotional stress analyzed by synchrotron infrared spectroscopy and a nootropic drug. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy. 2018; 204: 475–483. PubMed Abstract | Publisher Full Text
780. Tramarin M, Rusconi L, Pizzamiglio L, et al.: The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5. Hum. Mol. Genet. 2018; 27(12): 2052–2063. PubMed Abstract | Publisher Full Text
781. Scholey A, editor. Nutrients for neurocognition in health and disease: Measures, methodologies and mechanisms. Proceedings of the Nutrition Society. 2018; 77: 73–83. PubMed Abstract | Publisher Full Text
782. Gray NE, Alcazar Magana A, Lak P, et al.: Centella asiatica: phytochemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochem. Rev. 2018; 17(1): 161–194. PubMed Abstract | Publisher Full Text | Free Full Text
783. Gschwind YJ, Bridenbaugh SA, Reinhard S, et al.: Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clin. Exp. Res. 2017; 29(4): 609–619. Publisher Full Text
784. Racine E, Sattler S, Boehlen W: Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior. Sci. Eng. Ethics. 2021; 27(2): 19. PubMed Abstract | Publisher Full Text | Free Full Text
785. Tomczyk B: Knower at risk: Updating epistemology in the light of enhanced representations. Studia Semiotyczne. 2021; 35(1): 35–54.
786. Dave AA, Cabrera LY: Osteopathic Medical Students’ Attitudes Towards Different Modalities of Neuroenhancement: a Pilot Study. J. Cogn. Enhanc. 2020; 4(4): 422–433. Publisher Full Text
787. McDermott H, Lane H, Alonso M: Working smart: the use of ‘cognitive enhancers’ by UK university students. J. Furth. High. Educ. 2021; 45(2): 270–283. Publisher Full Text
788. Janssen E, Spilka S, Le Nézet O, et al.: On the question of non-medical cognitive enhancers among in-school adolescents: Prevalence, predictors and potential health-related harms. Int. J. Adolesc. Med. Health. 2020; 32(6). Publisher Full Text
789. Jotterand F, McCurdy J, Elger B: Cognitive enhancers, intellectual disability, and personal identity: emerging ethical issues. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. 2020; 1: 199–207. Publisher Full Text
790. Tzeng NS, Liu YP: Amphetamine exposure and dementia – A hypothesis of the long term sequelae of cognitive enhancers based on opponent process theory. Med. Hypotheses. 2019; 132: 109327. PubMed Abstract | Publisher Full Text
791. Jotterand F: Childhood brain development, the educational achievement gap, and cognitive enhancement. Front. Pharmacol. 2018; 9(OCT). PubMed Abstract | Publisher Full Text | Free Full Text
792. Wirsching HG, Silginer M, Ventura E, et al.: Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. Molecular Therapy Oncolytics. 2021; 20: 166–174. Publisher Full Text
793. Hamieh AM, Camperos E, Hernier AM, et al.: C57BL/6 mice as a preclinical model to study age-related cognitive deficits: Executive functions impairment and inter-individual differences. Brain Res. 2021; 1751: 147173. PubMed Abstract | Publisher Full Text
794. Khorshidi F, Poljak A, Liu Y, et al.: Resveratrol: A “miracle” drug in neuropsychiatry or a cognitive enhancer for mice only? A systematic review and meta-analysis. Ageing Res. Rev. 2021; 65: 101199. PubMed Abstract | Publisher Full Text
795. Kim J, Song Y, Lee SJ, et al.: Enzymatic preparation of food-grade l-α-glycerylphosphorylcholine from soy phosphatidylcholine or fractionated soy lecithin. Biotechnol. Prog. 2020; 36(1): e2910. PubMed Abstract | Publisher Full Text
796. Deguil J, Bordet R: Contributions of animal models of cognitive disorders to neuropsychopharmacology. Therapies. 2021; 76(2): 87–99. PubMed Abstract | Publisher Full Text
797. Dahal R, Tampi R: Cognitive enhancers. Absolute Geriatric Psychiatry Review: Essential Questions and Answers. 2021; 279–286. Publisher Full Text
798. Peltier MKR, Sofuoglu M: Pharmacological cognitive enhancers. Cognition and Addiction: A Researcher's Guide from Mechanisms Towards Interventions. 2020; 303–320. Publisher Full Text
799. Miroshnichenko II: Ways to Enhance and Restore Cognitive Functions. Psychiatry (Moscow). 2020; 18(1): 71–78.
800. Wessinger CM, Inman CL, Weinstock J, et al.: Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial. Int. J. Exerc. Sci. 2021; 14(2): 727–741. PubMed Abstract
801. Cutsem JV, Dessy E, Puyvelde MV, et al., editors. Trait Interindividual Differences in the Effectiveness of Modafinil. Lecture Notes in Networks and Systems.2021.
802. Giacomini ACVV, Bueno BW, Marcon L, et al.: An acetylcholinesterase inhibitor, donepezil, increases anxiety and cortisol levels in adult zebrafish. J. Psychopharmacol. 2020; 34(12): 1449–1456. Publisher Full Text
803. Sirinupong N, Chansuwan W, Kaewkaen P: Hydrolase-Treated Royal Jelly Attenuates H2O2- And Glutamate-Induced SH-SY5Y Cell Damage and Promotes Cognitive Enhancement in a Rat Model of Vascular Dementia. Int. J. Food Sci. 2021; 2021: 1–11. PubMed Abstract | Publisher Full Text | Free Full Text
804. Baghernejad B, Fiuzat M: A new strategy for the synthesis of 2-amino-4H-pyran derivatives in aqueous media using DABCO-Cucl complex as a novel and efficient catalyst. Eurasian Chemical Communications. 2020; 2(11): 1088–1092.
805. Chauveau F, De Job E, Poly-Thomasson B, et al.: Procognitive impact of ciproxifan (a histaminergic H3 receptor antagonist) on contextual memory retrieval after acute stress. CNS Neurosci. Ther. 2019; 25(8): 832–841. PubMed Abstract | Publisher Full Text | Free Full Text
806. Graham MA: The disciplinary borderlands of education: art and STEAM education (Los límites disciplinares de la educación: arte y educación STEAM). Infancia y Aprendizaje. 2021; 44(4): 769–800. Publisher Full Text
807. Damiri B, Safarini OA, Nazzal Z, et al.: Eating disorders and the use of cognitive enhancers and psychostimulants among university students: A cross-sectional study. Neuropsychiatr. Dis. Treat. 2021; 17: 1633–1645. PubMed Abstract | Publisher Full Text | Free Full Text
808. Park JM, Kim YW, Choi S: Atomoxetine (Strattera)-Induced Pathologic Laughing in a Patient with Pontine Hemorrhage: A Case Report. Clin. Neuropharmacol. 2021; 44(2): 77–79. PubMed Abstract | Publisher Full Text
809. Song Y, Roh S, Hwang J, et al.: Immobilized Phospholipase A1-Catalyzed Preparation of l -α-Glycerylphosphorylcholine from Phosphatidylcholine. J. Agric. Food Chem. 2020; 68(44): 12375–12383. Publisher Full Text
810. Saroya AS, Singh J: Psychoactive medicinal plants and fungal neurotoxins.2020; 1–121.
811. Dursun S, Dunn M, McKay FH: The availability and acquisition of modafinil on the internet. Drug Alcohol Rev. 2019; 38(6): 699–702. PubMed Abstract | Publisher Full Text
812. Bessey LJ, Walaszek A: Management of Behavioral and Psychological Symptoms of Dementia. Curr. Psychiatry Rep. 2019; 21(8). Publisher Full Text
813. Dresler M, Sandberg A, Bublitz C, et al.: Hacking the Brain: Dimensions of Cognitive Enhancement. ACS Chem. Neurosci. 2019; 10(3): 1137–1148. PubMed Abstract | Publisher Full Text | Free Full Text
814. Smith KE, Rogers JM, Strickland JC, et al.: When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use. Am. J. Drug Alcohol Abuse. 2021; 47(4): 455–466. PubMed Abstract | Publisher Full Text | Free Full Text
815. Pichini S, Di Trana A, Torrens M, et al.: Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances. Front. Psych. 2020; 11. Publisher Full Text
816. Tully JL, Forshaw M, Hall M, et al.: Introduction. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 1–12. Publisher Full Text
817. Wilms W, Woźniak-Karczewska M, Corvini PFX: Nootropic drugs: Methylphenidate, modafinil and piracetam – Population use trends, occurrence in the environment, ecotoxicity and removal methods – A review. Chemosphere. 2019; 233: 771–785. Publisher Full Text
818. Lelieveld I, Storre GJ, Sahand Mohammadi Ziabari S: A Temporal Cognitive Model of the Influence of Methylphenidate (Ritalin) on Test Anxiety. Advances in Intelligent Systems and Computing. 2020. Publisher Full Text
819. Fitzpatrick CJ, Geary T, Creeden JF, et al.: Sign-tracking behavior is difficult to extinguish and resistant to multiple cognitive enhancers. Neurobiol. Learn. Mem. 2019; 163: 107045. PubMed Abstract | Publisher Full Text | Free Full Text
820. Crespo-Bujosa HB, Suárez Rodríguez RLF: Nootropics: Phytochemicals with Neuroprotective and Neurocognitive Enhancing Properties. European Journal of Clinical and Experimental Medicine. 2019; 17(3): 250–255. Publisher Full Text
821. Mohammadi AB, Sadigh-Eteghad S, Torbati M, et al.: Identification and applications of neuroactive silk proteins: A narrative review. J. Appl. Biomed. 2019; 17(3): 147–156. Publisher Full Text
822. Gaiardo RB, Abreu TF, Tashima AK, et al.: Target proteins in the dorsal hippocampal formation sustain the memory-enhancing and neuroprotective effects of Ginkgo biloba. Front. Pharmacol. 2019; 9(JAN). PubMed Abstract | Publisher Full Text | Free Full Text
823. Woody EZ, Hoffman KL, Szechtman H: Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic research. Adv. Pharmacol. 2019; 86: 237–271. Publisher Full Text
824. Henkel PJ, Marvanova M: Rural Disparities in Alzheimer's Disease-Related Community Pharmacy Care in the United States. J. Rural. Health. 2018; 34(4): 347–358. PubMed Abstract | Publisher Full Text
825. Radünz L, Reuter H, Andresen-Streichert H: Modafinil in forensic and clinical toxicology-case reports, analytics and literature. J. Anal. Toxicol. 2018; 42(5): 353–359. Publisher Full Text
826. Schmidt A, Müller F, Dolder PC, et al.: Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing. Int. J. Neuropsychopharmacol. 2018; 21(4): 345–354. Publisher Full Text
827. Steurer J: Alzheimer's dementia - The cognitive "enhancers" hardly have a positive effect on the further progression. Praxis. 2018; 107(6): 335–336. Publisher Full Text
828. DeVito EE, Herman AI, Konkus NS, et al.: Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. Pharmacol. Biochem. Behav. 2017; 159: 55–61. PubMed Abstract | Publisher Full Text | Free Full Text
829. Havolli E, Hill MDW, Godley A, et al.: Spatial recognition test: A novel cognition task for assessing topographical memory in mice. J. Psychopharmacol. 2017; 31(6): 653–659. PubMed Abstract | Publisher Full Text
830. Tirumalasetti J, Patel MM, Shaikh U, et al.: Protective effect of aqueous extract of lagenaria siceraria (Molina) against maximal electroshock (MES)- induced convulsions in Albino Rats. Kathmandu Univ. Med. J. 2017; 15(58): 117–120.
831. Radin DP, Johnson S, Purcell R, et al.: Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain. Biomed. Pharmacother. 2018; 105: 540–544. Publisher Full Text
832. Cifelli JL, Dozier L, Chung TS, et al.: Benzothiazole amphiphiles promote the formation of dendritic spines in primary hippocampal neurons. J. Biol. Chem. 2016; 291(23): 11981–11992. PubMed Abstract | Publisher Full Text | Free Full Text
833. Sase A, Aher YD, Saroja SR, et al.: A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes. Neuropharmacology. 2016; 102: 186–196. PubMed Abstract | Publisher Full Text
834. Ip FC, Fu WY, Cheng EY, et al.: Anemoside A3 enhances cognition through the regulation of synaptic function and neuroprotection. Neuropsychopharmacology. 2015; 40(8): 1877–1887. PubMed Abstract | Publisher Full Text | Free Full Text
835. Meyerbröker K, Morina N, Emmelkamp PMG: Enhancement of exposure therapy in participants with specific phobia: A randomized controlled trial comparing yohimbine, propranolol and placebo. J. Anxiety Disord. 2018; 57: 48–56. PubMed Abstract | Publisher Full Text
836. Moss M: Half way to Scarborough fair? The cognitive and mood effects of rosemary and sage aromas. Phytotherapie. 2017; 15(1): 38–43. Publisher Full Text
837. Olden M, Wyka K, Cukor J, et al.: Pilot Study of a Telehealth-Delivered Medication-Augmented Exposure Therapy Protocol for PTSD. J. Nerv. Ment. Dis. 2017; 205(2): 154–160. PubMed Abstract | Publisher Full Text | Free Full Text
838. Changeai JP: Drug use and abuse. The Brain. 2017; 145–166. Publisher Full Text
839. Jotterand F: Cognitive enhancement of today may be the normal of tomorrow. Neuroethics: Anticipating the Future. 2017; 411–425.
840. Phillips S, Robinson D, Madaan V: Cognitive enhancers in children and Adolescents: What psychiatrists need to know. Psychiatr. Times. 2017; 34(1).
841. Suganthy N, Devi KP, Nabavi SF, et al.: Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomed. Pharmacother. 2016; 84: 892–908. Publisher Full Text
842. Mohamed AD: The Effects of Modafinil on Convergent and Divergent Thinking of Creativity: A Randomized Controlled Trial. J. Creat. Behav. 2016; 50(4): 252–267. Publisher Full Text
843. Hupli A, Didžiokaitė G, Ydema M: Toward the smarter use of smart drugs: Perceptions and experiences of university students in the Netherlands and Lithuania. Contemp. Drug Probl. 2016; 43(3): 242–257. Publisher Full Text
844. Chandramouleeswaran S, Edwin NC, Rajaleelan W: Dealing with requests for pharmacological cognitive enhancement from healthy students. Indian J Med Ethics. 2016; 1(3): 196. Publisher Full Text
845. Batistela S, Bueno OFA, Vaz LJ, et al.: Methylphenidate as a cognitive enhancer in healthy young people. Dementia e Neuropsychologia. 2016; 10(2): 134–142. PubMed Abstract | Publisher Full Text | Free Full Text
846. Jensen C, Forlini C, Partridge B, et al.: Australian University Students’ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers. Front. Psychol. 2016; 7. PubMed Abstract | Publisher Full Text | Free Full Text
847. Kantrowitz JT, Sharif Z, Medalia A, et al.: A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 2016; 77(6): 799–806. Publisher Full Text
848. Segev A, Gvirts HZ, Strouse K, et al.: A possible effect of methylphenidate on state anxiety: A single dose, placebo controlled, crossover study in a control group. Psychiatry Res. 2016; 241: 232–235. Publisher Full Text
849. Sharp C: Cognitive enhancers-performance or problem?. Occup. Med. 2016; 66(2): 88–89. Publisher Full Text
850. Garasic MD, Lavazza A: Moral and social reasons to acknowledge the use of cognitive enhancers in competitive-selective contexts. BMC Med. Ethics. 2016; 17(1): 18. PubMed Abstract | Publisher Full Text | Free Full Text
851. Cho N, Kim HW, Lee HK, et al.: Ameliorative effect of betulin from Betula platyphylla bark on scopolamineinduced amnesic mice. Bioscience, Biotechnology and Biochemistry. 2016; 80(1): 166–171. Publisher Full Text
852. Shafti SS, Akbari S: Intractability of deficit syndrome of schizophrenia against adjunctive modafinil. J. Clin. Psychopharmacol. 2016; 36(1): 45–49. PubMed Abstract | Publisher Full Text
853. Sahakian BJ, Bruhl AB, Cook J, et al.: The impact of neuroscience on society: Cognitive enhancement in neuropsychiatric disorders and in healthy people. Philosophical Transactions of the Royal Society B: Biological Sciences. 2015; 370(1677): 20140214. PubMed Abstract | Publisher Full Text | Free Full Text
854. Shanmugasundaram B, Korz V, Fendt M, et al.: Differential effects of wake promoting drug modafinil in aversive learning paradigms. Front. Behav. Neurosci. 2015; 9(AUGUST). PubMed Abstract | Publisher Full Text | Free Full Text
855. Sooy K, Noble J, McBride A, et al.: Cognitive and disease-modifying effects of 11β-hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer's disease. Endocrinology. 2015; 156(12): 4592–4603. PubMed Abstract | Publisher Full Text | Free Full Text
856. Zohny H: The Myth of Cognitive Enhancement Drugs. Neuroethics. 2015; 8(3): 257–269. Publisher Full Text
857. Porsdam-Mann S, Sahakian BJ: The increasing lifestyle use of modafinil by healthy people: Safety and ethical issues. Curr. Opin. Behav. Sci. 2015; 4: 136–141. Publisher Full Text
858. Talih F, Ajaltouni J: Probable nootropicinduced psychiatric adverse effects: A series of four cases. Innovations in Clinical Neuroscience. 2015; 12(11-12): 21–25. PubMed Abstract
859. Nevler N, Ash EL: TMS as a Tool for Examining Cognitive Processing. Curr. Neurol. Neurosci. Rep. 2015; 15(8): 52. PubMed Abstract | Publisher Full Text
860. Sahakian BJ, Morein-Zamir S: Pharmacological cognitive enhancement: Treatment of neuropsychiatric disorders and lifestyle use by healthy people. Lancet Psychiatry. 2015; 2(4): 357–362. Publisher Full Text
861. Frati P, Kyriakou C, Del Rio A, et al.: Smart drugs and synthetic androgens for cognitive and physical enhancement: Revolving doors of cosmetic neurology. Curr. Neuropharmacol. 2015; 13(1): 5–11. PubMed Abstract | Publisher Full Text | Free Full Text
862. Garasic MD, Lavazza A: Performance enhancement in the workplace: Why and when healthy individuals should disclose their reliance on pharmaceutical cognitive enhancers. Front. Syst. Neurosci. 2015; 9(FEB): 1–5. Publisher Full Text
863. Sumiyoshi T: Verbal memory. Handb. Exp. Pharmacol. 2015; 228: 237–247. Publisher Full Text
864. Young JW, Geyer MA: Developing treatments for cognitive deficits in schizophrenia: The challenge of translation. J. Psychopharmacol. 2015; 29(2): 178–196. PubMed Abstract | Publisher Full Text | Free Full Text
865. Benn A, Robinson ESJ: Investigating glutamatergic mechanism in attention and impulse control using rats in a modified 5-choice serial reaction time task. PLoS ONE. 2014; 9(12): e115374. PubMed Abstract | Publisher Full Text | Free Full Text
866. Dunlop M, Savulescu J: Distributive justice and cognitive enhancement in lower, normal intelligence. Monash Bioeth. Rev. 2014; 32(3-4): 189–204. Publisher Full Text
867. Maslen H, Faulmüller N, Savulescu J: Pharmacological cognitive enhancement-how neuroscientific research could advance ethical debate. Front. Syst. Neurosci. 2014; 8(JUNE). PubMed Abstract | Publisher Full Text | Free Full Text
868. Mohamed AD, Lewis CR: Modafinil increases the latency of response in the hayling sentence completion test in healthy volunteers: A randomised controlled trial. PLoS ONE. 2014; 9(11): e110639. PubMed Abstract | Publisher Full Text | Free Full Text
869. Urban KR, Gao WJ: Performance enhancement at the cost of potential brain plasticity: Neural ramifications of nootropic drugs in the healthy developing brain. Front. Syst. Neurosci. 2014; 8(MAY). PubMed Abstract | Publisher Full Text | Free Full Text
870. Plattner F, Hernández A, Kistler TM, et al.: Memory enhancement by targeting Cdk5 regulation of NR2B. Neuron. 2014; 81(5): 1070–1083. PubMed Abstract | Publisher Full Text | Free Full Text
871. Froestl W, Muhs A, Pfeifer A: Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014. J. Alzheimers Dis. 2014; 42(1): 1–68. PubMed Abstract | Publisher Full Text
872. Froestl W, Pfeifer A, Muhs A: Cognitive enhancers (Nootropics). Part 3: Drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. update 2014. J. Alzheimers Dis. 2014; 42(4): 1079–1149. PubMed Abstract | Publisher Full Text
873. Di Giovanni G, García I, Colangeli R, et al.: N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties. CNS Neurosci. Ther. 2014; 20(7): 633–640. PubMed Abstract | Publisher Full Text | Free Full Text
874. Uchiyama N, Matsuda S, Kawamura M, et al.: Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicology. 2014; 32(1): 9–18. Publisher Full Text
875. Ott R, Biller-Andorno N: Neuroenhancement among swiss students - A comparison of users and non-users. Pharmacopsychiatry. 2014; 47(1): 22–28.
876. McCleary L, Persaud M, Hum S, et al.: Pathways to dementia diagnosis among South Asian Canadians. Dementia. 2013; 12(6): 769–789. PubMed Abstract | Publisher Full Text
877. Smith DH: Cognitive enhancers. CMAJ Canadian Medical Association Journal. 2013; 185(9): 799. PubMed Abstract | Publisher Full Text
878. Partridge B, Bell S, Lucke J, et al.: Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: Perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 2013; 32(3): 295–302. Publisher Full Text
879. Bossaer JB, Gray JA, Miller SE, et al.: The use and misuse of prescription stimulants as "cognitive enhancers" by students at one academic health sciences center. Acad. Med. 2013; 88(7): 967–971. PubMed Abstract | Publisher Full Text
880. Enck GG: Ideals of student excellence and enhancement. Neuroethics. 2013; 6(1): 155–164. Publisher Full Text
881. Sofuoglu M, Devito EE, Waters AJ, et al.: Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013; 64: 452–463. Publisher Full Text
882. Ilieva I, Boland J, Farah MJ: Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2013; 64: 496–505. Publisher Full Text
883. Frenguelli BG: Cognitive enhancers: Molecules, mechanisms and minds. Neuropharmacology. 2013; 64: 1. Publisher Full Text
884. Müller U, Rowe JB, Rittman T, et al.: Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. 2013; 64: 490–495. PubMed Abstract | Publisher Full Text | Free Full Text
885. Ragan CI, Bard I, Singh I: What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology. 2013; 64: 588–595. PubMed Abstract | Publisher Full Text
886. Al Owesie RM, Morton CS: Psychopharmacologic intervention after hemorrhagic basal ganglia damage. J. Neurol. Sci. 2012; 322(1-2): 77–78. PubMed Abstract | Publisher Full Text
887. Schaefer TL, Braun AA, Amos-Kroohs RM, et al.: A new model of Pde4d deficiency: Genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects. Genes Brain Behav. 2012; 11(5): 614–622. PubMed Abstract | Publisher Full Text | Free Full Text
888. Gruss M, Appenroth D, Flubacher A, et al.: 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. J. Neurochem. 2012; 121(6): 924–931. Publisher Full Text
889. Bruggisser M, Bodmer M, Liechti ME: Misuse of methylphenidate - A problem in Switzerland?. Praxis. 2012; 101(5): 299–305. PubMed Abstract | Publisher Full Text
890. Peters MS, Sarter M: Cognitive enhancers versus stimulants. Sleep Deprivation, Stimulant Medications, and Cognition. 2012; 136–151. Publisher Full Text
891. Wise J: Cognitive enhancers are set to change workplaces. BMJ (Clinical research ed). 2012; 345. Publisher Full Text
892. Marlowe KH, Mbeah-Banks H: Mephedrone as a cognitive enhancer and its kinship to khat. Psychiatrist. 2011; 35(11): 432. Publisher Full Text
893. Wuo-Silva R, Fukushiro DF, Borçoi AR, et al.: Addictive potential of modafinil and cross-sensitization with cocaine: A pre-clinical study. Addict. Biol. 2011; 16(4): 565–579. Publisher Full Text
894. De Pauw E ["Cognitive doping": meaning and stakes.]. Journal international de bioéthique = International journal of bioethics.2011; 22(3-4): 79–92,195, PMID: PubMed Abstract
895. Shioda N, Yamamoto Y, Han F, et al.: Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior. Yakugaku Zasshi. 2011; 131(4): 505–511. Publisher Full Text
896. Van der Schyf CJ, Geldenhuys WJ: Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int. Rev. Neurobiol. 2011; 100: 107–125. PubMed Abstract | Publisher Full Text
897. Repantis D, Schlattmann P, Laisney O, et al.: Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol. Res. 2010; 62(3): 187–206. PubMed Abstract | Publisher Full Text
898. Advokat C: What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci. Biobehav. Rev. 2010; 34(8): 1256–1266. PubMed Abstract | Publisher Full Text
899. Outram SM: The use of methylphenidate among students: The future of enhancement?. J. Med. Ethics. 2010; 36(4): 198–202. PubMed Abstract | Publisher Full Text
900. Hyder N, Harris J: The criminal law and enhancement: None of the law’s business? Bioethics, Medicine and the Criminal Law Volume I: The Criminal Law and Bioethical Conflict: Walking the Tightrope.2010; 157–174.
901. Solomon LM, Noll RC, Mordkoff DS: Cognitive enhancements in human beings. Gend. Med. 2009; 6(2): 338–344. PubMed Abstract | Publisher Full Text
902. Victor M: Cognitive enhancers and Cosmetic Psychiatry: Are we ready? A case-report. Rev. Bras. Psiquiatr. 2009; 31(4): 393–394. PubMed Abstract
903. Stolerman IP, Smith JW: Recognising nicotine: The neurobiological basis of nicotine discrimination. Handb. Exp. Pharmacol. 2009; 192: 295–333.
904. Volkow ND, Fowler JS, Logan J, et al.: Effects of modafinil on dopamine and dopamine transporters in the male human brain clinical implications. JAMA. 2009; 301(11): 1148–1154. PubMed Abstract | Publisher Full Text | Free Full Text
905. Robbins TW: Special issue on cognitive enhancers. Psychopharmacology. 2009; 202(1-3): 1–2. Publisher Full Text
906. Day M, Balci F, Wan HI, et al.: Cognitive endpoints as disease biomarkers: Optimizing the congruency of preclinical models to the clinic. Curr. Opin. Investig. Drugs. 2008; 9(7): 696–706. PubMed Abstract
907. Volkow ND, Fowler JS, Wang GJ, et al.: Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task. PLoS ONE. 2008; 3(4): e2017. PubMed Abstract | Publisher Full Text | Free Full Text
908. Lanni C, Lenzken SC, Pascale A, et al.: Cognition enhancers between treating and doping the mind. Pharmacol. Res. 2008; 57(3): 196–213. PubMed Abstract | Publisher Full Text
909. Schwartz M, Patel M, Kazzi Z, et al.: Cardiotoxicity after massive amantadine overdose. Journal of medical toxicology: official journal of the American College of Medical Toxicology. 2008; 4(3): 173–179. PubMed Abstract | Publisher Full Text | Free Full Text
910. Morris K: Experts urge smart thinking on cognitive enhancers. The Lancet Neurology. 2008; 7(6): 476–477. PubMed Abstract | Publisher Full Text
911. Hohnadel E, Bouchard K, Terry AV Jr: Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology. 2007; 52(2): 542–551. PubMed Abstract | Publisher Full Text | Free Full Text
912. Miller LJ: The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. Consult. Pharm. 2007; 22(9): 754–762. Publisher Full Text
913. Prince JB: Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: Update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc. Psychiatr. Clin. N. Am. 2006; 15(1): 13–50. PubMed Abstract | Publisher Full Text
914. Voronina TA, Guzevatykh LS, Trofimov SS: Comparative study of the long-term behavioral effects of noopept and piracetam in adult male rats and female rats in postnatal period. Eksperimental'naya i Klinicheskaya Farmakologiya. 2005; 68(2): 3–7.
915. Randall DC, Viswanath A, Bharania P, et al.: Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?. J. Clin. Psychopharmacol. 2005; 25(2): 175–179. PubMed Abstract | Publisher Full Text
916. Turner DC, Clark L, Dowson J, et al.: Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2004; 55(10): 1031–1040. PubMed Abstract | Publisher Full Text
917. Turner DC, Clark L, Pomarol-Clotet E, et al.: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology. 2004; 29(7): 1363–1373. PubMed Abstract | Publisher Full Text
918. Bora E, Veznedaroǧlu B, Kayahan B: The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin. Neuropharmacol. 2005; 28(3): 139–141. Publisher Full Text
919. Friedman JI: Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology. 2004; 174(1): 45–53. PubMed Abstract | Publisher Full Text
920. Friedman JI, Stewart DG, Gorman JM: Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr. 2004; 9: 350–356. PubMed Abstract | Publisher Full Text
921. Staner L: Sleep-wake mechanisms and drug discovery: Sleep EEG as a tool for the development of CNS-acting drugs. Dialogues Clin. Neurosci. 2002; 4: 342–350. PubMed Abstract | Publisher Full Text | Free Full Text
922. Bernheim A, See RE, Reichel CM: Chronic methamphetamine self-administration disrupts cortical control of cognition. Neurosci. Biobehav. Rev. 2016; 69: 36–48. PubMed Abstract | Publisher Full Text | Free Full Text
923. Bisagno V, González B, Urbano FJ: Cognitive enhancers versus addictive psychostimulants: The good and bad side of dopamine on prefrontal cortical circuits. Pharmacol. Res. 2016; 109: 108–118. PubMed Abstract | Publisher Full Text
924. Chu R, Shumsky J, Waterhouse BD: Differentiation of rodent behavioral phenotypes and methylphenidate action in sustained and flexible attention tasks. Brain Res. 2016; 1641: 306–319. PubMed Abstract | Publisher Full Text | Free Full Text
925. Ban CX, Xiao SF, Lin X, et al.: Clinicians' prescription preferences for treating patients with Alzheimer's disease in Shanghai. Translational Neurodegeneration. 2016; 5(1): 8. PubMed Abstract | Publisher Full Text | Free Full Text
926. Gill SK, Leff AP: Dopaminergic therapy in aphasia. Pharmacology and Aphasia. 2016; 28–43. Publisher Full Text
927. Lochhead JD, Nelson MA, Maguire GA: The treatment of behavioral disturbances and psychosis associated with dementia. Psychiatr. Pol. 2016; 50(2): 311–322. PubMed Abstract | Publisher Full Text
928. Jwa A: Early adopters of the magical thinking cap: A study on do-it-yourself (DIY) transcranial direct current stimulation (tDCS) user community. J. Law Biosci. 2016; 2(3): 292–335. Publisher Full Text
929. Gligorov N: Cognitive Enhancement and Personal Identity. Studies in Brain and Mind. 2016; 11: 53–74. Publisher Full Text
930. Alvaro N, Conway M, Doan S, et al.: Crowdsourcing Twitter annotations to identify first-hand experiences of prescription drug use. J. Biomed. Inform. 2015; 58: 280–287. PubMed Abstract | Publisher Full Text
931. Bloomfield B, Dale K: Fit for work? Redefining ‘Normal’ and ‘Extreme’ through human enhancement technologies. Organization. 2015; 22(4): 552–569. Publisher Full Text
932. Enck GG: Pharmaceutical enhancement and medical professionals. Med. Health Care Philos. 2014; 17(1): 23–28. Publisher Full Text
933. Moskal JR, Burch R, Burgdorf JS, et al.: GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin. Investig. Drugs. 2014; 23(2): 243–254. PubMed Abstract | Publisher Full Text | Free Full Text
934. Emmelkamp P, Ehring T: The wiley handbook of anxiety disorders: Volume I theory and research volume II clinical assessment and treatment.2014; 1–1403.
935. Mohamed AD: Neuroethical issues in pharmacological cognitive enhancement. Wiley Interdiscip. Rev. Cogn. Sci. 2014; 5(5): 533–549. PubMed Abstract | Publisher Full Text
936. Goold I, Maslen H: Must the surgeon take the pill? Negligence duty in the context of cognitive enhancement. Mod. Law Rev. 2014; 77(1): 60–86. Publisher Full Text
937. Forlini C, Gauthier S, Racine E: Should physicians prescribe cognitive enhancers to healthy individuals?. CMAJ Canadian Medical Association Journal. 2013; 185(12): 1047–1050. PubMed Abstract | Publisher Full Text | Free Full Text
938. Ozcan H, Yucel A, Ates O: Visual hallucinations in an old patient after cataract surgery and treatment. Eur. J. Med. 2016; 48(1): 62–64.
939. Smith RC, Amiaz R, Si TM, et al.: Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: A double-blind randomized trial. PLoS ONE. 2016; 11(1). Publisher Full Text
940. Gao J, Midde N, Zhu J, et al.: Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 2016; 26(22): 5573–5579. PubMed Abstract | Publisher Full Text | Free Full Text
941. Lauterbach EC: Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early parkinson’s disease. Am. J. Neurodegener. Dis. 2016; 5(1): 29–51. PubMed Abstract
942. Dey A, Mukherjee A: Natural therapeutics against alzheimer’s Disease: Conventional treatment versus phytotherapy. Advances in Natural Products Discovery. 2016; 55–78.
943. Uddin MS, Mamun AA, Hossain MS, et al.: Exploring the effect of Phyllanthus emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: Promising natural gift for the mitigation of Alzheimer’s disease. Ann. Neurosci. 2016; 23(4): 218–229. Publisher Full Text
944. Cutuli D: Functional and structural benefits induced by omega-3 polyunsaturated fatty acids during aging. Curr. Neuropharmacol. 2016; 15: 534–542. Publisher Full Text
945. Pitt J, Leung Y: Cognitive effects of nutraceuticals. Nutraceuticals: Efficacy, Safety and Toxicity. 2016; 29–48. Publisher Full Text
946. Knöchel C, Voss M, Grüter F, et al.: Omega 3 fatty acids: Novel neurotherapeutic targets for cognitive dysfunction in mood disorders and schizophrenia?. Curr. Neuropharmacol. 2015; 13(5): 663–680. Publisher Full Text
947. Parfenov VA: Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2016; 8(3): 4–9.
948. Veroniki AA, Straus SE, Ashoor HM, et al.: Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: Protocol for a systematic review and individual patient data network meta-analysis. BMJ Open. 2016; 6(1): e010251. PubMed Abstract | Publisher Full Text | Free Full Text
949. McClam TD, Marano CM, Rosenberg PB, et al.: Interventions for Neuropsychiatric symptoms in Neurocognitive impairment due to Alzheimer's disease: A review of the literature. Harv. Rev. Psychiatry. 2015; 23(5): 377–393. Publisher Full Text
950. Page M, Pacico N, Ourtioualous S, et al.: Procognitive Compounds Promote Neurite Outgrowth. Pharmacology. 2015; 96(3-4): 131–136. PubMed Abstract | Publisher Full Text
951. Dafny N: The Characteristics of Acute and Chronic Methylphenidate, Dose, and Route on Female and Male Animal Behavior. Neuropathology of Drug Addictions and Substance Misuse Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. 2016; 3: 675–681. Publisher Full Text
952. Tripati A, Mathew M, Nayak V, et al.: Cognitive enhancers-truth vs. hype. Res. J. Pharm., Biol. Chem. Sci. 2016; 7(3): 729–741.
953. Pallardo FI: Cognitive enhancers in the treatment of ADHD. Psiquiatr. Biológica. 2015; 22(3): 61–66. Publisher Full Text
954. Naber M, Hommel B, Colzato LS: Improved human visuomotor performance and pupil constriction after choline supplementation in a placebo-controlled double-blind study. Sci. Rep. 2015; 5: 5. Publisher Full Text
955. Bishara D, Sauer J, Taylor D: The pharmacological management of Alzheimer's disease. Prog. Neurol. Psychiatry. 2015; 19(4): 9–16. Publisher Full Text
956. Sachdeva A, Kumar K, Anand KS: Non pharmacological cognitive enhancers – Current perspectives. J. Clin. Diagn. Res. 2015; 9(7). Publisher Full Text
957. Kelly ÁM: Non-pharmacological approaches to cognitive enhancement. Handb. Exp. Pharmacol. 2015; 228: 417–439. Publisher Full Text
958. Spencer RC, Devilbiss DM, Berridge CW: The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol. Psychiatry. 2015; 77(11): 940–950. PubMed Abstract | Publisher Full Text | Free Full Text
959. Murphy HM, Ekstrand D, Tarchick M, et al.: Modafinil as a cognitive enhancer of spatial working memory in rats. Physiol. Behav. 2015; 142: 126–130. PubMed Abstract | Publisher Full Text
960. Weger UW, Loughnan S: Using Participant Choice to Enhance Memory Performance. Appl. Cogn. Psychol. 2015; 29(3): 345–349. Publisher Full Text
961. Wetchateng T, Piyabhan P: Cognitive enhancement effects of Bacopa monnieri (Brahmi) on novel object recognition and neuronal density in the prefrontal cortex, striatum and hippocampus in sub-chronic phencyclidine administration rat model of schizophrenia. J. Med. Assoc. Thail. 2015; 98 Suppl 2: S56–S63. PubMed Abstract | Publisher Full Text
962. Bali ZK, Inkeller J, Csurgyók R, et al.: Differential effects of α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models. Behav. Brain Res. 2015; 278: 404–410. PubMed Abstract | Publisher Full Text
963. Dubljević V: Cognitive Enhancement: Ethical Considerations and a Look into the Future. Ethical Considerations and a Look into the Future. Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors. 2015; 343–365. Publisher Full Text
964. Knafo S, Venero C: Cognitive Enhancement: Pharmacologic. Environmental and Genetic Factors. 2015; 1–376. Publisher Full Text
965. Dresler M, Repantis D: Cognitive Enhancement in Humans. Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors. 2015; 273–306.
966. Nelson TJ, Sun MK, Alkon DL: Signaling Pathways Involved in Cognitive Enhancement. Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors. 2015; 11–42. Publisher Full Text
967. Yan WW, Yao LH, Chen C, et al.: Effects of modafinil on behavioral learning and hippocampal synaptic transmission in rats. Int. Neurourol. J. 2015; 19(4): 220–227. PubMed Abstract | Publisher Full Text | Free Full Text
968. Rezapour T, Hatami J, Farhoudian A, et al.: Neuro cognitive rehabilitation for disease of addiction (NECOREDA) program: From development to trial. Basic and Clinical Neuroscience. 2015; 6(4): 291–298. PubMed Abstract
969. Goold I, Maslen H: Responsibility enhancement and the law of negligence. Handbook of Neuroethics. 2015; 1363–1380. Publisher Full Text
970. Harvey J: Leptin and Alzheimer's Disease. Diet and Nutrition in Dementia and Cognitive Decline. 2015; 457–467. Publisher Full Text
971. Muralidhara KG: Dietary Supplements as Cognitive Enhancers: The Role of Flavonoid-Rich Foods and their Relevance in Age-Related Neurodegeneration. Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy. 2015; 281–290. Publisher Full Text
972. Fitz NS, Reiner PB: The challenge of crafting policy for do-it-yourself brain stimulation. J. Med. Ethics. 2015; 41(5): 410–412. PubMed Abstract | Publisher Full Text | Free Full Text
973. Grover S, Somaiya M, Kumar S, et al.: Psychiatric aspects of Parkinson's disease. Journal of Neurosciences in Rural Practice. 2015; 6(1): 65–76. PubMed Abstract | Publisher Full Text
974. Cera N, Tartaro A, Sensi SL: Modafinil alters intrinsic functional connectivity of the right posterior insula: A pharmacological resting state fMRI study. PLoS ONE. 2014; 9(9): e107145. PubMed Abstract | Publisher Full Text | Free Full Text
975. Vargo EJ, James RA, Agyeman K, et al.: Perceptions of assisted cognitive and sport performance enhancement among university students in England. Performance Enhancement and Health. 2014; 3(2): 66–77. Publisher Full Text
976. Sarkis RA, Kaur N, Camprodon JA: Transcranial Direct Current Stimulation (tDCS): Modulation of Executive Function in Health and Disease. Curr. Behav. Neurosci. Rep. 2014; 1(2): 74–85. Publisher Full Text
977. van Enkhuizen J , Acheson D, Risbrough V, et al.: Sleep deprivation impairs performance in the 5-choice continuous performance test: Similarities between humans and mice. Behav. Brain Res. 2014; 261: 40–48. PubMed Abstract | Publisher Full Text | Free Full Text
978. Fang A, Hofmann SG: Translational research in social anxiety: Summary of newest developments and future directions. The Wiley Blackwell Handbook of Social Anxiety Disorder. 2014; 389–408. Publisher Full Text
979. Jabbarpour Z, Shahidi S, Saidijam M, et al.: Effect of tempol on the passive avoidance and novel object recognition task in diabetic rats. Brain Res. Bull. 2014; 101: 51–56. PubMed Abstract | Publisher Full Text
980. Wang J, Wang X, Lv B, et al.: Effects of fructus akebiae on learning and memory impairment in a scopolamine-induced animal model of dementia. Exp. Ther. Med. 2014; 8(2): 671–675. Publisher Full Text
981. Saravanaraman P, Chinnadurai RK, Boopathy R: Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: A comprehensive review of evidences. Rev. Neurosci. 2014; 25(2): 231–246. PubMed Abstract | Publisher Full Text
982. Phillips TJ, Eastwood EC, Harkness JH: Drug abuse: Amphetamines. Behavioral Genetics of the Mouse Volume II: Genetic Mouse Models of Neurobehavioral Disorders. 2014; 330–349. Publisher Full Text
983. Steiner H, Warren BL, Van Waes V, et al.: Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior. Prog. Brain Res. 2014; 211: 13–30. Publisher Full Text
984. Sumiyoshi T, Kunugi H, Nakagome K: Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Front. Neurosci. 2014; 8(DEC). PubMed Abstract | Publisher Full Text | Free Full Text
985. Mereu M, Bonci A, Newman AH, et al.: The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology. 2013; 229(3): 415–434. PubMed Abstract | Publisher Full Text | Free Full Text
986. Haleem DJ: Extending therapeutic use of psychostimulants: Focus on serotonin-1A receptor. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2013; 46: 170–180. PubMed Abstract | Publisher Full Text
987. Steenbergen L, Sellaro R, Colzato LS: Tryptophan promotes charitable donating. Front. Psychol. 2014; 5(DEC). PubMed Abstract | Publisher Full Text | Free Full Text
988. Borhade SR, Rosenström U, Sävmarker J, et al.: Inhibition of insulin-regulated aminopeptidase (IRAP) by arylsulfonamides. ChemistryOpen. 2014; 3(6): 256–263. PubMed Abstract | Publisher Full Text | Free Full Text
989. García-Barroso C, Ugarte A, Martínez M, et al.: Phosphodiesterase inhibition in cognitive decline. J. Alzheimers Dis. 2014; 42: S561–S573. Publisher Full Text
990. Zhang H, Etherington LA, Hafner AS, et al.: Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol. Psychiatry. 2013; 18(4): 471–484. Publisher Full Text
991. Švestka J: Has the development of new psychopharmacological agents stopped? Part III - Cognitive enhancers. Psychiatrie. 2014; 18(3): 135–146.
992. Froestl W, Muhs A, Pfeifer A: Cognitive enhancers (Nootropics). Part 1: Drugs interacting with receptors. Update 2014. J. Alzheimers Dis. 2014; 41(4): 961–1019. Publisher Full Text
993. Tricco AC, Soobiah C, Berliner S, et al.: Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: A systematic review and meta-analysis. CMAJ Canadian Medical Association Journal. 2013; 185(16): 1393–1401. PubMed Abstract | Publisher Full Text | Free Full Text
994. Froestl W, Pfeifer A, Muhs A: Cognitive enhancers (Nootropics). Part 3: Drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. J. Alzheimers Dis. 2013; 34(1): 1–114. Publisher Full Text
995. Froestl W, Muhs A, Pfeifer A: Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes. J. Alzheimers Dis. 2013; 33(3): 547–658. PubMed Abstract | Publisher Full Text
996. Patočka J: Alzheimer's disease in a color of methylene blue. Psychiatrie. 2014; 18(4): 166–170.
997. Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, et al.: Donepezil improves gait performance in older adults with mild Alzheimer's disease: A phase II clinical trial. J. Alzheimers Dis. 2014; 43(1): 193–199. PubMed Abstract | Publisher Full Text
998. Franco R, Cedazo-Minguez A: Successful therapies for Alzheimer's disease: Why so many in animal models and none in humans?. Front. Pharmacol. 2014; 5. Publisher Full Text
999. Shohami E, Biegon A: Novel approach to the role of NMDA receptors in traumatic brain injury. CNS Neurol. Disord. Drug Targets. 2014; 13(4): 567–573. PubMed Abstract | Publisher Full Text
1000. Cho N, Lee KY, Huh J, et al.: Cognitive-enhancing effects of Rhus verniciflua bark extract and its active flavonoids with neuroprotective and anti-inflammatory activities. Food Chem. Toxicol. 2013; 58: 355–361. PubMed Abstract | Publisher Full Text
1001. Patočka J, Soukup O, Kuča K: Ladostigil - Another pursuit of a dual action cognitive enhancer. Psychiatrie. 2013; 17(2): 71–73.
1002. Herrmann N, Lanctôt KL, Hogan DB: Pharmacological recommendations for the symptomatic treatment of dementia: The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's Research and Therapy. 2013; 5(SUPPL. 1): S5. PubMed Abstract | Publisher Full Text | Free Full Text
1003. Rattinger GB, Burcu M, Dutcher SK, et al.: Pharmacotherapeutic management of dementia across settings of care. J. Am. Geriatr. Soc. 2013; 61(5): 723–733. PubMed Abstract | Publisher Full Text | Free Full Text
1004. Lukas SE: New perspectives on using brain imaging to study CNS stimulants. Neuropharmacology. 2014; 87: 104–114. Publisher Full Text
1005. Medalia A, Opler LA, Saperstein AM: Integrating psychopharmacology and cognitive remediation to treat cognitive dysfunction in the psychotic disorders. CNS Spectr. 2014; 19(2): 115–120. PubMed Abstract | Publisher Full Text
1006. Petrovsky N, Ettinger U, Quednow BB, et al.: Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls. Int. J. Neuropsychopharmacol. 2013; 16(7): 1473–1481. PubMed Abstract | Publisher Full Text
1007. Rajkumar R, Suri S, Min Deng H, et al.: Nicotine and clozapine cross-prime the locus coeruleus noradrenergic system to induce long-lasting potentiation in the rat hippocampus. Hippocampus. 2013; 23(7): 616–624. PubMed Abstract | Publisher Full Text
1008. Sofuoglu M, Herman AI, Robinson C, et al.: Cognitive Effects of Nicotine. The Effects of Drug Abuse on the Human Nervous System. 2013; 367–385. Publisher Full Text
1009. Esposito R, Cilli F, Pieramico V, et al.: Acute Effects of Modafinil on Brain Resting State Networks in Young Healthy Subjects. PLoS One. 2013; 8(7). Publisher Full Text
1010. Schmaal L: Effects of the cognitive enhancer modafinil on brain networks and cognitive control in alcohol-dependent people. Tijdschr. Psychiatr. 2013; 55(6): 456–457.
1011. Schmaal L, Goudriaan AE, Joos L, et al.: Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol. Psychiatry. 2013; 73(8): 789–795. PubMed Abstract | Publisher Full Text
1012. Goudriaan AE, Veltman DJ, Van Den Brink W, et al.: Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: A randomized placebo-controlled cross-over study using pharmacological fMRI. Addict. Behav. 2013; 38(2): 1509–1517. PubMed Abstract | Publisher Full Text
1013. Alleva L, Tirelli E, Brabant C: Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders. Behav. Brain Res. 2013; 237(1): 357–368. PubMed Abstract | Publisher Full Text
1014. Allison C, Shoaib M: Nicotine improves performance in an attentional set shifting task in rats. Neuropharmacology. 2013; 64: 314–320. PubMed Abstract | Publisher Full Text
1015. Beer AL, Vartak D, Greenlee MW: Nicotine facilitates memory consolidation in perceptual learning. Neuropharmacology. 2013; 64: 443–451. PubMed Abstract | Publisher Full Text
1016. Dubljević V, Sattler S, Racine É: Cognitive Enhancement and Academic Misconduct: A Study Exploring Their Frequency and Relationship. Ethics Behav. 2014; 24(5): 408–420. Publisher Full Text
1017. Dietz P, Ulrich R, Dalaker R, et al.: Associations between physical and cognitive doping - A cross-sectional study in 2.997 triathletes. PLoS ONE. 2013; 8(11): e78702. PubMed Abstract | Publisher Full Text | Free Full Text
1018. Kudlow PA, Treurnicht Naylor K, Xie B, et al.: Cognitive Enhancement in Canadian Medical Students. J. Psychoactive Drugs. 2013; 45(4): 360–365. Publisher Full Text
1019. Forlini C, Hall W, Maxwell B, et al.: Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. EMBO Rep. 2013; 14(2): 123–128. PubMed Abstract | Publisher Full Text | Free Full Text
1020. Ragan CI, Bard I, Singh I: Erratum: What should we do about student use of cognitive enhancers?: An analysis of current evidence (Neuropharmacology (2012) 64 (588-595)). Neuropharmacology. 2013; 65: 28. Publisher Full Text
1021. Kulikov AV, Fursenko DV, Khotskin NV, et al.: Spatial learning in the Morris water maze in mice genetically different in the predisposition to catalepsy: The effect of intraventricular treatment with brain-derived neurotrophic factor. Pharmacol. Biochem. Behav. 2014; 122: 266–272. Publisher Full Text
1022. Soto PL, Dallery J, Ator NA, et al.: A critical examination of best dose analysis for determining cognitive-enhancing potential of drugs: Studies with rhesus monkeys and computer simulations. Psychopharmacology. 2013; 228(4): 611–622. PubMed Abstract | Publisher Full Text | Free Full Text
1023. Mohamed T, Osman W, Tin G, et al.: Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations. Bioorg. Med. Chem. Lett. 2013; 23(15): 4336–4341. Publisher Full Text
1024. Savulescu J: A Liberal Consequentialist Approach to Regulation of Cognitive Enhancers. Am. J. Bioeth. 2013; 13(7): 53–55. PubMed Abstract | Publisher Full Text
1025. Brondino N, De Silvestri A, Re S, et al.: A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. Evid. Based Complement. Alternat. Med. 2013; 2013: 1–11. Publisher Full Text
1026. Neale C, Camfield D, Reay J, et al.: Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: A review and comparison of effect sizes. Br. J. Clin. Pharmacol. 2013; 75(3): 728–737. Publisher Full Text
1027. Lacaille-Dubois MA, Delaude C, Mitaine-Offer AC: Triterpenoid saponins: A focus on polygalaceae. Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes. 2013; 3205–3223. Publisher Full Text
1028. Koh MT, Rosenzweig-Lipson S, Gallagher M: Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology. 2013; 64: 145–152. PubMed Abstract | Publisher Full Text | Free Full Text
1029. Luchtman DW, Song C: Cognitive enhancement by omega-3 fatty acids from child-hood to old age: Findings from animal and clinical studies. Neuropharmacology. 2013; 64: 550–565. PubMed Abstract | Publisher Full Text
1030. Rapisarda A, Lim TF, Lim M, et al.: Applicability of the MATRICS consensus cognitive battery in Singapore. Clin. Neuropsychol. 2013; 27(3): 455–469. Publisher Full Text
1031. Jensen AA, Plath N, Pedersen MHF, et al.: Design, synthesis, and pharmacological characterization of N - And O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: Novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J. Med. Chem. 2013; 56(3): 1211–1227. PubMed Abstract | Publisher Full Text
1032. Lee N: Childhood and Mental Capital. Studies in Childhood and Youth. 2013; 79–93. Publisher Full Text
1033. Parashos SA, Wielinski CL, Giladi N, et al.: Falls in parkinson disease: Analysis of a large cross-sectional cohort. J. Parkinsons Dis. 2013; 3(4): 515–522. PubMed Abstract | Publisher Full Text
1034. Gräff J, Tsai LH: The potential of HDAC inhibitors as cognitive enhancers. Annu. Rev. Pharmacol. Toxicol. 2013; 53: 311–330. PubMed Abstract | Publisher Full Text
1035. Steiner H, Van Waes V: Addiction-related gene regulation: Risks of exposure to cognitive enhancers vs. other psychostimulants. Prog. Neurobiol. 2013; 100(1): 60–80. Publisher Full Text
1036. Kraft R, Kahn A, Medina-Franco JL, et al.: A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions. DMM Disease Models and Mechanisms. 2013; 6(1): 217–235. PubMed Abstract | Publisher Full Text
1037. Dong Z, Bai Y, Wu X, et al.: Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology. 2013; 64: 65–73. PubMed Abstract | Publisher Full Text
1038. De Bitencourt RM, Pamplona FA, Takahashi RN: A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: Potential extinction enhancers. Neuropharmacology. 2013; 64: 389–395. PubMed Abstract | Publisher Full Text
1039. Russo E, Citraro R, Davoli A, et al.: Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013; 64: 371–379. PubMed Abstract | Publisher Full Text
1040. Stackman RW Jr, Zhang G, Sgeirsdóttir HN, et al.: Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. Neuropharmacology. 2013; 64: 403–413. Publisher Full Text
1041. Curlik DM, Shors TJ: Training your brain: Do mental and physical (MAP) training enhance cognition through the process of neurogenesis in the hippocampus?. Neuropharmacology. 2013; 64: 506–514. PubMed Abstract | Publisher Full Text | Free Full Text
1042. Rodríguez MLC, Campos J, Forcato C, et al.: Enhancing a declarative memory in humans: The effect of clonazepam on reconsolidation. Neuropharmacology. 2013; 64: 432–442. PubMed Abstract | Publisher Full Text
1043. Panizzutti R, Hamilton SP, Vinogradov S: Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology. 2013; 64: 264–267. PubMed Abstract | Publisher Full Text | Free Full Text
1044. Kalechstein AD, Mahoney JJ 3rd, Yoon JH, et al.: Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology. 2013; 64: 472–478. Publisher Full Text
1045. Niepel G, Bibani RH, Vilisaar J, et al.: Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil. Neuropharmacology. 2013; 64: 380–388. PubMed Abstract | Publisher Full Text
1046. Scoriels L, Jones PB, Sahakian BJ: Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013; 64: 168–184. PubMed Abstract | Publisher Full Text
1047. Gacsályi I, Nagy K, Pallagi K, et al.: Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology. 2013; 64: 254–263. PubMed Abstract | Publisher Full Text
1048. Winterer G, Gallinat J, Brinkmeyer J, et al.: Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study. Neuropharmacology. 2013; 64: 197–204. Publisher Full Text
1049. Stenberg JH, Terevnikov V, Joffe M, et al.: Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - A path model investigation. Neuropharmacology. 2013; 64: 248–253. PubMed Abstract | Publisher Full Text
1050. Lapish CC, Belardetti F, Ashby DM, et al.: A preclinical assessment of d.l-govadine as a potential antipsychotic and cognitive enhancer. Int. J. Neuropsychopharmacol. 2012; 15(10): 1441–1455. Publisher Full Text
1051. Morozova MA, Beniashvili AG, Lepilkina TA, et al.: Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr. Danub. 2012; 24(2): 159–166. PubMed Abstract
1052. Kennedy AP, Gross RE, Whitfield N, et al.: A controlled trial of the adjunct use of d-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. Addict. Behav. 2012; 37(8): 900–907. PubMed Abstract | Publisher Full Text | Free Full Text
1053. Martorana A, Di Lorenzo F, Esposito Z, et al.: Dopamine D2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology. 2013; 64: 108–113. Publisher Full Text
1054. Ricciardi E, Handjaras G, Bernardi G, et al.: Cholinergic enhancement reduces functional connectivity and BOLD variability in visual extrastriate cortex during selective attention. Neuropharmacology. 2013; 64: 305–313. Publisher Full Text
1055. Lipina TV, Roder JC: Co-learning facilitates memory in mice: A new avenue in social neuroscience. Neuropharmacology. 2013; 64: 283–293. PubMed Abstract | Publisher Full Text
1056. Sebastião AM, Colino-Oliveira M, Assaife-Lopes N, et al.: Lipid rafts, synaptic transmission and plasticity: Impact in age-related neurodegenerative diseases. Neuropharmacology. 2013; 64: 97–107. Publisher Full Text
1057. Harms JE, Benveniste M, MacLean JKF, et al.: Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology. 2013; 64: 45–52. PubMed Abstract | Publisher Full Text | Free Full Text
1058. Smith SM, Uslaner JM, Cox CD, et al.: The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 2013; 64: 215–223. PubMed Abstract | Publisher Full Text
1059. Borrelli S, Musilli M, Martino A, et al.: Long-lasting efficacy of the cognitive enhancer Cytotoxic Necrotizing Factor 1. Neuropharmacology. 2013; 64: 74–80. PubMed Abstract | Publisher Full Text
1060. Abumaria N, Yin B, Zhang L, et al.: Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J. Neurosci. 2011; 31(42): 14871–14881. PubMed Abstract | Publisher Full Text | Free Full Text
1061. Mackenzie KF, Wallace DA, Hill EV, et al.: Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochem. J. 2011; 435(3): 755–769. Publisher Full Text
1062. Sallaberry C, Nunes F, Costa MS, et al.: Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats. Neuropharmacology. 2013; 64: 153–159. PubMed Abstract | Publisher Full Text
1063. Gilmour G, Broad LM, Wafford KA, et al.: In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013; 64: 224–239. PubMed Abstract | Publisher Full Text
1064. Cannon CE, Puri V, Vivian JA, et al.: The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology. 2013; 64: 191–196. Publisher Full Text
1065. Meltzer HY: Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. 2012; 212: 87–124. PubMed Abstract | Publisher Full Text
1066. Scholey A, MacPherson H, Sünram-Lea S, et al.: Glucose enhancement of recognition memory: Differential effects on effortful processing but not aspects of 'remember-know' responses. Neuropharmacology. 2013; 64: 544–549. PubMed Abstract | Publisher Full Text
1067. Demeter E, Sarter M: Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology. 2013; 64: 294–304. PubMed Abstract | Publisher Full Text | Free Full Text
1068. Rabinak CA, Angstadt M, Sripada CS, et al.: Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013; 64: 396–402. PubMed Abstract | Publisher Full Text | Free Full Text
1069. Nikiforuk A: Quetiapine ameliorates stress-induced cognitive inflexibility in rats. Neuropharmacology. 2013; 64: 357–364. Publisher Full Text
1070. Zhang L, Chen X, Feng W, et al.: Enhancing effects of chronic lithium treatment on detour learning in chicks. Biol. Trace Elem. Res. 2012; 148(1): 38–43. PubMed Abstract | Publisher Full Text
1071. Hammond S, Seymour CM, Burger A, et al.: D-serine facilitates the effectiveness of extinction to reduce drug-primed reinstatement of cocaine-induced conditioned place preference. Neuropharmacology. 2013; 64: 464–471. PubMed Abstract | Publisher Full Text | Free Full Text
1072. Achat-Mendes C, Nic Dhonnchadha BÁ, Platt DM, et al.: Glycine transporter-1 inhibition preceding extinction training inhibits reacquisition of cocaine seeking. Neuropsychopharmacology. 2012; 37(13): 2837–2845. PubMed Abstract | Publisher Full Text | Free Full Text
1073. Post AM, Wultsch T, Popp S, et al.: The COGITAT holeboard system as a valuable tool to assess learning, memory and activity in mice. Behav. Brain Res. 2011; 220(1): 152–158. PubMed Abstract | Publisher Full Text
1074. Andersson H, Hallberg M: Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int. J. Hypertens. 2012; 2012: 1–18. PubMed Abstract | Publisher Full Text | Free Full Text
1075. Raoof H, Michalow KA, Silberring J: Drug metabolism simulation using TiO2/UV system. Biomacromolecular Mass Spectrometry: Tips from the Bench. 2012; 139–152.
1076. Harvey AL, Young LC, Kornisiuk E, et al.: A novel dihydro-pyrazolo(3,4d)(1,2,4)triazolo(1,5a)pyrimidin-4-one (AJ23) is an antagonist at adenosine A1 receptors and enhances consolidation of step-down avoidance. Behav. Brain Res. 2012; 234(2): 184–191. PubMed Abstract | Publisher Full Text
1077. Tricco AC, Soobiah C, Lillie E, et al.: Use of cognitive enhancers for mild cognitive impairment: Protocol for a systematic review and network meta-analysis. Syst. Rev. 2012; 1(1). Publisher Full Text
1078. Ghafari M, Falsafi SK, Hoeger H, et al.: Hippocampal levels of GluR1 and GluR2 complexes are modulated by training in the multiple T-Maze in C57BL/6J mice. Brain Struct. Funct. 2012; 217(2): 353–362. PubMed Abstract | Publisher Full Text
1079. Battisti UM, Jozwiak K, Cannazza G, et al.: 5-arylbenzothiadiazine type compounds as positive allosteric modulators of AMPA/kainate receptors. ACS Med. Chem. Lett. 2012; 3(1): 25–29. PubMed Abstract | Publisher Full Text | Free Full Text
1080. Urben S, Baumann P, Barcellona S, et al.: Cognitive efficacy of quetiapine in early-onset first-episode psychosis: A 12-week open label trial. Psychiatry Q. 2012; 83(3): 311–324. Publisher Full Text
1081. Stepan J, Dine J, Fenzl T, et al.: Entorhinal theta-frequency input to the dentate gyrus trisynaptically evokes hippocampal CA1 LTP. Frontiers in Neural Circuits. 2012; 6. Publisher Full Text
1082. Castaldi S, Gelatti U, Orizio G, et al.: Use of cognitive enhancement medication among Northern Italian university students. J. Addict. Med. 2012; 6(2): 112–117. Publisher Full Text
1083. Mohamed AD, Sahakian BJ: The ethics of elective psychopharmacology. Int. J. Neuropsychopharmacol. 2012; 15(4): 559–571. PubMed Abstract | Publisher Full Text | Free Full Text
1084. Sadasivan S, Pond BB, Pani AK, et al.: Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS ONE. 2012; 7(3). Publisher Full Text
1085. Moriguchi S, Shioda N, Yamamoto Y, et al.: The T-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer ST101: Enhancement of long-term potentiation and CaMKII autophosphorylation in rat cortical slices. J. Neurochem. 2012; 121(1): 44–53. PubMed Abstract | Publisher Full Text
1086. Nic Dhonnchadha BÁ, Pinard E, Alberati D, et al.: Inhibiting glycine transporter-1 facilitates cocaine-cue extinction and attenuates reacquisition of cocaine-seeking behavior. Drug Alcohol Depend. 2012; 122(1-2): 119–126. PubMed Abstract | Publisher Full Text | Free Full Text
1087. Claussen CM, Chong SL, Dafny N: Selective bilateral lesion to caudate nucleus modulates the acute and chronic methylphenidate effects. Pharmacol. Biochem. Behav. 2012; 101(2): 208–216. Publisher Full Text
1088. Melo T, Videira RA, André S, et al.: Tacrine and its analogues impair mitochondrial function and bioenergetics: A lipidomic analysis in rat brain. J. Neurochem. 2012; 120(6): 998–1013. PubMed Abstract | Publisher Full Text
1089. Allen JS: "Theory of food" as a neurocognitive adaptation. Am. J. Hum. Biol. 2012; 24(2): 123–129. PubMed Abstract | Publisher Full Text | Free Full Text
1090. Falsafi SK, Deli A, Höger H, et al.: Scopolamine administration modulates muscarinic, nicotinic and nmda receptor systems. PLoS ONE. 2012; 7(2): e32082. PubMed Abstract | Publisher Full Text | Free Full Text
1091. Tanaka K, Furuyashiki T: A role of prostaglandin signaling in stress and its implication in pharmaceutical development of antidepressants. Folia Pharmacologica Japonica. 2012; 139(4): 152–156. PubMed Abstract | Publisher Full Text
1092. Salerno S, da Settimo F , Taliani S, et al.: Medicinal chemistry of indolylglyoxylamide GABA A/BzR high affinity ligands: Identification of novel anxiolytic/non sedative agents. Curr. Top. Med. Chem. 2012; 12(4): 286–311. PubMed Abstract | Publisher Full Text
1093. Zangara A, Wesnes KA: Herbal cognitive enhancers: New developments and challenges for therapeutic applications. Brain Aging and Therapeutic Interventions. 2012; 267–289. Publisher Full Text
1094. Berridge CW, Devilbiss DM: Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Psiquiatr. Biológica. 2012; 19(3): 84–94. Publisher Full Text
1095. Elliott GR, Elliott MD: Pharmacological cognitive enhancers: Comment on smith and farah (2011). Psychol. Bull. 2011; 137(5): 749–750. PubMed Abstract | Publisher Full Text
1096. Levy K, Lanctôt KL, Farber SB, et al.: Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden?. Drugs Aging. 2012; 29(3): 167–179. PubMed Abstract | Publisher Full Text
1097. Fischer CE, Cohen C, Forrest L, et al.: Psychotropic medication use in Canadian long-term care patients referred for psychogeriatric consultation. Canadian Geriatrics Journal. 2011; 14(3): 73–77. PubMed Abstract | Publisher Full Text | Free Full Text
1098. Li X, Ma X, Li W, et al.: Catalytic asymmetric hydrogenation of ethyl 2-(benzo [b]thiophen-5-yl)-2- oxoacetate with ru-sunphos in the formal synthesis of T-588. Chin. J. Chem. 2011; 29(12): 2581–2583. Publisher Full Text
1099. Wolman MA, Jain RA, Liss L, et al.: Chemical modulation of memory formation in larval zebrafish. Proc. Natl. Acad. Sci. USA. 2011; 108(37): 15468–15473. PubMed Abstract | Publisher Full Text | Free Full Text
1100. Bernard K, Danober L, Thomas JY, et al.: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer. CNS Neurosci. Ther. 2010; 16(5): e193–e212. PubMed Abstract | Publisher Full Text
1101. Marchant NL, King SL, Tabet N, et al.: Positive effects of cholinergic stimulation favor young APOE η4 carriers. Neuropsychopharmacology. 2010; 35(5): 1090–1096. Publisher Full Text
1102. Ko T, Evenden J: The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats. Psychopharmacology. 2009; 202(1-3): 67–78. PubMed Abstract | Publisher Full Text
1103. Chai SY, Yeatman HR, Parker MW, et al.: Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci. 2008; 9. PubMed Abstract | Publisher Full Text | Free Full Text
1104. Kostakis E, Jang MK, Russek SJ, et al.: A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons. J. Neurochem. 2011; 119(3): 486–496. PubMed Abstract | Publisher Full Text | Free Full Text
1105. Roesler R, Schröder N: Cognitive enhancers: Focus on modulatory signaling influencing memory consolidation. Pharmacol. Biochem. Behav. 2011; 99(2): 155–163. PubMed Abstract | Publisher Full Text
1106. Vasudev A, Thomas A: 'Bipolar disorder' in the elderly: What's in a name?. Maturitas. 2010; 66(3): 231–235. Publisher Full Text
1107. Goldberg TE, Keefe RSE, Goldman RS, et al.: Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology. 2010; 35(5): 1053–1062. PubMed Abstract | Publisher Full Text | Free Full Text
1108. Brown JT, Randall AD: Activity-dependent depression of the spike after-depolarization generates long-lasting intrinsic plasticity in hippocampal CA3 pyramidal neurons. J. Physiol. 2009; 587(6): 1265–1281. PubMed Abstract | Publisher Full Text | Free Full Text
1109. Albensi BC: Can in vitro assessment provide relevant end points for cognitive drug programs?. Expert Opin. Drug Discov. 2008; 3(12): 1377–1382. Publisher Full Text
1110. Albiston AL, Morton CJ, Hooi LN, et al.: Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J. 2008; 22(12): 4209–4217. Publisher Full Text
1111. Francotte P, Tullio P, Podona T, et al.: Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators. Bioorg. Med. Chem. 2008; 16(23): 9948–9956. PubMed Abstract | Publisher Full Text
1112. Faizi M, Bader PL, Tun C, et al.: Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 2011; 43(2): 397–413. PubMed Abstract | Publisher Full Text | Free Full Text
1113. Singh D, Singh B, Goel RK: Traditional uses, phytochemistry and pharmacology of Ficus religiosa: A review. J. Ethnopharmacol. 2011; 134(3): 565–583. PubMed Abstract | Publisher Full Text
1114. Farshchi A, Ghiasi G, Farshchi S, et al.: The effect of chronic administration of Aegle marmelos seed extract on learning and memory in diabetic rats. Iran. J. Basic Med. Sci. 2011; 14(1): 42–48.
1115. Merrill DA, Sultzer DL: Behavioural Management in Alzheimer's Disease - Pharmacology. Principles and Practice of Geriatric Psychiatry: Third Edition. 2010; 312–323. Publisher Full Text
1116. Meyer MR, Maurer HH: Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011; 12(2): 215–233. PubMed Abstract | Publisher Full Text
1117. Floresco SB, Jentsch JD: Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology. 2011; 36(1): 227–250. PubMed Abstract | Publisher Full Text | Free Full Text
1118. Ruigt GSF, Van Gerven J: Effects of Medication on Sleep and Wakefulness. Sleep Disorders in Neurology: A Practical Approach. 2010; 271–293. Publisher Full Text
1119. Wu J, Li Q, Bezprozvanny I: Evaluation of Dimebon in cellular model of Huntington's disease. Mol. Neurodegener. 2008; 3(1). PubMed Abstract | Publisher Full Text | Free Full Text
1120. Nemes A, Czibula L, Szántay C Jr, et al.: Synthesis and evaluation of 2′-hydroxyethyl trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents. J. Med. Chem. 2008; 51(3): 479–486. Publisher Full Text
1121. Slaughter SE, Eliasziw M, Morgan D, et al.: Incidence and predictors of excess disability in walking among nursing home residents with middle-stage dementia: A prospective cohort study. Int. Psychogeriatr. 2011; 23(1): 54–64. Publisher Full Text
1122. Husain M, Mehta MA: Cognitive enhancement by drugs in health and disease. Trends Cogn. Sci. 2011; 15(1): 28–36. PubMed Abstract | Publisher Full Text | Free Full Text
1123. Chen JF, Chern Y: Impacts of methylxanthines and adenosine receptors on neurodegeneration: Human and experimental studies. Handb. Exp. Pharmacol. 2011; 200: 267–310. PubMed Abstract | Publisher Full Text
1124. Hanson E, Healey K, Wolf D, et al.: Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr. Psychiatry Rep. 2010; 12(6): 563–571. Publisher Full Text
1125. Barak S, Weiner I: Dissociating scopolamine-induced disrupted and persistent latent inhibition: Stage-dependent effects of glycine and physostigmine. Psychopharmacology. 2010; 209(2): 175–184. Publisher Full Text
1126. Biedermann F: Arguments in favour of and against cognitive enhancement: A critical survey. Ethik Med. 2010; 22(4): 317–329. Publisher Full Text
1127. Lopez OL, Becker JT, Wahed AS, et al.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry. 2009; 80(6): 600–607. PubMed Abstract | Publisher Full Text | Free Full Text
1128. Vervliet B: Learning and memory in conditioned fear extinction: Effects of d-cycloserine. Acta Psychol. 2008; 127(3): 601–613. PubMed Abstract | Publisher Full Text
1129. Farshchia A, Ghiasia G, Ghiasi S: Aegle marmelos extract can enhance memory in rats. Iranian Journal of Pharmaceutical Sciences. 2010; 6(1): 25–32.
1130. Brown DC, Nichols JA, Thomas F, et al.: Nicotinic modulation of auditory attentional shift in the rat. Behav. Brain Res. 2010; 210(2): 273–279. PubMed Abstract | Publisher Full Text
1131. Banjo OC, Nadler R, Reiner PB: Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS ONE. 2010; 5(12): e14322. PubMed Abstract | Publisher Full Text | Free Full Text
1132. Yang YJ, Wu PF, Wang F, et al.: Modulation of long-term potentiation in the hippocampus by pharmacological approach: A novel strategy for the development of cognitive enhancers. Chin. Sci. Bull. 2010; 55(30): 3374–3382. Publisher Full Text
1133. Córdoba-Montoya DA, Albert J, López-Martín S: All together now: Long term potentiation in the human cortex. Rev. Neurol. 2010; 51(6): 367–374. PubMed Abstract
1134. Ferguson AL, Stone TW: Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors. Eur. J. Neurosci. 2010; 31(7): 1208–1218. PubMed Abstract | Publisher Full Text
1135. Johnson DJ, Forbes IT, Watson SP, et al.: The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3- benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. Bioorg. Med. Chem. Lett. 2010; 20(18): 5434–5438. PubMed Abstract | Publisher Full Text
1136. Rasetti R, Mattay VS, Stankevich B, et al.: Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology. 2010; 35(10): 2101–2109. PubMed Abstract | Publisher Full Text | Free Full Text
1137. Moreira KM, Ferreira TL, Hipolide DC, et al.: Modafinil prevents inhibitory avoidance memory deficit induced by sleep deprivation in rats. Sleep. 2010; 33(7): 990–993. PubMed Abstract | Publisher Full Text | Free Full Text
1138. Kennedy CD, Houmes SW, Wyrick KL, et al.: Methamphetamine enhances memory of operantly conditioned respiratory behavior in the snail Lymnaea stagnalis. J. Exp. Biol. 2010; 213(12): 2055–2065. Publisher Full Text
1139. Shioda N, Yamamoto Y, Han F, et al.: A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. J. Pharmacol. Exp. Ther. 2010; 333(1): 43–50. PubMed Abstract | Publisher Full Text
1140. Bishara D: The pharmacological management of Alzheimer's disease. Prog. Neurol. Psychiatry. 2010; 14(1): 16–22. Publisher Full Text
1141. Yuan D, Ma B, Jy Y, et al.: Anti-inflammatory effects of rhynchophylline and isorhynchophylline in mouse N9 microglial cells and the molecular mechanism. Int. Immunopharmacol. 2009; 9(13-14): 1549–1554. PubMed Abstract | Publisher Full Text
1142. Young JW, Sharkey J, Finlayson K: Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Impairment. Neurobiol. Aging. 2009; 30(9): 1430–1443. Publisher Full Text
1143. Montero-Odasso M, Wells JL, Borrie MJ, et al.: Can cognitive enhancers reduce the risk of falls in older people with Mild Cognitive Impairment? A protocol for a randomised controlled double blind trial. BMC Neurol. 2009; 9: 42. PubMed Abstract | Publisher Full Text | Free Full Text
1144. Shorvon SD: Piracetam. The Treatment of Epilepsy: Third Edition. 2009; 619–625. Publisher Full Text
1145. Yu H, Wang Y, Pattwell S, et al.: Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J. Neurosci. 2009; 29(13): 4056–4064. PubMed Abstract | Publisher Full Text | Free Full Text
1146. Powers MB, Smits JAJ, Otto MW, et al.: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation. J. Anxiety Disord. 2009; 23(3): 350–356. PubMed Abstract | Publisher Full Text
1147. Shuman T, Wood SC, Anagnostaras SG: Modafinil and Memory: Effects of Modafinil on Morris Water Maze Learning and Pavlovian Fear Conditioning. Behav. Neurosci. 2009; 123(2): 257–266. PubMed Abstract | Publisher Full Text | Free Full Text
1148. Barak S, Weiner I: Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: Scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. Int. J. Neuropsychopharmacol. 2009; 12(2): 227–241. Publisher Full Text
1149. Montero-Odasso M, Wells J, Borrie M: Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J. Am. Geriatr. Soc. 2009; 57(2): 359–360. PubMed Abstract | Publisher Full Text | Free Full Text
1150. Poyurovsky M, Faragian S, Fuchs C, et al.: Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: An add-on, double-blind placebo-controlled study. Isr. J. Psychiatry Relat. Sci. 2009; 46(3): 213–220. PubMed Abstract
1151. Lapish CC, Ahn S, Evangelista LM, et al.: Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology. 2009; 202(1-3): 521–530. PubMed Abstract | Publisher Full Text
1152. Deiana S, Harrington CR, Wischik CM, et al.: Methylthioninium chloride reverses cognitive deficits induced by scopolamine: Comparison with rivastigmine. Psychopharmacology. 2009; 202(1-3): 53–65. PubMed Abstract | Publisher Full Text
1153. Singer P, Feldon J, Yee BK: The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology. 2009; 202(1-3): 371–384. PubMed Abstract | Publisher Full Text
1154. Balci F, Ludvig EA, Gibson JM, et al.: Pharmacological manipulations of interval timing using the peak procedure in male C3H mice. Psychopharmacology. 2008; 201(1): 67–80. PubMed Abstract | Publisher Full Text
1155. Arushanyan EB, Beier EV: Ginkgo Biloba as a cognitive enhancer. Eksperimental'naya i Klinicheskaya Farmakologiya. 2008; 71(4): 57–63.
1156. Dave UP, Wasim P, Joshua JA, et al.: BacoMind®: A cognitive enhancer in children requiring individual education programme. J. Pharmacol. Toxicol. 2008; 3(4): 302–310.
1157. Pelton GH, Harper OL, Tabert MH, et al.: Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: A pilot study. Int. J. Geriatr. Psychiatry. 2008; 23(7): 670–676. PubMed Abstract | Publisher Full Text | Free Full Text
1158. Cutuli D, Foti F, Mandolesi L, et al.: Cognitive performance of healthy young rats following chronic donepezil administration. Psychopharmacology. 2008; 197(4): 661–673. PubMed Abstract | Publisher Full Text
1159. Stewart MG, Banks D: Enhancement of long-term memory retention by Colostrinin in one-day-old chicks trained on a weak passive avoidance learning paradigm. Neurobiol. Learn. Mem. 2006; 86(1): 66–71. Publisher Full Text
1160. Yamaguchi Y, Miyashita H, Tsunekawa H, et al.: Effects of a novel cognitive enhancer, spiro [imidazo-[1,2-a]pyridine-3,2- indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-β1-40 in the rat. J. Pharmacol. Exp. Ther. 2006; 317(3): 1079–1087. Publisher Full Text
1161. Shin EJ, Jin HJ, Nabeshima T, et al.: Growth hormone releaser attenuates β-amyloid (1-42)-induced memory impairment in mice. J. Pharmacol. Sci. 2005; 99(1): 117–120. PubMed Abstract | Publisher Full Text
1162. Yaari R, Tariot PN, Schneider LS, et al.: Cognitive Enhancers and Treatments for Alzheimer's Disease. Psychiatry: Third Edition. 2008; 2: 2294–2317. Publisher Full Text
1163. Yesavage J, Hoblyn J, Friedman L, et al.: Should one use medications in combination with cognitive training? If so, which ones. J. Gerontol. B Psychol. Sci. Soc. Sci. 2007; 62(SPEC. ISSUE 1): 11–18. PubMed Abstract | Publisher Full Text
1164. Herrmann N: Treatment of moderate to severe Alzheimer's disease: Rationale and trial design. Can. J. Neurol. Sci. 2007; 34: S103–S108. PubMed Abstract | Publisher Full Text
1165. Chiu SS, Lalone S, Goble L: Pharmacology of huperzine A, an alkaloid isolated from Huperzine Serrata, a novel cognition enhancer with dual cholinergic and NMDA action. Implications in schizophrenia and dementia. Journal of Complementary and Integrative Medicine. 2007; 4(1). Publisher Full Text
1166. Basil B, Mathews M, Mahmud J, et al.: Cognitive enhancers for treatment of noncognitive symptons of dementia. Clin. Geriatr. 2006; 14(6): 20–23.
1167. Werneke U, Turner T, Priebe S: Complementary medicines in psychiatry: Review of effectiveness and safety. Br. J. Psychiatry. 2006; 188(FEB): 109–121. Publisher Full Text
1168. Tokita K, Inoue T, Yamazaki S, et al.: FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur. J. Pharmacol. 2005; 527(1-3): 111–120. PubMed Abstract | Publisher Full Text
1169. Narahashi T, Moriguchi S, Zhao X, et al.: Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull. 2004; 27(11): 1701–1706. PubMed Abstract | Publisher Full Text
1170. Sunyer B, Shim KS, Höger H, et al.: The cognitive enhancer SGS742 does not involve major known signaling cascades in OF1 mice. Neurochem. Res. 2008; 33(7): 1384–1392. Publisher Full Text
1171. Arushanyan EB, Popov AV: Chronotropic activity of Semax as a cognitive enhancer. Eksperimental'naya i Klinicheskaya Farmakologiya. 2008; 71(2): 14–16.
1172. Reikhardt BA, Sapronov NS: Ethymisole: Reassessing and old drug. Eksperimental'naya i Klinicheskaya Farmakologiya. 2007; 70(3): 62–68.
1173. Faison WE, Schultz SK, Aerssens J, et al.: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: Challenges for the future. Int. Psychogeriatr. 2007; 19: 539–558. Publisher Full Text
1174. Devan BD, Pistell PJ, Daffin LW Jr, et al.: Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nω-nitro-L-arginine methyl ester. Eur. J. Pharmacol. 2007; 563(1-3): 134–140. PubMed Abstract | Publisher Full Text
1175. Arushanyan EB, Ovanesov KB, Ovanesova IM: Comparative action of melatonin and bilobil on light perception and some psychophysiological indices in patients with cerebral trauma anamnesis. Eksperimental'naya i Klinicheskaya Farmakologiya. 2007; 70(2): 20–23.
1176. Kart-Teke E, Dere E, Brandão ML, et al.: Reinstatement of episodic-like memory in rats by neurokinin-1 receptor antagonism. Neurobiol. Learn. Mem. 2007; 87(3): 324–331. Publisher Full Text
1177. Houslay MD, Schafer P, Zhang KYJ: Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today. 2005; 10(22): 1503–1519. PubMed Abstract | Publisher Full Text
1178. Sunyer B, Patil S, Frischer C, et al.: Strain-dependent effects of cognitive enhancers in the mouse. Amino Acids. 2008; 34(3): 485–495. PubMed Abstract | Publisher Full Text
1179. Swanson KA, Carnahan RM: Dementia and comorbidities: An overview of diagnosis and management. J. Pharm. Pract. 2007; 20(4): 296–317. Publisher Full Text
1180. Solfrizzi V, Colacicco AM, D'Introno A, et al.: Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia. J. Alzheimers Dis. 2006; 10(2-3): 303–330. PubMed Abstract | Publisher Full Text
1181. Quarta D, Naylor CG, Morris HV, et al.: Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine. Neuropharmacology. 2007; 53(3): 421–430. Publisher Full Text
1182. Tsaltas E, Kontis D, Boulougouris V, et al.: Enhancing effects of chronic lithium on memory in the rat. Behav. Brain Res. 2007; 177(1): 51–60. PubMed Abstract | Publisher Full Text
1183. Pull CB: Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr. Opin. Psychiatry. 2007; 20(1): 30–35. Publisher Full Text
1184. Geyer MA: Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. Dialogues Clin. Neurosci. 2006; 8(1): 9–16. PubMed Abstract | Publisher Full Text | Free Full Text
1185. Holenz J, Pauwels PJ, Díaz JL, et al.: Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today. 2006; 11(7-8): 283–299. PubMed Abstract | Publisher Full Text
1186. Nahas Z, George MS, Horner MD, et al.: Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 2003; 9(3): 274–282. PubMed Abstract | Publisher Full Text
1187. Hoff AL, Kremen WS: Neuropsychology in schizophrenia: An update. Curr. Opin. Psychiatry. 2003; 16(2): 149–155. Publisher Full Text
1188. Guastella AJ, Dadds MR, Lovibond PF, et al.: A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J. Psychiatr. Res. 2007; 41(6): 466–471. PubMed Abstract | Publisher Full Text
1189. Nihalani ND, Schwartz TL: Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Curr. Opin. Investig. Drugs. 2007; 8(7): 563–569. PubMed Abstract
1190. Chouinard S, Stip E, Poulin J, et al.: Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr. Med. Res. Opin. 2007; 23(3): 575–583. PubMed Abstract | Publisher Full Text
1191. Ezoulin MJM, Dong CZ, Liu Z, et al.: Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. Toxicology in Vitro. 2006; 20(6): 824–831. PubMed Abstract | Publisher Full Text
1192. Roesler R, Luft T, Oliveira SHS, et al.: Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology. 2006; 51(2): 350–357. Publisher Full Text
1193. Mehta MA, Riedel WJ: Dopaminergic enhancement of cognitive function. Curr. Pharm. Des. 2006; 12(20): 2487–2500. Publisher Full Text
1194. Braszko JJ: D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV. Physiol. Behav. 2006; 88(1-2): 152–159. Publisher Full Text
1195. Holenz J, Pauwels PJ, Díaz JL, et al.: Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today. 2006; 11(7-8): 283–299. PubMed Abstract | Publisher Full Text
1196. Lee SW, Kim YH: A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for cognitive impairments in chronic schizophrenia. Clinical Psychopharmacology and Neuroscience. 2005; 3(1): 10–15.
1197. Eremin KO, Kudrin VS, Saransaari P, et al.: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem. Res. 2005; 30(12): 1493–1500. PubMed Abstract | Publisher Full Text
1198. Moutsimilli L, Farley S, Dumas S, et al.: Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology. 2005; 49(6): 890–900. PubMed Abstract | Publisher Full Text
1199. Nuechterlein KH, Barch DM, Gold JM, et al.: Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004; 72: 29–39. Publisher Full Text
1200. Mise M, Hashizume T, Matsumoto S, et al.: Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics. 2004; 14(11): 769–773. PubMed Abstract | Publisher Full Text
1201. Ressler KJ, Rothbaum BO, Tannenbaum L, et al.: Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry. 2004; 61(11): 1136–1144. PubMed Abstract | Publisher Full Text
1202. Manktelow T, Zangara A: The cognitive assessment of herbal products - Are the effects imagined or real?. Eur. Pharm. Contract. 2004; (SPRING): 36–41.
1203. Bunce JG, Sabolek HR, Chrobak JJ: Timing of administration mediates the memory effects of intraseptal carbachol infusion. Neuroscience. 2004; 127(3): 593–600. PubMed Abstract | Publisher Full Text
1204. Domingos JLO, Lima EC, Dias AG, et al.: Stereoselective preparation of pyrrolidin-2-ones from a Z-enoate derived from D-(+)-mannitol. Tetrahedron Asymmetry. 2004; 15(15): 2313–2314. Publisher Full Text
1205. Koyama Y, Egawa H, Osakada M, et al.: Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes. Biochem. Pharmacol. 2004; 68(2): 275–282. Publisher Full Text
1206. O'Kane EM, Stone TW, Morris BJ: Increased long-term potentiation in the CA1 region of rat hippocampus via modulation of GTPase signalling or inhibition of Rho kinase. Neuropharmacology. 2004; 46(6): 879–887. Publisher Full Text
1207. Castilho JC, Perry JC, Andreatini R, et al.: Phosphatidylserine: An antidepressive or a cognitive enhancer?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2004; 28(4): 731–738. Publisher Full Text
1208. Mise M, Yadera S, Matsuda M, et al.: Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab. Dispos. 2004; 32(2): 240–245. PubMed Abstract | Publisher Full Text
1209. Birks J, Wilcock GG: Velnacrine for Alzheimer's disease. Cochrane database of systematic reviews (Online). 2004; 2: CD004748. Publisher Full Text
1210. Phuagphong P, Fukushima T, Hatanaka R, et al.: T-588, a cognitive enhancer, protects against sodium nitroprusside-induced toxicity in cultured astrocytes. J. Pharmacol. Sci. 2004; 95(1): 135–138. PubMed Abstract | Publisher Full Text
1211. Abdi Z, Sharma T: Social cognition and its neural correlates in schizophrenia and autism. CNS Spectr. 2004; 9: 335–343. Publisher Full Text
1212. Caston JC, Diehl LA, Hedgepath AW: Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia. J. S. C. Med. Assoc. 1975. 2004; 100(2): 32–8.
1213. Herrmann N: Cognitive pharmacotherapy of Alzheimer's disease and other dementias. Can. J. Psychiatr. 2002; 47(8): 715–722. Publisher Full Text
1214. Riby LM: The impact of age and task domain on cognitive performance: A meta-analytic review of the glucose facilitation effect. Brain Impairment. 2004; 5(2): 145–165. Publisher Full Text
1215. Yamamuro A, Ago Y, Takuma K, et al.: Possible Involvement of Astrocytes in Neuroprotection by the Cognitive Enhancer T-588. Neurochem. Res. 2003; 28(12): 1779–1783. Publisher Full Text
1216. Bentué-Ferrer D, Tribut O, Polard E, et al.: Clinically Significant Drug Interactions with Cholinesterase Inhibitors: A Guide for Neurologists. CNS Drugs. 2003; 17(13): 947–963. Publisher Full Text
1217. Yokoyama I, Sakai Y, Hatayama Y, et al.: T-588, a cognitive enhancer, stimulates in vivo phosphorylation of extracellular signal-regulated kinases in the hippocampus. Cogn. Brain Res. 2003; 17(2): 522–525. PubMed Abstract | Publisher Full Text
1218. Harvey J: Novel actions of leptin in the hippocampus. Ann. Med. 2003; 35(3): 197–206. PubMed Abstract | Publisher Full Text
1219. Freir DB, Herron CE: Nicotine enhances the depressive actions of Aβ1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J. Neurophysiol. 2003; 89(6): 2917–2922. PubMed Abstract | Publisher Full Text
1220. Chazot P: British Neuroscience Association - 17th National Meeting: 13-16 April 2003. Harrogate, UK: IDrugs; 2003.
1221. Rosa RM, Flores DG, Appelt HR, et al.: Facilitation of long-term object recognition memory by pretraining administration of diphenyl diselenide in mice. Neurosci. Lett. 2003; 341(3): 217–220. PubMed Abstract | Publisher Full Text
1222. Bellemère G, Morain P, Vaudry H, et al.: Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and α-melanocyte-stimulating hormone breakdown in the rat brain. J. Neurochem. 2003; 84(5): 919–929. PubMed Abstract | Publisher Full Text
1223. Petrella JR, Coleman RE, Doraiswamy PM: Neuroimaging and early diagnosis of alzheimer disease: A look to the future. Radiology. 2003; 226(2): 315–336. Publisher Full Text
1224. Turner DC, Robbins TW, Clark L, et al.: Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003; 165(3): 260–269. Publisher Full Text
1225. Zangara A: The psychopharmacology of huperzine A: An alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 2003; 75(3): 675–686. PubMed Abstract | Publisher Full Text
1226. Pazourková M, Lojek A, Číž M, et al.: Antioxidative activity of pyridoindoles and N-(alkoxyphenyl)-2-(2-oxo-1-aza-1-cykloalkyl) acetamides in biological, enzymatic, and chemical systems. Ceska Slov. Farm. 2003; 52(4): 171–175. PubMed Abstract
1227. Golde TE: Alzheimer disease therapy: Can the amyloid cascade be halted?. J. Clin. Invest. 2003; 111(1): 11–18. PubMed Abstract | Publisher Full Text | Free Full Text
1228. Adunsky A, Chesnin V, Davidson M, et al.: A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2002; 57(11): M757–M761. PubMed Abstract | Publisher Full Text
1229. Das A, Shanker G, Nath C, et al.: A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba - Anticholinesterase and cognitive enhancing activities. Pharmacol. Biochem. Behav. 2002; 73(4): 893–900. PubMed Abstract | Publisher Full Text
1230. Ghelardini C, Galeotti N, Gualtieri F, et al.: DM235 (sunifiram): A novel nootropic with potential as a cognitive enhancer. Naunyn Schmiedeberg's Arch. Pharmacol. 2002; 365(6): 419–426. PubMed Abstract
1231. Ward CP, Redd K, Williams BM, et al.: Ginkgo biloba extract: Cognitive enhancer or antistress buffer. Pharmacol. Biochem. Behav. 2002; 72(4): 913–922. PubMed Abstract | Publisher Full Text
1232. Ishihara K, Sasa M: Modulation of neuronal activities in the central nervous system via sigma receptors. Japanese Journal of Psychopharmacology. 2002; 22(1): 23–30. PubMed Abstract
1233. Maurice T: Beneficial effect of the σ1 receptor agonist PRE-084 against the spatial learning deficits in aged rats. Eur. J. Pharmacol. 2001; 431(2): 223–227. PubMed Abstract | Publisher Full Text
1234. Gold PE, Cahill L, Wenk GL: Ginkgo biloba: A Cognitive Enhancer?. Psychol. Sci. Public Interest. 2002; 3(1): 2–11. Publisher Full Text
1235. Rose SPR: 'Smart Drugs': Do they work? Are they ethical? Will they be legal?. Nat. Rev. Neurosci. 2002; 3(12): 975–979. PubMed Abstract | Publisher Full Text
1236. Izquierdo I: Cognitive enhancers: A view from two developing countries. Int. J. Psychol. 1998; 33(2): 87–94. Publisher Full Text
1237. Shulman MB, Barr W: Treatment of memory disorders in epilepsy. Epilepsy Behav. 2002; 3(5 SUPPL. 1): 30–34. Publisher Full Text
1238. Cassel CK: Successful aging: How increased life expectancy and medical advances are changing geriatric care. Geriatrics. 2001; 56(1): 35–9; quiz 40. PubMed Abstract
1239. Grundman M, Thal LJ: Treatment of Alzheimer's disease: Rationale and strategies. Neurol. Clin. 2000; 18(4): 807–827. Publisher Full Text
1240. Winter JC, Helsley SE, Rabin RA: The discriminative stimulus effects of KA 672, a putative cognitive enhancer: Evidence for a 5-HT(1A) component. Pharmacol. Biochem. Behav. 1998; 60(3): 703–707. Publisher Full Text
1241. Scott R, Bourtchuladze R, Gossweiler S, et al.: CREB and the discovery of cognitive enhancers. J. Mol. Neurosci. 2002; 19(1-2): 171–177. PubMed Abstract | Publisher Full Text
1242. Yamaguchi H, Tamura R, Kuriwaki JI, et al.: Effects of T-588, a cognitive enhancer compound, on synaptic plasticity in the dentate gyrus of freely moving rats. J. Pharmacol. Exp. Ther. 2001; 298(1): 354–361. PubMed Abstract | Publisher Full Text
1243. Hodgkiss JP, Kelly JS: Effect of FK960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus. J. Pharmacol. Exp. Ther. 2001; 297(2): 620–628. PubMed Abstract | Publisher Full Text
1244. Nakada Y, Tamura R, Kuriwaki JI, et al.: Ameliorative effects of a cognitive enhancer, T-588, on place learning deficits induced by transient forebrain ischemia in rats. Physiol. Behav. 2001; 74(1-2): 227–235. PubMed Abstract | Publisher Full Text
1245. Zorumski CF, Mennerick S, Isenberg KE, et al.: Potential clinical uses of neuroactive steroids. Curr. Opin. Investig. Drugs. 2000; 1(3): 360–369. PubMed Abstract
1246. Zorumski CF, Mennerick S, Isenberg KE, et al.: Potential clinical uses of neuroactive steroids. IDrugs. 2000; 3(9): 1053–1063. PubMed Abstract
1247. Zhang HT, Crissman AM, Dorairaj NR, et al.: Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology. 2000; 23(2): 198–204. PubMed Abstract | Publisher Full Text
1248. Tariska P, Paksy A: Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia. Orv. Hetil. 2000; 141(22): 1189–1193. PubMed Abstract
1249. Wang HS, Brown BS, McKinnon D, et al.: Molecular basis for differential sensitivity of KCNQ and I (Ks) channels to the cognitive enhancer XE991. Mol. Pharmacol. 2000; 57(6): 1218–1223. PubMed Abstract | Publisher Full Text
1250. Matsuoka N, Satoh M: FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices. Brain Res. 1998; 794(2): 248–254. PubMed Abstract | Publisher Full Text
1251. Barros DM, Izquierdo LA, Medina JH, et al.: Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats. Behav. Pharmacol. 2002; 13(3): 215–220. PubMed Abstract | Publisher Full Text
1252. Morris RGM, Kelly S, Burney D, et al.: Tianeptine and its enantiomers: Effects on spatial memory in rats with medial septum lesions. Neuropharmacology. 2001; 41(2): 272–281. PubMed Abstract | Publisher Full Text
1253. Mook-Jung I, Hong HS, Boo JH, et al.: Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J. Neurosci. Res. 2001; 63(6): 509–515. PubMed Abstract | Publisher Full Text
1254. Das A, Dikshit M, Nath C: Profile of acetylcholinesterase in brain areas of male and female rats of adult and old age. Life Sci. 2001; 68(13): 1545–1555. PubMed Abstract | Publisher Full Text
1255. Zhao R, McDaniel WF: Ginseng improves strategic learning by normal and brain-damaged rats. NeuroReport. 1998; 9(7): 1619–1624. PubMed Abstract | Publisher Full Text
1256. File SE, Fluck E, Fernandes C: Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. J. Clin. Psychopharmacol. 1999; 19(6): 506–512. PubMed Abstract | Publisher Full Text
1257. McArthur RA, Carfagna N, Banfi L, et al.: Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels. Brain Res. Bull. 1997; 43(3): 305–311. Publisher Full Text
1258. Hirata K, Katayama S: The role of nicotinic receptor in memory impairment: A study using event-related potentials and midlatency responses. Clinical Neurology. 1996; 36(12): 1318–1321. PubMed Abstract
1259. Marincola R: Neurobiology and Quantified Pharmaco E.E.G. of Coenzyme Q10. Journal of Orthomolecular Medicine. 1997; 12(2): 87–95.
1260. Yoshii M, Watabe S, Sakurai T, et al.: Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav. Brain Res. 1997; 83: 185–188. Publisher Full Text
1261. Saito H, Nishiyama N, Zhang Y, et al.: Learning disorders in thymectomized mice: A new screening model for cognitive enhancer. Behav. Brain Res. 1997; 83: 63–69. PubMed Abstract | Publisher Full Text
1262. Mazurov AA, Andronati SA, Korotenko TI, et al.: Design of a novel cognitive enhancer (8S, 10aS)-8-carbamoyl-1,2,3,6,7,8,9,10a-octahydro-5H,10H-pyrrolo[1,2a][1,4]diazocin-5,10-dione. Bioorg. Med. Chem. Lett. 1996; 6(21): 2595–2600. Publisher Full Text
1263. Fillit HM, Butler RN, O’Connell AW, et al.: Achieving and maintaining cognitive vitality with aging. Mayo Clin. Proc. 2002; 77(7): 681–696. PubMed Abstract
1264. Moskal JR, Yamamoto H, Colley PA: The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Curr. Drug Targets. 2001; 2(3): 331–345. PubMed Abstract | Publisher Full Text
1265. Lelong V, Dauphin F, Boulouard M: RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology. 2001; 41(4): 517–522. PubMed Abstract | Publisher Full Text
1266. Yamaguchi Y, Higashi M, Matsuno T, et al.: Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn. J. Pharmacol. 2001; 87(3): 240–244. PubMed Abstract | Publisher Full Text
1267. Teismann P, Ferger B: Effects of ensaculin on dopamine metabolite levels and K+-induced glutamate release. Eur. J. Pharmacol. 2000; 398(2): 247–250. PubMed Abstract | Publisher Full Text
1268. Hilgert M, Nöldner M, Chatterjee SS, et al.: KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo. Neurosci. Lett. 1999; 263(2-3): 193–196. PubMed Abstract | Publisher Full Text
1269. Senda T, Matsuno K, Kobayashi T, et al.: Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. Pharmacol. Biochem. Behav. 1998; 59(1): 129–134. PubMed Abstract
1270. Matsuno K, Mita S: SA4503: A novel sigma1 receptor agonist. CNS Drug Rev. 1998; 4(1): 1–24. Publisher Full Text
1271. Sarter M, Bruno JP: Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: A rational approach for the development of cognition enhancers. Behav. Brain Res. 1997; 83: 7–14. Publisher Full Text
1272. Park CH, Kim SH, Choi W, et al.: Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med. 1996; 62(5): 405–409. Publisher Full Text
1273. Coull JT, Sahakian BJ, Hodges JR: The α2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology. 1996; 123(3): 239–249. PubMed Abstract | Publisher Full Text
1274. Camp-Bruno JA, Herting RL: Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology. 1994; 115(1-2): 46–52. PubMed Abstract | Publisher Full Text
1275. Patent evaluation: 1-azabicycloalkanes containing ether or thioether side-chains as muscarinic agonists. Expert Opin. Ther. Pat. 1992; 2(3): 277–278. Publisher Full Text
1276. Hisashi K, Sakutaro T: Aspects op animal experiments for evaluation of cognitive enhancers: In particular, the behavioral characteristics of mongolian gerbils. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1992; 16(3): 389–396. Publisher Full Text
1277. Means LW, Comer TR, Moore R: BMY 21502 and piracetam facilitate performance of two-choice win-stay water-escape in normal rats. J. Neural Transm. 1991; 85(2): 109–116. PubMed Abstract | Publisher Full Text
1278. Herrmann N: Pharmacotherapy for Alzheimer's disease and other dementias. Curr. Opin. Psychiatry. 2002; 15(4): 403–409. Publisher Full Text
1279. Švestka J: Galantamine - A dual action cognitive enhancer. Psychiatrie. 2001; 5(4): 265–274.
1280. Carey GJ, Billard W, Binch H 3rd, et al.: SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur. J. Pharmacol. 2001; 431(2): 189–200. PubMed Abstract | Publisher Full Text
1281. Kumar V, Singh PN, Singh HK: Alzheimer's disease: An update. Acta Pharmaceutica Turcica. 2001; 43(2): 121–142.
1282. Van Reekum R, Simard M, Farcnik K: Diagnosis of dementia and treatment of Alzheimer's disease: Pharmacologic management of disease progression and cognitive impairment. Can. Fam. Physician. 1999; 45(APR): 945–952.
1283. Svestka J: Cognitive enhancer donepezil. Psychiatrie. 1999; 3(1): 36–44.
1284. Svestka J: New psychotropics: Cognitive enhancer rivastigmine. Psychiatrie. 1999; 3(2): 110–118.
1285. Macvinish LJ, Guo Y, Dixon AK, et al.: XE991 reveals differences in K+ channels regulating chloride secretion in murine airway and colonic epithelium. Mol. Pharmacol. 2001; 60(4): 753–760. Publisher Full Text
1286. Yoshii M, Watabe S, Murashima YL, et al.: Cellular mechanism of action of cognitive enhancers: Effects of nefiracetam on neuronal Ca2+ channels. Alzheimer Dis. Assoc. Disord. 2000; 14: S95–S102. PubMed Abstract | Publisher Full Text
1287. Iwata N, Kozuka M, Hara T, et al.: Activation of cerebral function by CS-932, a functionally selective M1 partial agonist: Neurochemical characterization and pharmacological studies. Jpn. J. Pharmacol. 2000; 84(3): 266–280. Publisher Full Text
1288. Vernier JM, El-Abdellaoui H, Holsenback H, et al.: 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]- phenol hydrochloride (SIB- 1553A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1999; 42(10): 1684–1686. PubMed Abstract | Publisher Full Text
1289. Reisner E, Noldner M, Rossner S, et al.: Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain. Neurosci. Lett. 1999; 274(3): 187–190. PubMed Abstract | Publisher Full Text
1290. Robbins TW, McAlonan G, Muir JL, et al.: Cognitive enhancers in theory and practice: Studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav. Brain Res. 1997; 83: 15–23. PubMed Abstract | Publisher Full Text
1291. Matsuno K, Senda T, Kobayashi T, et al.: SA4503, a novel cognitive enhancer, with σ1 receptor agonistic properties. Behav. Brain Res. 1997; 83: 221–224. Publisher Full Text
1292. Goodwin GM, Conway SC, Peyro-Saint-Paul H, et al.: Executive function and uptake of 99mTc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia. Psychopharmacology. 1997; 131(4): 371–378. PubMed Abstract | Publisher Full Text
1293. Ribeiro JA, De Mendonça A , Correia-de-Sá P, et al.: Purinoceptors and synaptic plasticity. Drug Dev. Res. 1996; 39: 353–360. Publisher Full Text
1294. Reidel W, Hogervorst E, Leboux R, et al.: Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology. 1995; 122(2): 158–168. Publisher Full Text
1295. Deckert J, Jorgensen MB: Unilateral entorhinal cortex lesion - an animal model for cognitive impairment in human disease: Effects on adenosine receptors and second messengers. Nucleosides and Nucleotides. 1991; 10(5): 1175–1176. Publisher Full Text
1296. Patočka J, Fusek J, Vázquez MV, editors. Epibatidine - Design for new cognitive enhancers. Psychiatrie. 2001.
1297. Farsa O, Poláchová K, Beneš L, editors. 2-Pyrrolidinone derivatives as potential therapeutic agents of CNS. Psychiatrie. 2001.
1298. Lebrun C, Pillière E, Lestage P: Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur. J. Pharmacol. 2000; 401(2): 205–212. Publisher Full Text
1299. Taylor EM, Yan Y, Hauptmann N, et al.: AIT-082, a cognitive enhancer, is transported into brain by a nonsaturable influx mechanism and out of brain by a saturable efflux mechanism. J. Pharmacol. Exp. Ther. 2000; 293(3): 813–821. PubMed Abstract | Publisher Full Text
1300. Kimura M, Okano S, Inoué S: Effects of aniracetam on impaired sleep patterns in stroke-prone spontaneously hypertensive rats. Psychiatry Clin. Neurosci. 2000; 54: 314–316. PubMed Abstract | Publisher Full Text
1301. Darnaudéry M, Bouyer JJ, Pallarés M, et al.: The promnesic neurosteroid pregnenolone sulfate increases paradoxical sleep in rats. Brain Res. 1999; 818(2): 492–498. Publisher Full Text
1302. Dreixler JC, Bian JT, Cao YJ, et al.: Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur. J. Pharmacol. 2000; 401(1): 1–7. Publisher Full Text
1303. Maekawa M, Satoh S, Murayama T, et al.: Involvement of Hg2+-sensitive sulfhydryl groups in regulating noradrenaline release induced by S-nitrosocysteine in rat brain slices. Biochem. Pharmacol. 2000; 59(7): 839–845. PubMed Abstract | Publisher Full Text
1304. Tsukada H, Sato K, Kakiuchi T, et al.: Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain. Brain Res. 2000; 857(1-2): 158–164. Publisher Full Text
1305. Antuono P, Beyer J: The burden of dementia: A medical and research perspective. Theor. Med. Bioeth. 1999; 20(1): 3–13. Publisher Full Text
1306. Sakurai T, Kato T, Mori K, et al.: Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: An in vivo microdialysis study. Neurosci. Lett. 1998; 246(2): 69–72. PubMed Abstract | Publisher Full Text
1307. Roesler R, Quevedo J, Walz R, et al.: Drugs acting at the glycine site on the NMDA receptor as cognitive enhancers in patients with Alzheimer's disease [2]. Neurology. 1998; 50(4): 1195. PubMed Abstract | Publisher Full Text
1308. Naranjo CA, Best TS: Advances in the pharmacotherapy of cognitive deficits and behavioural disorders in dementia. Can. J. Clin. Pharmacol. 1998; 5(2): 98–109.
1309. Van Reekum R, Black SE, Conn D, et al.: Cognition-enhancing drugs in dementia: A guide to the near future. Can. J. Psychiatr. 1997; 42(SUPPL. 1): 35S–50S.
1310. Maurice T, Privat A: SA4503, a novel cognitive enhancer with σ1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur. J. Pharmacol. 1997; 328(1): 9–18. PubMed Abstract | Publisher Full Text
1311. Senda T, Matsuno K, Okamoto K, et al.: Ameliorating effect of SA4503, a novel σ1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur. J. Pharmacol. 1996; 315(1): 1–10. Publisher Full Text
1312. Teismann P, Ferger B: In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2000; 24(2): 337–348. PubMed Abstract
1313. Kimura T, Tamura R, Kurimoto H, et al.: Effects of T-588, a newly synthesized cognitive enhancer, on hippocampal CA1 neurons in rat brain tissue slices. Brain Res. 1999; 831(1-2): 175–183. PubMed Abstract | Publisher Full Text
1314. Maekawa M, Miyazaki H, Ono S, et al.: Effects of T-588, a novel cognitive enhancer, on ADP-ribosylation of G (sα) by cholera toxin and cyclic AMP accumulation in rat cerebral cortex. Neurochem. Int. 1999; 34(2): 149–155. Publisher Full Text
1315. Lishko PV, Maximyuk OP, Chatterjee SS, et al.: The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage- dependent NMDA receptor antagonist. NeuroReport. 1998; 9(18): 4193–4197. Publisher Full Text
1316. Maekawa M, Ono S, Narita H, et al.: Stimulation of noradrenaline release by T-588, a cognitive enhancer, in PC12 cells. Jpn. J. Pharmacol. 2000; 82(1): 59–66. PubMed Abstract | Publisher Full Text
1317. Akula MR, Kabalka GW: Synthesis of 7-[123I]idotacrine: A potential SPECT agent to map acetylcholinesterase. J. Label. Compd. Radiopharm. 1999; 42(10): 959–964. Publisher Full Text
1318. Yoshii M, Watabe S, Nishizaki T: Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: Their intracellular signal transduction pathways. Folia Pharmacologica Japonica. 1998; 112: 41–43. PubMed Abstract | Publisher Full Text
1319. Yamada K, Nabeshima T: Nefiracetam (DM-9384): A novel antiamnesic drug. CNS Drug Rev. 1996; 2(3): 322–342. Publisher Full Text
1320. Gudasheva TA, Boyko SS, Ostrovskaya RU, et al.: The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur. J. Drug Metab. Pharmacokinet. 1997; 22(3): 245–252. PubMed Abstract | Publisher Full Text
1321. Hasegawa M, Noda Y, Maeda Y, et al.: The 1998 domestic state of development of cognitive enhancers. Folia Pharmacologica Japonica. 1999; 114(6): 327–336. PubMed Abstract | Publisher Full Text
1322. Markowska AL: Life-long diet restriction failed to retard cognitive aging in Fischer-344 rats. Neurobiol. Aging. 1999; 20(2): 177–189. PubMed Abstract | Publisher Full Text
1323. Allain H, Bentué-Ferrer D: Clinical efficacy of almitrine-raubasine. An overview. Eur. Neurol. 1998; 39: 39–44. Publisher Full Text
1324. Caputi A, Di Luca M, Pastorino L, et al.: Nicergoline and its metabolite induce translocation of PKC isoforms in selective rat brain areas. Neurosci. Res. Commun. 1998; 23(3): 159–167. Publisher Full Text
1325. Winder R, Borrill J: Fuels for memory: The role of oxygen and glucose in memory enhancement. Psychopharmacology. 1998; 136(4): 349–356. PubMed Abstract | Publisher Full Text
1326. Pavone F, Capone F, Battaglia M, et al.: Shuttle-box avoidance learning in mice: Improvement by combined glucose and tacrine. Neurobiol. Learn. Mem. 1998; 69(2): 204–210. PubMed Abstract | Publisher Full Text
1327. Maekawa M, Murayama T, Ono S, et al.: The effects of T-588, a novel cognitive enhancer, on noradrenaline uptake and release in rat cerebral cortical slices. Jpn. J. Pharmacol. 1998; 77(2): 155–160. PubMed Abstract | Publisher Full Text
1328. Koss E, Weiner M, Ernesto C, et al.: Assessing patterns of agitation in Alzheimer's disease patients with the cohen-mansfield agitation inventory. Alzheimer Dis. Assoc. Disord. 1997; 11(SUPPL. 2): 45–S50. Publisher Full Text
1329. Ihl R, Kretschmar C: Evaluation of nootropika in the practice. Nervenarzt. 1997; 68(11): 853–861. PubMed Abstract | Publisher Full Text
1330. Hiramatsu M, Shiotani T, Kameyama T, et al.: Effects of nefiracetam on amnesia animal models with neuronal dysfunctions. Behav. Brain Res. 1997; 83: 107–115. PubMed Abstract | Publisher Full Text
1331. Xiong ZQ, Tang XC, Lin JL, et al.: Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment. Acta Pharmacol. Sin. 1995; 16(1): 21–25. PubMed Abstract
1332. Iijima S, Greig NH, Garofalo P, et al.: Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology. 1993; 112(4): 415–420. PubMed Abstract | Publisher Full Text
1333. Kawasaki K, Eigyo M, Ikeda M, et al.: A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 1996; 20(8): 1413–1425. Publisher Full Text
1334. Tsukada H, Kakiuchi T, Ando I, et al.: Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: A positron emission tomography study in unanesthetized monkeys. J. Pharmacol. Exp. Ther. 1997; 281(3): 1408–1414. PubMed Abstract | Publisher Full Text
1335. Miyazaki H, Murayama T, Satoshi O, et al.: Effects of R(-)-1-(benzo [b]thiophen-5-yl)-2-[2-(N,N-diethylamino) ethoxy] ethanol hydrochloride (T-588), a novel cognitive enhancer, on noradrenaline release in rat cerebral cortical slices. Biochem. Pharmacol. 1997; 53(9): 1263–1269. Publisher Full Text
1336. Costello TD, Jensen JH, Teleha CA, et al.: Preparation of 9,9-disubstituted 4,5-diazafluorenes useful as cognitive enhancers. Org. Process. Res. Dev. 1997; 1(6): 407–410. Publisher Full Text
1337. Tang YP, Noda Y, Hasegawa T, et al.: (+)-Eburnamenine-14-carboxylic acid (2-nitroxyethyl) ester (VA-045), a putative cognitive enhancer, facilitates recovery from concussive brain injury-induced learning and memory impairments in mice. Behav. Brain Res. 1997; 83: 195–199. PubMed Abstract | Publisher Full Text
1338. Katsura M, Iino T, Xu J, et al.: Vinconate, a cognitive enhancer, and PI turnover-phospholipase C systems in the brain. Behav. Brain Res. 1997; 83: 75–81. PubMed Abstract | Publisher Full Text
1339. Temple MD, Hamm RJ: Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res. 1996; 741(1-2): 246–251. PubMed Abstract | Publisher Full Text
1340. Ishikawa K, Kubo T, Shibanoki S, et al.: Hippocampal degeneration inducing impairment of learning in rats: Model of dementia?. Behav. Brain Res. 1997; 83: 39–44. Publisher Full Text
1341. Kaneko S, Maeda T, Satoh M: Cognitive enhancers and hippocampal long-term potentiation in vitro. Behav. Brain Res. 1997; 83: 45–49. Publisher Full Text
1342. Coull JT, editor. α2-Adrenoceptors in the treatment of dementia: An attentional mechanism?. J. Psychopharmacol. 1996.
1343. Vender JR, Nair SN, Lehmann JC: Monthlyupdate - Central & peripheral nervous systems: Pharmacotherapeutic potential for compounds acting at NMDA receptors: Update 1995. Expert Opin. Investig. Drugs. 1995; 4(5): 475–485. Publisher Full Text
1344. Pauwels PJ, Van Assouw HP, Peeters L, et al.: Chronic treatment with sabeluzole protects cultured rat brain neurons from the neurotoxic effects of excitatory amino acids. Synapse. 1992; 12(4): 271–280. PubMed Abstract | Publisher Full Text
1345. Endo H, Tajima T, Yamada H, et al.: Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease. Behav. Brain Res. 1997; 83: 243–244. PubMed Abstract | Publisher Full Text
1346. Watanabe H: Candidates for cognitive enhancer extracted from medicinal plants: Paeniflorin and tetramethylpyrazine. Behav. Brain Res. 1997; 83: 135–141. Publisher Full Text
1347. Nomura Y, Kitamura Y, Ohnuki T, et al.: Alterations in acetylcholine, NMDA, benzodiazepine receptors and protein kinase C in the brain of the senescence-accelerated mouse: An animal model useful for studies on cognitive enhancers. Behav. Brain Res. 1997; 83: 51–55. PubMed Abstract | Publisher Full Text
1348. Hirata K, Katayama S, Tanaka H, et al.: Efficacy of nicotine administration in dementia - A study using event-related potentials and middle latency responses. Therapeutic Research. 1995; 97: S42. Publisher Full Text
1349. Warburton DM: Nicotine as a cognitive enhancer. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1992; 16(2): 181–192. Publisher Full Text
1350. Honma A, editor. Cognitive enhancers: Current state from Japanese and Canadian perspectives. Japanese Journal of Psychopharmacology. 1995.
1351. Schneider LS, Tariot PN, Goldstein B: Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 1994; 56(6): 750–756. PubMed Abstract | Publisher Full Text
1352. Nabeshima T, De Wied D, Pepeu G, et al.: Neurochemical and psychopharmacological approaches to cognitive enhancers: Preface. Behav. Brain Res. 1997; 83(1-2): v–vi. Publisher Full Text
1353. Nitta A, Nabeshima T: Experimental techniques for developing new drugs acting on dementia (10) Alzheimer's disease animal model induced by β-amyloid protein. Japanese Journal of Psychopharmacology. 1996; 16(3): 85–90. PubMed Abstract
1354. Sclan SG, Saillon A, Franssen E, et al.: The behavior pathology in Alzheimer's Disease rating scale (BEHAVE-AD): Reliability and analysis of symptom category scores. Int. J. Geriatr. Psychiatry. 1996; 11(9): 819–830. Publisher Full Text
1355. Wong YN, Quon CY, Holm KA, et al.: Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in rats. Drug Metab. Dispos. 1996; 24(2): 172–179. PubMed Abstract | Publisher Full Text
1356. Haupt M: Psychotherapeutic intervention in dementia. Dement. Geriatr. Cogn. Disord. 1996; 7(4): 207–209. Publisher Full Text
1357. Kawajiri S, Taniguchi K, Sakurai T, et al.: Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat. J. Neural Transm. 1994; 98(1): 15–22. PubMed Abstract | Publisher Full Text
1358. Baxter MG, Lanthorn TH, Frick KM, et al.: D-cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol. Aging. 1994; 15(2): 207–213. PubMed Abstract | Publisher Full Text
1359. Chessell IP, Procter AW, Francis PT, et al.: d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 1991; 565(2): 345–348. PubMed Abstract | Publisher Full Text
1360. Nelson KE, Camarata SM: Improving english literacy and speech-acquisition learning conditions for children with severe to profound hearing impairments. Volta Review. 1996; 98(2): 17–41.
1361. Chang RK, Hussein MA: Biodegradable Polyester Implants and Suspension Injection for Sustained Release of a Cognitive Enhancer. Pharm. Technol. 1996; 20(1): 80–84.
1362. Maeda N, Matsuoka N, Yamazaki M, et al.: Involvement of Raphe-Hippocampal Serotonergic and Septo-Hippocampal Cholinergic Mechanisms in the Penile Erection Induced by FR121196, a Putative Cognitive Enhancer. The Japanese Journal of Pharmacology. 1995; 68(1): 85–94. Publisher Full Text
1363. Diamond S, Rakestraw D, O'Neil J, et al.: Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab. Dispos. 1994; 22(1): 65–73. PubMed Abstract | Publisher Full Text
1364. Provan SD, Miyamoto MD: Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction. Br. J. Pharmacol. 1994; 111(4): 1103–1110. PubMed Abstract | Publisher Full Text | Free Full Text
1365. Herrmann N, Lanctôt KL, Naranjo CA: Behavioural disorders in demented elderly patients. Current issues in pharmacotherapy. CNS Drugs. 1996; 6(4): 280–300. Publisher Full Text
1366. Witkin JM, Brave S, French D, et al.: Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor. J. Pharmacol. Exp. Ther. 1995; 275(3): 1267–1273. Publisher Full Text
1367. Toide K, Okamiya K, Iwamoto Y, et al.: Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem. 1995; 65(1): 234–240. PubMed Abstract | Publisher Full Text
1368. Toide K, Iwamoto Y, Fujiwara T, et al.: JTP-4819: A novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J. Pharmacol. Exp. Ther. 1995; 274(3): 1370–1378. PubMed Abstract | Publisher Full Text
1369. Matsuoka N, Maeda N, Yamaguchi I, et al.: Possible involvement of brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res. 1994; 642(1-2): 11–19. PubMed Abstract | Publisher Full Text
1370. Kapil RP, Lee W Jr, Padovani PK, et al.: Determination of a novel cognitive enhancer, X9121, and its mono N-oxide metabolite, XG696, in dog plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl. 1995; 665(1): 226–231. PubMed Abstract | Publisher Full Text
1371. Garner DM, Pieniaszek HJ, Connell JM, et al.: Determination of linopirdine and its mono-n-oxide metabolite in human plasma and urine by high-performance liquid chromatography. J. Liq. Chromatogr. 1994; 17(20): 4541–4555. Publisher Full Text
1372. Nordholm AF, Moore E, Wenger GR: Linopirdine does not improve matching performance in the titrating matching-to-sample paradigm. Pharmacol. Biochem. Behav. 1995; 52(1): 205–210. Publisher Full Text
1373. Nugiel DA, Voss ME, Brittelli DR, et al.: An approach to the design of novel cognitive enhancers using molecular modeling and X-ray crystallography. Drug Des. Discov. 1995; 12(4): 289–295. PubMed Abstract
1374. Popik P, Mamczarz J, Vetulani J: The effect of electroconvulsive shock and nifedipine on spatial learning and memory in rats. Biol. Psychiatry. 1994; 35(11): 864–869. PubMed Abstract | Publisher Full Text
1375. Ritzmann RF, Glasky A, Steinberg A, et al.: The interaction of ethanol with the cognitive enhancers tacrine, physostigmine, and AIT-082. Journals of Gerontology. 1994; 49(2): B51–B53. PubMed Abstract | Publisher Full Text
1376. Maeda N, Matsuoka N, Yamazaki M, et al.: A Screening Concept Based on a Hypothesis Led to the Development of a Putative Cognitive Enhancer That Stimulates Penile Erection. The Japanese Journal of Pharmacology. 1994; 64(3): 147–154. PubMed Abstract | Publisher Full Text
1377. Matsuoka N, Yamaguchi I, Satoh M: Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur. J. Pharmacol. 1993; 241(1): 27–34. PubMed Abstract | Publisher Full Text
1378. Matsuoka N, Maeda N, Yamazaki M, et al.: Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. J. Pharmacol. Exp. Ther. 1992; 263(2): 436–444. PubMed Abstract | Publisher Full Text
1379. Ohjimi H, Kushiku K, Yamada H, et al.: Increase of acetylcholine release by nebracetam in dog cardiac sympathetic ganglion. J. Pharmacol. Exp. Ther. 1994; 268(1): 396–402. Publisher Full Text
1380. Domeney AM: Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents. J. Psychiatry Neurosci. 1994; 19(1): 46–50.
1381. Dent GW, Rule BL, Tam SW, et al.: Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats. Brain Res. 1993; 620(1): 7–15. PubMed Abstract | Publisher Full Text
1382. Bryant WM, Huhn GF, Jensen JH, et al.: A large scale preparation of the cognitive enhancer linopirdine. Synth. Commun. 1993; 23(11): 1617–1625. Publisher Full Text
1383. De Souza EB, Rule BL, Tam SW: [3H] Linopirdine (DuP 996) labels a novel binding site in rat brain involved in the enhancement of stimulus-induced neurotransmitter release: autoradiographic localization studies. Brain Res. 1992; 582(2): 335–341. PubMed Abstract | Publisher Full Text
1384. Tam SW, Rominger D, Nickolson VJ: Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release. Mol. Pharmacol. 1991; 40(1): 16–21. PubMed Abstract | Publisher Full Text
1385. Saletu B, Darragh A, Breuel HP, et al.: EEG mapping central effects of multiple doses of linopirine—a cognitive enhancer—in healthy elderly male subjects. Hum. Psychopharmacol. Clin. Exp. 1991; 6(4): 267–275. Publisher Full Text
1386. Pang K, Williams MJ, Olton DS: Activation of the medial septal area attenuates LTP of the lateral perforant path and enhances heterosynaptic LTD of the medial perforant path in aged rats. Brain Res. 1993; 632(1-2): 150–160. PubMed Abstract | Publisher Full Text
1387. Pierce JES, Smith DH, Eison MS, et al.: The nootropic compound BMY-21502 improves spatial learning ability in brain injured rats. Brain Res. 1993; 624(1-2): 199–208. PubMed Abstract | Publisher Full Text
1388. Sirviö J, Ekonsalo T, Riekkinen P Jr, et al.: d-Cycloserine, a modulator of the N-methyl-d-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist. Neurosci. Lett. 1992; 146(2): 215–218. PubMed Abstract | Publisher Full Text
1389. Chopin P, Briley M: Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology. 1992; 106(1): 26–30. PubMed Abstract | Publisher Full Text
1390. Rupniak NMJ: Profile of cholinomimetic drugs in primates: Status of screens for potential Alzheimer therapies. Drug Dev. Res. 1992; 27(2): 77–88. Publisher Full Text
1391. Lambrecht JJ: Applications software as cognitive enhancers. J. Res. Comput. Educ. 1993; 25(4): 506–520. Publisher Full Text
1392. Lacroix P, Reymann JM, Rocher N, et al.: Effects of S.12024-2 on memory impairment in aged rats. Eur. Neuropsychopharmacol. 1993; 3: 419–420. Publisher Full Text
1393. Sahgal A: Cognitive enhancers: The current status. J. Psychopharmacol. 1992; 6(4): 549–550. Publisher Full Text
1394. Cognitive enhancers illegal, says FDA. Clin. Pharm. 1992; 11(6): 467. PubMed Abstract
1395. Calvani M, Carta A: Clinical issues of cognitive enhancers in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1991; 5: S25–S31. Publisher Full Text
1396. Allain H, Bentue-Ferrer D, Decombe R: Choosing a target for cognitive enhancers. Clin. Ther. 1990; 12(4): 298–305.
1397. Vogel-Scibilia S, Gershon S: An update on cognitive enhancers for the elderly. New Trends in Clinical Neuropharmacology. 1989; 3(4): 207–216.
1398. Cutler NR, Narang PK: Cognitive enhancers in Alzheimer's disease. Clinical Research Practices and Drug Regulatory Affairs. 1989; 7(4-5): 213–243. Publisher Full Text
1399. Cutler NR, Narang PK: Cognitive enhancers in alzheimer's disease. Clin. Res. Regul. Aff. 1989; 7(4-5): 213–243. Publisher Full Text
1400. Allain H, Carraro JC, Morel G, et al.: Comparative placebo-controlled clinical trial of raubasine-dihydroergocristine in cognitive complaint in elderly. Psychol. Med. 1992; 24(12): 1315–1329.
1401. Shimizu M: Current clinical trials of cognitive enhancers in Japan. Alzheimer Dis. Assoc. Disord. 1991; 5: S13–S14. Publisher Full Text
1402. Wenk GL: An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology. 1989; 99(4): 431–438. PubMed Abstract | Publisher Full Text
1403. Gatti G, Barzaghi N, Acuto G, et al.: A comparative study of free plasma choline levels following intramuscular administration of L-α-glycerylphosphorylcholine and citicoline in normal volunteers. International Journal of Clinical Pharmacology Therapy and Toxicology. 1992; 30(9): 331–335.
1404. Rupniak NMJ, Duchnowski M, Tye SJ, et al.: Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencylidine in primates. Life Sci. 1992; 50(25): 1959–1962. PubMed Abstract | Publisher Full Text
1405. Domeney AM, Costall B, Gerrard PA, et al.: The effect of ondansetron on cognitive performance in the marmoset. Pharmacol. Biochem. Behav. 1991; 38(1): 169–175. PubMed Abstract | Publisher Full Text
1406. De Ryck M, Duytschaever H, Pauwels PJ, et al.: Ionic channels, cholinergic mechanisms, and recovery of sensorimotor function after neocortical infarcts in rats. Stroke. 1990; 21(11 Suppl): III158–III163. PubMed Abstract
1407. Groóa D, Pálosi E, Szporny L: Cognitive enhancers prevent the hypoxia-induced disruption of conditioned avoidance response. Drug Dev. Res. 1989; 18(1): 19–28. Publisher Full Text
1408. Means LW, Dent MF: The effects of number of trials per day, retention interval, gender and time of day on acquisition of a two-choice, win-stay water-escape working memory task in the rat. J. Neurosci. Methods. 1991; 39(1): 77–87. PubMed Abstract | Publisher Full Text
1409. Olton DS, Wenk L: Keynote lecture 4: The development of behavioral tests to assess the effects of cognitive enhancers. Pharmacopsychiatry. 1990; 23: 65–69. Publisher Full Text
1410. Rupniak NMJ, Field MJ, Samson NA, et al.: Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol. Aging. 1990; 11(6): 609–613. PubMed Abstract | Publisher Full Text
1411. Monahan JB, Handelmann GE, Hood WF, et al.: D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol. Biochem. Behav. 1989; 34(3): 649–653. PubMed Abstract | Publisher Full Text
1412. Deckert J, Morgan PF, Jacobson KA, et al.: Seizures induced by methylxanthines, potential cognitive enhancers in dementia syndromes. J. Neural Transm. - Parkinson's Dis. Dement. Sect. 1989; 1(1-2): 45. Publisher Full Text
1413. Williams M: Adenosine: The prototypic neuromodulator. Neurochem. Int. 1989; 14(3): 249–264. Publisher Full Text
1414. Wenk GL, Olton DS: Cognitive enhancers: Potential strategies and experimental results. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1989; 13(SUPPL. 1): S117–S139. Publisher Full Text
1415. Jea S: Therapeutic potential of Ginkgo biloba in neurocognitive disorders. Neuropharmacology. 2020; 179.
1416. Kim EJea.: Ginkgo biloba and cognitive function: A meta-analysis. J. Clin. Med. 2021; 10(1): 68.
1417. Xea W: Pharmacological properties of Ginkgo biloba. Front. Pharmacol. 2022; 13(82): 34–56.
1418. Yea L: Safety and efficacy of Ginkgo biloba extracts. Phytomedicine. 2020; 77.
1419. Hea Z: Clinical applications of Ginkgo biloba in cognitive impairment. Curr. Neuropharmacol. 2021; 19: 945–955.
1420. Saleh AY: Gingko Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus data Base. A bibliometric studi from 1988 to 2024. figshare. 2024 [cited 2025Feb11]. Reference Source

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 07 Mar 2025

Author details Author details

Dwi Arwandi Yogi Saputra
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Riezky Valentina
Roles: Writing – Review & Editing

Tirta Darmawan Susanto
Roles: Writing – Review & Editing

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Article Versions (2)

version 2

Revised

Published: 15 May 2025, 14:275

https://doi.org/10.12688/f1000research.160416.2

version 1

Published: 07 Mar 2025, 14:275

https://doi.org/10.12688/f1000research.160416.1

© 2025 SALEH AY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

	Views	Downloads
F1000Research	-	-
PubMed Central Data from PMC are received and updated monthly.	-	-

Citations

SEE MORE DETAILS

CITE

how to cite this article

SALEH AY, Saputra DAY, Valentina R and Susanto TD. Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024 [version 1; peer review: 1 approved with reservations]. F1000Research 2025, 14:275 (https://doi.org/10.12688/f1000research.160416.1)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Version 1

VERSION 1

PUBLISHED 07 Mar 2025

Views

Reviewer Report 10 May 2025

Tasawar Iqbal, University of Agriculture Faisalabad, Faisalabad, Punjab, Pakistan

Approved with Reservations

https://doi.org/10.5256/f1000research.176313.r380845

Summary of the Article
This manuscript presents a bibliometric analysis of literature published from 1988 to 2024 focusing on Ginkgo biloba as a cognitive enhancer. The study uses data sourced from the Scopus database and analyzes trends, influential authors, key journals, and subject areas using Biblioshiny and VOSviewer tools. The authors identify niche, motor, and emerging themes using thematic mapping and network visualization to assess the evolution of research topics over time. Qualitative discussions are included on the traditional and pharmacological uses of Ginkgo biloba, with citations of clinical trial data and historical usage.
Evaluation of Core Criteria
1. Is the work clearly and accurately presented and does it cite the current literature?
Answer: Partly
Comments:

The manuscript is generally well-structured and references a wide range of studies, including both foundational and recent works. However, some citations appear incorrectly formatted or poorly integrated (e.g., inconsistent referencing of citation numbers, limited context around cited findings).
The discussion on Ginkgo biloba's pharmacological mechanisms includes up-to-date research but occasionally blends bibliometric content with pharmacological summaries without clear separation.
Recommendation: Improve citation clarity and maintain a stricter distinction between bibliometric analysis and pharmacological narrative.

2. Is the study design appropriate and is the work technically sound?
Answer: Partly
Comments:

The use of bibliometric tools (Scopus, Biblioshiny, VOSviewer) is methodologically appropriate.
However, the design lacks details on inclusion/exclusion criteria, filtering strategies, and search limitations (e.g., language or document types), which are critical to ensure replicability and to reduce selection bias.
Furthermore, the decision to not apply any filters (as stated) weakens the rigor of the bibliometric scope and could introduce irrelevant data noise.
Recommendation: The authors should specify search criteria more clearly and provide justification for their decision to include unfiltered results.

3. Are sufficient details of methods and analysis provided to allow replication by others?
Answer: Partly
Comments:

While the tools used are named, the description of the search strategy is too vague.
The article mentions keyword use (e.g., “cognitive enhancer”) but does not provide exact queries or document identifiers for replication.
The structure and format of exported data files are listed, but there is no access to the raw search results or scripts used for Biblioshiny or VOSviewer analysis.
Recommendation: Include complete search strings, filters (if any), time range parameters, and preferably a supplementary dataset or repository link to raw export files.

4. If applicable, is the statistical analysis and its interpretation appropriate?
Answer: Partly
Comments:

The article primarily uses descriptive statistics and visualization tools, which are valid for bibliometric analysis.
However, no inferential statistics or statistical validation of clusters/themes is presented, nor are confidence measures or citation impact normalization addressed.
Recommendation: Include basic bibliometric performance metrics (e.g., h-index, average citations per item) and clarify the method used to define cluster themes (e.g., co-occurrence thresholds).

5. Are all the source data underlying the results available to ensure full reproducibility?
Answer: Partly
Comments:

The article references an extended dataset on Figshare https://doi.org/10.6084/m9.figshare.28081709.v1, which contains visualizations and thematic maps.
However, the raw Scopus CSV or RIS files used for analysis are not provided, and key elements such as search queries or metadata fields are not included.
Recommendation: The authors should upload all exported files and search history from Scopus as supplementary material or Figshare content.

6. Are the conclusions drawn adequately supported by the results?
Answer: Partly
Comments:

The conclusions reflect findings from both the bibliometric mapping and the qualitative narrative on Ginkgo biloba's therapeutic effects.
However, some extrapolations such as effectiveness and safety in clinical contexts—are based on limited bibliometric evidence, rather than systematic reviews or meta-analyses.
Recommendation: Limit claims on clinical efficacy unless substantiated by the specific bibliometric content reviewed; distinguish bibliometric findings from clinical interpretation.

Overall Strengths

Addresses a valuable niche topic within cognitive enhancement research.
Employs credible bibliometric tools and platforms (Scopus, Biblioshiny, VOSviewer).
Provides useful visualization and clustering analysis.

Major Revisions Required to be Scientifically Sound

Clarify and document the search methodology in full detail to ensure reproducibility.
Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data validity.
Avoid merging clinical conclusions with bibliometric findings unless systematically substantiated.
Improve citation consistency and integrate references more clearly throughout the discussion.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

Partly
If applicable, is the statistical analysis and its interpretation appropriate?

Partly
Are all the source data underlying the results available to ensure full reproducibility?

Partly
Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacology, Phytochemical, Rheumatoid Arthritis, Plants base Medicine, Animal related study, Different Disease treatment, Drug Delivery, plant study, insect physiology, Mushroom related study, Entomology, Poultry Management, Zoology, Microbiology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

CITE

Report a concern

Author Response 24 Jun 2025

ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, Universitas Pembangunan Nasional (UPN) Veteran Jakarta, Jakarta, 12450, Indonesia

24 Jun 2025

Author Response

Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full ... Continue reading Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full detail to ensure reproducibility.
2. Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data
validity.
3.
Avoid merging clinical conclusions with bibliometric findings unless systematically
substantiated.
4.
Improve citation consistency and integrate references more clearly throughout the
discussion.

Peer Review :
1. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
2. All data we used in the study have been uploaded to The article references an extended dataset on Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly
3. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
4. All citations are in Table 1 Qualitative analysis of the research summary of each abstract that has been uploaded is also in Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly

Thank you again for the opportunity to enhance the quality of this manuscript.
Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full detail to ensure reproducibility.
2. Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data
validity.
3.
Avoid merging clinical conclusions with bibliometric findings unless systematically
substantiated.
4.
Improve citation consistency and integrate references more clearly throughout the
discussion.

Peer Review :
1. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
2. All data we used in the study have been uploaded to The article references an extended dataset on Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly
3. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
4. All citations are in Table 1 Qualitative analysis of the research summary of each abstract that has been uploaded is also in Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly

Thank you again for the opportunity to enhance the quality of this manuscript.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 24 Jun 2025

ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, Universitas Pembangunan Nasional (UPN) Veteran Jakarta, Jakarta, 12450, Indonesia

24 Jun 2025

Author Response

Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full ... Continue reading Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full detail to ensure reproducibility.
2. Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data
validity.
3.
Avoid merging clinical conclusions with bibliometric findings unless systematically
substantiated.
4.
Improve citation consistency and integrate references more clearly throughout the
discussion.

Peer Review :
1. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
2. All data we used in the study have been uploaded to The article references an extended dataset on Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly
3. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
4. All citations are in Table 1 Qualitative analysis of the research summary of each abstract that has been uploaded is also in Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly

Thank you again for the opportunity to enhance the quality of this manuscript.
Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full detail to ensure reproducibility.
2. Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data
validity.
3.
Avoid merging clinical conclusions with bibliometric findings unless systematically
substantiated.
4.
Improve citation consistency and integrate references more clearly throughout the
discussion.

Peer Review :
1. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
2. All data we used in the study have been uploaded to The article references an extended dataset on Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly
3. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
4. All citations are in Table 1 Qualitative analysis of the research summary of each abstract that has been uploaded is also in Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly

Thank you again for the opportunity to enhance the quality of this manuscript.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 07 Mar 2025

Open Peer Review

Reviewer Status

Reviewer Reports

	Invited Reviewers
	1	2
Version 2 (revision) 15 May 25	read	read
Version 1 07 Mar 25	read

Tasawar Iqbal, University of Agriculture Faisalabad, Faisalabad, Pakistan
Arne Reimers, Lund University, Lund, Sweden

Comments on this article

All Comments(0)

Add a comment

Browse by related subjects

Back to all reports

Reviewer Report

4 Views

22 Aug 2025 | for Version 2

Arne Reimers, Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Lund University, Lund, Skåne County, Sweden

4 Views Cite this report Responses(0)

Approved With Reservations

This bibliometric study aims at analyzing trends and the current status of published research on Ginkgo biloba. It uses different outcome variables and visualization methods.

There are countless small issues that make this paper difficult to read and understand. For example:

Abstract, results and discussion: this part is supposed to reflect the study's findings. However, the authors state some arbitrarily chosen historical facts about the medical use of Ginkgo biloba.

Abstract, conclusion: instead of a conclusion, the authors state the aims of the study.

The title of this paper says 1420 documents. Also, the list of references consists of 1420 documents. However, in the text it is stated that 1414 documents were retrieved. This should be resolved.

P4: the authors state that they retrieved 1414 relevant documents. Please state how 'relevant' was defined and how many irrelevant documents were excluded.

P4: according to the authors, figure 1 shows that the annual numbers of papers culminated in 61 papers by 2023. From what I can see, the annual number culminated with 130 papers in 2014.

P4: The authors state that the journal Psychopharmacology accepts many manuscripts. It is unclear what is meant by 'many'. Does it have a high acceptance rate? Does it publish a high number of papers per year? (if so, please quantify). Or does it mean that the journal accepts a broad variety of subjects or article types?

P5: 'Ranking three is the Journal of Behavioral Brain Research. This contains information regarding the Journal of Behavioral Brain Research.' This does not make sense, please rephrase.

P5: 'the journal titled Identification of separable cognitive factors in schizophrenia, authored by Keith H. Nuechterlein (…). The journal's abstract states that (…)'. I believe that the word 'journal' should be changed to 'article'.

P6: 'two major receptors that function as primary excitatory neurotransmitters'. Receptors do not function as neurotransmitters. Please rephrase.

Figure 4: This figure is difficult to understand without an explanation. Please explain in the text what dim1 and dim2 are. Further, clusters 1 and 2 appear to be only one single point each, so why are they called clusters? On the other hand, the articles displayed in the figure form a cluster, but this is not mentioned in the text. Moreover, the text mentions a study by Difede et al. (2013). In the figure, there is no study by Difede published in 2013.

P8: 'shows the percentage of documents classified into different subject areas'. Please state how that classification was done.

P9: 'indicates that the examined areas remained unassociated with the other regions delineated by the edges'. That does not make sense. Please rephrase.

P9/10: 'according to Figure 11, in the overlay visualization, it appears that the keywords that are being researched a lot approaching 2016 are the parts colored yellow, namely gluthahione, malonaldehyde, metabolism, prescription, major clinical study, randomized controlled trial (t, addiction, student, students, universities, oxidative stress, chemistry, and nerve degeneration.' To me, it appears that the most researched key words are the green ones in the middle.

P12: 'According to Figure 13, on the thematic map based on the title, the following is an explanation for each keyword in each quadrant in the thematic map resulting from the bibliometric analysis. Here is an explanation of the meaning of each quadrant in the thematic map, and examples of document titles relevant to keywords in each quadrant.' This does not make sense, please rephrase.

Figure 13 looks like a screen shot and should be replaced or at least be cropped to the figure itself.

Results and discussion: the first two sentences are already stated in the introduction and should be deleted. The discussion does not refer to the authors' (= this study's) own findings but represents a medical/historical review of Ginkgo biloba. It needs to be re-written with a clear focus on the bibliometric findings.

Points that must be addressed to make the article scientifically sound:
The abstract and the discussion need to be re-written. The manuscript body needs thorough revision. As a minimum, all issues mentioned above should be resolved.

Note: Almost all figures are impossible to read due to very low resolution. I do not know whether this is the publisher's fault. Fortunately, the authors provide a link to a repository where the figures are available in high resolution.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

Yes
Are sufficient details of methods and analysis provided to allow replication by others?

Partly
If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable
Are all the source data underlying the results available to ensure full reproducibility?

Yes
Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Clinical neuro- and psychopharmacology

Respond to this report

Responses (0)

Back to all reports

Reviewer Report

6 Views

09 Aug 2025 | for Version 2

Tasawar Iqbal, University of Agriculture Faisalabad, Faisalabad, Punjab, Pakistan

6 Views Cite this report Responses(0)

Approved

Accept the article.

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Pharmacology, Phytochemical, Rheumatoid Arthritis, Plants base Medicine, Animal related study, Different Disease treatment, Drug Delivery, plant study, insect physiology, Mushroom related study, Entomology, Poultry Management, Zoology, Microbiology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Respond to this report

Responses (0)

Back to all reports

Reviewer Report

9 Views

10 May 2025 | for Version 1

Tasawar Iqbal, University of Agriculture Faisalabad, Faisalabad, Punjab, Pakistan

9 Views Cite this report Responses(1)

Approved With Reservations

The manuscript is generally well-structured and references a wide range of studies, including both foundational and recent works. However, some citations appear incorrectly formatted or poorly integrated (e.g., inconsistent referencing of citation numbers, limited context around cited findings).
The discussion on Ginkgo biloba's pharmacological mechanisms includes up-to-date research but occasionally blends bibliometric content with pharmacological summaries without clear separation.
Recommendation: Improve citation clarity and maintain a stricter distinction between bibliometric analysis and pharmacological narrative.

2. Is the study design appropriate and is the work technically sound?
Answer: Partly
Comments:

The use of bibliometric tools (Scopus, Biblioshiny, VOSviewer) is methodologically appropriate.
However, the design lacks details on inclusion/exclusion criteria, filtering strategies, and search limitations (e.g., language or document types), which are critical to ensure replicability and to reduce selection bias.
Furthermore, the decision to not apply any filters (as stated) weakens the rigor of the bibliometric scope and could introduce irrelevant data noise.
Recommendation: The authors should specify search criteria more clearly and provide justification for their decision to include unfiltered results.

3. Are sufficient details of methods and analysis provided to allow replication by others?
Answer: Partly
Comments:

While the tools used are named, the description of the search strategy is too vague.
The article mentions keyword use (e.g., “cognitive enhancer”) but does not provide exact queries or document identifiers for replication.
The structure and format of exported data files are listed, but there is no access to the raw search results or scripts used for Biblioshiny or VOSviewer analysis.
Recommendation: Include complete search strings, filters (if any), time range parameters, and preferably a supplementary dataset or repository link to raw export files.

4. If applicable, is the statistical analysis and its interpretation appropriate?
Answer: Partly
Comments:

The article primarily uses descriptive statistics and visualization tools, which are valid for bibliometric analysis.
However, no inferential statistics or statistical validation of clusters/themes is presented, nor are confidence measures or citation impact normalization addressed.
Recommendation: Include basic bibliometric performance metrics (e.g., h-index, average citations per item) and clarify the method used to define cluster themes (e.g., co-occurrence thresholds).

5. Are all the source data underlying the results available to ensure full reproducibility?
Answer: Partly
Comments:

The article references an extended dataset on Figshare https://doi.org/10.6084/m9.figshare.28081709.v1, which contains visualizations and thematic maps.
However, the raw Scopus CSV or RIS files used for analysis are not provided, and key elements such as search queries or metadata fields are not included.
Recommendation: The authors should upload all exported files and search history from Scopus as supplementary material or Figshare content.

6. Are the conclusions drawn adequately supported by the results?
Answer: Partly
Comments:

The conclusions reflect findings from both the bibliometric mapping and the qualitative narrative on Ginkgo biloba's therapeutic effects.
However, some extrapolations such as effectiveness and safety in clinical contexts—are based on limited bibliometric evidence, rather than systematic reviews or meta-analyses.
Recommendation: Limit claims on clinical efficacy unless substantiated by the specific bibliometric content reviewed; distinguish bibliometric findings from clinical interpretation.

Overall Strengths

Addresses a valuable niche topic within cognitive enhancement research.
Employs credible bibliometric tools and platforms (Scopus, Biblioshiny, VOSviewer).
Provides useful visualization and clustering analysis.

Major Revisions Required to be Scientifically Sound

Clarify and document the search methodology in full detail to ensure reproducibility.
Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data validity.
Avoid merging clinical conclusions with bibliometric findings unless systematically substantiated.
Improve citation consistency and integrate references more clearly throughout the discussion.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

Partly
If applicable, is the statistical analysis and its interpretation appropriate?

Partly
Are all the source data underlying the results available to ensure full reproducibility?

Partly
Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Respond to this report

Responses (1)

Author Response

24 Jun 2025

ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, Universitas Pembangunan Nasional (UPN) Veteran Jakarta, Jakarta, 12450, Indonesia

Thank you for the detailed and constructive feedback during the peer review process.

Major Revisions Required to be Scientifically Sound
1. Clarify and document the search methodology in full detail to ensure reproducibility.
2. Provide access to the raw Scopus data exports and search strings.
Justify the absence of filters or explain how the lack of filtering does not compromise data
validity.
3.
Avoid merging clinical conclusions with bibliometric findings unless systematically
substantiated.
4.
Improve citation consistency and integrate references more clearly throughout the
discussion.

Peer Review :
1. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
2. All data we used in the study have been uploaded to The article references an extended dataset on Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly
3. We have revised the manuscript according to the reviewer's request and have also submitted the new version of the manuscript.
4. All citations are in Table 1 Qualitative analysis of the research summary of each abstract that has been uploaded is also in Figshare : https://doi.org/10.6084/m9.figshare.28081709.v1 and can be accessed publicly

Thank you again for the opportunity to enhance the quality of this manuscript.

View more View less

Competing Interests

No competing interests were disclosed.

Alongside their report, reviewers assign a status to the article:

Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested

Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions

[1] 1. Smith J: Ethical considerations in the use of cognitive enhancers. Neuroethics. 2020; 13(1): 45–58.

[2] 2. Brown A, Brown A, Green B: J. Neurosci. 2019; 2019(39): 123–135.

[3] 3. White R: Regulatory challenges in the development of cognitive enhancers. J. Law Med. 2018; 35(3): 201–210.

[4] 4. Johnson C: The impact of cognitive enhancers on academic performance: A meta-analysis. J. Educ. Psychol. 2021; 113(2): 234–245.

[5] 5. Porsolt RD, Lenègre A, Avril I, et al.: Antagonism by exifone, a new cognitive enhancing agent, of the amnesias induced by four benzodiazepines in mice. Psychopharmacology. 1988; 95(3): 291–297. Publisher Full Text

[6] 6. Groó D, Pálosi É, Szporny L: Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats. Drug Dev. Res. 1988; 15(1): 75–85. Publisher Full Text

[7] 7. Morè L, Privitera L, Lopes M, et al.: MSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF. Neuropharmacology. 2024; 261: 110110. PubMed Abstract | Publisher Full Text

[8] 8. Dorer CL, Manktelow AE, Allanson J, et al.: Methylphenidate-mediated motor control network enhancement in patients with traumatic brain injury. Brain Inj. 2018; 32(8): 1040–1049. PubMed Abstract | Publisher Full Text

[9] 9. Savulich G, Piercy T, Brühl AB, et al.: Focusing the Neuroscience and Societal Implications of Cognitive Enhancers. Clin. Pharmacol. Ther. 2017; 101(2): 170–172. Publisher Full Text

[10] 10. Passamonti L, Luijten M, Ziauddeen H, et al.: Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals. Psychopharmacology. 2017; 234(15): 2289–2297. PubMed Abstract | Publisher Full Text | Free Full Text

[11] 11. Kaser M, Deakin JB, Michael A, et al.: Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2017; 2(2): 115–122. PubMed Abstract | Publisher Full Text

[12] 12. d'Angelo LSC, Savulich G, Sahakian BJ: Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br. J. Pharmacol. 2017; 174(19): 3257–3267. PubMed Abstract | Publisher Full Text | Free Full Text

[13] 13. Lamoureux L, Beverley J, Steiner H, et al.: Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats. Neuropsychopharmacology. 2024; 49(6): 953–960. Publisher Full Text

[14] 14. Hrabak M, Ahmed R, Soriano MG, et al.: Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats. Mol. Neurobiol. 2024. Publisher Full Text

[15] 15. Thanos PK, McCarthy M, Senior D, et al.: Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior. Curr. Pharm. Biotechnol. 2023; 24(10): 1307–1314. PubMed Abstract | Publisher Full Text

[16] 16. Lamoureux L, Beverley JA, Marinelli M, et al.: Fluoxetine potentiates methylphenidate-induced behavioral responses: Enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. Addiction Neuroscience. 2023; 9: 100131. Publisher Full Text

[17] 17. Moon C, Marion M, Thanos PK, et al.: Fluoxetine Potentiates Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum. Mol. Neurobiol. 2021; 58(10): 4856–4870. PubMed Abstract | Publisher Full Text | Free Full Text

[18] 18. Thukham-Mee W, Wattanathorn J, Kirisattayakul W, et al.: Effect of Single Administration of Mulberry Milk on the Cognitive Function of 6-12-Year-Old Children: Results from a Randomized, Placebo-Controlled, Crossover Study. Oxidative Med. Cell. Longev. 2020; 2020: 1–10. PubMed Abstract | Publisher Full Text | Free Full Text

[19] 19. Muchimapura S, Thukhummee W, Wattanathorn J: Evaluation of the neuroprotective and cognitive enhancing effects of cucurbita moschata. J. Med. Assoc. Thail. 2020; 103(1): 105–112.

[20] 20. Wu M, Muchimapura S, Wattanathorn J, et al.: Mung bean-derived protein protects against neurodegeneration and memory impairment in animal model of menopause with obesity. J. Med. Assoc. Thail. 2019; 102(4): 43–51.

[21] 21. Ohnon W, Wattanathorn J, Thukham-Mee W, et al.: The combined extract of black sticky rice and dill improves poststroke cognitive impairment in metabolic syndrome condition. Oxidative Med. Cell. Longev. 2019; 2019: 1–19. Publisher Full Text

[22] 22. Wattanathorn J, Kirisattayakul W, Suriharn B, et al.: Functional Drink Containing the Extracts of Purple Corn Cob and Pandan Leaves, the Novel Cognitive Enhancer, Increases Spatial Memory and Hippocampal Neuron Density Through the Improvement of Extracellular Signal Regulated Protein Kinase Expression, Cholinergic Function, and Oxidative Status in Ovariectomized Rats. Rejuvenation Res. 2018; 21(5): 431–441. PubMed Abstract | Publisher Full Text

[23] 23. Dehbozorgi M, Fereidooni F, Bozorgmehr R, et al.: Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis. BMC Anesthesiol. 2024; 24(1): 256. PubMed Abstract | Publisher Full Text | Free Full Text

[24] 24. Chandra P, Sharma H: PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE. Indian Drugs. 2024; 61(7): 7–22. Publisher Full Text

[25] 25. Nesbit MO, Ahn S, Zou H, et al.: Potentiation of prefrontal cortex dopamine function by the novel cognitive enhancer d-govadine. Neuropharmacology. 2024; 246: 109849. PubMed Abstract | Publisher Full Text

[26] 26. Zhong X, Xu L, Wang L, et al.: Caffeine and modafinil modulate the effects of sleep deprivation on thalamic resting-state functional connectivity: A double-blind pilot study. Sleep Med. 2024; 122: 71–83. PubMed Abstract | Publisher Full Text

[27] 27. Loureiro JA, Andrade S, Ramalho MJ, et al.: Caffeine and beneficial cognitive effects. Tea in Health and Disease Prevention. 2024; 765–769. Publisher Full Text

[28] 28. Sharif S, Fergus S, Guirguis A, et al.: Exploring the understanding, source of availability and level of access of cognitive enhancers among university students in the United Arab Emirates: A qualitative study. Hum. Psychopharmacol. 2024; 39(1). Publisher Full Text

[29] 29. Jones F, Newton PM: Prevalence of the use of prescription stimulants as “study drugs” by UK university students: A brief report. Brain Behav. 2024; 14(2). Publisher Full Text

[30] 30. Bakota EL, Nandrea JM: Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements. Journal of Dietary Supplements. 2024; 22: 329–344. Publisher Full Text

[31] 31. Shehata SA, Kolieb E, Ali DA, et al.: Selenium alleviates modafinil-induced neurobehavioral toxicity in rat via PI3K/Akt/mTOR/GSK3B signaling pathway and suppression of oxidative stress and apoptosis: in vivo and in silico study. Environ. Sci. Pollut. Res. Int. 2024; 31(1): 458–480.

[32] 32. Cutsem JV, Pattyn N: Pharmacological Strategies to Improve Mental Performance. Handbook of Mental Performance: Lessons from High Performance Domains. 2024; 119–134. Publisher Full Text

[33] 33. Beveridge J, Söderström M, Prieto-Díaz R, et al.: Benzylhydroxamic acids as inhibitors of insulin regulated aminopeptidase (IRAP). European Journal of Medicinal Chemistry Reports. 2024; 12: 100215. Publisher Full Text

[34] 34. Gising J, Honarnejad S, Bras M, et al.: The Discovery of New Inhibitors of Insulin-Regulated Aminopeptidase by a High-Throughput Screening of 400,000 Drug-like Compounds. Int. J. Mol. Sci. 2024; 25(7). PubMed Abstract | Publisher Full Text | Free Full Text

[35] 35. Forsell P, Parrado Fernández C, Nilsson B, et al.: Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease. Pharmaceuticals. 2024; 17(8). PubMed Abstract | Publisher Full Text | Free Full Text

[36] 36. Lenoir H: Comment on “The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia”. Drugs Aging. 2024; 41(10): 859–861. PubMed Abstract | Publisher Full Text

[37] 37. DeMercy HM, Brenner CA: The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia. Drugs Aging. 2024; 41(10): 847–858. PubMed Abstract | Publisher Full Text | Free Full Text

[38] 38. Ebell MH: Cognitive Enhancers Significantly Improve Mini-Mental State Examination Score in Patients With Alzheimer Dementia. Am. Fam. Physician. 2024; 110(1): 91–92. PubMed Abstract

[39] 39. Fernandes D, Suryadevara U, Bruijnzeel D, et al.: Update on Cognitive Enhancers Among the Older Adult Population: A Clinical Review. Curr. Psychiatry Rep. 2024; 26(3): 73–77. PubMed Abstract | Publisher Full Text

[40] 40. Cohen CI, Reisberg B, Yaffee R: Global cognitive trajectory patterns in Alzheimer's disease. Int. Psychogeriatr. 2024; 36(3): 200–209. Publisher Full Text

[41] 41. Gharat R, Dixit G, Khambete M, et al.: Targets, trials and tribulations in Alzheimer therapeutics. Eur. J. Pharmacol. 2024; 962: 176230. PubMed Abstract | Publisher Full Text

[42] 42. Tan SY, Teo SP: Audit of Alzheimer’s disease management from a tertiary hospital in Brunei Darussalam. Palliative Medicine in Practice. 2024; 18(3): 133–138.

[43] 43. Portlock GE, Smith MD, van Poelgeest EP , et al.: Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults—a clinical review. European Geriatric Medicine. 2023; 14(4): 721–732. PubMed Abstract | Publisher Full Text | Free Full Text

[44] 44. Parrado Fernandez C, Juric S, Backlund M, et al.: Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. Int. J. Mol. Sci. 2023; 24(13). PubMed Abstract | Publisher Full Text | Free Full Text

[45] 45. Nakhostin-Khayyat M, Borjali M, Zeinali M, et al.: The relationship between self-regulation, cognitive flexibility, and resilience among students: a structural equation modeling. BMC Psychology. 2024; 12(1): 337. PubMed Abstract | Publisher Full Text | Free Full Text

[46] 46. Whitehurst LN, Morehouse A, Mednick SC: Can stimulants make you smarter, despite stealing your sleep?. Trends Cogn. Sci. 2024; 28(8): 702–713. PubMed Abstract | Publisher Full Text

[47] 47. Hartmann H, Forkmann K, Schmidt K, et al.: Open-label placebo treatment does not enhance cognitive abilities in healthy volunteers. Sci. Rep. 2023; 13(1): 19468. PubMed Abstract | Publisher Full Text | Free Full Text

[48] 48. Sharma K, Fallon SJ, Davis T, et al.: Preliminary evidence that caffeine improves attention in multiple sclerosis. Mult. Scler. Relat. Disord. 2022; 64: 103924. PubMed Abstract | Publisher Full Text

[49] 49. Das A, Brasseux S: Improvement in Memory Deficits with Memantine in Mania Secondary to Traumatic Brain Injury and Preexisting Perinatal Birth Injury. J. Psychiatr. Pract. 2021; 27(5): 390–394. PubMed Abstract | Publisher Full Text

[50] 50. Zhao WN, Ghosh B, Tyler M, et al.: Class i Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory. ACS Chem. Neurosci. 2018; 9(9): 2262–2273. PubMed Abstract | Publisher Full Text

[51] 51. Wu HF, Chen PS, Hsu YT, et al.: D-Cycloserine Ameliorates Autism-Like Deficits by Removing GluA2-Containing AMPA Receptors in a Valproic Acid-Induced Rat Model. Mol. Neurobiol. 2018; 55(6): 4811–4824. PubMed Abstract | Publisher Full Text

[52] 52. Portero-Tresserra M, Martí-Nicolovius M, Tarrés-Gatius M, et al.: Intra-hippocampal d-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats. Psychopharmacology. 2018; 235(5): 1463–1477. PubMed Abstract | Publisher Full Text

[53] 53. Fazio L, Pergola G, Papalino M, et al.: Transcriptomic context of DRD1 is associated with prefrontal activity and behavior during working memory. Proc. Natl. Acad. Sci. USA. 2018; 115(21): 5582–5587. PubMed Abstract | Publisher Full Text | Free Full Text

[54] 54. Kodama T, Kojima T, Honda Y, et al.: Oral administration of methylphenidate (Ritalin) affects dopamine release differentially between the prefrontal cortex and striatum: A microdialysis study in the monkey. J. Neurosci. 2017; 37(9): 2387–2394. PubMed Abstract | Publisher Full Text | Free Full Text

[55] 55. Bellebaum C, Kuchinke L, Roser P: Modafinil alters decision making based on feedback history - A randomized placebo-controlled double blind study in humans. J. Psychopharmacol. 2017; 31(2): 243–249. Publisher Full Text

[56] 56. Tse TJ, Chicilo F, Wiens DJ, et al.: Production of α-Glycerylphosphorylcholine in Fermented Roots, Tubers, and Fruits. Foods. 2024; 13(19). PubMed Abstract | Publisher Full Text | Free Full Text

[57] 57. Frankenfeld F, Wagmann L, Jacobs CM, et al.: Quantitative analysis of drugs of abuse and cognitive enhancers in influent wastewater by means of two chromatographic methods. Drug Test. Anal. 2024; 16(9): 893–902. Publisher Full Text

[58] 58. Frankenfeld F, Wagmann L, Jacobs CM, et al.: Prevalence of Drugs of Abuse and Cognitive Enhancer Consumption Monitored in Grab Samples and Composite Wastewater via Orbitrap Mass Spectrometry Analysis. Molecules. 2024; 29(16). PubMed Abstract | Publisher Full Text | Free Full Text

[59] 59. Hnin HM, Tun T, Jansook P: Development and validation of high-performance liquid chromatography method for the simultaneous quantification of rivastigmine hydrogen tartrate and asiaticoside co-loaded in niosomes: A Box–Behnken design approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2024; 1241: 124170. Publisher Full Text

[60] 60. Daher F, Villalobos NA, Hanley M, et al.: Basmisanil, an α5-GABAAR negative allosteric modulator, produces rapid and sustained antidepressant-like responses in male mice. Neurosci. Lett. 2024; 833: 137828. PubMed Abstract | Publisher Full Text | Free Full Text

[61] 61. Stepan J, Heinz DE, Dethloff F, et al.: Inhibiting Hippo pathway kinases releases WWC1 to promote AMPAR-dependent synaptic plasticity and long-term memory in mice. Sci. Signal. 2024; 17(834): eadj6603. PubMed Abstract | Publisher Full Text

[62] 62. Kim Y, Kim IH, See HJ, et al.: Immobilized Talaromyces leycettanus phospholipase A1 as a reusable biocatalyst for l-α-glycerylphosphorylcholine preparation from phosphatidylcholine. JAOCS, Journal of the American Oil Chemists' Society. 2024. Publisher Full Text

[63] 63. Twomey R, Young A, Clarke C: A case series of musical hallucinations in psychiatry of old age—in search of the sound of silence. Ir. J. Med. Sci. 2024; 193(5): 2427–2431. PubMed Abstract | Publisher Full Text

[64] 64. Aomine Y, Shimo Y, Sakurai K, et al.: Sex-dependent differences in the ability of nicotine to modulate discrimination learning and cognitive flexibility in mice. J. Neurochem. 2024.

[65] 65. Sheldon P, Mendez-Montejano J, Michalak AJ, et al.: Pharmacological Cognitive Enhancement Among International Medical Students: Assessing Study Habits as a Novel Factor. Medical Science Educator. 2024; 34: 1353–1360. PubMed Abstract | Publisher Full Text | Free Full Text

[66] 66. Fleetwood J, Chatwin C: Gender representations in online modafinil markets. Digital Transformations of Illicit Drug Markets: Reconfiguration and Continuity. 2023; 109–126. Publisher Full Text

[67] 67. Imran S, Ahmad W, Saltanat S: Therapeutic Evaluation of Unani Medicine, Including Single Drugs and Polyherbal Formulations with Special Reference to Neurodegenerative Disorders. Altern. Ther. Health Med. 2024; 30(9): 54–64.

[68] 68. Bouabdallah S, Ibrahim MH, Brinza I, et al.: Anxiolytic and Antidepressant Effects of Tribulus terrestris Ethanolic Extract in Scopolamine-Induced Amnesia in Zebrafish: Supported by Molecular Docking Investigation Targeting Monoamine Oxidase A. Pharmaceuticals. 2024; 17(9). Publisher Full Text

[69] 69. Kang S, Lee N, Jung B, et al.: Anti-Amnesic Effect of Agastache rugosa on Scopolamine-Induced Memory Impairment in Mice. Pharmaceuticals. 2024; 17(9). PubMed Abstract | Publisher Full Text | Free Full Text

[70] 70. Kolesnikova TO, Demin KA, Costa FV, et al.: Zebrafish models for studying cognitive enhancers. Neurosci. Biobehav. Rev. 2024; 164: 105797. PubMed Abstract | Publisher Full Text

[71] 71. Maher S, Donlon E, Mullane G, et al.: Treatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology. J. Clin. Med. 2024; 13(8). PubMed Abstract | Publisher Full Text | Free Full Text

[72] 72. Jia F, Shen X: Rejuvenation factor PF4: a potential gatekeeper for neurodegenerative diseases. Front. Aging Neurosci. 2024; 16. PubMed Abstract | Publisher Full Text | Free Full Text

[73] 73. Ming X, Fu L, Wang L: Biotechnological Enhancements in Micro learning: Integrating Chinese and Western Cultural English Vocabulary for Second Language Acquisition in the Context of Digital Health. J. Commer. Biotechnol. 2024; 29(3): 344–352.

[74] 74. Premachandran K, Wilson Alphonse CR, Soundharapandiyan N: Nourishing the Cognition with Millets: A Comprehensive Review of Their Nutritional Impact and Potential as Cognitive Enhancers. Mol. Nutr. Food Res. 2023; 67(24): e2300450. PubMed Abstract | Publisher Full Text

[75] 75. Bhavsar P, Shah P, Sinha S, et al.: Musical Neurofeedback Advancements, Feedback Modalities, and Applications: A Systematic Review. Appl. Psychophysiol. Biofeedback. 2024; 49(3): 347–363. PubMed Abstract | Publisher Full Text

[76] 76. Rastogi S, Farswan TS, Pandey MM: Seasonal variation in the phytoconstituents and antioxidant activity in Moringa oleifera Lam. leaves of North India. S. Afr. J. Bot. 2024; 166: 492–502. Publisher Full Text

[77] 77. Wooten T, Sansevere KS, Siqueira S, et al.: Evaluating the efficacy of cranial electrotherapy stimulation in mitigating anxiety-induced cognitive deficits. Int. J. Psychophysiol. 2024; 202: 112388. PubMed Abstract | Publisher Full Text

[78] 78. Rapp SR, Dressler EV, Brown WM, et al.: Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors after Adjuvant Chemotherapy (WF-97116). J. Clin. Oncol. 2024; 42(21): 2546–2557. PubMed Abstract | Publisher Full Text | Free Full Text

[79] 79. Ernyey AJ, Kassai F, Kozma K, et al.: Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP). GeroScience. 2024; 46(1): 417–429. PubMed Abstract | Publisher Full Text

[80] 80. Francotte P, Bay Y, Goffin E, et al.: Exploring thienothiadiazine dioxides as isosteric analogues of benzo- and pyridothiadiazine dioxides in the search of new AMPA and kainate receptor positive allosteric modulators. Eur. J. Med. Chem. 2024; 264: 116036. PubMed Abstract | Publisher Full Text

[81] 81. Frileux S, Boltri M, Doré J, et al.: Cognition and gut microbiota in schizophrenia spectrum and mood disorders: A systematic review. Neurosci. Biobehav. Rev. 2024; 162: 105722. Publisher Full Text

[82] 82. Nowrouzi S, Richelle L: The misuse of cognitive enhancers by medical students: a cross-sectional study using questionnaires. The British journal of general practice: the journal of the Royal College of General Practitioners. 2024; 74: bjgp24X737625. PubMed Abstract | Publisher Full Text

[83] 83. Ke T, Poquette KE, Amro Gazze SL, et al.: Amphetamine Exposure during Embryogenesis Alters Expression and Function of Tyrosine Hydroxylase and the Vesicular Monoamine Transporter in Adult C. elegans. Int. J. Mol. Sci. 2024; 25(8). Publisher Full Text

[84] 84. Zahavi E, Lev-Shalem L, Yehoshua I, et al.: Methylphenidate use and misuse among medical residents in Israel: a cross-sectional study. Hum. Resour. Health. 2023; 21(1): 5. PubMed Abstract | Publisher Full Text | Free Full Text

[85] 85. Bowman E, Coghill D, Murawski C, et al.: Not so smart? "Smart" drugs increase the level but decrease the quality of cognitive effort. Sci. Adv. 2023; 9(24). Publisher Full Text

[86] 86. Martin R, Buffenstein I, Cho D, et al.: Toxidrome of an Easily Obtainable Nootropic: A Case Report of Phenibut Intoxication and Withdrawal Delirium. J. Clin. Psychopharmacol. 2023; 43(6): 507–510. PubMed Abstract | Publisher Full Text

[87] 87. Mei D, Wang F, Yuan B, et al.: Cognitive Enhancer Donepezil Attenuates Heroin-Seeking Behavior Induced by Cues in Rats. J. Integr. Neurosci. 2023; 22(3). PubMed Abstract | Publisher Full Text

[88] 88. Medrano MC, Darlot F, Cador M, et al.: Poor inhibitory control predicts sex-specific vulnerability to nicotine rewarding properties in mice. Psychopharmacology. 2023; 240(9): 1973–1986. PubMed Abstract | Publisher Full Text

[89] 89. Shen W, Mei D, Liu Y, et al.: Cognitive Enhancers: What They Are and How They Are Used in Heroin Addiction. Handbook of Substance Misuse and Addictions: From Biology to Public Health. 2022; 1831–1849. Publisher Full Text

[90] 90. Coghill D: The Benefits and Limitations of Stimulants in Treating ADHD. Curr. Top. Behav. Neurosci. 2022; 57: 51–77. PubMed Abstract | Publisher Full Text

[91] 91. Garg S, Goel D, Krishna ST: Pharmacological management of behavioral and psychological symptoms of dementia: Brief review. Archives of Mental Health. 2022; 23(1): 67–71. Publisher Full Text

[92] 92. Kim ES, Lee A: Cognitive enhancers in healthy individuals have little benefit and significant potential harms. Drugs and Therapy Perspectives. 2023; 39(5): 187–190. Publisher Full Text

[93] 93. Merwid-Ląd A, Passon M, Drymluch P, et al.: Do Medical Universities Students Use Cognitive Enhancers while Learning?—Conclusions from the Study in Poland. Life. 2023; 13(3). PubMed Abstract | Publisher Full Text | Free Full Text

[94] 94. Jensen KL, Jensen SB, Madsen KL: A mechanistic overview of approaches for the treatment of psychostimulant dependence. Front. Pharmacol. 2022; 13. PubMed Abstract | Publisher Full Text | Free Full Text

[95] 95. Peterkin AF, Abraham R, Harris MTH: A Case of Phenibut Directed Detoxification Leading to Toxicity During the COVID-19 Pandemic. J. Addict. Med. 2022; 16(5): 602–605. PubMed Abstract | Publisher Full Text | Free Full Text

[96] 96. Jahangeer SMA, Hamdan M, Ansari US, et al.: Cognition improvement strategies, study behaviours and stress among medical students of Dow University of Health Sciences: A cross-sectional study. J. Pak. Med. Assoc. 2022; 72(7): 1363–1368.

[97] 97. Tomažič T, Čelofiga AK: The Role of Different Behavioral and Psychosocial Factors in the Context of Pharmaceutical Cognitive Enhancers’ Misuse. Healthcare (Switzerland). 2022; 10(6). Publisher Full Text

[98] 98. Flavell J: Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder. Australas. Psychiatry. 2021; 29(3): 366–367. Publisher Full Text

[99] 99. Deconinck E, Vanhee C, Keizers P, et al.: The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Test. Anal. 2021; 13(4): 833–840. PubMed Abstract | Publisher Full Text

[100] 100. Sharif S, Guirguis A, Fergus S, et al.: The use and impact of cognitive enhancers among university students: A systematic review. Brain Sci. 2021; 11(3). PubMed Abstract | Publisher Full Text | Free Full Text

[101] 101. Miranda M, Barbosa M: Use of cognitive enhancers by Portuguese medical students: Do academic challenges matter?. Acta Medica Portuguesa. 2021; 34(13).

[102] 102. Milić J, Zeković J, Stankić D, et al.: Cognition-enhancing drugs and applications to aging. Assessments, Treatments and Modeling in Aging and Neurological Disease: The Neuroscience of Aging. 2021; 367–378. Publisher Full Text

[103] 103. Urban KR, Gao WJ: Cognitive-Enhancing Substances and the Developing Brain: Risks and Benefits. Contemporary Clinical Neuroscience. 2021; 661–677. Publisher Full Text

[104] 104. Ram S, Russell BR, Stewart K, et al.: Psychiatrists’ attitudes towards and willingness to prescribe cognitive enhancers in academic settings. Drugs: Education, Prevention and Policy. 2021; 28(1): 59–66.

[105] 105. Ram S, Russell B, Kirkpatrick C, et al.: Professionals’ attitudes towards the use of cognitive enhancers in academic settings. PLoS ONE. 2020; 15(11 November): e0241968. PubMed Abstract | Publisher Full Text | Free Full Text

[106] 106. Kapur A: Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?. CNS Drugs. 2020; 34(10): 1045–1062. Publisher Full Text

[107] 107. Roberts CA, Jones A, Sumnall H, et al.: How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur. Neuropsychopharmacol. 2020; 38: 40–62. Publisher Full Text

[108] 108. Vas S, Casey JM, Schneider WT, et al.: Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington’s Disease. Neurotherapeutics. 2020; 17(3): 1075–1086. PubMed Abstract | Publisher Full Text | Free Full Text

[109] 109. Sousa A, Dinis-Oliveira RJ: Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst. Abus. 2020; 41(2): 155–173. PubMed Abstract | Publisher Full Text

[110] 110. Humby T, Smith GE, Small R, et al.: Effects of 5-HT2C, 5-HT1A receptor challenges and modafinil on the initiation and persistence of gambling behaviours. Psychopharmacology. 2020; 237(6): 1745–1756. PubMed Abstract | Publisher Full Text | Free Full Text

[111] 111. Hockenhull J, Wood DM, Dargan PI: The Availability of Modafinil and Methylphenidate Purchased from the Internet in the United Kingdom Without a Prescription. Subst. Use Misuse. 2020; 55(1): 56–65. PubMed Abstract | Publisher Full Text

[112] 112. Sagheddu C, Pintori N, Kalaba P, et al.: Neurophysiological and neurochemical effects of the putative cognitive enhancer (S)-CE-123 on mesocorticolimbic dopamine system. Biomolecules. 2020; 10(5). PubMed Abstract | Publisher Full Text | Free Full Text

[113] 113. Zaami S, Tagliabracci A, Berretta P, et al.: Use of Methylphenidate Analogues as Cognitive Enhancers: The Prelude to Cosmetic Neurology and an Ethical Issue. Front. Psych. 2020; 10: 10. Publisher Full Text

[114] 114. Tully JL, Forshaw M, Montgomery C, et al.: Afterword. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 175–179. Publisher Full Text

[115] 115. Cakic V: A Familiar Landscape in the Brave New World: Ethics of Cognitive Enhancement Introduction. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 135–173. Publisher Full Text

[116] 116. Wojszel ZB: Dementia diagnoses and treatment in geriatric ward patients: A cross-sectional study in poland. Clin. Interv. Aging. 2020; 15: 2183–2194. PubMed Abstract | Publisher Full Text | Free Full Text

[117] 117. Kredlow MA, Keshishian A, Oppenheimer S, et al.: The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis. J. Clin. Psychopharmacol. 2019; 39(5): 455–461. PubMed Abstract | Publisher Full Text

[118] 118. Steward A, Pickersgill M: Developing expertise, customising sleep, enhancing study practices: exploring the legitimisation of modafinil use within the accounts of UK undergraduate students. Drugs: Education, Prevention and Policy. 2019; 26(4): 347–355. PubMed Abstract | Publisher Full Text

[119] 119. Demiral ŞB, Tomasi D, Wiers CE, et al.: Methylphenidate’s effects on thalamic metabolism and functional connectivity in cannabis abusers and healthy controls. Neuropsychopharmacology. 2019; 44(8): 1389–1397. PubMed Abstract | Publisher Full Text | Free Full Text

[120] 120. Soobiah C, Tadrous M, Knowles S, et al.: Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer’s Dementia. PLoS ONE. 2019; 14(4): e0215225. PubMed Abstract | Publisher Full Text | Free Full Text

[121] 121. Salman T, Nawaz S, Waraich RS, et al.: Repeated administration of methylphenidate produces reinforcement and downregulates 5-HT-1A receptor expression in the nucleus accumbens. Life Sci. 2019; 218: 139–146. PubMed Abstract | Publisher Full Text

[122] 122. Rozenek EB, Górska M, Wilczyńska K, et al.: In search of optimal psychoactivation: Stimulants as cognitive performance enhancers. Arh. Hig. Rada Toksikol. 2019; 70(3): 150–159. PubMed Abstract | Publisher Full Text

[123] 123. Carlier J, Giorgetti R, Varì MR, et al.: Use of cognitive enhancers: Methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(1): 3–15.

[124] 124. Mousavi F, Shojaei P, Markeh HP: The use of cognitive enhancers among medical students. International Journal of High Risk Behaviors and Addiction. 2019; 8(2). Publisher Full Text

[125] 125. Pighi M, Pontoni G, Sinisi A, et al.: Use and propensity to use substances as cognitive enhancers in Italian medical students. Brain Sci. 2018; 8(11). PubMed Abstract | Publisher Full Text | Free Full Text

[126] 126. González B, Jayanthi S, Gomez N, et al.: Repeated methamphetamine and modafinil induce differential cognitive effects and specific histone acetylation and DNA methylation profiles in the mouse medial prefrontal cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2018; 82: 1–11. PubMed Abstract | Publisher Full Text | Free Full Text

[127] 127. Dolder PC, Müller F, Schmid Y, et al.: Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology. 2018; 235(2): 467–479. PubMed Abstract | Publisher Full Text | Free Full Text

[128] 128. Major AJ, Vijayraghavan S, Everling S: Cholinergic overstimulation attenuates rule selectivity in macaque prefrontal cortex. J. Neurosci. 2018; 38(5): 1137–1150. PubMed Abstract | Publisher Full Text | Free Full Text

[129] 129. Franke AG, Dietz P, Ranft K, et al.: The Use of Pharmacologic Cognitive Enhancers in Competitive Chess. Epidemiology. 2017; 28(6): E57–e58. PubMed Abstract | Publisher Full Text

[130] 130. Urban KR, Gao WJ: Psychostimulants As Cognitive Enhancers in Adolescents: More Risk than Reward? Frontiers. Public Health. 2017; 5: 5. Publisher Full Text

[131] 131. Van Zyl PM, Joubert G, Fechter L, et al.: Methylphenidate use among students living in junior on-campus residences of the University of the Free State. S. Afr. Fam. Pract. 2017; 59(4): 123–127.

[132] 132. Corazza O, Bersani FS, Brunoro R, et al.: The diffusion of Performance and Image-Enhancing Drugs (PIEDs) on the internet: The abuse of the cognitive enhancer piracetam. Subst. Use Misuse. 2014; 49(14): 1849–1856. PubMed Abstract | Publisher Full Text

[133] 133. Carrozzo MM, Battisti UM, Cannazza G, et al.: Design, stereoselective synthesis, configurational stability and biological activity of 7-chloro-9-(furan-3-yl)-2,3,3a,4-tetrahydro-1H-benzo [e]pyrrolo[2,1- c][1,2,4] thiadiazine 5,5-dioxide. Bioorg. Med. Chem. 2014; 22(17): 4667–4676. PubMed Abstract | Publisher Full Text

[134] 134. Smits JAJ, Rosenfield D, Davis ML, et al.: Yohimbine enhancement of exposure therapy for social anxiety disorder: A randomized controlled trial. Biol. Psychiatry. 2014; 75(11): 840–846. PubMed Abstract | Publisher Full Text

[135] 135. Dafny N: The effect of brain augmenting drug Ritalin on animal behavior. Current Topics in Pharmacology. 2014; 18(1-2): 61–69.

[136] 136. Ku LJE, Pai MC: Use of cognitive enhancers and associated medical care costs among patients with dementia: A nationwide study in Taiwan. Int. Psychogeriatr. 2014; 26(5): 795–804. Publisher Full Text

[137] 137. Sattler S, Forlini C, Racine É, et al.: Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE. 2013; 8(8): e71452. PubMed Abstract | Publisher Full Text | Free Full Text

[138] 138. Goeldner C, Ballard TM, Knoflach F, et al.: Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 2013; 64: 337–346. PubMed Abstract | Publisher Full Text

[139] 139. Gould RW, Garg PK, Garg S, et al.: Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology. 2013; 64: 479–488. PubMed Abstract | Publisher Full Text | Free Full Text

[140] 140. Dresler M, Sandberg A, Ohla K, et al.: Non-pharmacological cognitive enhancement. Neuropharmacology. 2013; 64: 529–543. Publisher Full Text

[141] 141. Pang TYC, Hannan AJ: Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity. Neuropharmacology. 2013; 64: 515–528. Publisher Full Text

[142] 142. Bidwell LC, McClernon FJ, Kollins SH: Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 2011; 99(2): 262–274. PubMed Abstract | Publisher Full Text | Free Full Text

[143] 143. Kantak KM, Hofmann SG: Cognitive enhancers for the treatment of neuropsychiatric disorders: Clinical and preclinical investigations. Pharmacol. Biochem. Behav. 2011; 99(2): 113–115. PubMed Abstract | Publisher Full Text

[144] 144. Hofmann SG, Smits JAJ, Asnaani A, et al.: Cognitive enhancers for anxiety disorders. Pharmacol. Biochem. Behav. 2011; 99(2): 275–284. PubMed Abstract | Publisher Full Text | Free Full Text

[145] 145. Kaplan GB, Moore KA: The use of cognitive enhancers in animal models of fear extinction. Pharmacol. Biochem. Behav. 2011; 99(2): 217–228. PubMed Abstract | Publisher Full Text

[146] 146. Byrne SP, Farrell LJ, Rapee RM: Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D-cycloserine to augment exposure for child anxiety. Clin. Psychol. 2011; 15(1): 1–9. Publisher Full Text

[147] 147. Van Waes V, Beverley J, Marinelli M, et al.: Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur. J. Neurosci. 2010; 32(3): 435–447. PubMed Abstract | Publisher Full Text | Free Full Text

[148] 148. Steiner H, Van Waes V, Marinelli M: Fluoxetine Potentiates Methylphenidate-Induced Gene Regulation in Addiction-Related Brain Regions: Concerns for Use of Cognitive Enhancers?. Biol. Psychiatry. 2010; 67(6): 592–594. PubMed Abstract | Publisher Full Text | Free Full Text

[149] 149. Singer P, Feldon J, Yee BK: Interference of glycine transporter 1: Modulation of cognitive functions via activation of glycine-B site of the NMDA receptor. Cent. Nerv. Syst. Agents Med. Chem. 2007; 7(4): 259–268. Publisher Full Text

[150] 150. Saxena G, Singh SP, Pal R, et al.: Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol. Biochem. Behav. 2007; 86(4): 797–805. PubMed Abstract | Publisher Full Text

[151] 151. Wang C, Zhang T, Ma H, et al.: Prolonged effects of poly (lactic-co-glycolic acid) microsphere-containing huperzine A on mouse memory dysfunction induced by scopolamine. Basic Clin. Pharmacol. Toxicol. 2007; 100(3): 190–195. Publisher Full Text

[152] 152. Waight JL, Arias N, Jiménez-García AM, et al.: From functional neuroimaging to neurostimulation: fNIRS devices as cognitive enhancers. Behav. Res. Methods. 2024; 56(3): 2227–2242.

[153] 153. Tsotsokou G, Kouri V, Papatheodoropoulos C: α7 nicotinic acetylcholine receptors induce long-term synaptic enhancement in the dorsal but not ventral hippocampus. Synapse. 2024; 78(1). Publisher Full Text

[154] 154. Ertosun GB, Ergen M, Bardakci H, et al.: Cholinergic cognitive enhancer effect of Salvia triloba L. essential oil inhalation in rats. Marmara Medical Journal. 2023; 36(3): 361–370. Publisher Full Text

[155] 155. Gaiardo RB, Pedroso AP, Ribeiro EB, et al.: Proteome Analysis Indicates Participation of the Dorsal Hippocampal Formation in Fear-Motivated Memory in a Time-Dependent Manner. Behav. Neurosci. 2023; 137(5): 303–318. PubMed Abstract | Publisher Full Text

[156] 156. Gligorov N: NOT EXTENDED, BUT ENHANCED: Internal improvements to cognition and the maintenance of cognitive agency. The Routledge Handbook of the Ethics of Human Enhancement. 2023; p. 214–23. Publisher Full Text

[157] 157. Yelanchezian YMM, Waldvogel HJ, Faull RLM, et al.: Neuroprotective Effect of Caffeine in Alzheimer’s Disease. Molecules. 2022; 27(12). PubMed Abstract | Publisher Full Text | Free Full Text

[158] 158. Satoh R, Kawakami K, Nakadate K: Effects of Smart Drugs on Cholinergic System and Non-Neuronal Acetylcholine in the Mouse Hippocampus: Histopathological Approach. J. Clin. Med. 2022; 11(12). PubMed Abstract | Publisher Full Text | Free Full Text

[159] 159. Hayes LJ, Bays RB, Arthur S, et al.: Predictors of Attitudes Toward Pharmacological Cognitive Enhancers in College Students. Emerg. Adulthood. 2022; 10(3): 609–619. Publisher Full Text

[160] 160. Sharif S, Fergus S, Guirguis A, et al.: Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. PLoS ONE. 2022; 17(1 January): e0262704. PubMed Abstract | Publisher Full Text | Free Full Text

[161] 161. Ang YS, Cusin C, Petibon Y, et al.: A multi-pronged investigation of option generation using depression, PET and modafinil. Brain. 2022; 145(5): 1854–1865. PubMed Abstract | Publisher Full Text | Free Full Text

[162] 162. Gaillard C, Lago TR, Gorka AX, et al.: Methylphenidate modulates interactions of anxiety with cognition. Transl. Psychiatry. 2021; 11(1): 544. PubMed Abstract | Publisher Full Text | Free Full Text

[163] 163. Salman T, Afroz R, Nawaz S, et al.: Differential effects of memory enhancing and impairing doses of methylphenidate on serotonin metabolism and 5-HT1A, GABA, glutamate receptor expression in the rat prefrontal cortex. Biochimie. 2021; 191: 51–61. PubMed Abstract | Publisher Full Text

[164] 164. Devanand DP, Liu X, Cohen H, et al.: Long-Term Test-Retest Reliability of the UPSIT in Cognitively Intact Older Adults. Chem. Senses. 2019; 44(6): 365–369. PubMed Abstract | Publisher Full Text | Free Full Text

[165] 165. Veroniki AA, Bender R, Glasziou P, et al.: The number needed to treat in pairwise and network meta-analysis and its graphical representation. J. Clin. Epidemiol. 2019; 111: 11–22. PubMed Abstract | Publisher Full Text

[166] 166. Motaghinejad M, Safari S, Feizipour S, et al.: Crocin may be useful to prevent or treatment of alcohol induced neurodegeneration and neurobehavioral sequels via modulation of CREB/BDNF and Akt/GSK signaling pathway. Med. Hypotheses. 2019; 124: 21–25. PubMed Abstract | Publisher Full Text

[167] 167. McGregor G, Harvey J: Leptin Regulation of Synaptic Function at Hippocampal TA-CA1 and SC-CA1 Synapses: Implications for Health and Disease. Neurochem. Res. 2019; 44(3): 650–660. PubMed Abstract | Publisher Full Text | Free Full Text

[168] 168. Chang EH, Chavan SS, Pavlov VA: Cholinergic control of inflammation, metabolic dysfunction, and cognitive impairment in obesity-associated disorders: Mechanisms and novel therapeutic opportunities. Front. Neurosci. 2019; 13(APR). Publisher Full Text

[169] 169. Dubljević V: Are There Problems with the Economic Disincentives Model of Regulation?. International Library of Ethics, Law and Technology. 2019; 19: 109–122. Publisher Full Text

[170] 170. Woźniak-Karczewska M, Čvančarová M, Chrzanowski Ł, et al.: Isolation of two Ochrobactrum sp. strains capable of degrading the nootropic drug—Piracetam. New Biotechnol. 2018; 43: 37–43. Publisher Full Text

[171] 171. Dolder PC, Strajhar P, Vizeli P, et al.: Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects. Psychopharmacology. 2018; 235(5): 1389–1402. Publisher Full Text

[172] 172. Van Duinen MA, Sambeth A, Heckman PRA, et al.: Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology. 2018; 131: 31–38. PubMed Abstract | Publisher Full Text

[173] 173. Chierrito TPC, Pedersoli-Mantoani S, Roca C, et al.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 2018; 145: 431–444. PubMed Abstract | Publisher Full Text

[174] 174. Brolin E, Johansson J, Zelleroth S, et al.: The mRNA expression of insulin-like growth factor-1 (Igf1) is decreased in the rat frontal cortex following gamma-hydroxybutyrate (GHB) administration. Neurosci. Lett. 2017; 646: 15–20. PubMed Abstract | Publisher Full Text

[175] 175. Dowling G, Kavanagh PV, Talbot B, et al.: Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog. Drug Test. Anal. 2017; 9(3): 518–528. PubMed Abstract | Publisher Full Text

[176] 176. Shoaib M, Hall FS: Preclinical Models of Nicotine Withdrawal: Targeting Impaired Cognition. Negative Affective States and Cognitive Impairments in Nicotine Dependence. 2017; 37–52. Publisher Full Text

[177] 177. Cavallo M, Signorino A, Perucchini ML: Benefits of Cognitive Treatments Administered to Patients Affected by Mild Cognitive Impairment/Mild Neurocognitive Disorder. Drug Dev. Res. 2016; 77(8): 444–452. PubMed Abstract | Publisher Full Text

[178] 178. Deguil J, Ravasi L, Lanteaume L, et al.: Translational challenge models in support of efficacy studies: Effect of cerebral hypoxia on cognitive performances in rodents. CNS Neurol. Disord. Drug Targets. 2016; 15(7): 765–776. PubMed Abstract | Publisher Full Text

[179] 179. Benn A, Barker GRI, Stuart SA, et al.: Optogenetic stimulation of prefrontal glutamatergic neurons enhances recognition memory. J. Neurosci. 2016; 36(18): 4930–4939. Publisher Full Text

[180] 180. Diwakarla S, Nylander E, Grönbladh A, et al.: Binding to and inhibition of insulin-regulated aminopeptidase by macrocyclic disulfides enhances spine density. Mol. Pharmacol. 2016; 89(4): 413–424. PubMed Abstract | Publisher Full Text

[181] 181. Veroniki AA, Straus SE, Ashoor H, et al.: Contacting authors to retrieve individual patient data: Study protocol for a randomized controlled trial. Trials. 2016; 17(1): 138. PubMed Abstract | Publisher Full Text | Free Full Text

[182] 182. Martinez-Ramirez D, Giugni JC, Almeida L, et al.: Association between antidepressants and falls in Parkinson’s disease. J. Neurol. 2016; 263(1): 76–82. PubMed Abstract | Publisher Full Text

[183] 183. Robitsek J, Ratner MH, Stewart T, et al.: Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus. Hippocampus. 2015; 25(12): 1541–1555. PubMed Abstract | Publisher Full Text | Free Full Text

[184] 184. Dubljević V, Ryan CJ: Cognitive enhancement with methylphenidate and modafinil: Conceptual advances and societal implications. Neurosci. Neuroecon. 2015; 4: 25–33.

[185] 185. Baroni A, Castellanos FX: Stimulants, cognition and ADHD. Curr. Opin. Behav. Sci. 2015; 4: 109–114. Publisher Full Text

[186] 186. Jellen LC, Aliper A, Buzdin A, et al.: Screening and personalizing nootropic drugs and cognitive modulator regimens in silico. Front. Syst. Neurosci. 2015; 9(FEB). PubMed Abstract | Publisher Full Text | Free Full Text

[187] 187. Hermans SJ, Ascher DB, Hancock NC, et al.: Crystal structure of human insulin-regulated aminopeptidase with specificity for cyclic peptides. Protein Sci. 2015; 24(2): 190–199. Publisher Full Text

[188] 188. Jotterand F, McCurdy JL, Elger B: Cognitive Enhancers and Mental Impairment: Emerging Ethical Issues. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. Fifth Edition2014; p. 119–26. Publisher Full Text

[189] 189. Smith CC, Gibbs TT, Farb DH: Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology. 2014; 231(17): 3537–3556. PubMed Abstract | Publisher Full Text | Free Full Text

[190] 190. Wade L, Forlini C, Racine E: Generating genius: How an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals. BMC Med. Ethics. 2014; 15(1). PubMed Abstract | Publisher Full Text | Free Full Text

[191] 191. Micoulaud-Franchi JA, Macgregor A, Fond G: A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(13): 1875–1878. PubMed Abstract

[192] 192. Pereira LM, Bastos CP, de Souza JM , et al.: Estradiol enhances object recognition memory in Swiss female mice by activating hippocampal estrogen receptor α. Neurobiol. Learn. Mem. 2014; 114: 1–9. PubMed Abstract | Publisher Full Text

[193] 193. Potier MC, Braudeau J, Dauphinot L, et al.: Reducing Gabaergic inhibition restores cognitive functions in a mouse model of down syndrome. CNS Neurol. Disord. Drug Targets. 2014; 13(1): 8–15. PubMed Abstract | Publisher Full Text

[194] 194. Zhang MZ, Zhou ZZ, Yuan X, et al.: Chlorbipram: A novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer. Eur. J. Pharmacol. 2013; 721(1-3): 56–63. PubMed Abstract | Publisher Full Text

[195] 195. Borbély T, Scheich B, Helyes Z: Neuropeptides in learning and memory. Neuropeptides. 2013; 47(6): 439–450. Publisher Full Text

[196] 196. Harvey J: Leptin regulation of neuronal morphology and hippocampal synaptic function. Frontiers in Synaptic Neuroscience. 2013; 5(AUG). PubMed Abstract | Publisher Full Text | Free Full Text

[197] 197. Laws KR, Sweetnam H, Kondel TK: Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis. Hum. Psychopharmacol. 2012; 27(6): 527–533. PubMed Abstract | Publisher Full Text

[198] 198. Stepan J, Dine J, Fenzl T, et al.: Entorhinal theta-frequency input to the dentate gyrus trisynaptically evokes hippocampal CA1 LTP. Frontiers in Neural Circuits. 2012; 6(SEPTEMBER). PubMed Abstract | Publisher Full Text | Free Full Text

[199] 199. Andersson RH, Johnston A, Herman PA, et al.: Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc. Natl. Acad. Sci. USA. 2012; 109(32): 13118–13123. PubMed Abstract | Publisher Full Text | Free Full Text

[200] 200. Steckler T, Risbrough V: Pharmacological treatment of PTSD - Established and new approaches. Neuropharmacology. 2012; 62(2): 617–627. PubMed Abstract | Publisher Full Text | Free Full Text

[201] 201. Wattanathorn J, Muchimapura S, Thukhammee W, et al.: Mulberry fruits protects against age-related cognitive decline. Am. J. Appl. Sci. 2012; 9(9): 1503–1511.

[202] 202. Saenghong N, Wattanathorn J, Tong-Un T, et al.: Ginger supplementation enhances working memory of the post-menopause women. Am. J. Appl. Sci. 2011; 8(12): 1241–1248. Publisher Full Text

[203] 203. Yamaguchi Y, Saito K, Matsuno T, et al.: Effects of ZSET1446/ST101 on cognitive deficits and amyloid β deposition in the senescence accelerated prone mouse brain. J. Pharmacol. Sci. 2012; 119(2): 160–166. Publisher Full Text

[204] 204. Modi ME, Young LJ: D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol. Psychiatry. 2011; 70(3): 298–304. Publisher Full Text

[205] 205. Chen Z, Zhao Y, Yang Y, et al.: Leptin withdrawal after birth: A neglected factor account for cognitive deficit in offspring of GDM mother. Med. Hypotheses. 2011; 77(1): 125–127. PubMed Abstract | Publisher Full Text

[206] 206. Urani A, Philbert J, Cohen C, et al.: The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. Pharmacol. Biochem. Behav. 2011; 98(3): 425–431. PubMed Abstract | Publisher Full Text

[207] 207. Subramanian L, Hindle JV, Jackson MC, et al.: Dopamine boosts memory for angry faces in Parkinson's disease. Mov. Disord. 2010; 25(16): 2792–2799. PubMed Abstract | Publisher Full Text

[208] 208. Homayoun H, Moghaddam B: Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition. Eur. J. Pharmacol. 2010; 639(1-3): 33–39. PubMed Abstract | Publisher Full Text

[209] 209. Francotte P, Goffin E, Fraikin P, et al.: New Fluorinated 1,2,4-Benzothiadiazine 1,1-Dioxides: Discovery of an Orally Active Cognitive Enhancer Acting through Potentiation of the 2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic Acid Receptors. J. Med. Chem. 2010; 53(4): 1700–1711. Publisher Full Text

[210] 210. Montgomery KE, Kessler M, Arai AC: Modulation of agonist binding to AMPA receptors by 1-(1,4-benzodioxan-6- ylcarbonyl) piperidine (CX546): Differential effects across brain regions and GluA1-4/transmembrane AMPA receptor regulatory protein combinations. J. Pharmacol. Exp. Ther. 2009; 331(3): 965–974. PubMed Abstract | Publisher Full Text | Free Full Text

[211] 211. Detrait ERAY, Hanon E, Dardenne B, et al.: The inhibitory avoidance test optimized for discovery of cognitive enhancers. Behav. Res. Methods. 2009; 41(3): 805–811. PubMed Abstract | Publisher Full Text

[212] 212. Ballard TM, Knoflach F, Prinssen E, et al.: RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors. Psychopharmacology. 2009; 202(1-3): 207–223. PubMed Abstract | Publisher Full Text

[213] 213. Tsaltas E, Kontis D, Boulougouris V, et al.: Lithium and cognitive enhancement: Leave it or take it?. Psychopharmacology. 2009; 202(1-3): 457–476. Publisher Full Text

[214] 214. Fisher A: M1 muscarinic agonists target major hallmarks of Alzheimer's disease - The pivotal role of brain M1 receptors. Neurodegener. Dis. 2008; 5: 237–240. Publisher Full Text

[215] 215. Yamada K, Sawada H, Nishii K, et al.: Expression levels of Egr-1 and Nur77 proteins in mouse brain are increased by withdrawal of nicotine. Biogenic Amines. 2007; 21(4): 183–194.

[216] 216. Arushanyan EB, Beier EV: Hippocampus: A target for cognition enhancers. Eksperimental'naya i Klinicheskaya Farmakologiya. 2007; 70(4): 59–65.

[217] 217. Franz CE, Barker JC, Kravitz RL, et al.: Nonmedical influences on the use of cholinesterase inhibitors in dementia care. Alzheimer Dis. Assoc. Disord. 2007; 21(3): 241–248. PubMed Abstract | Publisher Full Text

[218] 218. Bromley E: Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia. Psychiatr. Serv. 2007; 58(4): 475–481. PubMed Abstract | Publisher Full Text

[219] 219. Bowie CR, Harvey PD: Treatment of cognitive deficits in schizophrenia. Curr. Opin. Investig. Drugs. 2006; 7(7): 608–613. PubMed Abstract

[220] 220. Harvey J, Shanley LJ, O'Malley D, et al.: Leptin: A potential cognitive enhancer?. Biochem. Soc. Trans. 2005; 33(5): 1029–1032. PubMed Abstract | Publisher Full Text

[221] 221. Fowler JH, Whalley K, Murray T, et al.: The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J. Cereb. Blood Flow Metab. 2004; 24(10): 1098–1109. PubMed Abstract | Publisher Full Text

[222] 222. Lynch G: AMPA receptor modulators as cognitive enhancers. Curr. Opin. Pharmacol. 2004; 4(1): 4–11. Publisher Full Text

[223] 223. Stromme Johannesen T, Myhrer T: Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat. Eur. J. Pharmacol. 2002; 437(1-2): 73–77. PubMed Abstract | Publisher Full Text

[224] 224. Soares JM, Barbosa M: The use of pharmacological and non-pharmacological cognitive enhancers in the Portuguese population. Performance Enhancement and Health. 2024; 12(1): 100274. Publisher Full Text

[225] 225. Guthrie OW, Yang L: Oral intake of carboxy alkyl ester improves attention: A randomized double-blind cross-over placebo-controlled study. Hum. Psychopharmacol. 2023; 38(6): e2885. PubMed Abstract | Publisher Full Text

[226] 226. Phogat J, Bali A, Kapoor N: Smart drugs in cognitive disorders. Applications of Synthetic Biology in Health, Energy, and Environment. 2023; 188–211. Publisher Full Text

[227] 227. Theleritis C, Siarkos K, Politis A, et al.: A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders. Brain Sci. 2023; 13(7). PubMed Abstract | Publisher Full Text | Free Full Text

[228] 228. Soliani AG, Muratori BG, dos Santos AL , et al.: Standardized extract of Ginkgo biloba enhances memory persistence over time. Phytomedicine Plus. 2023; 3(2): 100441. Publisher Full Text

[229] 229. Vinarskaya AK, Zuzina AB, Balaban PM: Histone acetylation increase rescues a weak remote fear memory in rats. Genes Cells. 2023; 18(4): 739–741. Publisher Full Text

[230] 230. Goffin E, Fraikin P, Abboud D, et al.: New insights in the development of positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides: Introduction of (mono/difluoro) methyl groups at the 2-position of the thiadiazine ring. Eur. J. Med. Chem. 2023; 250: 115221. Publisher Full Text

[231] 231. Lane HY, Wang SH, Lin CH: Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease. Psychiatry Clin. Neurosci. 2023; 77(2): 102–109. PubMed Abstract | Publisher Full Text | Free Full Text

[232] 232. Malík M, Tlustoš P: Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients. 2022; 14(16). PubMed Abstract | Publisher Full Text | Free Full Text

[233] 233. Wei J, Sinnott SM: Harms and benefits of non-medical methylphenidate use among young adults: a scoping review of the literature. J. Subst. Abus. 2023; 1–6. Publisher Full Text

[234] 234. Meshkat S, Tello-Gerez TJ, Gholaminezhad F, et al.: Impact of psilocybin on cognitive function: A systematic review. Psychiatry Clin. Neurosci. 2024; 78: 744–764. PubMed Abstract | Publisher Full Text | Free Full Text

[235] 235. Rogawski MA: A New SV2A Ligand for Epilepsy. Cell. 2016; 167(3): 587. PubMed Abstract | Publisher Full Text

[236] 236. Ghisoni K, Aguiar AS, de Oliveira PA , et al.: Neopterin acts as an endogenous cognitive enhancer. Brain Behav. Immun. 2016; 56: 156–164. PubMed Abstract | Publisher Full Text

[237] 237. Ahmad N, Lesa KN, Ujiantari NSO, et al.: Development of White Cabbage, Coffee, and Red Onion Extracts as Natural Phosphodiesterase-4B (PDE4B) Inhibitors for Cognitive Dysfunction: in vitro and in Silico Studies. Advances in Pharmacological and Pharmaceutical Sciences. 2024; 2024: 1–39. PubMed Abstract | Publisher Full Text | Free Full Text

[238] 238. Yechiam E: Behavioral economics enhancers. Judgm. Decis. Mak. 2024; 19: 19. Publisher Full Text

[239] 239. Sagheddu C, Cancedda E, Bagheri F, et al.: The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study. Int. J. Neuropsychopharmacol. 2023; 26(11): 784–795. Publisher Full Text

[240] 240. Remok F, Saidi S, Gourich AA, et al.: Phenolic Content, Antioxidant, Antibacterial, Antihyperglycemic, and α-Amylase Inhibitory Activities of Aqueous Extract of Salvia lavandulifolia Vahl. Pharmaceuticals. 2023; 16(3). Publisher Full Text

[241] 241. Stazi M, Zampar S, Klafki HW, et al.: A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model. Int. J. Mol. Sci. 2023; 24(3). PubMed Abstract | Publisher Full Text | Free Full Text

[242] 242. Stazi M, Zampar S, Nadolny M, et al.: Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice. Eur. Arch. Psychiatry Clin. Neurosci. 2023; 273(1): 269–281. Publisher Full Text

[243] 243. Ott K, Heikkinen T, Lehtimäki KK, et al.: Vertigoheel promotes rodent cognitive performance in multiple memory tests. Front. Neurosci. 2023; 17. PubMed Abstract | Publisher Full Text | Free Full Text

[244] 244. Kolesnikova TO, Galstyan DS, Demin KA, et al.: Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish. J. Psychopharmacol. 2022; 36(7): 892–902. PubMed Abstract | Publisher Full Text

[245] 245. Shikanai H, Matsuzaki H, Kasai R, et al.: 5-HT Neural System Abnormalities in PTSD Model Rats. NeuroMethods. 2023; 198: 203–213.

[246] 246. De Ridder M, Mograbi D, Wolmarans DW: Spontaneous alternation and stereotypical behaviour in deer mice: Response to escitalopram and levetiracetam. Behav. Pharmacol. 2022; 33(4): 282–290. Publisher Full Text

[247] 247. Mani V: Piracetam-induced neuroprotection in lipopolysaccharides-challenged EOC-20 cells and mouse brain via attenuating oxidative stress. Braz. J. Pharm. Sci. 2022; 58: 58. Publisher Full Text

[248] 248. Kassai F, Ernyey AJ, Kozma K, et al.: Lack of general learning ability factor in a rat test battery measuring a wide spectrum of cognitive domains. J. Integr. Neurosci. 2022; 21(1). Publisher Full Text

[249] 249. Ip FCF, Fu G, Yang F, et al.: A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice. Eur. J. Med. Chem. 2021; 226: 113827. PubMed Abstract | Publisher Full Text

[250] 250. Shepherd A, Zhang T, Hoffmann LB, et al.: A Preclinical Model of Computerized Cognitive Training: Touchscreen Cognitive Testing Enhances Cognition and Hippocampal Cellular Plasticity in Wildtype and Alzheimer’s Disease Mice. Front. Behav. Neurosci. 2021; 15. PubMed Abstract | Publisher Full Text | Free Full Text

[251] 251. Batabyal A, Lukowiak K: Configural learning memory can be transformed from intermediate-term to long-term in pond snail Lymnaea stagnalis. Physiol. Behav. 2021; 239: 113509. Publisher Full Text

[252] 252. Mistarz N, Andersen K, Nielsen AS, et al.: Pharmacological enhancing agents targeting cognition in patients with alcohol-induced neurocognitive disorders: A systematic review. Neurosci. Biobehav. Rev. 2021; 125: 608–626. PubMed Abstract | Publisher Full Text

[253] 253. Nelson M, Jensen C, Lenton S: Study drug use among university students in Western Australia: Results of a web survey and their policy and practice implications. Drug Alcohol Rev. 2021; 40(4): 530–539. Publisher Full Text

[254] 254. Damiri B, Khatib O, Nazzal Z, et al.: Metabolic syndrome associated with tobacco and caffeine products use among refugee adolescents: Risk of dyslipidemia. Diabetes, Metabolic Syndrome and Obesity. 2021; 14: 4121–4133. PubMed Abstract | Publisher Full Text | Free Full Text

[255] 255. Gyertyán I, Kassai F, Kozma K, et al.: Procognitive profiling of a serotonin 5-HT6 receptor antagonist in a complex model system in rats: A novel translational approach for clinical prediction. Brain Res. Bull. 2020; 165: 238–245. Publisher Full Text

[256] 256. Fakhrudin N, Nurrochmad A, Sudarmanto A, et al.: Wood is a potential source of natural phosphodiesterase-1 inhibitors. Pharm. J. 2020; 12(6): 1206–1217.

[257] 257. Sainz I, Collado-Mateo D, Coso JD: Effect of acute caffeine intake on hit accuracy and reaction time in professional e-sports players. Physiol. Behav. 2020; 224: 113031. PubMed Abstract | Publisher Full Text

[258] 258. Hoffman JR, Markus I, Dubnov-Raz G, et al.: Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women. J. Strength Cond. Res. 2020; 34(9): 2476–2481. PubMed Abstract | Publisher Full Text

[259] 259. Gyertyán I: How can preclinical cognitive research further neuropsychiatric drug discovery? Chances and challenges. Expert Opin. Drug Discov. 2020; 15(6): 659–670. PubMed Abstract | Publisher Full Text

[260] 260. Zuccarello E, Acquarone E, Calcagno E, et al.: Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. Biochem. Pharmacol. 2020; 176: 113818. Publisher Full Text

[261] 261. Baek JH, Jung S, Son H, et al.: Glutamine supplementation prevents chronic stress-induced mild cognitive impairment. Nutrients. 2020; 12(4). PubMed Abstract | Publisher Full Text | Free Full Text

[262] 262. Balkrishna A, Thakur P, Varshney A: Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies. Front. Pharmacol. 2020; 11. PubMed Abstract | Publisher Full Text | Free Full Text

[263] 263. Kusturica J, Hajdarević A, Nikšić H, et al.: Neuroenhancing Substances Use, Exam Anxiety and Academic Performance in Bosnian-Herzegovinian First-Year University Students. Acta medica academica. 2019; 48(3): 286–293. PubMed Abstract | Publisher Full Text

[264] 264. Yabuki Y, Wu L, Fukunaga K: Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway. J. Pharmacol. Sci. 2019; 140(3): 263–272. Publisher Full Text

[265] 265. London-Nadeau K, Chan P, Wood S: Building Conceptions of Cognitive Enhancement: University Students’ Views on the Effects of Pharmacological Cognitive Enhancers. Subst. Use Misuse. 2019; 54(6): 908–920. PubMed Abstract | Publisher Full Text

[266] 266. Tomažič T, Čelofiga AK: Ethical aspects of the abuse of pharmaceutical enhancements by healthy people in the context of improving cognitive functions. Philos. Ethics Humanit. Med. 2019; 14(1): 7. PubMed Abstract | Publisher Full Text | Free Full Text

[267] 267. Kozma K, Kassai F, Ernyey AJ, et al.: Establishment of a rodent cooperation assay as a model of social cognition. J. Pharmacol. Toxicol. Methods. 2019; 97: 44–51. Publisher Full Text

[268] 268. Ram SS, Hussainy S, Henning M, et al.: Cognitive Enhancers (CE) and Learning Strategies. J. Cogn. Enhanc. 2019; 3(1): 124–130. Publisher Full Text

[269] 269. Burk JA, Maness EB, Blumenthal SA, et al.: Orexins and cognition: Neuroanatomical and neurochemical substrates. The Orexin/Hypocretin System: Functional Roles and Therapeutic Potential. 2019; 139–153. Publisher Full Text

[270] 270. Michael T, Schanz CG, Mattheus HK, et al.: Do adjuvant interventions improve treatment outcome in adult patients with posttraumatic stress disorder receiving trauma-focused psychotherapy? A systematic review. Eur. J. Psychotraumatol. 2019; 10(1). PubMed Abstract | Publisher Full Text | Free Full Text

[271] 271. Noble LJ, Meruva VB, Hays SA, et al.: Vagus nerve stimulation promotes generalization of conditioned fear extinction and reduces anxiety in rats. Brain Stimul. 2019; 12(1): 9–18. PubMed Abstract | Publisher Full Text | Free Full Text

[272] 272. Chung SW, Rogasch NC, Hoy KE, et al.: The effect of single and repeated prefrontal intermittent theta burst stimulation on cortical reactivity and working memory. Brain Stimul. 2018; 11(3): 566–574. Publisher Full Text

[273] 273. Waterhouse U, Brennan KA, Ellenbroek BA: Nicotine self-administration reverses cognitive deficits in a rat model for schizophrenia. Addict. Biol. 2018; 23(2): 620–630. Publisher Full Text

[274] 274. Machek SB, Bagley JR: Creatine monohydrate supplementation: Considerations for cognitive performance in athletes. Strength and Conditioning Journal. 2018; 40(2): 82–93. Publisher Full Text

[275] 275. Noreen H, Yabuki Y, Fukunaga K: Novel spiroimidazopyridine derivative SAK3 improves methimazole-induced cognitive deficits in mice. Neurochem. Int. 2017; 108: 91–99. Publisher Full Text

[276] 276. Carrio Sampedro A, Pérez Triviño JL: On the Compatibility of Brain Enhancement and the Internal Values of Sport. Sport, Ethics Philos. 2017; 11(3): 307–322. Publisher Full Text

[277] 277. Zeleznikow-Johnston A, Burrows EL, Renoir T, et al.: Environmental enrichment enhances cognitive flexibility in C57BL/6 mice on a touchscreen reversal learning task. Neuropharmacology. 2017; 117: 219–226. Publisher Full Text

[278] 278. Buschler A, Manahan-Vaughan D: Metabotropic glutamate receptor, mGlu5, mediates enhancements of hippocampal long-term potentiation after environmental enrichment in young and old mice. Neuropharmacology. 2017; 115: 42–50. Publisher Full Text

[279] 279. Tang SW, Tang WH, Leonard BE: Managing interactions between cognitive enhancers and other psychotropics. Int. Clin. Psychopharmacol. 2017; 32(4): 175–183. PubMed Abstract | Publisher Full Text

[280] 280. Kunath N, Müller NCJ, Tonon M, et al.: Ghrelin modulates encoding-related brain function without enhancing memory formation in humans. NeuroImage. 2016; 142: 465–473. PubMed Abstract | Publisher Full Text

[281] 281. Kasparbauer AM, Meyhöfer I, Steffens M, et al.: Neural effects of methylphenidate and nicotine during smooth pursuit eye movements. NeuroImage. 2016; 141: 52–59. Publisher Full Text

[282] 282. Ben-Eliezer D, Yechiam E: Hypericum perforatum as a cognitive enhancer in rodents: A meta-analysis. Sci. Rep. 2016; 6: 6. Publisher Full Text

[283] 283. Colzato LS, Steenbergen L, Sellaro R, et al.: Effects of L-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial. Cortex. 2016; 82: 217–224. PubMed Abstract | Publisher Full Text

[284] 284. Fagundo AB, Jiménez-Murcia S, Giner-Bartolomé C, et al.: Modulation of irisin and physical activity on executive functions in obesity and morbid obesity. Sci. Rep. 2016; 6: 6. Publisher Full Text

[285] 285. Ghosh B, Zhao WN, Reis SA, et al.: Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation. Bioorg. Med. Chem. Lett. 2016; 26(4): 1265–1271. PubMed Abstract | Publisher Full Text | Free Full Text

[286] 286. Nikiforuk A: Serotonergic and cholinergic strategies as potential targets for the treatment of schizophrenia. Curr. Pharm. Des. 2016; 22(14): 2093–2116. PubMed Abstract | Publisher Full Text

[287] 287. Forsyth JK, Bachman P, Mathalon DH, et al.: Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain. Proc. Natl. Acad. Sci. USA. 2015; 112(50): 15331–15336. PubMed Abstract | Publisher Full Text | Free Full Text

[288] 288. Saridoğan GE, Aykaç A, Cabadak H, et al.: D-Cycloserine acts via increasing the GluN1 protein expressions in the frontal cortex and decreases the avoidance and risk assessment behaviors in a rat traumatic stress model. Behav. Brain Res. 2015; 293: 227–233. PubMed Abstract | Publisher Full Text

[289] 289. Hvoslef-Eide M, Oomen CA, Fisher BM, et al.: Facilitation of spatial working memory performance following intra-prefrontal cortical administration of the adrenergic alpha1 agonist phenylephrine. Psychopharmacology. 2015; 232(21-22): 4005–4016. PubMed Abstract | Publisher Full Text | Free Full Text

[290] 290. Kim CH, Hvoslef-Eide M, Nilsson SRO, et al.: The continuous performance test (rCPT) for mice: A novel operant touchscreen test of attentional function. Psychopharmacology. 2015; 232(21-22): 3947–3966. PubMed Abstract | Publisher Full Text | Free Full Text

[291] 291. Segev Y, Barrera I, Ounallah-Saad H, et al.: PKR inhibition rescues memory deficit and atf4 overexpression in apoe ε4 human replacement mice. J. Neurosci. 2015; 35(38): 12986–12993. PubMed Abstract | Publisher Full Text | Free Full Text

[292] 292. Khalil RB: Non-antidepressant psychopharmacologic treatment of specific phobias. Curr. Clin. Pharmacol. 2015; 10(2): 131–138. PubMed Abstract | Publisher Full Text

[293] 293. Marin MF, Lonak SF, Milad MR: Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers. Curr. Psychiatry Rep. 2015; 17(6): 39. PubMed Abstract | Publisher Full Text

[294] 294. Mohr C, Schneider S: The role of exposure in the treatment of anxiety disorders. Verhaltenstherapie. 2015; 25(1): 32–39. Publisher Full Text

[295] 295. Ramakrishnan NK, Schepers M, Luurtsema G, et al.: Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy. Mol. Imaging Biol. 2015; 17(3): 364–372. PubMed Abstract | Publisher Full Text

[296] 296. Malik M, Rangel-Barajas C, Sumien N, et al.: The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. Br. J. Pharmacol. 2015; 172(10): 2519–2531. PubMed Abstract | Publisher Full Text | Free Full Text

[297] 297. Talpos J, Shoaib M: Executive function. Handb. Exp. Pharmacol. 2015; 228: 191–213. Publisher Full Text

[298] 298. McGregor G, Malekizadeh Y, Harvey J: Minireview: Food for thought: Regulation of synaptic function by metabolic hormones. Mol. Endocrinol. 2015; 29(1): 3–13. PubMed Abstract | Publisher Full Text | Free Full Text

[299] 299. Kutlu MG, Gould TJ: Nicotinic receptors, memory, and hippocampus. Curr. Top. Behav. Neurosci. 2015; 23: 137–163. Publisher Full Text

[300] 300. Hosking JG, Lam FCW, Winstanley CA: Nicotine increases impulsivity and decreases willingness to exert cognitive effort despite improving attention in "Slacker" rats: Insights into cholinergic regulation of cost/benefit decision making. PLoS One. 2014; 9(10). Publisher Full Text

[301] 301. Bishara D, Harwood D: Safe prescribing of physical health medication in patients with dementia. Int. J. Geriatr. Psychiatry. 2014; 29(12): 1230–1241. Publisher Full Text

[302] 302. Pollard M, Bartolome JM, Conn PJ, et al.: Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 Positive allosteric modulator. J. Psychopharmacol. 2014; 28(10): 935–946. PubMed Abstract | Publisher Full Text | Free Full Text

[303] 303. Lungwitz EA, Stuber GD, Johnson PL, et al.: The role of the medial prefrontal cortex in regulating social familiarity-induced anxiolysis. Neuropsychopharmacology. 2014; 39(4): 1009–1019. PubMed Abstract | Publisher Full Text | Free Full Text

[304] 304. Rabinak CA, Phan KL: Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment. Curr. Pharm. Des. 2014; 20(13): 2212–2217. PubMed Abstract | Publisher Full Text | Free Full Text

[305] 305. Shaw D: Neuroenhancing public health. J. Med. Ethics. 2014; 40(6): 389–391. Publisher Full Text

[306] 306. Qian W, Schweizer TA, Fischer CE: Impact of socioeconomic status on initial clinical presentation to a memory disorders clinic. Int. Psychogeriatr. 2014; 26(4): 597–603. PubMed Abstract | Publisher Full Text

[307] 307. Gill SK, Leff AP: Dopaminergic therapy in aphasia. Aphasiology. 2014; 28(2): 155–170. PubMed Abstract | Publisher Full Text | Free Full Text

[308] 308. Colavito V, Fabene PF, Grassi-Zucconi G, et al.: Experimental sleep deprivation as a tool to test memory deficits in rodents. Front. Syst. Neurosci. 2013; 7(DEC). PubMed Abstract | Publisher Full Text | Free Full Text

[309] 309. Birch AM, McGarry NB, Kelly AM: Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus. 2013; 23(6): 437–450. PubMed Abstract | Publisher Full Text

[310] 310. Sanderson TM, Sher E: The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology. 2013; 74: 86–95. Publisher Full Text

[311] 311. Lipina TV, Palomo V, Gil C, et al.: Dual inhibitor of PDE7 and GSK-3 - VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology. 2013; 64: 205–214. PubMed Abstract | Publisher Full Text

[312] 312. Hahn B, Gold JM, Buchanan RW: The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology. 2013; 64: 185–190. PubMed Abstract | Publisher Full Text

[313] 313. Schmeichel BE, Zemlan FP, Berridge CW: A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder. Neuropharmacology. 2013; 64: 321–328. PubMed Abstract | Publisher Full Text | Free Full Text

[314] 314. Fernandes HA, Zanin KA, Patti CL, et al.: Inhibitory effects of modafinil on emotional memory in mice. Neuropharmacology. 2013; 64: 365–370. Publisher Full Text

[315] 315. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Pascual-Leone A: Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?. Neuropharmacology. 2013; 64: 566–578. PubMed Abstract | Publisher Full Text | Free Full Text

[316] 316. Uchiumi O, Kasahara Y, Fukui A, et al.: Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology. 2013; 64: 348–356. Publisher Full Text

[317] 317. Silverman JL, Oliver CF, Karras MN, et al.: AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013; 64: 268–282. PubMed Abstract | Publisher Full Text | Free Full Text

[318] 318. Allman AA, Ettinger U, Joober R, et al.: Effects of methylphenidate on basic and higher-order oculomotor functions. J. Psychopharmacol. 2012; 26(11): 1471–1479. PubMed Abstract | Publisher Full Text

[319] 319. Yehuda S: Polyunsaturated fatty acids as putative cognitive enhancers. Med. Hypotheses. 2012; 79(4): 456–461. PubMed Abstract | Publisher Full Text

[320] 320. Bruce J, Hancock L, Roberg B, et al.: Impact of armodafinil on cognition in multiple sclerosis: A randomized, double-blind crossover pilot study. Cogn. Behav. Neurol. 2012; 25(3): 107–114. PubMed Abstract | Publisher Full Text

[321] 321. Boyle J, Stanley N, James LM, et al.: Acute sleep deprivation: The effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J. Psychopharmacol. 2012; 26(8): 1047–1057. PubMed Abstract | Publisher Full Text

[322] 322. Alberini CM, Chen DY: Memory enhancement: Consolidation, reconsolidation and insulin-like growth factor 2. Trends Neurosci. 2012; 35(5): 274–283. PubMed Abstract | Publisher Full Text | Free Full Text

[323] 323. Knafo S, Venero C, Sánchez-Puelles C, et al.: Facilitation of ampa receptor synaptic delivery as a molecular mechanism for cognitive enhancement. PLoS Biol. 2012; 10(2): e1001262. PubMed Abstract | Publisher Full Text | Free Full Text

[324] 324. Froestl W, Muhs A, Pfeifer A: Cognitive enhancers (Nootropics). Part 1: Drugs interacting with receptors. J. Alzheimers Dis. 2012; 32(4): 793–887. PubMed Abstract | Publisher Full Text

[325] 325. Deiana S, Platt B, Riedel G: The cholinergic system and spatial learning. Behav. Brain Res. 2011; 221(2): 389–411. Publisher Full Text

[326] 326. Levin ED, Bushnell PJ, Rezvani AH: Attention-modulating effects of cognitive enhancers. Pharmacol. Biochem. Behav. 2011; 99(2): 146–154. PubMed Abstract | Publisher Full Text | Free Full Text

[327] 327. Valade A, Cross SB, Brown C, et al.: Discovery of novel selective Sigma-1 ligands as cognitive enhancers. MedChemComm. 2011; 2(7): 655–660. Publisher Full Text

[328] 328. Berridge CW, Devilbiss DM: Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2011; 69(12): e101–e111. PubMed Abstract | Publisher Full Text | Free Full Text

[329] 329. Mioranzza S, Costa MS, Botton PHS, et al.: Blockade of adenosine A1 receptors prevents methylphenidate-induced impairment of object recognition task in adult mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011; 35(1): 169–176. PubMed Abstract | Publisher Full Text

[330] 330. Wang T, Yang YJ, Wu PF, et al.: Tetrahydroxystilbene glucoside, a plant-derived cognitive enhancer, promotes hippocampal synaptic plasticity. Eur. J. Pharmacol. 2011; 650(1): 206–214. PubMed Abstract | Publisher Full Text

[331] 331. Köfeler HC, Tiboldi A, Hoeger H, et al.: Hippocampal lipids linked to spatial memory in the C57bl/6j mouse. Neurochem. Int. 2010; 57(8): 935–939. Publisher Full Text

[332] 332. Botton PH, Costa MS, Ardais AP, et al.: Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav. Brain Res. 2010; 214(2): 254–259. PubMed Abstract | Publisher Full Text

[333] 333. Muramatsu RS, Litzinger MHJ, Takeshita J: Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am. J. Geriatr. Pharmacother. 2010; 8(2): 98–114. PubMed Abstract | Publisher Full Text

[334] 334. Weiner I, Arad M: Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav. Brain Res. 2009; 204(2): 369–386. Publisher Full Text

[335] 335. Edgar CJ, Pace-Schott EF, Wesnes KA: Approaches to measuring the effects of wake-promoting drugs: A focus on cognitive function. Hum. Psychopharmacol. 2009; 24(5): 371–389. PubMed Abstract | Publisher Full Text | Free Full Text

[336] 336. John JPP, Sunyer B, Höger H, et al.: Hippocampal synapsin isoform levels are linked to spatial memory enhancement by SGS742. Hippocampus. 2009; 19(8): 731–738. Publisher Full Text

[337] 337. Kelly SJ, Bernard K, Muñoz C, et al.: Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats. Psychopharmacology. 2009; 202(1-3): 225–235. Publisher Full Text

[338] 338. Kelly MP, Cheung YF, Favilla C, et al.: Constitutive activation of the G-protein subunit Gαs within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. Learn. Mem. 2008; 15(2): 75–83. Publisher Full Text

[339] 339. Warren MF, Serby MJ, Roane DM: The effects of testosterone on cognition in elderly men: A review. CNS Spectr. 2008; 13(10): 887–897. PubMed Abstract | Publisher Full Text

[340] 340. Stone WS, Seidman LJ: Toward a model of memory enhancement in schizophrenia: Glucose administration and hippocampal function. Schizophr. Bull. 2008; 34(1): 93–108. PubMed Abstract

[341] 341. Bertaina-Anglade V, Drieu La Rochelle C, Muñoz C, et al.: Comparison of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the object recognition task in rats. Fundam. Clin. Pharmacol. 2007; 21(4): 349–354. Publisher Full Text

[342] 342. Wang Y, Wang L, Wu J, et al.: The in vivo synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. Br. J. Pharmacol. 2006; 148(2): 147–153. PubMed Abstract | Publisher Full Text | Free Full Text

[343] 343. Yang YL, Su YW, Ng MC, et al.: Extract of Ginkgo biloba EGb 761 facilitates fear conditioning measured by fear-potentiated startle. Neurosci. Lett. 2005; 383(1-2): 145–150. Publisher Full Text

[344] 344. Belluardo N, Olsson PA, Mudo G, et al.: Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience. 2005; 133(3): 787–796. Publisher Full Text

[345] 345. Kew JNC, Kemp JA: Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology. 2005; 179(1): 4–29. Publisher Full Text

[346] 346. Mayo W, Lemaire V, Malaterre J, et al.: Pregnenolone sulfate enhances neurogenesis and PSA-NCAM in young and aged hippocampus. Neurobiol. Aging. 2005; 26(1): 103–114. Publisher Full Text

[347] 347. Belluardo N, Mudò G, Blum M, et al.: Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging. Neurobiol. Aging. 2004; 25(10): 1333–1342. Publisher Full Text

[348] 348. Frick KM, Fernandez SM: Enrichment enhances spatial memory and increases synaptophysin levels in aged female mice. Neurobiol. Aging. 2003; 24(4): 615–626. PubMed Abstract | Publisher Full Text

[349] 349. Rodríguez-Alcázar J, Bermejo-Luque L: Human enhancement technologies and the arguments for cosmopolitanism. Enrahonar. 2024; 72: 15–33. Publisher Full Text

[350] 350. Wu KCC: PHARMACEUTICAL COGNITIVE ENHANCEMENT: Entanglement with emotion, morality, and context. The Routledge Handbook of the Ethics of Human Enhancement. 2023; 340–355. Publisher Full Text

[351] 351. Dasgupta J, Lockwood Estrin G, Summers J, et al.: Cognitive Enhancement and Social Mobility: Skepticism from India. AJOB Neurosci. 2023; 14(4): 341–351. PubMed Abstract | Publisher Full Text

[352] 352. Keary S, Ivers M, O’Connor C, et al.: Exploring Irish students’ attitudes towards nootropic supplements. Drugs: Education, Prevention and Policy. 2023; 30(5): 516–527.

[353] 353. Monnet F, Ergler C, Pilot E, et al.: ‘Cognitive enhancers’: A qualitative exploration of university students’ experiences with prescription medicines for academic purposes. Policy Futures in Education. 2022; 20(7): 762–779. Publisher Full Text

[354] 354. Edgren N, Dubljević V: The ubiquity of the fallacy of composition in cognitive enhancement and in education. Theor. Med. Bioeth. 2023; 44(1): 41–56. PubMed Abstract | Publisher Full Text

[355] 355. Carder P, Zimmerman S, Wretman CJ, et al.: As-Needed Prescribing and Administration of Psychotropic Medications in Assisted Living: A 7-State Study. J. Am. Med. Dir. Assoc. 2022; 23(6): 1038–44.e3. PubMed Abstract | Publisher Full Text | Free Full Text

[356] 356. Martos D, Tuka B, Tanaka M, et al.: Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission. Biomedicines. 2022; 10(4). PubMed Abstract | Publisher Full Text | Free Full Text

[357] 357. Herrmann N, Ismail Z, Collins R, et al.: CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2022; 8(1). Publisher Full Text

[358] 358. Shakeel S, Iffat W, Qamar A, et al.: Concept generation of cognitive enhancement: healthcare professionals' approach towards the impact and utilization of cognitive enhancers in academic context. Heliyon. 2021; 7(10): e08118. PubMed Abstract | Publisher Full Text | Free Full Text

[359] 359. Bystad M, Storø B, Gundersen N, et al.: Can accelerated transcranial direct current stimulation improve memory functions? An experimental, placebo-controlled study. Heliyon. 2020; 6(10): e05132. PubMed Abstract | Publisher Full Text | Free Full Text

[360] 360. Ferreira de Sá DS, Römer S, Brückner AH, et al.: Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study. Neuropsychopharmacology. 2020; 45(5): 753–760. Publisher Full Text

[361] 361. Palamenghi L, Bonfiglioli C: Cognitive Enhancement vs. Plagiarism: a Quantitative Study on the Attitudes of an Italian Sample. Neuroethics. 2019; 12(3): 279–292. Publisher Full Text

[362] 362. Petersen MA, Petersen TS: Why prohibit study drugs?: On attitudes and practices concerning prohibition and coercion to use pharmaceutical cognitive enhancement. Drugs: Education, Prevention and Policy. 2019; 26(4): 356–364.

[363] 363. Petersen TS: Should the state prohibit healthy people's access to pharmacological cognitive enhancers? On arguments from coercion and individualization. Int. J. Law Psychiatry. 2019; 65: 101382. PubMed Abstract | Publisher Full Text

[364] 364. Getting smart to cognitive enhancers. EClinicalMedicine. 2019; 11: 1–2. PubMed Abstract | Publisher Full Text | Free Full Text

[365] 365. Mayor E, Daehne M, Bianchi R: How perceived substance characteristics affect ethical judgement towards cognitive enhancement. PLoS ONE. 2019; 14(3): e0213619. PubMed Abstract | Publisher Full Text | Free Full Text

[366] 366. Bocchio M, Lukacs IP, Stacey R, et al.: Group II metabotropic glutamate receptors mediate presynaptic inhibition of excitatory transmission in pyramidal neurons of the human cerebral cortex. Front. Cell. Neurosci. 2019; 12. PubMed Abstract | Publisher Full Text | Free Full Text

[367] 367. Mihailov E, Savulescu J: Social Policy and Cognitive Enhancement: Lessons from Chess. Neuroethics. 2018; 11(2): 115–127. Publisher Full Text

[368] 368. Porsdam Mann S, de Lora DP , Cochrane T, et al.: Is the use of modafinil, a pharmacological cognitive enhancer, cheating?. Ethics and Education. 2018; 13(2): 251–267. Publisher Full Text

[369] 369. Wagner NF, Robinson J, Wiebking C: The societal hazards of neuroenhancement technologies. The Changing Scope of Technoethics in Contemporary Society. 2018; 163–196. Publisher Full Text

[370] 370. Chao PC, Chien WC, Chung CH, et al.: Cognitive enhancers associated with decreased risk of injury in patients with dementia: A nationwide cohort study in Taiwan. J. Investig. Med. 2018; 66(3): 684–692. PubMed Abstract | Publisher Full Text

[371] 371. Cummings J, Lee G, Ritter A, et al.: Alzheimer's disease drug development pipeline: 2018. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018; 4: 195–214. PubMed Abstract | Publisher Full Text | Free Full Text

[372] 372. Marvanova M, Henkel PJ: Community pharmacists' knowledge of Alzheimer disease care in high- and low-income Chicago. J. Am. Pharm. Assoc. 2017; 57: 596–600.e1. PubMed Abstract | Publisher Full Text

[373] 373. Gyertyán I: Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets. Trends Pharmacol. Sci. 2017; 38(2): 113–126. PubMed Abstract | Publisher Full Text

[374] 374. Tiunova AA, Komissarova NV, Nenaidenko VG, et al.: Pro-cognitive effects of non-peptide analogues of soluble amyloid peptide precursor fragment SAPP. Bull. Exp. Biol. Med. 2016; 161(4): 447–450. Publisher Full Text

[375] 375. Ram S, Hussainy S, Henning M, et al.: Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug Alcohol Rev. 2016; 35(3): 345–351. PubMed Abstract | Publisher Full Text

[376] 376. Lengvenyte A, Strumila R, Grikiniene J: Use of cognitive enhancers among medical students in Lithuania. NAD Nordic Studies on Alcohol and Drugs. 2016; 33(2): 173–188. Publisher Full Text

[377] 377. Toma ID, Gil LM, Ossowski S, et al.: Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders. Neural Plast. 2016; 2016: 1–20. Publisher Full Text

[378] 378. Lyon R: Smart drugs mean society loses out. Pharm. J. 2015; 295(7882): 329.

[379] 379. Whetstine LM: Cognitive Enhancement: Treating or Cheating?. Semin. Pediatr. Neurol. 2015; 22(3): 172–176. Publisher Full Text

[380] 380. Van Waes V, Steiner H: Fluoxetine and other SSRI antidepressants potentiate addiction-related gene regulation by psychostimulant medications. Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects. 2015; 207–225.

[381] 381. Kantak KM, Wettstein JG: Closing thoughts for cognitive enhancement. Handb. Exp. Pharmacol. 2015; 228: 451–459. Publisher Full Text

[382] 382. Levy N, Savulescu J. The Neuroethics of Transcranial Electrical. Stimulation. The Stimulated Brain: Cognitive Enhancement Using Non-Invasive Brain Stimulation2014. p. 499–521, DOI: Publisher Full Text

[383] 383. Rojas-Fernandez C, Mikhail M, Brown SG: Psychotropic and Cognitive-Enhancing Medication Use and Its Documentation in Contemporary Long-term Care Practice. Ann. Pharmacother. 2014; 48(4): 438–446. PubMed Abstract | Publisher Full Text

[384] 384. Wolbring G, Diep L, Yumakulov S, et al.: Social Robots, Brain Machine Interfaces and Neuro/Cognitive Enhancers: Three Emerging Science and Technology Products through the Lens of Technology Acceptance Theories, Models and Frameworks. Technologies. 2013; 1(1): 3–25. Publisher Full Text

[385] 385. Chinthapalli K: Bioethics researchers support use of cognitive enhancers. BMJ (Clinical research ed). 2013; 346: 346. Publisher Full Text

[386] 386. Lucke J, Partridge B: Towards a smart population: A public health framework for cognitive enhancement. Neuroethics. 2013; 6(2): 419–427. Publisher Full Text

[387] 387. Yamamoto Y, Shioda N, Han F, et al.: The novel cognitive enhancer st101 enhances acetylcholine release in mouse dorsal hippocampus through t-type voltage-gated calcium channel stimulation. J. Pharmacol. Sci. 2013; 121(3): 212–226. PubMed Abstract | Publisher Full Text

[388] 388. Tuboly G, Vécsei L: Somatostatin and cognitive function in neurodegenerative disorders. Mini-Rev. Med. Chem. 2013; 13(1): 34–46. Publisher Full Text

[389] 389. Chneiweiss H: Does Cognitive Enhancement Fit with the Physiology of Our Cognition? Oxford Handbook of Neuroethics.2012.

[390] 390. Ashare RL, Ray R, Lerman C, et al.: Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: A pilot feasibility study. Drug Alcohol Depend. 2012; 126(1-2): 263–267. PubMed Abstract | Publisher Full Text | Free Full Text

[391] 391. Nirogi R, Bhyrapuneni G, Kandikere V, et al.: Concurrent administration of atypical antipsychotics and donepezil: Drug interaction study in rats. Eur. J. Drug Metab. Pharmacokinet. 2012; 37(3): 155–161. Publisher Full Text

[392] 392. Kaewkaen P, Tong-Un T, Wattanathorn J, et al.: Mulberry fruit extract protects against memory impairment and hippocampal damage in animal model of vascular dementia. Evid. Based Complement. Alternat. Med. 2012; 2012: 1–9. PubMed Abstract | Publisher Full Text | Free Full Text

[393] 393. Franke AG, Bonertz C, Christmann M, et al.: Attitudes Toward Cognitive Enhancement in Users and Nonusers of Stimulants for Cognitive Enhancement: A Pilot Study. AJOB Prim. Res. 2012; 3(1): 48–57. Publisher Full Text

[394] 394. Lundström L, Bissantz C, Beck J, et al.: Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: Mechanistic studies with new potent negative allosteric modulators. Br. J. Pharmacol. 2011; 164(2 B): 521–537. PubMed Abstract | Publisher Full Text | Free Full Text

[395] 395. Outram SM, Racine E: Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics. 2011; 4: 93–105. Publisher Full Text

[396] 396. Sahakian BJ, Morein-Zamir S: Neuroethical issues in cognitive enhancement. J. Psychopharmacol. 2011; 25(2): 197–204. Publisher Full Text

[397] 397. Chiamulera C: Research is needed on the use of cognitive enhancer drugs in sport. J. Sci. Med. Sport. 2011; 14(1): 2–3. Publisher Full Text

[398] 398. Rossé G, Schaffhauser H: 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem. 2010; 10(2): 207–221. PubMed Abstract | Publisher Full Text

[399] 399. Houslay MD: Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 2010; 35(2): 91–100. PubMed Abstract | Publisher Full Text

[400] 400. Förstl H: Neuro-enhancement: BBrain doping. Nervenarzt. 2009; 80(7): 840–846. Publisher Full Text

[401] 401. Liu KG, Robichaud AJ: 5-HT 6 antagonists as potential treatment for cognitive dysfunction. Drug Dev. Res. 2009; 70(2): 145–168. Publisher Full Text

[402] 402. Racine E, Forlini C: Expectations regarding cognitive enhancement create substantial challenges. J. Med. Ethics. 2009; 35(8): 469–470. PubMed Abstract | Publisher Full Text

[403] 403. Levy N, Clarke S: Neuroethics and psychiatry. Curr. Opin. Psychiatry. 2008; 21(6): 568–571. Publisher Full Text

[404] 404. Omar SH: Unravelling the Threads: A Brief Insight into Vascular Dementia. Journal of Vascular Diseases. 2023; 2(4): 419–437. Publisher Full Text

[405] 405. Ozturk Y, Bozkurt I, Guvenc Y, et al.: Modafinil attenuates the neuroinflammatory response after experimental traumatic brain injury. J. Neurosurg. Sci. 2023; 67(4): 498–506. PubMed Abstract | Publisher Full Text

[406] 406. Ma W, Si T, Wang Z, et al.: Astrocytic α4-containing nAChR signaling in the hippocampus governs the formation of temporal association memory. Cell Rep. 2023; 42(7): 112674. PubMed Abstract | Publisher Full Text

[407] 407. Power SK, Venkatesan S, Lambe EK: Xanomeline restores endogenous nicotinic acetylcholine receptor signaling in mouse prefrontal cortex. Neuropsychopharmacology. 2023; 48(4): 671–682. PubMed Abstract | Publisher Full Text | Free Full Text

[408] 408. Muralidhara M, Rajini PS: Ayurvedic herbs–derived cognitive enhancers for the management of Alzheimer's disease (AD). Ayurvedic Herbal Preparations in Neurological Disorders. 2023; 367–398. Publisher Full Text

[409] 409. Kang M, Lee DB, Kwon S, et al.: Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data. J. Clin. Med. 2022; 11(16). PubMed Abstract | Publisher Full Text | Free Full Text

[410] 410. Pulido LN, Pochapski JA, Sugi A, et al.: Pre-clinical evidence that methylphenidate increases motivation and/or reward preference to search for high value rewards. Behav. Brain Res. 2023; 437: 114065. PubMed Abstract | Publisher Full Text

[411] 411. Isaacson RS: Treatment Updates in Alzheimer's Disease: Tailoring Management and Care Approaches to Improve Outcomes. Journal of Managed Care Medicine. 2023; 26(1): 8–12.

[412] 412. Pal D, Sahu P, Mishra AK, et al.: Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior. Curr. Drug Targets. 2023; 24(9): 728–750. PubMed Abstract | Publisher Full Text

[413] 413. Torrisi SA, Geraci F, Contarini G, et al.: Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside. Curr. Top. Behav. Neurosci. 2023; 60: 133–156. Publisher Full Text

[414] 414. Veroniki AA, Ashoor HM, Rios P, et al.: Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open. 2022; 12(4): e053012. PubMed Abstract | Publisher Full Text | Free Full Text

[415] 415. Phelps EB, Swantek S: Efficacy and Safety of Cognitive Enhancers for Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis. Essential Reviews in Geriatric Psychiatry. 2022; 325–329. Publisher Full Text

[416] 416. Mitra S, Muni M, Shawon NJ, et al.: Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential. Oxidative Med. Cell. Longev. 2022; 2022: 1–22. PubMed Abstract | Publisher Full Text | Free Full Text

[417] 417. Singh M, Sharma P, Arora S: Development of 1,2,3,4-tetrahydrocarbazole derivatives as dual binding cholinestarse inhibitors. Alzheimer's and Dementia. 2021; 17(S9). Publisher Full Text

[418] 418. Oliveira AWC, Pacheco JVN, Costa CS, et al.: Scopolamine and MK-801 impair recognition memory in a new spontaneous object exploration task in monkeys. Pharmacol. Biochem. Behav. 2021; 211: 173300. PubMed Abstract | Publisher Full Text

[419] 419. Bruszt N, Bali ZK, Tadepalli SA, et al.: Potentiation of cognitive enhancer effects of Alzheimer’s disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task. Psychopharmacology. 2021; 238(11): 3273–3281. PubMed Abstract | Publisher Full Text | Free Full Text

[420] 420. Oláh V, Knakker B, Trunk A, et al.: Dissociating cholinergic influence on alertness and temporal attention in primates in a simple reaction time paradigm. Eur. J. Neurosci. 2020; 52(7): 3776–3789. Publisher Full Text

[421] 421. Sepehri H, Nasiri H: Filgrastim improved spatial memory functions in rat model of scopolamine induced alzheimer type memory dysfunction. Bulletin of Pharmaceutical Sciences Assiut. 2021; 44(2): 579–585. Publisher Full Text

[422] 422. Cummings J: New approaches to symptomatic treatments for Alzheimer’s disease. Mol. Neurodegener. 2021; 16(1). Publisher Full Text

[423] 423. Nelissen E, Argyrousi EK, Van Goethem NP, et al.: Soluble guanylate cyclase stimulator vericiguat enhances long-term memory in rats without altering cerebral blood volume. Biomedicines. 2021; 9(8). PubMed Abstract | Publisher Full Text | Free Full Text

[424] 424. Gongora M, Nicoliche E, Magalhães J, et al.: Event-related potential (P300): the effects of levetiracetam in cognitive performance. Neurol. Sci. 2021; 42(6): 2309–2316. PubMed Abstract | Publisher Full Text

[425] 425. Stanczak A, Lewgowd W: Cognitive enhancers - what we should know about them. Farm. Pol. 2021; 77(4): 201–219. Publisher Full Text

[426] 426. Hamilton K, Harvey J: Leptin regulation of hippocampal synaptic function in health and disease. Vitam. Horm. 2021; 115: 105–127. PubMed Abstract | Publisher Full Text

[427] 427. Berthier ML: Ten key reasons for continuing research on pharmacotherapy for post-stroke aphasia. Aphasiology. 2021; 35(6): 824–858. Publisher Full Text

[428] 428. Mejido DCP, Peny JA, Vieira MNN, et al.: Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. Neuropharmacology. 2020; 171: 108115. PubMed Abstract | Publisher Full Text

[429] 429. Elliott JM: The Role of Glycaemic Control in Cognitive Functioning. Chemically Modified Minds: Substance Use for Cognitive Enhancement. 2020; 101–134. Publisher Full Text

[430] 430. Choi JG, Kahn Z, Hong SM, et al.: The mixture of gotu kola, cnidium fruit, and goji berry enhances memory functions by inducing nerve-growth-factor-mediated actions both in vitro and in vivo. Nutrients. 2020; 12(5). PubMed Abstract | Publisher Full Text | Free Full Text

[431] 431. Dashniani MG, Chighladze MR, Solomonia RO, et al.: Memantine treatment prevents okadaic acid induced neurotoxicity at the systemic and molecular levels. NeuroReport. 2020; 31(4): 281–286. Publisher Full Text

[432] 432. Tan YX, Liu GC, Chen HL, et al.: Exercise-Induced Cognitive Improvement Is Associated with Sodium Channel-Mediated Excitability in APP/PS1 Mice. Neural Plast. 2020; 2020: 1–18. PubMed Abstract | Publisher Full Text | Free Full Text

[433] 433. Voulgaropoulou SD, van Amelsvoort TAMJ , Prickaerts J, et al.: The effect of curcumin on cognition in Alzheimer's disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Res. 2019; 1725: 146476. PubMed Abstract | Publisher Full Text

[434] 434. De Toma I, Ortega M, Aloy P, et al.: DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment. Front. Mol. Neurosci. 2019; 12. Publisher Full Text

[435] 435. Jin BR, Liu HY: Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: Systematic review and Bayesian network meta-analysis. Neural Regen. Res. 2019; 14(5): 805–816. PubMed Abstract | Publisher Full Text

[436] 436. Montero-Odasso M, Speechley M, Chertkow H, et al.: Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. Eur. J. Neurol. 2019; 26(4): 651–659. Publisher Full Text

[437] 437. Mesa-Gresa P, Redolat R: Nicotine and Agonists of Alpha 7 Nicotinic Acetylcholine Receptors Combined With Environmental Enrichment. Acetylcholine Receptors in Health and Disease. 2019; 69–116.

[438] 438. Pifferi F, Epelbaum J, Aujard F: Strengths and weaknesses of the gray mouse lemur (Microcebus murinus) as a model for the behavioral and psychological symptoms and neuropsychiatric symptoms of dementia. Front. Pharmacol. 2019; 10(OCT). PubMed Abstract | Publisher Full Text | Free Full Text

[439] 439. Witkin JM, Shenvi RA, Li X, et al.: Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochem. Pharmacol. 2018; 155: 61–70. PubMed Abstract | Publisher Full Text | Free Full Text

[440] 440. Bali ZK, Bruszt N, Tadepalli SA, et al.: Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front. Pharmacol. 2019; 10(FEB). PubMed Abstract | Publisher Full Text | Free Full Text

[441] 441. Sinkeviciute I, Begemann M, Prikken M, et al.: Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophr. 2018; 4(1): 22. PubMed Abstract | Publisher Full Text | Free Full Text

[442] 442. Ovsepian SV, O’Leary VB: Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer’s Disease?. Neurotherapeutics. 2018; 15(4): 1032–1035. PubMed Abstract | Publisher Full Text | Free Full Text

[443] 443. Zhou D, Lv D, Wang Z, et al.: GLYX-13 ameliorates schizophrenia-like phenotype induced by MK-801 in mice: role of hippocampal NR2B and DISC1. Front. Mol. Neurosci. 2018; 11. PubMed Abstract | Publisher Full Text | Free Full Text

[444] 444. Guercio GD, Panizzutti R: Potential and challenges for the clinical use of D-Serine as a cognitive enhancer. Front. Psych. 2018; 9(FEB). PubMed Abstract | Publisher Full Text | Free Full Text

[445] 445. Cès A, Burg T, Herbeaux K, et al.: Age-related vulnerability of pattern separation in C57BL/6J mice. Neurobiol. Aging. 2018; 62: 120–129. PubMed Abstract | Publisher Full Text

[446] 446. PRA H, Argyrousi EK, Prickaerts J: Phosphodiesterase Inhibitors in Object Recognition and Object Location Memory Tests. Handbook of Behavioral Neuroscience. 2018; 27: 567–574. Publisher Full Text

[447] 447. Whittaker DS, Wang HB, Loh DH, et al.: Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease. Pharmacol. Res. Perspect. 2017; 5(5). PubMed Abstract | Publisher Full Text | Free Full Text

[448] 448. Cummings J, Lee G, Mortsdorf T, et al.: Alzheimer's disease drug development pipeline: 2017. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2017; 3(3): 367–384. PubMed Abstract | Publisher Full Text | Free Full Text

[449] 449. Pardo M, Beurel E, Jope RS: Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome. Eur. J. Neurosci. 2017; 45(4): 490–498. PubMed Abstract | Publisher Full Text | Free Full Text

[450] 450. Moskal JR, Burgdorf JS, Stanton PK, et al.: The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr. Neuropharmacol. 2017; 15(1): 47–56. PubMed Abstract | Publisher Full Text | Free Full Text

[451] 451. Yellamma K, Vanaja D: Evolvulus alsinoides plant extract as a cognitive enhancer of spacial memory in AD-induced rat model. Res. J. Pharm., Biol. Chem. Sci. 2016; 7(6): 2050–2054.

[452] 452. Kim HY, Kim HV, Lee DK, et al.: Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. Sci. Rep. 2016; 6: 6. Publisher Full Text

[453] 453. Kehagia AA: A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. J. Psychopharmacol. 2016; 30(10): 957–966. PubMed Abstract | Publisher Full Text

[454] 454. Hommel B, Sellaro R, Fischer R, et al.: High-frequency binaural beats increase cognitive flexibility: Evidence from dual-task crosstalk. Front. Psychol. 2016; 7(AUG). PubMed Abstract | Publisher Full Text | Free Full Text

[455] 455. Jawale A, Datusalia AK, Bishnoi M, et al.: Reversal of diabetes-induced behavioral and neurochemical deficits by cinnamaldehyde. Phytomedicine. 2016; 23(9): 923–930. PubMed Abstract | Publisher Full Text

[456] 456. Wolfe MS: Developing Therapeutics for Alzheimer's Disease: Progress and Challenges.2016; 1–656.

[457] 457. Fisher A, Bezprozvanny I, Wu L, et al.: AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. Neurodegener. Dis. 2016; 16: 95–110. PubMed Abstract | Publisher Full Text | Free Full Text

[458] 458. Jones KC, Han JY, Shah AA: Cognitive continuum: Areas of controversy with cognitive enhancers. Psychiatr. Ann. 2016; 46(2): 110–117. Publisher Full Text

[459] 459. Zhou X, Li Y, Shi X, et al.: An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am. J. Transl. Res. 2016; 8(2): 246–269. PubMed Abstract

[460] 460. Stoeber J, Hotham S: Perfectionism and attitudes toward cognitive enhancers (“smart drugs”). Personal. Individ. Differ. 2016; 88: 170–174. Publisher Full Text

[461] 461. Maier LJ, Liakoni E, Schildmann J, et al.: Swiss university students' attitudes toward pharmacological cognitive enhancement. PLoS ONE. 2015; 10(12): e0144402. PubMed Abstract | Publisher Full Text | Free Full Text

[462] 462. Shniderman AB, Solberg LB: Cosmetic Psychopharmacology for Prisoners: Reducing Crime and Recidivism Through Cognitive Intervention. Neuroethics. 2015; 8(3): 315–326. Publisher Full Text

[463] 463. Burgdorf J, Zhang XL, Weiss C, et al.: The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015; 308: 202–211. PubMed Abstract | Publisher Full Text | Free Full Text

[464] 464. Sirichoat A, Chaijaroonkhanarak W, Prachaney P, et al.: Effects of Asiatic acid on spatial working memory and cell proliferation in the adult rat hippocampus. Nutrients. 2015; 7(10): 8413–8423. Publisher Full Text

[465] 465. Zhang H, He Y, Li AP: The Role of Leptin in Cognitive Development During Aging. Sheng li ke xue jin zhan [Progress in physiology]. 2015; 46(5): 321–326. PubMed Abstract

[466] 466. Stützle M, Flamm J, Carle S, et al.: Nose-to-brain delivery of insulin for Alzheimer's disease. ADMET and DMPK. 2015; 3(3): 190–202. Publisher Full Text

[467] 467. Ragen BJ, Seidel J, Chollak C, et al.: Investigational drugs under development for the treatment of PTSD. Expert Opin. Investig. Drugs. 2015; 24(5): 659–672. PubMed Abstract | Publisher Full Text

[468] 468. Hegedüs N, Laszy J, Gyertyán I, et al.: Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. J. Psychopharmacol. 2015; 29(4): 447–455. PubMed Abstract | Publisher Full Text

[469] 469. Hashimoto T, Hatayama Y, Nakamichi K, et al.: Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice. Eur. J. Pharmacol. 2014; 745: 123–128. PubMed Abstract | Publisher Full Text

[470] 470. Ostrovskaya RU, Vakhitova YV, Kuzmina US, et al.: Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J. Biomed. Sci. 2014; 21(1): 74. PubMed Abstract | Publisher Full Text | Free Full Text

[471] 471. Wan WB, Cao L, Liu LM, et al.: EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model. PLoS One. 2014; 9(11): e113126. PubMed Abstract | Publisher Full Text | Free Full Text

[472] 472. Balsera B, Mulet J, Fernández-Carvajal A, et al.: Chalcones as positive allosteric modulators of α7 nicotinic acetylcholine receptors: A new target for a privileged structure. Eur. J. Med. Chem. 2014; 86: 724–739. PubMed Abstract | Publisher Full Text

[473] 473. Luzny J, Holmerova I, Wija P, et al.: Dementia still diagnosed too late – data from the Czech Republic. Iran. J. Public Health. 2014; 43(10): 1436–1443. PubMed Abstract

[474] 474. Wergeland JN, Selbæk G, Hogset LD, et al.: Dementia, neuropsychiatric symptoms, and the use of psychotropic drugs among older people who receive domiciliary care: A cross-sectional study. Int. Psychogeriatr. 2014; 26(3): 383–391. PubMed Abstract | Publisher Full Text

[475] 475. Gulcan HO, Unlu S, Esiringu I, et al.: Design, synthesis and biological evaluation of novel 6H-benzo [c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo [c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg. Med. Chem. 2014; 22(19): 5141–5154. PubMed Abstract | Publisher Full Text

[476] 476. Irving AJ, Harvey J: Leptin regulation of hippocampal synaptic function in health and disease. Philosophical Transactions of the Royal Society B: Biological Sciences. 2014; 369(1633): 20130155. PubMed Abstract | Publisher Full Text | Free Full Text

[477] 477. Braidy N, Poljak A, Jayasena T, et al.: Drug treatments for alzheimer's disease: Hopes and challenges. Handbook of Neurotoxicity. 2014; 2: 1173–1190. Publisher Full Text

[478] 478. Szuhany KL, Alexandra Kredlow M, Otto MW: Combination psychological and pharmacological treatments for panic disorder. Int. J. Cogn. Ther. 2014; 7(2): 122–135. Publisher Full Text

[479] 479. Whittle N, Singewald N: HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?. Biochem. Soc. Trans. 2014; 42(2): 569–581. PubMed Abstract | Publisher Full Text | Free Full Text

[480] 480. Smith I, Williamson EM, Putnam S, et al.: Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr. Rev. 2014; 72(5): 319–333. Publisher Full Text

[481] 481. Park CA, Kang CK, Son YD, et al.: The effects of caffeine ingestion on cortical areas: Functional imaging study. Magn. Reson. Imaging. 2014; 32(4): 366–371. PubMed Abstract | Publisher Full Text

[482] 482. Pohanka M: Alzheimer's disease and oxidative stress: A review. Curr. Med. Chem. 2014; 21(3): 356–364. PubMed Abstract

[483] 483. Shineman DW, Carman AJ, Dacks PA, et al.: Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease. Alzheimer's Research and Therapy. 2013; 5(5): 45. PubMed Abstract | Publisher Full Text | Free Full Text

[484] 484. Porciúncula LO, Sallaberry C, Mioranzza S, et al.: The Janus face of caffeine. Neurochem. Int. 2013; 63(6): 594–609. Publisher Full Text

[485] 485. Klusa V, Muceniece R, Isajevs S, et al.: Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats. Pharmacol. Biochem. Behav. 2013; 106: 68–76. PubMed Abstract | Publisher Full Text

[486] 486. Capurro V, Busquet P, Lopes JP, et al.: Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease. PLoS ONE. 2013; 8(2): e56870. PubMed Abstract | Publisher Full Text | Free Full Text

[487] 487. Piyabhan P, Wetchateng T, Sirseeratawong S: Cognitive enhancement effects of Bacopa Monnieri (Brahmi) on novel object recognition and NMDA receptor immunodensity in the prefrontal cortex and hippocampus of sub-chronic phencyclidine rat model of schizophrenia. J. Med. Assoc. Thail. 2013; 96(2): 231–238. PubMed Abstract

[488] 488. Singer P, Hauser J, Lopez LL, et al.: Prepulse inhibition predicts working memory performance whilst startle habituation predicts spatial reference memory retention in C57BL/6 mice. Behav. Brain Res. 2013; 242(1): 166–177. PubMed Abstract | Publisher Full Text

[489] 489. Sutalangka C, Wattanathorn J, Muchimapura S, et al.: Moringa oleifera mitigates memory impairment and neurodegeneration in animal model of age-related dementia. Oxidative Med. Cell. Longev. 2013; 2013: 1–9. Publisher Full Text

[490] 490. Doherty GH, Beccano-Kelly D, Yan SD, et al.: Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid β. Neurobiol. Aging. 2013; 34(1): 226–237. PubMed Abstract | Publisher Full Text

[491] 491. Dobarro M, Orejana L, Aguirre N, et al.: Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013; 64: 137–144. PubMed Abstract | Publisher Full Text

[492] 492. Sierksma ASR, Rutten K, Sydlik S, et al.: Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology. 2013; 64: 124–136. PubMed Abstract | Publisher Full Text

[493] 493. Klaassen EB, De Groot RHM, Evers EAT, et al.: The effect of caffeine on working memory load-related brain activation in middle-aged males. Neuropharmacology. 2013; 64: 160–167. PubMed Abstract | Publisher Full Text

[494] 494. Schulz R, Gerloff C, Hummel FC: Non-invasive brain stimulation in neurological diseases. Neuropharmacology. 2013; 64: 579–587. Publisher Full Text

[495] 495. García-Barroso C, Ricobaraza A, Pascual-Lucas M, et al.: Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology. 2013; 64: 114–123. PubMed Abstract | Publisher Full Text

[496] 496. Chambon C, Jatzke C, Wegener N, et al.: Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. Eur. J. Pharmacol. 2012; 697(1-3): 73–80. PubMed Abstract | Publisher Full Text

[497] 497. Laatikainen LM, Sharp T, Bannerman DM, et al.: Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. J. Psychopharmacol. 2012; 26(12): 1561–1568. PubMed Abstract | Publisher Full Text | Free Full Text

[498] 498. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al.: Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem. Neurosci. 2012; 3(11): 832–844. PubMed Abstract | Publisher Full Text | Free Full Text

[499] 499. Gur S, Kadowitz PJ, Serefoglu EC, et al.: PDE5 inhibitor treatment Options for urologic and non-urologic indications: 2012 update. Curr. Pharm. Des. 2012; 18(34): 5590–5606. PubMed Abstract | Publisher Full Text

[500] 500. Stewart AM, Kalueff AV: The developing utility of zebrafish models for cognitive enhancers research. Curr. Neuropharmacol. 2012; 10(3): 263–271. PubMed Abstract | Publisher Full Text | Free Full Text

[501] 501. Hu D, Cao Y, He R, et al.: Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ 1-142-induced memory impairment in mice. Oxidative Med. Cell. Longev. 2012; 2012: 1–7. PubMed Abstract | Publisher Full Text | Free Full Text

Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

Abstract

1) Introduction

2) Methods

3) Results and discussion

4) Conclusions

Keywords

Introduction

Methods

Data Collection

Data Analysis

Quantitative Analysis

Figure 1. Documents by year.

Figure 2. Most Relevant Sources.

Figure 3. Most Global Cited Documents.

Figure 4. Factorial map of the documents with the highest contributes.

Figure 5. Documents by Author.

Figure 6. Documents by country or territory.

Figure 7. Documents by Subject Area.

Figure 8. Documents by affiliation.

Figure 9. Documents by funding sponsor.

Figure 10. Network Visualization.

Figure 11. Overlay visualization of scopus, database using Vosviewer.

Figure 12. Density visualization.

Figure 13. Thematic map.

Figure 14. Thematic Evolution.

Figure 15. Dendogram.

Results and Discussion

Conclusions

Ethics and consent

Reporting guidelines

Software availability

Author Contribution

Data availability statement

Extended data

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Reviewer Reports

Comments on this article

Browse by related subjects

Competing Interests Policy

Stay Updated